EAU ESUR ESTRO SIOG Guidelines On Prostate Cancer Large Text V2

EAU - ESTRO - ESUR -
SIOG Guidelines on
Prostate Cancer
N. Mottet (Chair), R.C.N. van den Bergh,
E. Briers (Patient Representative), L. Bourke,
P. Cornford (Vice-chair), M. De Santis, S. Gillessen, A. Govorov,
J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, H.G. van der
Poel, T.H. van der Kwast, O. Rouvière, T. Wiegel
Guidelines Associates: T. Van den Broeck, M. Cumberbatch,
N. Fossati, T. Gross, M. Lardas, M. Liew,
L. Moris, I.G. Schoots, P.M. Willemse
European Society
of Urogenital Radiology
© European Association of Urology 2018

TABLE OF CONTENTS PAGE
1. INTRODUCTION 9
1.1 Aims and scope 9
1.2 Panel composition 9
1.2.1 Acknowledgement 9
1.3 Available publications 9
1.4 Publication history and summary of changes 9
1.4.1 Publication history 9
1.4.2 Summary of changes 9
2. METHODS 10
2.1 Data identification 10
2.2 Review 10
2.3 Future goals 11
3. EPIDEMIOLOGY AND AETIOLOGY 11

3.1 Epidemiology 11
3.2 Aetiology 11
3.2.1 Family history/genetics 11
3.2.2 Risk factors 11
3.2.2.1 Metabolic syndrome (MetS) 12
3.2.2.1.1 Diabetes/metformin 12
3.2.2.1.2 Cholesterol/statins 12
3.2.2.1.3 Obesity 12
3.2.2.2 Dietary factors 12
3.2.2.3 Hormonally active medication 12
3.2.2.3.1 5-alpha-reductase inhibitors (5-ARIs) 12
3.2.2.3.2 Testosterone 13
3.2.2.4 Other potential risk factors 13
3.2.3 Summary of evidence and guidelines for epidemiology and aetiology 13
4. CLASSIFICATION AND STAGING SYSTEMS 13

4.1 Classification 13
4.2 Gleason score and International Society of Urological Pathology 2014 grade 14
4.3 Prognostic relevance of stratification 15
5. DIAGNOSTIC EVALUATION 15
5.1 Screening and early detection 15
5.1.1 Guidelines for screening and early detection 17
5.2 Clinical diagnosis 17
5.2.1 Digital rectal examination 17
5.2.2 Prostate-specific antigen 17
5.2.2.1 PSA density 18
5.2.2.2 PSA velocity and doubling time 18
5.2.2.3 Free/total PSA ratio 18
5.2.2.4 Additional serum testing 18
5.2.2.5 PCA3 marker/SelectMDX 18
5.2.2.6 Guidelines for risk-assessment of asymptomatic men 19
5.2.3 Prostate biopsy 19
5.2.3.1 Baseline biopsy 19
5.2.3.2 Repeat biopsy after previously negative biopsy 19
5.2.3.3 Saturation biopsy 20
5.2.3.4 Sampling sites and number of cores 20
5.2.3.5 Diagnostic transurethral resection of the prostate 20
5.2.3.6 Seminal vesicle biopsy 20
5.2.3.7 Transition zone biopsy 20
5.2.3.8 Antibiotics prior to biopsy 20
5.2.3.9 Local anaesthesia prior to biopsy 20
5.2.3.10 Fine-needle aspiration biopsy 20
2 PROSTATE CANCER - UPDATE MARCH 2018

5.2.3.11 Complications 20
5.2.4 The role of imaging in clinical diagnosis 21
5.2.4.1 Transrectal ultrasound (TRUS) and ultrasound-based techniques 21
5.2.4.2 Multiparametric magnetic resonance imaging (mpMRI) 21
5.2.4.3 Guidelines for imaging 22
5.2.5 Pathology of prostate needle biopsies 22
5.2.5.1 Processing 22
5.2.5.2 Microscopy and reporting 22
5.2.5.3 Tissue-based prognostic biomarker testing 23
5.2.6 Histopathology of radical prostatectomy specimens 24
5.2.6.1 Processing of radical prostatectomy specimens 24
5.2.6.1.1 Guidelines for processing prostatectomy specimens 24
5.2.6.2 Radical prostatectomy specimen report 24
5.2.6.2.1 Gleason score in prostatectomy specimens 25
5.2.6.2.2 Definition of extraprostatic extension 25
5.2.6.3 PCa volume 26
5.2.6.4 Surgical margin status 26
5.2.7 Guidelines for the clinical diagnosis of prostate cancer 26
5.3 Diagnosis: Clinical staging 26
5.3.1 T-staging 26
5.3.1.1 Definitions 26
5.3.1.2 DRE, PSA level and biopsy findings 26
5.3.1.3 TRUS 27
5.3.1.4 mpMRI 27
5.3.2 N-staging 27
5.3.2.1 Computed tomography (CT) and magnetic resonance imaging 27
5.3.2.2 Choline PET/CT 28
5.3.2.3 Prostate-specific membrane antigen-based PET/CT 28
5.3.3 M-staging 28
5.3.3.1 Bone scan 28
5.3.3.2 Fluoride PET and PET/CT, choline PET/CT and MRI 28
5.3.3.3 Prostate-specific membrane antigen-based PET/CT 29
5.3.3.4 Summary of evidence and practical considerations on initial
N/M staging 29
5.3.4 Guidelines for staging of prostate cancer 29
5.4 Evaluating health status and life expectancy 30
5.4.1 Introduction 30
5.4.2 Health status screening 30
5.4.2.1 Comorbidity 30
5.4.2.2 Nutritional status 30
5.4.2.3 Cognitive function 30
5.4.2.4 Physical function 30
5.4.3 Conclusion 30
5.4.4 Guidelines for evaluating health status and life expectancy 33
6. TREATMENT 33
6.1 Treatment modalities 33
6.1.1 Deferred treatment (active surveillance/watchful waiting) 33
6.1.1.1 Definitions 33
6.1.1.2 Active surveillance 34
6.1.1.3 Watchful Waiting 34
6.1.1.3.1 Introduction 34
6.1.1.3.2 Outcome of watchful waiting compared with
active treatment 34
6.1.1.4 The ProtecT study 35
6.1.2 Radical prostatectomy 35
6.1.2.1 Surgical techniques 35
6.1.2.1.1 Pelvic lymph node dissection 36
6.1.2.1.2 Sentinel node biopsy analysis 36
6.1.2.1.3 Nerve-sparing surgery 36
PROSTATE CANCER - UPDATE MARCH 2018 3

6.1.2.1.4 Neoadjuvant ADT 36
6.1.2.2 Comparing effectiveness of radical prostatectomy vs. other
interventions for localised disease 36
6.1.2.2.1 Radical prostatectomy vs. deferred treatment 36
6.1.2.2.2 Radical prostatectomy vs. radiotherapy 37
6.1.2.3 Acute complications of surgery 37
6.1.2.3.1 Early complications of extended lymph node dissection 37
6.1.3 Radiotherapy 37
6.1.3.1 External Beam Radiation Therapy: 38
6.1.3.1.1 Technical aspects: intensity-modulated external-beam
radiotherapy (IMRT) and volumetric arc
external-beam radiotherapy (VMAT) 38
6.1.3.1.2 Dose escalation 38
6.1.3.1.3 Hypofractionation (HFX) 39
6.1.3.1.4 Neoadjuvant or adjuvant hormone therapy
plus radiotherapy 40
6.1.3.1.5 Combined dose-escalated radiotherapy and
androgen-deprivation therapy 42
6.1.3.2 Proton beam therapy 42
6.1.3.3 Brachytherapy 42
6.1.3.3.1 Low-dose rate (LDR) brachytherapy 42
6.1.3.3.2 High-dose rate (HDR) brachytherapy 42
6.1.3.4 Side-effects of external beam radiotherapy and brachytherapy 43
6.1.4 Hormonal therapy 43
6.1.4.1 Introduction 43
6.1.4.1.1 Different types of hormonal therapy 43
6.1.4.1.1.1 Testosterone-lowering therapy (castration) 43
6.1.4.1.1.1.1 Castration level 43
6.1.4.1.1.1.2 Bilateral orchiectomy 44
6.1.4.1.1.2 Oestrogens 44
6.1.4.1.1.3 Luteinising-hormone-releasing
hormone agonists 44
6.1.4.1.1.4 Luteinising-hormone-releasing
hormone antagonists 44
6.1.4.1.1.5 Anti-androgens 44
6.1.4.1.1.5.1 Steroidal anti-androgens 44
6.1.4.1.1.5.1.1 Cyproterone acetate 45
6.1.4.1.1.5.2 Non-steroidal anti-androgens 45
6.1.4.1.1.5.2.1 Nilutamide 45
6.1.4.1.1.5.2.2 Flutamide 45
6.1.4.1.1.5.2.3 Bicalutamide 45
6.1.4.1.1.6 New compounds 45
6.1.4.1.1.6.1 Abiraterone acetate 45
6.1.4.1.1.6.2 Enzalutamide 45
6.1.5 Investigational therapies 45
6.1.5.1 Background 45
6.1.5.2 Cryotherapy 46
6.1.5.3 High-intensity focused ultrasound 46
6.1.5.4 Focal therapy 46
6.1.5.5 General guidelines for active treatment 47
6.1.6 Discussing treatment options 47
6.2 Treatment by disease stages 47
6.2.1 Treatment of low-risk disease 47
6.2.1.1 Selection criteria for active surveillance 47
6.2.1.1.1 Clinical and pathological variables 47
6.2.1.1.2 Biological markers 48
6.2.1.1.3 Imaging for treatment selection 48
6.2.1.1.4 Follow up 48
6.2.1.1.5 Switching to active treatment 48
6.2.1.2 Active treatment 48

6.2.1.2.1 Radical prostatectomy 48
6.2.1.2.2 Radiation therapy treatment policy 49
6.2.1.3 Other treatments 49
6.2.1.4 Guidelines for the treatment of low-risk disease 49
6.2.2 Treatment of Intermediate-risk disease 50
6.2.2.1 Active Surveillance 50
6.2.2.2 Surgery 50
6.2.2.3 Radiation therapy 50
6.2.2.3.1 Recommended external beam radiation therapy
for intermediate-risk PCa 50
6.2.2.3.2 Brachytherapy monotherapy 50
6.2.2.4 Other options for the primary treatment of intermediate-risk PCa
(experimental therapies) 50
6.2.2.5 Guidelines for the treatment of intermediate-risk disease 51
6.2.3 Treatment of high-risk localised disease 51
6.2.3.1 Radical prostatectomy 51
6.2.3.1.1 Gleason score 8-10 (ISUP grade 4-5) 51
6.2.3.1.2 Prostate-specific antigen > 20 ng/mL 51
6.2.3.1.3 Radical prostatectomy in cN0 patients who are found to
have pathologically confirmed lymph node invasion (pN1) 51
6.2.3.2 External beam radiation therapy 52
6.2.3.2.1 Recommended external beam radiation therapy
treatment policy for localised high-risk PCa 52
6.2.3.2.2 Lymph node irradiation in cN0 52
6.2.3.2.3 Low-dose rate brachytherapy boost 52
6.2.3.3 Options other than surgery and radiotherapy for the primary
treatment of localised prostate cancer. 52
6.2.3.4 Guidelines for radical treatment of high-risk localised disease 52
6.2.4 Treatment of locally advanced prostate cancer 52
6.2.4.1 Surgery 53
6.2.4.2 Radiotherapy for locally advanced PCa 53
6.2.4.3 Options other than surgery and radiotherapy for primary treatment 53
6.2.4.4 Guidelines for radical treatment of locally-advanced disease 53
6.2.4.5 Adjuvant treatment after radical prostatectomy 54
6.2.4.5.1 Risk factors for relapse 54
6.2.4.5.2 Immediate (adjuvant) post-operative external irradiation
after RP (cN0 or pN0) 54
6.2.4.5.3 Adjuvant androgen ablation 55
6.2.4.5.3.1 Adjuvant androgen ablation in men with
N0 disease 55
6.2.4.5.3.2 Adjuvant androgen ablation in men with
pN1 disease 55
6.2.4.5.3.3 Adjuvant radiotherapy combined with
ADT in men with pN1 disease 55
6.2.4.5.3.4 Adjuvant chemotherapy 55
6.2.4.5.4 Guidelines for adjuvant treatment options after
radical prostatectomy 55
6.2.4.5.5 Guidelines for non-curative or palliative treatments
in prostate cancer 56
6.3 Management of PSA-only recurrence after treatment with curative intent 56
6.3.1 Background 56
6.3.2 Definitions of clinically relevant PSA relapse 56
6.3.3 Natural history of biochemical recurrence 56
6.3.3.1 Post-radical prostatectomy biochemical recurrence 56
6.3.3.2 Post-radiotherapy biochemical recurrence 57
6.3.4 The role of imaging in PSA-only recurrence 57
6.3.4.1 Assessment of metastases 57
6.3.4.1.1 Bone scan and abdominopelvic CT 57
6.3.4.1.2 Choline PET/CT 57
6.3.4.1.3 Fluoride PET and PET/CT 58

6.3.4.1.4 Prostate-specific membrane antigen-based PET/CT 58
6.3.4.1.5 Whole-body and axial MRI 58
6.3.4.2 Assessment of local recurrences 58
6.3.4.2.1 Local recurrence after radical prostatectomy 58
6.3.4.2.2 Local recurrence after radiation therapy 58
6.3.4.3 Summary of evidence on imaging in case of biochemical recurrence 59
6.3.4.4 Guidelines for imaging in patients with biochemical recurrence 59
6.3.5 Treatment of PSA-only recurrences 59
6.3.5.1 Salvage radiotherapy [SRT] for PSA-only recurrence after radical
prostatectomy 59
6.3.5.1.1 Target volume, dose, toxicity 62
6.3.5.1.2 Comparison of adjuvant radiotherapy (ART) and salvage
radiotherapy (SRT) 62
6.3.5.2 Management of PSA failures after radiation therapy 63
6.3.5.2.1 Salvage radical prostatectomy 63
6.3.5.2.1.1 Oncological outcomes 63
6.3.5.2.1.2 Morbidity 63
6.3.5.2.1.3 Summary of salvage radical prostatectomy 64
6.3.5.2.2 Salvage cryoablation of the prostate 64
6.3.5.2.2.2 Morbidity 64
6.3.5.2.2.3 Summary of salvage cryoablation of the
prostate 65
6.3.5.2.3 Salvage brachytherapy for radiotherapy failure 65
6.3.5.2.4 Salvage high-intensity focused ultrasound 65
6.3.5.2.4.2 Morbidity 66
6.3.5.2.4.3 Summary of salvage high-intensity
focused ultrasound 66
6.3.6 Salvage lymph node dissection 66
6.3.8 Observation 66
6.3.9 Guidelines for second-line therapy after treatment with curative intent 67
6.4 Treatment: Metastatic prostate cancer 67
6.4.2 Prognostic factors 67
6.4.3 First-line hormonal treatment 67
6.4.4 Combination therapies 67
6.4.4.1 Complete androgen blockade 67
6.4.4.2 Non-steroidal anti-androgen monotherapy 68
6.4.4.3 Intermittent versus continuous androgen deprivation therapy 68
6.4.4.4 Immediate versus deferred androgen deprivation therapy 68
6.4.5 Androgen deprivation combined with other agents 69
6.4.5.1 Combination with abiraterone acetate 69
6.4.5.2 ADT combined with chemotherapy 70
6.4.5.3 Treatment selection and patient selection 70
6.4.6 Deferred treatment for metastatic PCa (stage M1) 71
6.4.7 Treatment of the primary tumour in newly diagnosed metastatic disease 71
6.4.8 Metastasis-directed therapy 71
6.4.9 Guidelines for the first-line treatment of metastatic disease 71
6.5 Treatment: Castration-resistant PCa (CRPC) 72
6.5.1 Definition of Castration-resistant PCa 72
6.5.2 Non-metastatic castration-resistant PCa 72
6.5.3 Metastatic castration-resistant PCa 72
6.5.3.1 Conventional androgen deprivation in castration-resistant PCa 72
6.5.4 First-line treatment of metastatic castration-resistant PCa 73
6.5.4.1 Abiraterone 73
6.5.4.2 Enzalutamide 73
6.5.4.3 Docetaxel 74
6.5.4.4 Sipuleucel-T 74

6.5.5 Second-line treatment for mCRPC 75
6.5.5.1 Cabazitaxel 75
6.5.5.2 Abiraterone acetate after prior docetaxel 75
6.5.5.3 Enzalutamide after docetaxel 76
6.5.5.4 Radium-223 76
6.5.6 Treatment after docetaxel and one line of hormonal treatment for mCRPC 76
6.5.7 Monitoring of treatment 76
6.5.8 When to change treatment 76
6.5.9 Symptomatic management in metastatic castration-resistant PCa 77
6.5.9.1 Common complications due to bone metastases 77
6.5.10 Preventing skeletal-related events 77
6.5.10.1 Bisphosphonates 77
6.5.10.2 RANK ligand inhibitors 77
6.5.11 Summary of evidence and guidelines for life-prolonging treatments of
castrate-resistant disease 78
6.5.12 Guidelines for cytotoxic treatment of castrate-resistant disease 78
6.5.13 Guidelines for supportive care of castrate-resistant disease 78
6.6 Summary of guidelines for the treatment of prostate cancer 79
6.6.1 General guidelines recommendations for active treatment 79
6.6.2 Guidelines recommendations for the various disease stages – first line treatment 79
6.6.3 Guidelines for second-line and palliative treatments 82
7. FOLLOW-UP 83
7.1 Follow-up: After local treatment 83
7.1.1 Definition 83
7.1.2 Why follow-up? 83
7.1.3 How to follow-up? 83
7.1.3.1 Prostate-specific antigen monitoring 83
7.1.3.2 Definition of prostate-specific antigen progression 83
7.1.3.3 Prostate-specific antigen monitoring after radical prostatectomy 84
7.1.3.4 Prostate-specific antigen monitoring after radiotherapy 84
7.1.3.5 Digital rectal examination 84
7.1.3.6 Transrectal ultrasound, bone scintigraphy, computed tomography,
magnetic resonance imaging, and 11C-choline positron emission
tomography computed tomography 84
7.1.3.6.1 Transrectal ultrasonography/magnetic resonance
imaging guided biopsy. 84
7.1.4 When to follow-up? 84
7.1.5 Summary of evidence and guidelines for follow-up after treatment with
curative intent 85
7.2 Follow-up: during first line hormonal treatment (androgen sensitive period) 85
7.2.2 Purpose of follow-up 85
7.2.3 Methods of follow-up 85
7.2.3.1 Clinical follow-up 85
7.2.3.1.1 Prostate-specific antigen monitoring 85
7.2.3.1.2 Creatinine, haemoglobin and liver function monitoring 85
7.2.3.1.3 Bone scan, ultrasound and chest X-ray 86
7.2.3.1.4 Testosterone monitoring 86
7.2.3.1.5 Monitoring of metabolic complications 86
7.2.4 When to follow-up 86
7.2.4.1 Stage M0 - M1 patients 86
7.2.5 Imaging as a marker of response in metastatic prostate cancer 86
7.2.6 Guidelines for follow-up during hormonal treatment 87
8. QUALITY OF LIFE OUTCOMES IN PROSTATE CANCER 87

8.1 Introduction 87
8.2 Adverse effects of prostate cancer therapies 87
8.2.1 Surgery 87
8.2.2 Radiotherapy 88

8.2.2.1 Side-effects of external beam radiotherapy 88
8.2.2.2 Side-effects from brachytherapy 88
8.2.3 Local primary whole-gland treatments other than surgery or radiotherapy 89
8.2.3.1 Cryosurgery 89
8.2.3.2 High-intensity focused ultrasound 89
8.2.4.1 Sexual function 89
8.2.4.2 Hot flushes 89
8.2.4.3 Non-metastatic bone fractures 89
8.2.4.3.1 Hormonal treatment modalities 90
8.2.4.3.2 Bisphosphonates 90
8.2.4.3.3 Denosumab 90
8.2.4.4 Metabolic effects 90
8.2.4.5 Cardiovascular morbidity 90
8.2.4.6 Fatigue 91
8.2.4.7 Neurological side-effects 91
8.3 Overall quality of life in men with prostate cancer 91
8.3.1 Long-term (≥ 12 months) quality of life outcomes in men with localised disease. 92
8.3.1.1 Men undergoing local treatments 92
8.3.1.2 Guidelines for quality of life in men undergoing local treatments 92
8.3.2 Improving quality of life in men who have been diagnosed with prostate cancer 92
8.3.2.1 Guidelines for quality of life in men undergoing systemic treatments 93
9. REFERENCES 93
10. CONFLICT OF INTEREST 145
11. CITATION INFORMATION 145

1. INTRODUCTION
1.1 Aims and scope
The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical
professionals in the evidence-based management of PCa.
It must be emphasised that clinical guidelines present the best evidence available to the experts
but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never
replace clinical expertise when making treatment decisions for individual patients, but rather help to focus
decisions - also taking personal values and preferences/individual circumstances of patients into account.
Guidelines are not mandates and do not purport to be a legal standard of care.
1.2 Panel composition

The PCa Guidelines Panel consists of an international multidisciplinary group of urologists, radiation
oncologists, medical oncologists, radiologists, a pathologist and a patient representative.
All imaging sections in the text have been developed, jointly with the European Society of Urogenital Radiology
(ESUR). Representatives of ESUR in the PCa Guidelines Panel are (in alphabetical order): Prof.Dr. O Rouvière
and Dr. I.G. Schoots.
Section 6.3: Treatment - Definitive Radiotherapy, has been developed jointly with the European
Society for Radiotherapy & Oncology (ESTRO). Representatives of ESTRO in the PCa Guidelines Panel are (in
alphabetical order): Prof.Dr. A.M. Henry, Prof.Dr. M.D. Mason and Prof.Dr. T. Wiegel.
All experts involved in the production of this document have submitted potential conflict
of interest statements which can be viewed on the EAU website Uroweb: http://uroweb.org/guideline/
prostatecancer/?type=panel.
1.2.1 Acknowledgement
The PCa Guidelines Panel are most grateful for the support and considerable expertise provided by Prof.Dr.
J-P. Droz, Emeritus Professor of Medical Oncology (Lyon, France) on the topic of ‘Evaluating health status and
life expectancy’. As a leading expert in this field and prominent member of the International Society of Geriatric
Oncology, his contribution has been invaluable.
1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android
devices. These are abridged versions which may require consultation together with the full text version. Several
scientific publications are available [1, 2] as are a number of translations of all versions of the PCa Guidelines.
All documents can be accessed on the EAU website: http://uroweb.org/guideline/prostate-cancer/.
1.4 Publication history and summary of changes

1.4.1 Publication history
The EAU PCa Guidelines were first published in 2001. This 2018 document presents a full update of the 2017
full text document.
1.4.2 Summary of changes

New and relevant evidence has been identified, collated and appraised through a structured assessment of the
literature and incorporated in all chapters of the 2018 EAU PCa Guidelines.
Key changes for the 2018 print:

The literature for the complete document has been assessed and updated, where relevant. The treatment
sections have been completely restructured and evidence summaries and recommendations have been
amended throughout the current document.
Several new sections have been added:

• Section 5.3.3.2 - Fluoride PET and PET/CT, choline PET/CT and MRI
• Section 5.3.3.3 - Prostate-specific membrane antigen-based PET/CT
• Section 5.3.3.4 - Summary of evidence and practical consideration regarding initial N/M staging

Specific sections of the text have been updated based on systematic review (SR) questions prioritised by
the Guidelines Panel. These reviews were performed using standard Cochrane SR methodology; http://www.
cochranelibrary.com/about/about-cochrane-systematic-reviews.html:
• Section 5.2.4.2 - Multiparametric magnetic resonance imaging (mpMRI) and Section 6.2.1.1.3 – Imaging
for treatment selection [3].
• Section - 6.1.2.1.1 Pelvic lymph node dissection and Section 6.1.2.3.1 - Early complications of extended
lymph node dissection [4].
2. METHODS
2.1 Data identification
For the 2018 PCa Guidelines, new and relevant evidence has been identified, collated and appraised through a
structured assessment of the literature.
A broad and comprehensive literature search, covering all sections of the PCa Guidelines was
performed. The search was limited to studies representing only high levels of evidence (i.e. SRs with meta-
analysis, randomised controlled trials (RCTs), and prospective comparative studies) published in the English
language. Databases searched included Medline, EMBASE and the Cochrane Libraries, covering a time
frame between June 23rd 2016 and May 10th 2017. After deduplication, a total of 1,753 unique records
were identified, retrieved and screened for relevance. A total of 97 new papers were added to the 2018 PCa
Guidelines.
A detailed search strategy is available online:
http://uroweb.org/guideline/prostatecancer/?type=appendices-publications.
For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE
methodology across all 20 guidelines [5, 6]. For each recommendation within the guidelines there is an
accompanying online strength rating form which addresses a number of key elements namely:
1. the overall quality of the evidence which exists for the recommendation, references used in
this text are graded according to a classification system modified from the Oxford Centre for
Evidence-Based Medicine Levels of Evidence [7];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study
related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.
These key elements are the basis which panels use to define the strength rating of each recommendation.
The strength of each recommendation is represented by the words ‘strong’ or ‘weak’ [8]. The strength of each
recommendation is determined by the balance between desirable and undesirable consequences of alternative
management strategies, the quality of the evidence (including certainty of estimates), and nature and variability
of patient values and preferences. The strength rating forms will be available online.
Additional information can be found in the general Methodology section of this print, and online at
the EAU website; http://www.uroweb.org/guideline/.
A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.
In addition, the International Society of Geriatric Oncology (SIOG), the European Society for Radiotherapy
& Oncology (ESTRO) and the European Society for Urogenital Radiology (ESUR) have endorsed the PCa
Guidelines.
2.2 Review
Publications ensuing from SRs have all been peer-reviewed.

2.3 Future goals
The results of ongoing and new SRs will be included in the 2019 update of the PCa Guidelines.
Ongoing SRs:
• How does biochemical recurrence following curative treatment for prostate cancer impact on overall
survival, cancer-specific survival and development of metastatic disease? [9].
• What evidence-based supportive interventions improve disease-specific quality of life in men with
prostate cancer?
• A SR of oncological effectiveness and harms of primary local interventions for high-risk localised and
locally advanced prostate cancer [10].
• Systematic review of deferred treatment with curative intent for localised prostate cancer to explore
heterogeneity of definitions, thresholds and criteria and clinical effectiveness [11].
• The findings of the ‘SR of deferred treatment with curative intent for localised prostate cancer to explore
heterogeneity of definitions, thresholds and criteria and clinical effectiveness’ will be integrated in a formal
consensus-finding project, the findings of which will be published in the 2019 edition of the EAU - ESTRO
- ESUR - SIOG Prostate Cancer Guidelines.
3. EPIDEMIOLOGY AND AETIOLOGY

3.1 Epidemiology
Prostate cancer is the second most commonly diagnosed cancer in men, with an estimated 1.1 million
diagnoses worldwide in 2012, accounting for 15% of all cancers diagnosed [12]. The frequency of autopsy-
detected PCa is roughly the same worldwide [13]. A SR of autopsy studies reported a prevalence of PCa at age
< 30 years of 5% (95% CI: 3-8%), increasing by an odds ratio (OR) of 1.7 (1.6-1.8) per decade, to a prevalence
of 59% (48-71%) by age > 79 years [14].
The incidence of PCa diagnosis varies widely between different geographical areas, being highest
in Australia/New Zealand and Northern America (age-standardised rates [ASR] per 100,000 of 111.6 and 97.2,
respectively), and in Western and Northern Europe (ASRs 94.9 and 85, respectively), largely due to the use of
prostate-specific antigen (PSA) testing and the aging population. The incidence is low in Eastern and South-
Central Asia (ASRs 10.5 and 4.5, respectively), whilst rates in Eastern and Southern Europe, which were low,
have showed a steady increase [12, 13].
There is relatively less variation in mortality rates worldwide, although rates are generally high in
populations of African descent (Caribbean: ASR 29 and Sub-Saharan Africa: ASRs 19-24), intermediate in the
USA and very low in Asia (South-Central Asia: ASR 2.9) [12].
3.2 Aetiology
3.2.1 Family history/genetics
Family history and racial/ethnic background are associated with an increased PCa incidence suggesting
a genetic predisposition [15, 16]. However, only a small subpopulation of men with PCa (~9%) have true
hereditary disease. This is defined as three or more affected relatives, or at least two relatives who have
developed early-onset PCa (< 55 years) [16]. It is associated with disease onset six-seven years earlier than
average, but the disease aggressiveness and clinical course does not seem to differ in other ways [16, 17]. Men
of African descent show a higher incidence of PCa and generally have a more aggressive course of disease
[18].
Of the underlying determinants of genomic diversity and mechanisms between genetic and
environmental factors, much remains unknown. Genome-wide association studies have identified 100 common
susceptibility loci contributing to the risk for PCa, explaining ~38.9% of the familial risk for this disease [19,
20]. Furthermore, among men with metastatic PCa, an incidence of 11.8% was found for germline mutations
in genes mediating DNA-repair processes [21]. Germline mutations in genes such as BRCA1/2 and HOXB13
have been associated with an increased risk of PCa and targeted genomic analysis of these genes could
offer options to identify families at high risk [22, 23]. Prostate cancer screening trials targeting BRCA mutation
carriers are ongoing [24].
3.2.2 Risk factors

A wide variety of exogenous/environmental factors have been discussed as being associated with the risk
of developing PCa or as being aetiologically important for the progression from latent to clinical PCa [25].
Japanese men have a lower PCa risk compared to men from the Western world. However, as Japanese men
move from Japan to California, their risk of PCa increases, approaching that of American men, implying a

role of environmental or dietary factors [26]. However, currently there are no effective preventative dietary or
pharmacological interventions.
3.2.2.1 Metabolic syndrome (MetS)

The single components of MetS hypertension (p = 0.035) and waist circumference > 102 cm (p = 0.007) have
been associated with a significantly greater risk of PCa, but in contrast, having ≥ 3 components of MetS is
associated with a reduced risk (OR: 0.70, 95% CI: 0.60-0.82) [27, 28].
3.2.2.1.1 Diabetes/metformin
On a population level, metformin users (but not other oral hypoglycaemic agents) were found to be at a
decreased risk of PCa diagnosis compared with never-users (adjusted OR: 0.84; 95% CI: 0.74-0.96) [29].
In 540 diabetic participants of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study,
metformin use was not significantly associated with PCa (OR: 1.19; p = 0.50) [30].
3.2.2.1.2 Cholesterol/statins
A meta-analysis of fourteen large prospective studies did not show an association between blood total
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol levels and the risk of either
overall PCa or high-grade PCa [31]. Results of the REDUCE study also did not show a preventive effect of
statins on PCa risk [30].
3.2.2.1.3 Obesity
Within the REDUCE study, obesity was associated with lower risk of low-grade PCa in multivariable analyses
(OR: 0.79; p = 0.01), but increased risk of high-grade PCa (OR: 1.28; p = 0.042) [32]. This effect seems mainly
explained by environmental determinants of height/body mass index (BMI) rather than genetically elevated
height or BMI [33].
3.2.2.2 Dietary factors

The association between a wide variety of dietary factors and PCa have been studied (Table 3.1).
Table 3.1: Dietary factors that have been associated with PCa
Alcohol High alcohol intake, but also total abstention from alcohol has been associated with
a higher risk of PCa and PCa-specific mortality [34]. A meta-analysis shows a dose-
response relationship with PCa [35].
Dairy A weak correlation between high intake of protein from dairy products and the risk of
PCa was found [36].
Fat No association between intake of long-chain omega-3 poly-unsaturated fatty acids
and PCa was found [37]. A relation between intake of fried foods and risk of PCa may
exist [38].
Lycopenes A trend towards a favourable effect of lycopene on PCa incidence has been identified
(carotenes) in meta-analyses [39]. Randomised controlled trials comparing lycopene with placebo
did not identify a significant decrease in the incidence of PCa [40].
Meat A meta-analysis did not show an association between red meat or processed meat
consumption and PCa [41].
Phytoestrogens Phytoestrogen intake was significantly associated with a reduced risk of PCa in a
meta-analysis [42].
Vitamin D A U-shaped association has been observed, with both low- and high vitamin-D
concentrations being associated with an increased risk of PCa, and more strongly for
high-grade disease [43, 44].
Vitamin E/Selenium An inverse association of blood, but mainly nail selenium levels (reflecting long-term
exposure) with aggressive PCa have been found [45, 46]. Selenium and Vitamin E
supplementation were, however, found not to affect PCa incidence [47].
3.2.2.3 Hormonally active medication

3.2.2.3.1 5-alpha-reductase inhibitors (5-ARIs)
Although it seems that 5-ARIs have the potential of preventing or delaying the development of PCa (~25%, for
Gleason 6 cancer only), this must be weighed against treatment-related side-effects as well as the potential

small increased risk of high-grade PCa [48-50]. None of the available 5-ARIs have been approved by the
European Medicines Agency (EMA) for chemoprevention.
3.2.2.3.2 Testosterone
Hypogonadal men receiving testosterone supplements do not have an increased risk of PCa [51].
3.2.2.4 Other potential risk factors

Balding was associated with a higher risk of PCa death [52]. Gonorrhoea was significantly associated with
an increased incidence of PCa (OR: 1.31; 95% CI: 1.14-1.52) [53]. Occupational exposure may also play
a role, based on a meta-analysis which revealed that night-shift work is associated with an increased risk
(2.8%; p = 0.030) of PCa [54]. Current cigarette smoking was associated with an increased risk of PCa death
(relative risk [RR] 1.24; 95% CI: 1.18-1.31) [55]. A meta-analysis on Cadmium (Cd) found a positive association
(magnitude of risk unknown due to heterogeneity) between high Cd exposure and risk of PCa for occupational
exposure, but not for non-occupational exposure, potentially due to higher Cd levels during occupational
exposure [56].
A number of other factors previously linked to an increased risk of PCa have been disproved
including vasectomy [57] and self-reported acne [58]. There are conflicting data about the use of aspirin or non-
steroidal anti-inflammatory drugs and the risk of PCa [59, 60].
Ultraviolet radiation exposure decreased the risk of PCa (hazard ratio [HR]: 0.91; 95% CI: 0.88-0.95)
[61]. A protective effect for PCa of circumcision was found [62]. Higher ejaculation frequency (≥ 21 times a
month vs. four to seven times) has been associated with a 20% lower risk of PCa [63].
3.2.3 Summary of evidence and guidelines for epidemiology and aetiology
Summary of evidence
Prostate cancer is a major health concern in men, with incidence mainly dependent on age.
Genetic factors are associated with risk of (aggressive) PCa but ongoing trials will need to define the clinical
applicability of screening for genetic susceptibility to PCa.
A variety of exogenous/environmental factors may have an impact on PCa incidence and the risk of
progression.
5-alpha-reductase inhibitors are not EMA-approved for PCa prevention.
Selenium or vitamin-E supplements have no beneficial effect in preventing PCa.
In hypogonadal men, testosterone supplements do not increase the risk of PCa.
Recommendation Strength rating

No specific preventive or dietary measures are recommended to reduce the risk of Strong
developing prostate cancer.
4. CLASSIFICATION AND STAGING SYSTEMS

4.1 Classification
The objective of a tumour classification system is to combine patients with a similar clinical outcome. This
allows for the design of clinical trials on relatively homogeneous patient populations, the comparison of
clinical and pathological data obtained from different hospitals across the world, and the formulation of
recommendations for the treatment of these patient populations. Throughout these Guidelines the 2017
Tumour, Node, Metastasis (TNM) classification for staging of PCa (Table 4.1) [64] and the EAU risk group
classification, which is essentially based on D’Amico’s classification system for PCa, are used (Table 4.3) [65].
The latter classification is based on the grouping of patients with a similar risk of biochemical recurrence (BCR)
after radical prostatectomy (RP) or external beam radiotherapy (EBRT).

Table 4.1: Clinical Tumour Node Metastasis (TNM) classification of PCa [64]
T - Primary Tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Clinically inapparent tumour that is not palpable
T1a Tumour incidental histological finding in 5% or less of tissue resected
T1b Tumour incidental histological finding in more than 5% of tissue resected
T1c T
umour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA])
T2 Tumour that is palpable and confined within the prostate
T2a Tumour involves one half of one lobe or less
T2b Tumour involves more than half of one lobe, but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the prostatic capsule*
T3a E
xtracapsular extension (unilateral or bilateral) including microscopic bladder neck
involvement
T3b Tumour invades seminal vesicle(s)
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter,
rectum, levator muscles, and/or pelvic wall
N - Regional Lymph Nodes1
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M - Distant Metastasis2
M0 No distant metastasis
M1 Distant metastasis
M1a Non-regional lymph node(s)
M1b Bone(s)
M1c Other site(s)
*Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified as T3, but as T2.
1Metastasis no larger than 0.2 cm can be designated pNmi.
2When more than one site of metastasis is present, the most advanced category is used. (p)M1c is the most
advanced category.
Pathological staging (pTNM) is based on histopathological tissue assessment and largely parallels the clinical
TNM, except for clinical stage T1c and the T2 substages. All histopathologically confirmed organ-confined
PCas after RP are pathological stage T2 and the current Union for International Cancer Control (UICC) no
longer recognises pT2 substages [64].
4.2 Gleason score and International Society of Urological Pathology 2014 grade
The 2005 International Society of Urological Pathology (ISUP) modified Gleason score (GS) of biopsy-detected
PCa comprises the Gleason grade of the most extensive (primary) pattern, plus the second most common
(secondary) pattern, if two are present. If one pattern is present, it needs to be doubled to yield the GS. For
three grades, the GS comprises the most common grade plus the highest grade, irrespective of its extent.
When a carcinoma is largely grade 4/5, identification of < 5% of Gleason grade 2 or 3 glands should not be
incorporated in the GS. A GS ≤ 4 should not be given based on prostate biopsies [66]. In addition to reporting
of the carcinoma features for each biopsy, an overall (or global) GS based on the carcinoma-positive biopsies
can be provided. The global GS takes into account the extent of each grade from all prostate biopsies. The
2014 ISUP Gleason Grading Conference of Prostatic Carcinoma [67, 68] limits the number of PCa grades,
ranging them from 1 to 5 (see Table 4.2), in order to:
1. align the PCa grading with the grading of other carcinomas;
2. eliminate the anomaly that the most highly differentiated PCas have a GS 6;
3. to further define the clinically highly significant distinction between GS 7(3+4) and 7(4+3) PCa.

Table 4.2: International Society of Urological Pathology 2014 grades
Gleason score ISUP grade

2-6 1
7 (3+4) 2
7 (4+3) 3
8 (4+4 or 3+5 or 5+3) 4
9-10 5
Definition
Low-risk Intermediate-risk High-risk
PSA < 10 ng/mL PSA 10-20 ng/mL PSA > 20 ng/mL any PSA
and GS < 7 (ISUP grade 1) or GS 7 (ISUP grade 2/3) or GS > 7 (ISUP grade 4/5) any GS (any ISUP grade)
and cT1-2a or cT2b or cT2c cT3-4 or cN+
Localised Locally advanced
GS = Gleason score; ISUP = International Society for Urological Pathology; PSA = prostate-specific antigen.
4.3 Prognostic relevance of stratification

A more precise stratification of the clinically heterogeneous subset of intermediate-risk group patients could
provide a better framework for their management. The adoption of the current ISUP grading system, defining
the split-up of GS 7 cancers into ISUP grade 2 (primary Gleason grade 3) and ISUP grade 3 (primary Gleason
grade 4) because of their distinct prognostic impact [68] strengthens such a separation of the intermediate-risk
group into a low-intermediate (ISUP grade 2) and high intermediate-risk (ISUP grade 3) group.
Emerging clinical data support this distinction between favourable- and unfavourable-risk patient
categories within the intermediate-risk group [69].
5. DIAGNOSTIC EVALUATION
5.1 Screening and early detection
Population or mass screening is defined as the ‘systematic examination of asymptomatic men (at risk)’ and
is usually initiated by health authorities. In contrast, early detection or opportunistic (ad-hoc) testing consists
of individual case finding, which are initiated by the man being tested (patient) and/or his physician. The
co-primary objectives of both strategies are:
• reduction in mortality due to PCa;
• a maintained quality of life (QoL) as expressed by QoL-adjusted gain in life years (QALYs).
Prostate cancer mortality trends range widely from country to country in the industrialised world [70]. Mortality
due to PCa has decreased in most Western nations but the magnitude of the reduction varies between
countries. The reduced mortality rate seen recently in the USA is considered to be partly due to a widely
adopted aggressive PCa screening policy [71].
Currently, screening for PCa is one of the most controversial topics in the urological literature [72]. Three large
prospective RCTs published data on screening in 2009 [73-75] resulting in conflicting positions and policy
papers. Some authors argue that following the current American Urological Association (AUA) guidelines
[76] or the US Preventive Services Task Force (USPSTF) recommendations for screening [77-79] may lead
to a substantial number of men with aggressive disease being missed [80, 81]. In 2017 the USPSTF issued
an updated statement suggesting that men aged 55-69 should be informed about the benefits and harms of
PSA-based screening as this might be associated with a small survival benefit. The USPSTF upgraded this
recommendation to a grade C, whilst it was previously graded as ‘D’ [79, 82]. The grade D recommendation
remains in place for men over 70 years old. This represents a major switch from discouraging PSA-based
screening (grade D) to offering screening to selected patients depending on individual circumstances but a final
statement is still pending. A comparison of systematic and opportunistic screening suggested over-diagnosis
and mortality reduction in the systematic screening group compared to a higher over-diagnosis with a marginal

survival benefit, at best, in the opportunistic screening regimen [83]. The potential impact of this topic would
necessitate the highest level of evidence produced through a systematic literature search of all published
trials or cohorts summarised in a meta-analysis. Subgroup analyses of cohorts that are part of large trials, or
mathematical projections alone, cannot provide the quality of evidence needed to appropriately address this
clinical question.
A Cochrane review published in 2013 [84], which has since been updated [85], presents the main overview
to date. The findings of the updated publication (based on a literature search until April 3, 2013) are almost
identical to the 2009 review:
• Screening is associated with an increased diagnosis of PCa (RR: 1.3; 95% CI: 1.02-1.65).
• Screening is associated with detection of more localised disease (RR: 1.79; 95% CI: 1.19-2.70) and less
advanced PCa (T3-4, N1, M1) (RR: 0.80, 95% CI: 0.73-0.87).
• From the results of five RCTs, randomising more than 341,000 men, no PCa-specific survival benefit was
observed (RR: 1.00, 95% CI: 0.86-1.17). This was the main endpoint in all trials.
• From the results of four available RCTs, no overall survival (OS) benefit was observed
(RR: 1.00, 95% CI: 0.96-1.03).
Moreover, screening was associated with minor and major harms such as over-diagnosis and over-treatment.
Surprisingly, the diagnostic tool (i.e. biopsy) was not associated with any mortality in the selected papers,
which is in contrast with other known data [49, 50].
The impact on the patient’s overall QoL is still unclear [86-88], although screening has never been
shown to be detrimental at population level. Nevertheless, all these findings have led to strong advice against
systematic population-based screening in all countries, including Europe.
Since 2013, the European Randomized Study of Screening for Prostate Cancer (ERSPC) data have been
updated with thirteen years of follow up (see Table 5.1) [89]. The key message is that with extended follow up,
the mortality reduction remains unchanged (21%, and 29% after non-compliance adjustment). However the
number needed to screen and to treat is decreasing, and is now below the number needed to screen observed
in breast cancer trials [90].
Table 5.1: Follow-up data from the ERSPC study [89]
Years of follow-up Number needed to screen Number needed to treat

9 1,410 48
11 979 35
13 781 27
An individualised risk-adapted strategy for early detection might be offered to a well-informed man with at least
ten to fifteen years of life expectancy. However, this approach may still be associated with a substantial risk
of over-diagnosis. It is therefore important to carefully identify the patient cohorts likely to benefit most from
individual early diagnosis, taking into account the potential balances and harms involved.
Men at elevated risk of having PCa are those > 50 years, or at age > 45 years with a family history
of PCa (either paternal or maternal [91]), or African-Americans [92]. In addition, men with a PSA > 1 ng/mL at
40 years and > 2 ng/mL at 60 years [93, 94] are also at increased risk of PCa metastasis or death from PCa
several decades later. The long-term survival and QoL benefits of such an approach remain to be proven
at a population level. In 2014, as for breast cancer, a genetic abnormality associated with an increased risk
has been shown prospectively i.e. BRCA2 [24, 69]. Several new biological markers such as TMPRSS2-ERG
fusion, PCA3 [95, 96] or kallikreins as incorporated in the Phi or 4Kscore tests [97, 98] have been shown to
add sensitivity and specificity on top of PSA, potentially avoiding unnecessary biopsies and lowering over-
diagnosis. At this time there is too limited data to implement these markers into routine screening programmes.
Risk calculators may be useful in helping to determine (on an individual basis) what the potential risk of cancer
may be, thereby reducing the number of unnecessary biopsies. Several tools developed from cohort studies
are available including:
• the PCPT cohort: PCPTRC 2.0 http://deb.uthscsa.edu/URORiskCalc/Pages/calcs.jsp;
• the ERSPC cohort: http://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-riskcalculators;
An updated version was presented in 2017 including prediction of low and high risk now also based on
the ISUP grading system and presence of cribriform growth in histology [99].
• a local Canadian cohort: http://sunnybrook.ca/content/?page=occ-prostatecalc (among others).

Since none of these risk calculators has clearly shown superiority, it remains a personal decision as to which
one to use [100].
Informed men requesting an early diagnosis should be given a PSA test and undergo a digital rectal
examination (DRE) [101]. The optimal intervals for PSA testing and DRE follow-up are unknown, as they varied
between several prospective trials. A risk-adapted strategy might be considered based on the initial PSA level.
This could be every two years for those initially at risk, or postponed up to eight to ten years in those not at
risk [102]. Data from the Goteborg arm of the ERSPC trial suggest that the age at which early diagnosis should
be stopped remains controversial, but an individual’s life expectancy must definitely be taken into account.
Men who have less than a fifteen-year life expectancy are unlikely to benefit, based on data from the Prostate
Cancer Intervention Versus Observation Trial (PIVOT) and the ERSPC trials. Furthermore, although there is no
simple tool to evaluate individual life expectancy, comorbidity is at least as important as age. A detailed review
can be found in Section 5.4 ‘Evaluating health status and life expectancy’ and in the SIOG Guidelines [103].
Based on the tools currently available, an individualised strategy will diagnose many insignificant lesions
(> 50% in some trials), most of which will not require any form of active treatment (see Section 6.1.1 – Deferred
treatment). It is important to realise that breaking the link between diagnosis and active treatment is the only
way to decrease over-treatment, while still maintaining the potential benefit of individual early diagnosis for men
requesting it.
5.1.1 Guidelines for screening and early detection
Recommendations LE Strength rating

Do not subject men to prostate-specific antigen (PSA) testing without counselling 3 Strong
them on the potential risks and benefits.
Offer an individualised risk-adapted strategy for early detection to a well-informed 3 Strong
man with a good performance status (PS) and a life-expectancy of at least ten to
fifteen years.
Offer early PSA testing in well-informed men at elevated risk of having PCa: 2b Strong
• men > 50 years of age;
• men > 45 years of age and a family history of PCa;
• African-Americans > 45 years of age.
Offer a risk-adapted strategy (based on initial PSA level), with follow-up intervals 3 Weak
of two years for those initially at risk:
• men with a PSA level of > 1 ng/mL at 40 years of age;
• men with a PSA level of > 2 ng/mL at 60 years of age;
Postpone follow-up to eight years in those not at risk.
Stop early diagnosis of PCa based on life expectancy and PS; men who have a 3 Strong
life-expectancy of < fifteen years are unlikely to benefit.
5.2 Clinical diagnosis

Prostate cancer is usually suspected on the basis of DRE and/or PSA levels. Definitive diagnosis depends
on histopathological verification of adenocarcinoma in prostate biopsy cores or specimens from transurethral
resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE).
5.2.1 Digital rectal examination

Most PCas are located in the peripheral zone and may be detected by DRE when the volume is ≥ 0.2 mL.
In ~18% of cases, PCa is detected by suspect DRE alone, irrespective of PSA level [104]. A suspect DRE
in patients with a PSA level ≤ 2 ng/mL has a positive predictive value of 5-30% [105]. An abnormal DRE is
associated with an increased risk of higher GS and is an indication for biopsy [106, 107].
5.2.2 Prostate-specific antigen

The use of PSA as a serum marker has revolutionised PCa diagnosis [108]. Prostate-specific antigen is organ
but not cancer-specific, therefore, it may be elevated in benign prostatic hypertrophy (BPH), prostatitis and
other non-malignant conditions. As an independent variable, PSA is a better predictor of cancer than either
DRE or transrectal ultrasound (TRUS) [109].

There are no agreed standards defined for measuring PSA [110]. It is a continuous parameter, with higher levels
indicating greater likelihood of PCa. Many men may harbour PCa despite having low serum PSA [111]. Table
5.2.1 demonstrates the occurrence of GS ≥ 7 (or ISUP grade 2) PCa at low PSA levels, precluding an optimal
PSA threshold for detecting non-palpable but clinically significant PCa. The use of nomograms may help in
predicting indolent PCa [112].
Table 5.2.1: Risk of PCa in relation to low PSA values
PSA level (ng/mL) Risk of PCa (%) Risk of Gleason > 7 PCa (%)
0.0-0.5 6.6 0.8
0.6-1.0 10.1 1.0
1.1-2.0 17.0 2.0
2.1-3.0 23.9 4.6
3.1-4.0 26.9 6.7
5.2.2.1 PSA density

Prostate-specific antigen density is the level of serum PSA divided by the TRUS-determined prostate volume.
The higher the PSA density, the more likely it is that the PCa is clinically significant (see Section 6.2.1 –
Treatment of low-risk disease).
5.2.2.2 PSA velocity and doubling time

There are two methods of measuring PSA kinetics:
• PSA velocity (PSAV): absolute annual increase in serum PSA (ng/mL/year) [113];
• PSA doubling time (PSA-DT): which measures the exponential increase in serum PSA over time [114].
Prostate specific antigen velocity and PSA-DT may have a prognostic role in treating PCa [115], but limited
diagnostic use because of background noise (total prostate volume, and BPH), different intervals between PSA
determinations, and acceleration/deceleration of PSAV and PSA-DT over time. These measurements do not
provide additional information compared with PSA alone [116-119].
5.2.2.3 Free/total PSA ratio

Free/total (f/t) PSA must be used cautiously because it may be adversely affected by several pre-analytical and
clinical factors (e.g., instability of free PSA at 4°C and room temperature, variable assay characteristics, and
concomitant BPH in large prostates) [120]. However, it continues to have value in stratifying the risk of PCa in
men with 4-10 ng/mL total PSA and negative DRE. Prostate cancer was detected by biopsy in 56% of men
with f/t PSA < 0.10, but in only 8% with f/t PSA > 0.25 ng /mL [121]. Free/total PSA is of no clinical use if total
serum PSA is > 10 ng/mL or during follow up of known PCa.
5.2.2.4 Additional serum testing

A few assays measuring a panel of kallikreins in serum or plasma are now commercially available, including the
U.S. Food and Drug Administration (FDA) approved Prostate Health Index (PHI) test, (combining free and total
PSA and the [-2]pro-PSA isoform [p2PSA]), and the four kallikrein (4K) score test (measuring free, intact and
total PSA and kallikrein-like peptidase 2 [hK2]). Both tests are intended to reduce the number of unnecessary
prostate biopsies in PSA-tested men. A few prospective multicentre studies demonstrated that both the PHI
and 4K test out-performed f/t PSA PCa detection, with an improved prediction of clinically significant PCa
in men with a PSA between 2-10 ng /mL [98, 122, 123]. In a head to head comparison both tests performed
equally [124].
5.2.2.5 PCA3 marker/SelectMDX

Prostate cancer gene 3 (PCA3) is a prostate-specific, non-coding mRNA biomarker that is detectable in urine
sediments obtained after three strokes of prostatic massage during DRE. The commercially available Progensa
urine test for PCA3 is superior to total and percent-free PSA for detection of PCa in men with elevated PSA as
it shows significant increases in the area under the receiver-operator characteristic curve for positive biopsies
[125-128].
PCA3 score increases with PCa volume, but there are conflicting data about whether it
independently predicts the GS, and its use for monitoring in active surveillance (AS) is, as yet, not confirmed
[129]. Currently, the main indication for the Progensa test is to determine whether repeat biopsy is needed after
an initially negative biopsy, but its clinical effectiveness for this purpose is uncertain [130].

The SelectMDX test is similarly based on mRNA biomarker isolation from urine. The presence of
HOXC6 and DLX1 mRNA levels is assessed to provide an estimate of the risk of both presence of PCa on
biopsy as well as presence of high-risk cancer [131]. Based of the available evidence, some biomarkers could
help in discriminating between aggressive and non-aggressive tumours with an additional value compared to
the prognostic parameters currently used by clinicians [132].
5.2.2.6 Guidelines for risk-assessment of asymptomatic men
Recommendation LE Strength rating

In order to avoid unnecessary biopsies, offer further risk-assessment to 3 Strong
asymptomatic men with a normal digital rectal examination (DRE) and a prostate-
specific antigen (PSA) level between 2-10 ng/mL prior to performing a prostate
biopsy. Use one of the following tools:
• risk-calculator;
• an additional serum or urine-based test (e.g. Prostate Health Index test [PHI],
four kallikrein [4K]score, Prostate cancer gene 3 [PCA3], HOXC6/DLX1) or;
• imaging.
5.2.3 Prostate biopsy

5.2.3.1 Baseline biopsy
The need for prostate biopsy is based on PSA level and/or suspicious DRE and/or imaging (see Section
5.2.4.2). Age, potential comorbidity, and therapeutic consequences should also be considered and discussed
beforehand [133]. Risk stratification is a potential tool for reducing unnecessary biopsies [133].
Limited PSA elevation alone should not prompt immediate biopsy. Prostate specific antigen
level should be verified after a few weeks, in the same laboratory, using the same assay under standardised
conditions (i.e., no ejaculation, manipulations, and urinary tract infections [UTIs]) [134, 135]. Empiric use of
antibiotics in an asymptomatic patient in order to lower the PSA should not be undertaken [136].
Ultrasound (US)-guided biopsy is now the standard of care. Prostate biopsy is performed by either
the transrectal or transperineal approach. Cancer detection rates, when performed without prior imaging
with magnetic resonance imaging (MRI), are comparable between the two approaches [137], however some
evidence suggests reduced infection risk with the transperineal route (see Section 5.2.3.11). Rectal disinfection
with povidone-iodine may be considered [138].
5.2.3.2 Repeat biopsy after previously negative biopsy

The indications for repeat biopsy are:
• rising and/or persistently elevated PSA (see Table 5.2.1 for risk estimates);
• suspicious DRE, 5-30% cancer risk [104, 105];
• atypical small acinar proliferation (i.e., atypical glands suspicious for cancer), 31-40% risk [139, 140];
• extensive (multiple biopsy sites, i.e., ≥ 3) high-grade prostatic intraepithelial neoplasia (HGPIN), ~30% risk
[140, 141];
• a few atypical glands immediately adjacent to high-grade prostatic intraepithelial neoplasia (i.e.,
PINATYP), ~50% risk [142];
• intraductal carcinoma as a solitary finding, > 90% risk of associated high-grade PCa [143];
• positive multiparametric MRI (mpMRI) findings (see Section 5.2.4).
Additional information may be gained by the Progensa-PCA3 and SelectMDX DRE urine tests, the serum
4Kscore and PHI tests or a tissue-based epigenetic test (ConfirmMDx). The role of PHI, Progensa PCA3, and
SelectMDX in deciding whether to take a repeat biopsy in men who had a previous negative biopsy is uncertain
and probably not cost-effective [130]. The ConfirmMDx test is based on the concept that benign prostatic
tissue in the vicinity of a PCa focus shows distinct epigenetic alterations. If the PCa is missed at biopsy,
demonstration of epigenetic changes in the benign tissue would indicate the presence of carcinoma. The
ConfirmMDX test quantifies the methylation level of promoter regions of three genes in benign prostatic tissue.
A multicentre study found a negative predictive value (NPV) of 88% when methylation was absent in all three
markers, implying that a repeat biopsy could be avoided in these men [144]. Given the limited available data,
no recommendation can be made regarding its routine application.

Table 5.2.2: Description of additional investigational tests after a negative prostate biopsy*
Name of test Test substrate Molecular FDA approved

Progensa DRE urine lncRNA PCA3 yes
SelectMDX DRE urine mRNA HOXC6, DLX1 no
PHI Serum Total, free and p2PSA yes
4Kscore Test Serum/plasma Total, free, intact PSA, hK2 no
ConfirmMDX Benign prostate biopsy Methylated APC, RASSF1 and GSTP1 no
*Isolated high-grade prostatic intraepithelial neoplasia (PIN) in one or two biopsy sites is no longer an indication
for repeat biopsy [145].
5.2.3.3 Saturation biopsy

The incidence of PCa detected by saturation repeat biopsy (> 20 cores) is 30-43% and depends on the number
of cores sampled during earlier biopsies [146]. Saturation biopsy may be performed with the transperineal
technique, which detects an additional 38% of PCa. The rate of urinary retention (10%) is a drawback [147].
5.2.3.4 Sampling sites and number of cores

On baseline biopsies, the sample sites should be bilateral from apex to base, as far posterior and lateral as
possible in the peripheral gland. Additional cores should be obtained from suspect areas by DRE/TRUS.
Sextant biopsy is no longer considered adequate. At least eight systematic biopsies are recommended in prostates
with a size of about 30 cc [148]. Ten to twelve core biopsies are recommended in larger prostates, with > twelve
cores not being significantly more conclusive [149, 150].
5.2.3.5 Diagnostic transurethral resection of the prostate

Transurethral resection of the prostate should not be used as a tool for cancer detection [151].
5.2.3.6 Seminal vesicle biopsy

Indications for seminal vesicle (staging) biopsies are poorly defined. At a PSA of > 15 ng/mL, the odds of
tumour involvement are 20-25% [152]. A seminal vesicle staging biopsy is only useful if it has a decisive impact
on treatment, such as ruling out radical tumour resection or for potential subsequent radiotherapy (RT). Its
added value compared with mpMRI is questionable.
5.2.3.7 Transition zone biopsy

Transition zone sampling during baseline biopsies has a low detection rate and should be limited to repeat
biopsies [153].
5.2.3.8 Antibiotics prior to biopsy

Oral or intravenous antibiotics are recommended. Quinolones are the drugs of choice, with ciprofloxacin being
superior to ofloxacin [154]. Increased quinolone resistance is associated with a rise in severe post-biopsy
infection [155, 156]. Regional and local antibiotic resistance patterns should be taken into account when
deciding on the choice of antibiotic.
5.2.3.9 Local anaesthesia prior to biopsy

Ultrasound-guided periprostatic block is recommended [157]. It is not important whether the depot is apical or
basal. Intrarectal instillation of local anaesthesia is inferior to periprostatic infiltration [158].
5.2.3.10 Fine-needle aspiration biopsy

Fine-needle aspiration biopsy is no longer recommended.
5.2.3.11 Complications
Biopsy complications are listed in Table 5.2.3 [159]. Severe post-procedural infections were initially reported in
< 1% of cases, but have increased as a consequence of antibiotic resistance [160]. Low-dose aspirin is no longer
an absolute contraindication [161]. A SR found favourable infections rates for transperineal compared to transrectal
biopsies with similar rates of haematuria, haematospermia and urinary retention [162] but a meta-analysis of 4,280
men randomised between transperineal vs. transrectal biopsies in thirteen studies found no significant differences
in complication rates although the transperineal approach required more (local)anaesthesia [137].

Table 5.2.3: Percentage of complications per biopsy session, irrespective of the number of cores
Complications Percentage of patients affected

Haematospermia 37.4
Haematuria > 1 day 14.5
Rectal bleeding < 2 days 2.2
Prostatitis 1.0
Fever > 38.5°C 0.8
Epididymitis 0.7
Rectal bleeding > 2 days +/− surgical intervention 0.7
Urinary retention 0.2
Other complications requiring hospitalisation 0.3
5.2.4 The role of imaging in clinical diagnosis

5.2.4.1 Transrectal ultrasound (TRUS) and ultrasound-based techniques
Grey-scale TRUS is not reliable at detecting PCa [163]. Thus, there is no evidence that US-targeted biopsies
can replace systematic biopsies. New sonographic modalities such as sonoelastography and contrast-
enhanced US are still under investigation and not ready for routine use.
5.2.4.2 Multiparametric magnetic resonance imaging (mpMRI)

Correlation with RP shows that mpMRI, associating T2-weighted imaging with at least one functional imaging
technique (DWI, DCE, H1-spectroscopy) has good sensitivity for the detection and localisation of GS ≥ 7
cancers (see Table 5.2.4) [164-168].
Table 5.2.4: P
Ca detection rates (%) by mpMRI for tumour volume and Gleason score in radical
prostatectomy specimen [166]
Gleason score Tumour volume (mL)

< 0.5 0.5-2 >2
GS 6 21-29% 43-54% 67-75%
GS 7 63% 82-88% 97%
GS >7 80% 93% 100%
As a result, mpMRI is increasingly performed before prostate biopsy. Theoretically, pre-biopsy mpMRI could
be used in two different ways. Strategy 1 uses mpMRI to improve the detection of clinically significant PCa
(csPCa). In this diagnostic pathway, magnetic resonance imaging-targeted biopsies (MRI-TBx) would be added
to systematic biopsies in case of a positive mpMRI, and systematic biopsies would be performed in all patients
with a negative mpMRI. Strategy 2 consists in using mpMRI as a triage test before biopsy. In this diagnostic
pathway, only MRI-TBx would be performed in case of a positive mpMRI. Patients with a negative mpMRI
would not undergo prostate biopsy at all.
Strategy 1: A large body of evidence suggests that MRI-TBx have a higher detection rate of csPCa
compared to systematic biopsy [169-173]. However, sub-group analysis showed that MRI-TBx significantly
improved the detection of csPCa in the repeat-biopsy setting, but not in biopsy-naïve men [169, 170].
Single-centre RCTs performed in biopsy-naïve men provided contradictory findings as to whether or not the
combination of systematic biopsies and MRI-TBx had a higher detection rate for PCa and csPCa as compared
to systematic biopsies alone [174-176]. The Prostate MRI Imaging Study (PROMIS) evaluated mpMRI and
TRUS-guided systematic biopsy against template prostate mapping (TPM) biopsy in 576 biopsy-naïve men
[177]. For detection of csPCa (GS ≥ 4+3 or cancer core length (CCL) ≥ 6 mm), mpMRI showed a significantly
higher sensitivity than TRUS (93% [95% CI: 88-96] vs. 48% [95% CI: 42-55], p < 0.0001). This result must,
however, be interpreted with care, since no MRI-TBx were performed in this study design. Since the analysis
was made at the patient level, no spatial concordance was required between the location of mpMRI lesions
and the location of the positive TPM cores. Some patients, considered as true positives for mpMRI in the
PROMIS study, may in fact have had a TPM-detected csPCa at any distance from the MR lesion, resulting in
both a MR false positive and false negative. This is likely since mpMRI showed poor specificity in the PROMIS
population (41% [95% CI: 36-46]). Thus, the results of the PROMIS study cannot be extrapolated to evaluate
the diagnostic yield of targeted biopsy in biopsy-naïve patients [178]. As a result, there is insufficient evidence
to recommend routine use of mpMRI in biopsy-naïve men. Several multicentre controlled trials are currently
ongoing and should clarify this matter in the near future.

Magnetic resonance imaging-targeted biopsies can be obtained through cognitive guidance, US/
MR fusion software or direct in-bore guidance. Current literature does not show a clear superiority of one
technique over the others [172, 179-181].
Strategy 2: Whether systematic biopsies can be omitted in patients (or prostate lobes) with negative
mpMRI depends on the NPV of mpMRI. A single-centre RCT recently randomised 212 biopsy-naïve men in two
arms. Patients in arm A underwent pre-biopsy mpMRI and TBx only when mpMRI was positive (arm A+) and
systematic biopsy when mpMRI was negative (arm A-). Patients in arm B underwent systematic biopsy without
any mpMRI. The detection rates for csPCa (GS ≥ 3+4 or CCL ≥ 5 mm) were 56.8%, 3.8%, and 18.1% in arms
A+, A- and B, respectively (p < 0.001) [182].
If the PROMIS study would not allow for the assessment of the role of mpMRI in strategy 1 (see
above), its design is perfect to evaluate the mpMRI NPV. In this study, mpMRI showed a significantly higher
NPV than systematic biopsy (89% [95% CI: 83-94] vs. 74% [95% CI: 69-78], p < 0.0001) [177]. Negative
predictive value (NPV), however, depends not only on the sensitivity of the test, but also on the disease
prevalence (40% in the PROMIS population). A SR performed under the auspices of the EAU-ESTRO-ESUR-
SIOG Prostate Cancer Guidelines Panel showed a highly variable prevalence of overall PCa (13.0-74.7%) and
csPCa (13.7-50.9%) in patients undergoing pre-biopsy mpMRI [3]. As the population of patients referred to
pre-biopsy mpMRI varies so much from one institution to another, it is necessary to risk-stratify patients before
defining the patients that could safely omit biopsy in case of a negative mpMRI. Prostate-specific antigen
density [183] or risk calculators [100] can be used to identify groups of patients with low risk of PCa in whom
mpMRI would have a high NPV. The impact of these risk-stratification tools on the NPV of pre-biopsy mpMRI
needs to be carefully evaluated, both in the biopsy-naïve and in the repeat-biopsy setting.
Despite the use of the new PIRADS v2 scoring system [184], mpMRI inter-reader reproducibility remains
moderate at best [185-188], which currently limits its broad use outside expert centres. It is of note that the
good results of the PROMIS study were obtained after intensive training of the radiologists involved. This
remains a major unresolved issue that may lead to substantial patient mismanagement if the results obtained
with mpMRI in expert hospitals cannot be reproduced in less-experienced centres. It is currently too early to
define if quantitative approaches and computer-aided diagnosis systems will improve the characterisation of
lesions seen at mpMRI in the future [189-191].
5.2.4.3 Guidelines for imaging

Perform multiparametric magnetic resonance imaging (mpMRI) before repeat biopsy 1a Strong
when clinical suspicion of PCa persists in spite of negative biopsies.
Include systematic biopsies and targeting of any mpMRI lesions seen during repeat 2a Strong
biopsy.
5.2.5 Pathology of prostate needle biopsies

5.2.5.1 Processing
Prostate core biopsies from different sites are processed separately. Before processing, the number and length
of the cores are recorded. The length of biopsy tissue significantly correlates with the PCa detection rate
[192]. To achieve optimal flattening and alignment, a maximum of three cores should be embedded per tissue
cassette, and sponges or paper used to keep the cores stretched and flat [193, 194]. To optimise detection of
small lesions, paraffin blocks should be cut at three levels [153] and intervening unstained sections kept for
immunohistochemistry.
5.2.5.2 Microscopy and reporting

Diagnosis of PCa is based on histology. The diagnostic criteria include features pathognomonic of cancer,
major and minor features favouring cancer and features against cancer. Ancillary staining and additional
(deeper) sections should be considered if a suspect lesion is identified [195-197]. Diagnostic uncertainty is
resolved by intradepartmental or external consultation [195]. Table 5.2.5 lists the recommended terminology for
reporting prostate biopsies [193].

Table 5.2.5: Recommended terminology for reporting prostate biopsies [193]
Recommended terminology LE Strength rating

Benign/negative for malignancy; if appropriate, include a description 3 Strong
Active inflammation
Granulomatous inflammation
High-grade prostatic intraepithelial neoplasia (PIN)
High-grade PIN with atypical glands, suspicious for adenocarcinoma (PINATYP)
Focus of atypical glands/lesion suspicious for adenocarcinoma/atypical small
acinar proliferation, suspicious for cancer
Adenocarcinoma
Intraductal carcinoma
Each biopsy site should be reported individually, including its location (in accordance with the sampling site)
and histopathological findings, which include the histological type and the ISUP 2014 Gleason grading system
[67]. A global GS comprising all biopsies is also reported according to the ISUP grade system (see Section 4.2).
The global ISUP grade takes into account all biopsies positive for carcinoma, by estimating the total extent
of each grade present. For instance, if three biopsy sites are entirely composed of Gleason grade 3 and one
biopsy site of Gleason grade 4 only, the global GS would be 7(3+4), i.e. ISUP grade 2 or 7(4+3), i.e. ISUP grade
3, dependent on whether the extent of Gleason grade 3 exceeds that of Gleason grade 4, whereas the worse
grade would be GS 8(4+4), i.e. ISUP grade 4. Recent publications demonstrated that global ISUP grade is
somewhat superior in predicting prostatectomy GS [198] and BCR [199].
Intraductal carcinoma, lymphovascular invasion (LVI) and extraprostatic extension (EPE) must each
be reported, if identified. More recently, expansile cribriform pattern of PCa as well as intraductal carcinoma in
biopsies were identified as independent prognosticators of metastatic disease [200] and PCa-specific survival
[201].
The proportion of carcinoma-positive cores as well as the extent of tumour involvement per biopsy core
correlate with the GS, tumour volume, surgical margins and pathologic stage in RP specimens and predict
BCR, post-prostatectomy progression and RT failure. These parameters are included in nomograms created
to predict pathologic stage and seminal vesicle invasion after RP and RT failure [202-204]. A pathology report
should therefore provide both the proportion of carcinoma-positive cores and the extent of cancer involvement
for each core. The length in mm and percentage of carcinoma in the biopsy have equal prognostic impact
[205]. An extent of > 50% of adenocarcinoma in a single core is used in some AS protocols as a cut off [206]
triggering immediate treatment vs. AS in patients with GS 6.
A prostate biopsy that does not contain glandular tissue should be reported as diagnostically
inadequate. Mandatory elements to be reported for a carcinoma-positive prostate biopsy are:
• type of carcinoma;
• primary and secondary/worst Gleason grade (per biopsy site and global);
• percentage high-grade carcinoma (global);
• extent of carcinoma (in mm or percentage) (at least per biopsy site);
• if present: EPE, seminal vesicle invasion, LVI, intraductal carcinoma/cribriform pattern, peri-neural
invasion;
• ISUP 2014 grade (global).
5.2.5.3 Tissue-based prognostic biomarker testing

The Prolaris test (Myriad Genetics) measures the expression of 31 cell-cycle associated genes in biopsy-
derived PCa tissue and may be of clinical use to determine whether a patient needs curative treatment or may
have his treatment deferred [207]. A SR on the topic concluded that cell-cycle-associated gene expression can
be helpful in predicting BCR risk after local treatment and may alter clinical decision-making but the economic
impact on healthcare systems remains to be determined [208].
Similarly, Oncotype Dx® is a RNA-based test based on twelve carcinoma-associated genes
and five reference genes which can be applied to carcinoma tissue in prostate biopsies to determine the
aggressiveness of the carcinoma. Both tests were shown in prospective studies to provide prognostic
information in men with clinically localised PCa, additional to conventional clinico-pathological parameters,
including GS and PSA level. The results of prospective multicentre studies are awaited before a
recommendation can be made regarding their routine application.

5.2.6 Histopathology of radical prostatectomy specimens
5.2.6.1 Processing of radical prostatectomy specimens
Histopathological examination of RP specimens describes the pathological stage, histopathological type,
grade and surgical margins of PCa. It is recommended that RP specimens are totally embedded, to enable
assessment of cancer location, multifocality and heterogeneity. For cost-effectiveness, partial embedding may
also be considered, particularly for prostates > 60 g. The most widely accepted method includes complete
embedding of the posterior prostate, and a single mid-anterior left and right section. Compared with total
embedding, partial embedding detected 98% of PCa with a GS ≥ 7 with accurate staging in 96% of cases
[209].
Ink the entire RP specimen upon receipt in the laboratory, to demonstrate the surgical margins. Specimens
are fixed by immersion in buffered formalin for at least 24 hours, preferably before slicing. Fixation can be
enhanced by injecting formalin, which provides more homogeneous fixation and sectioning after 24 hours
[210]. After fixation, the apex and the base (bladder neck) are removed and cut into (para)sagittal or radial
sections; the shave method is not recommended [66]. The remainder of the specimen is cut in transverse,
3-4 mm sections, perpendicular to the long axis of the urethra. The resultant tissue slices can be embedded
and processed as whole-mounts or after quadrant sectioning. Whole-mounts provide better topographic
visualisation, faster histopathological examination and better correlation with pre-operative imaging, although
they are more time-consuming and require specialist handling. For routine sectioning, the advantages of whole
mounts do not outweigh their disadvantages.
5.2.6.1.1 Guidelines for processing prostatectomy specimens

Ensure total embedding, by conventional (quadrant) or whole-mount sectioning. 3 Strong
Ink the entire surface before cutting, to evaluate the surgical margin. 3 Strong
Examine the apex and base separately, using the cone method with sagittal or 3 Strong
radial sectioning.
5.2.6.2 Radical prostatectomy specimen report

The pathology report provides essential information on the prognostic characteristics relevant for clinical
decision-making (Table 5.2.6). As a result of the complex information to be provided for each RP specimen, the
use of synoptic(-like) or checklist reporting is recommended (Table 5.2.7). Synoptic reporting results in more
transparent and complete pathology reporting [211].
Table 5.2.6: Mandatory elements provided by the pathology report
Histopathological type: > 95% of PCa represents conventional (acinar) adenocarcinoma.

Grading according to GS (or therapy-related changes) and ISUP 2014 grade group.
Tumour (sub)staging and surgical margin status: location and extent of EPE, presence of bladder neck
invasion, laterality of EPE or seminal vesicle invasion, location and extent of positive surgical margins.
Additional information may be provided on multifocality, and diameter/volume and zonal location of the
dominant tumour.

Table 5.2.7: Example checklist: reporting of prostatectomy specimens
Histopathological type
Type of carcinoma, e.g. conventional acinar, or ductal
Histological grade
Primary (predominant) Gleason grade
Secondary Gleason grade
Tertiary Gleason grade (if applicable)
Global Gleason score/ISUP 2014 grade
Approximate percentage of Gleason grade 4 or 5
Tumour quantitation (optional)
Percentage of prostate involved
Size/volume of dominant tumour nodule
Pathological staging (pTNM)
If extraprostatic extension is present:
indicate whether it is focal or extensive;
specify sites;
indicate whether there is seminal vesicle invasion.
If applicable, regional lymph nodes:
location;
number of nodes retrieved;
number of nodes involved.
Surgical margins
If carcinoma is present at the margin:
specify sites.
Other
Presence of lymphovascular/angio-invasion
Location of dominant tumour
Presence of intraductal carcinoma/cribriform architecture
5.2.6.2.1 Gleason score in prostatectomy specimens

Grading of conventional prostatic adenocarcinoma using the (ISUP 2014 modified) Gleason system [67] is
the strongest prognostic factor for clinical behaviour and treatment response. The GS is incorporated in
nomograms that predict disease-specific survival (DSS) after prostatectomy [212].
The GS is the sum of the most and second-most dominant (in terms of volume) Gleason grade. If only one
grade is present, the primary grade is doubled. If a grade comprises ≤ 5% of the cancer volume, it is not
incorporated in the GS (5% rule). The primary and secondary grades are reported in addition to the GS.
A global GS is given for multiple tumours, but a separate tumour focus with a higher GS should also be
mentioned. Tertiary Gleason grade 4 or 5, particularly if > 5% of the PCa volume, is an unfavourable prognostic
indicator for BCR. The tertiary grade and its approximate proportion of the cancer volume should also be
reported [213] in addition to the global GS as well as the ISUP 2014 grade group (see Section 4.2).
5.2.6.2.2 Definition of extraprostatic extension

Extraprostatic extension is defined as carcinoma mixed with periprostatic adipose tissue, or tissue that extends
beyond the prostate gland boundaries (e.g., neurovascular bundle, anterior prostate). Microscopic bladder
neck invasion is considered EPE. It is useful to report the location and extent of EPE because the latter is
related to recurrence risk [214].
There are no internationally accepted definitions of focal or microscopic, vs. non-focal or extensive
EPE. Some describe focal as a few glands [215] or extension as < 1 per high-power field (HPF) [216], whereas
others measure the depth of extent in millimetres [217].
At the apex of the prostate, tumour mixed with skeletal muscle does not constitute EPE. In the
bladder neck, microscopic invasion of smooth muscle fibres is not equated to bladder wall invasion, i.e., not as

pT4, because it does not carry independent prognostic significance for PCa recurrence [218, 219] and should
be recorded as EPE (pT3a). A positive margin at the bladder neck should be reported as EPE (pT3a) with
positive margin, and not as pT4.
Stage pT4 is only assigned when the tumour invades the bladder muscle wall as determined
macroscopically [220].
5.2.6.3 PCa volume

The independent prognostic value of PCa volume in RP specimens has not been established [216, 221-224].
Nevertheless, a cut-off of 0.5 mL is commonly used to distinguish insignificant from clinically relevant cancer
[221]. Improvement in prostatic radio-imaging allows more accurate pre-operative measurement of cancer
volume. It is recommended that at least the diameter/volume of the dominant tumour nodule should be
assessed, or a rough estimate of the percentage of cancer tissue provided [225].
5.2.6.4 Surgical margin status

Surgical margin is an independent risk factor for BCR. Margin status is positive if tumour cells are in contact
with the ink on the specimen surface. Margin status is negative if tumour cells are close to the inked surface
[222] or at the surface of the tissue lacking ink. In tissues that have severe crush artefacts, it may not be
possible to determine margin status [226].
Surgical margin is separate from pathological stage, and a positive margin is not evidence of EPE
[227]. There is insufficient evidence to prove a relationship between margin extent and recurrence risk [216].
However, some indication must be given of the multifocality extent of margin positivity, such as the linear extent
in mm of involvement: focal, ≤ 1 mm vs. extensive, > 1 mm [228], or number of blocks with positive margin
involvement.
5.2.7 Guidelines for the clinical diagnosis of prostate cancer

Do not use transurethral resection of the prostate as a tool for cancer detection. 2a Strong
Use the International Society of Urological Pathology (ISUP) 2014 Gleason grading 2a Strong
system for grading of PCa.
In symptomatic men, base the initial decision to perform a biopsy on prostate- 2b Strong
specific antigen testing and digital rectal examination.
Do not initially offer transition zone biopsies due to low detection rates. 2b Weak
For initial diagnosis, perform a core biopsy of ten to twelve systematic transrectal 2a Strong
or transperineal peripheral zone biopsies under ultrasound guidance.
Perform transrectal prostate needle biopsies under antibiotic protection. 1b Strong
Use a local anaesthetic by periprostatic infiltration for transrectal prostate needle 1a Strong
biopsies.
Ensure that prostate core biopsies from different sites are submitted separately for 3 Strong
processing and pathology reporting.
Adhere to the 2010 ISUP Consensus Meeting Guidelines for processing and 3 Strong
reporting of prostatectomy specimens.
5.3 Diagnosis: Clinical staging

The extent of PCa is evaluated by DRE and PSA, and may be supplemented with mpMRI, bone scanning and
computed tomography (CT) or mpMRI.
5.3.1 T-staging
5.3.1.1 Definitions
Extraprostatic extension is defined as carcinoma mixed with periprostatic adipose tissue, or tissue that extends
beyond the prostate gland (e.g., neurovascular bundle, anterior prostate, or bladder neck) and corresponds to
stage T3a. It is to be distinguished from seminal vesicle invasion (SVI) which corresponds to stage T3b (see
Section 5.2.5 for details).
5.3.1.2 DRE, PSA level and biopsy findings

The first level of assessment is local tumour stage as the distinction between organ-confined (T1/T2) and
extraprostatic (T3/T4) disease affects treatment decisions. Digital rectal examination is positively correlated

with tumour stage in < 50% of cases [229], although it often underestimates tumour extension. More extensive
T-staging is only recommended if it directly affects treatment decisions.
Serum PSA levels increase with tumour stage, although they are limited for accurate prediction of final
pathological stage [230]. In prostate needle biopsy, the percentage of cancerous tissue is a strong predictor of
positive surgical margins, SVI, and non-organ-confined disease [231]. An increase in tumour-positive biopsies
is an independent predictor of EPE, margin involvement, and lymph node (LN) invasion [232]. Serum PSA, GS,
and T-stage are more useful together than alone in predicting final pathological stage [212, 233]. Models may
help to select candidates for nerve-sparing surgery and lymphadenectomy (LND) (see Section 6.1.2.1.1).
Seminal vesicle invasion is predictive of local relapse and distant metastatic failure. Seminal vesicle
biopsies can improve pre-operative staging accuracy [234]. This is not recommended for first-line examination,
but should be reserved for patients with high risk of SVI in whom a positive biopsy would modify treatment.
Patients with T-stage > 2a and serum PSA > 10 ng/mL are candidates for seminal vesicle biopsy [235, 236].
Patients with positive biopsies from the base of the prostate are more likely to have positive SV biopsies [237].
Transperineal 3D prostate mapping biopsy is an alternative to transrectal biopsies because it
provides more accurate tumour localisation, extent and Gleason grading [238], and has acceptable morbidity
[162].
5.3.1.3 TRUS
Transrectal ultrasound is no more accurate at predicting organ-confined disease than DRE [239]. Transrectal
ultrasound derived techniques (e.g. 3D-TRUS, colour Doppler) [240, 241] cannot differentiate between T2 and
T3 tumours with sufficient accuracy to be recommended for staging.
5.3.1.4 mpMRI
T2-weighted imaging remains the most useful method for local staging on mpMRI. At 1.5 Tesla, mpMRI has
good specificity but low sensitivity for detecting T3 stages. Pooled data from a meta-analysis for EPE, SVI, and
overall stage T3 showed a sensitivity and specificity of 0.57 (95% CI: 0.49-0.64) and 0.91 (95% CI: 0.88-0.93)
and 0.58 (95% CI: 0.47-0.68) and 0.96 (95% CI: 0.95-0.97), and 0.61 (95% CI: 0.54-0.67) and 0.88 (95% CI:
0.85-0.91), respectively [242]. Multiparametric MRI cannot detect microscopic EPE. Its sensitivity increases
with the radius of extension within periprostatic fat. In one study, the EPE detection rate increased from 14
to 100% when the radius of extension increased from < 1 mm to > 3 mm [243]. In another study, mpMRI
sensitivity, specificity and accuracy for detecting pT3 stage were 40%, 95% and 76%, respectively, for focal
(i.e. microscopic) EPE, and 62%, 95% and 88% for extensive EPE [244].
The use of high field (3 Tesla) or functional imaging in addition to T2-weighted imaging improves sensitivity for
EPE or SVI detection [242], but the experience of the reader remains of paramount importance [245] and the
inter-reader agreement remains moderate with kappa values ranging from 0.41 to 0.68 [246]. Multiparametric
magnetic resonance imaging, although not perfect for local staging, may improve prediction of the pathological
stage when combined with clinical data [247, 248]. Other MRI-derived parameters such as the tumour volume
or the contact length of the tumour with the capsule [249-251], or the GS obtained through MRI-TBx [252]
could further improve the local staging.
Given its low sensitivity for focal (microscopic) EPE, mpMRI is not recommended for local staging in low-risk
patients [247, 253, 254]. However, mpMRI can still be useful for treatment planning in selected low-risk patients
(e.g. candidates for brachytherapy) [255].
5.3.2 N-staging
5.3.2.1 Computed tomography (CT) and magnetic resonance imaging
Abdominal CT and T1-T2-weighted MRI indirectly assess nodal invasion by using LN diameter and
morphology. However, the size of non-metastatic LNs varies widely and may overlap the size of LN metastases,
since microscopic invasion does not enlarge LNs. The normal range for non-metastatic LNs also varies with
different anatomical regions. Usually, LNs with a short axis > 8 mm in the pelvis and > 10 mm outside the pelvis
are considered malignant. Decreasing these thresholds improves sensitivity but decreases specificity. As a
result, the ideal size threshold remains unclear [256, 257]. Computed tomography and MRI sensitivity is less
than 40% [258, 259]. Among 4,264 patients, 654 (15.3%) of whom had positive LNs at LND, CT was positive in
only 105 patients (2.5%) [256]. In a multicentre database of 1,091 patients who underwent pelvic LN dissection,
CT sensitivity and specificity were 8.8% and 98% respectively [260]. Detection of microscopic LN invasion by
CT is < 1% in patients with a GS < 8, PSA < 20 ng/mL, or localised disease [261-263].
Diffusion-weighted MRI may detect metastases in normal-sized nodes, but a negative diffusion-
weighted MRI cannot rule out the presence of LN metastases [257, 264].

Because of their low sensitivity, CT or MRI should not be used for nodal staging in low-risk patients.
5.3.2.2 Choline PET/CT

11C- or 18F-choline positron emission tomography (PET)/CT have good specificity for LN metastases, but their
reported sensitivity falls in a wide range of 10-73% [265, 266].

In a meta-analysis of 609 patients, pooled sensitivity and specificity of choline PET/CT for pelvic
LN metastases were 62% (95% CI: 51-66%) and 92% (95% CI: 89-94%), respectively [267]. In a prospective
trial of 75 patients at intermediate risk of nodal involvement (10-35%), the sensitivity was only 8.2% in a region
based and 18.9% at a patient-based analysis, which is too low to be of clinical value [268].
In intermediate/high-risk patients, comparisons between choline PET/CT and diffusion-weighted
MRI yielded contradictory results, with PET/CT sensitivity found to be superior [269], similar [270, 271] or
inferior [268] than that of diffusion-weighted MRI.
Due of its low sensitivity, choline PET/CT does not reach clinically acceptable diagnostic accuracy
for detection of LN metastases, or to rule out a nodal dissection based on risk factors or nomograms (see
Section 6.1.2.1.1).
5.3.2.3 Prostate-specific membrane antigen-based PET/CT

68Ga- or 18F-labelled prostate-specific membrane antigen PET/CT (PSMA PET/CT) is increasingly used,
because it provides excellent contrast-to-noise ratio, thereby improving the detectability of lesions. Prostate-
specific membrane antigen is also an attractive target because of its specificity for prostate tissue, even if non-
prostatic expression of PSMA in other malignancies, sarcoidosis or Paget disease may cause incidental false-
positive findings [272, 273, 274]. Preliminary assessment showed promising sensitivity for LN involvement.
A meta-analysis of five retrospective studies performed in an initial staging and/or recurrence
setting reported combined sensitivities and specificities of 86% (95% CI: 37-98%) and 86% (95% CI: 3-100%)
at patient level, and 80% (95% CI: 66-89%) and 97% (95% CI: 92-99%) at lesion level [275]. A multicentre
prospective study has recently compared PSMA PET/CT and LN dissection in 51 high-risk patients with
negative 99mTc bone scan. At patient level, PSMA PET/CT sensitivity and specificity were 53% and 86%,
respectively. The mean maximal length of metastases within LNs detected and missed by PSMA PET/CT was
13.1 ± 7.7 mm and 3.9 ± 2.7 mm respectively [276]. Another prospective single-centre study also found that
metastatic LNs missed by PSMA PET/CT were on average < 5 mm [277]. The tracer uptake is also influenced
by the GS and the PSA level. In a series of 90 patients with primary PCa, tumours with a GS of 6, 7(3+4) and
7(4+3) showed significantly lower tracer uptake than tumours with a GS of ≥ 8. Similarly patients with PSA
levels ≥ 10 ng/mL showed significantly higher uptake than those with PSA levels < 10 ng/mL [278].

5.3.3 M-staging
5.3.3.1 Bone scan
99mTc-Bone scan has been the most widely used method for evaluating bone metastases of PCa. A recent
meta-analysis showed combined sensitivity and specificity of 79% (95% CI: 73-83%) and 82% (95% CI:
78-85%) at patient level and 59% (95% CI: 55-63%) and 75% (95% CI: 71-79%) at lesion level [279]. Bone
scan diagnostic yield is significantly influenced by the PSA level, the clinical stage and the tumour GS and
these three factors were the only independent predictors of bone scan positivity in a study of 853 patients
[280]. The mean bone scan positivity rate in 23 different series was 2.3% in patients with PSA levels < 10 ng/mL,
5.3% in patients with PSA levels between 10.1 and 19.9 ng/mL and 16.2% in patients with PSA levels of 20.0-
49.9 ng/mL. It was 6.4% in men with organ-confined cancer and 49.5% in men with locally advanced cancers.
Detection rates were 5.6% and 29.9% for GS of 7 and ≥ 8, respectively [256]. In two studies, a major Gleason
pattern of 4 was found to be a significant predictor of positive bone scan [281, 282].
Bone scanning should be performed in symptomatic patients, independent of PSA level, GS or
clinical stage [256].
5.3.3.2 Fluoride PET and PET/CT, choline PET/CT and MRI

18F-sodium fluoride (18F-NaF) PET or PET/CT shows similar specificity and superior sensitivity to bone scan
[283, 284]. However, unlike choline PET/CT, it does not detect LN metastases, and it is less cost-effective
compared to bone scan [283].
It remains unclear whether choline PET/CT is more sensitive than conventional bone scan, but it has
higher specificity, with fewer indeterminate bone lesions [265, 267, 285].
Diffusion-weighted whole-body and axial MRI are more sensitive than bone scan and targeted
conventional radiography in detecting bone metastases in high-risk PCa [286, 287]. Whole-body MRI is also
more sensitive and specific than combined bone scan, targeted radiography and abdominopelvic CT [288].
A meta-analysis found that MRI is more sensitive than choline PET/CT and bone scan for detecting bone
metastases on a per-patient basis, although choline PET/CT had the highest specificity [279].

It is of note that choline PET/CT and diffusion-weighted MRI can also detect visceral metastases.
Bone scan and 18F-NaF PET/CT only assess the presence of bone metastases.
5.3.3.3 Prostate-specific membrane antigen-based PET/CT

Only limited evidence is available on the performance of 68Ga-PSMA PET/CT in initial staging. In one
retrospective study of 37 patients, PSMA PET/CT significantly outperformed bone scan at patient-based and
region-based analysis. At region-based analysis, PSMA PET/CT sensitivity and specificity were 100% and
99.3-100% respectively, depending whether equivocal lesions were considered positive or not. Bone scan
sensitivity and specificity were 46.2-61.5% and 92.1-97.9%, respectively.
One prospective multicentre study evaluated changes in planned management before and after
PSMA PET/CT in 108 intermediate- and high-risk patients referred for primary staging. As compared to
conventional staging, additional LNs and bone/visceral metastases were detected in 25% and 6% of
patients respectively. Management changes occurred in 21% of patients. The main changes resulted in
7 patients undergoing prostatectomy and regional LN dissection rather than prostatectomy alone and 5
patients undergoing unplanned chemotherapy. Clearly, this study could not assess whether this changes in
management induced better outcome [289].
5.3.3.4 Summary of evidence and practical considerations on initial N/M staging

The field of non-invasive nodal and metastatic staging of PCa is evolving very rapidly. Evidence shows that
choline PET/CT, MRI and PSMA PET/CT provide a more sensitive detection of LN and bone metastases than
the classical work-up associating bone scan and abdominopelvic CT. It could then be tempting to conclude
that bone scan and abdominopelvic CT must be replaced by more sensitive tests in all patients undergoing
initial PCa staging. Yet, the clinical benefit of detecting metastases at an earlier time-point remains unclear
[290].
The prognosis and ideal management of patients diagnosed as metastatic by these more sensitive
tests is unknown. It is unclear whether these patients should be contraindicated to local treatments and
managed using systemic therapies, or whether they should be submitted to aggressive local and metastases-
directed therapies. It needs to be kept in mind that generally oligometastatic PCa should be considered a
systemic disease, which cannot be detected due to the insensitivity of the current diagnostic tests [291].
Well-designed controlled trials evaluating the management and outcome of patients with (and
without) metastases detected by choline PET/CT, MRI and PSMA PET/CT are needed before the decision can
be made to treat patients or not based on the results of these tests.
5.3.4 Guidelines for staging of prostate cancer
Any risk group staging LE Strength rating

Do not use computed tomography and transrectal ultrasound for local staging. 2a Strong
Low-risk localised PCa LE Strength rating

Do not use additional imaging for staging purposes. 2a Strong
Intermediate-risk PCa LE Strength rating

In predominantly Gleason pattern 4 (≥ ISUP 3), use prostate multiparametric 2b Weak
magnetic resonance imaging (mpMRI) for local staging.
In predominantly Gleason pattern 4, include at least a cross-sectional 2a Weak
abdominopelvic imaging and bone-scan for metastatic screening.
High-risk localised PCa/locally advanced PCa LE Strength rating

Use prostate mpMRI for local staging. 2b Strong
Perform metastatic screening including at least cross-sectional abdominopelvic 2a Strong
imaging and a bone-scan.

5.4 Evaluating health status and life expectancy
5.4.1 Introduction
Evaluation of health status and life expectancy is important in clinical decision-making on screening, diagnosis,
and treatment of PCa. Prostate cancer is common in older men (median age 68) and diagnoses in men > 65 will
result in a 70% increase in annual diagnosis by 2030 in Europe and the USA [292, 293].
Active treatment mostly benefits patients with intermediate- or high-risk PCa and longest expected
survival. In localised disease, over ten years life expectancy is considered mandatory for any benefit from local
treatment. Older age and worse baseline health status have been associated with a smaller benefit in PCa-
specific mortality (PCSM) and life expectancy of surgery vs. AS [294]. Although in a RCT the benefit of surgery
with respect to death from PCa was largest in men < 65 years of age (RR: 0.45), RP was associated with a
reduced risk of metastases and use of androgen deprivation therapy (ADT) among older men (RR: 0.68 and
0.60, respectively) [295]. External beam radiotherapy shows similar cancer control regardless of age, assuming
a dose of > 72 Gy when using intensity-modulated or image-guided RT [296].
Older men with a high incidence of PCa may be under-treated despite the high overall mortality
rates [297, 298]. Of all PCa-related deaths 71% occur in men aged ≥ 75 years [299], probably due to the
higher incidence of advanced disease and death from PCa despite higher death rates from competing causes
[300-302]. In the USA, only 41% of patients aged > 75 years with intermediate- and high-risk disease receive
curative treatment compared to 88% aged 65-74 [303].
5.4.2 Health status screening

The International SIOG PCa Working Group recommends that treatment for senior adults should be based
on a systematic evaluation of health status using the G8 (Geriatric 8) screening tool (Table 5.4.1) [304].
Healthy patients with a G8 score > 14 or frail patients with reversible impairment after resolution of their
geriatric problems should receive the same treatment as younger patients. Disabled patients with irreversible
impairment should receive adapted treatment. Patients who are too ill should receive only palliative treatment
(Figure 1) [304]. Patients with a G8 score ≤ 14 should undergo a full geriatric evaluation as this score
is associated with 3-year mortality, assessing comorbidity, nutritional status, and cognitive and physical
functions, to determine if the impairment is reversible [305].
5.4.2.1 Comorbidity
Comorbidity is a major predictor of non-cancer-specific death in localised PCa treated with RP and is more
important than age [306, 307]. Ten years after not receiving active treatment for PCa, most men with a high
comorbidity score had died from competing causes, irrespective of age or tumour aggressiveness [306]
Measures for comorbidity include: Cumulative Illness Score Rating-Geriatrics (CISR-G) [308, 309] (Table 5.4.2)
and Charlson Comorbidity Index (CCI) [310].
5.4.2.2 Nutritional status

Malnutrition can be estimated from body weight during the previous three months (good nutritional status < 5%
weight loss; risk of malnutrition: 5-10% weight loss; severe malnutrition: > 10% weight loss) [311].
5.4.2.3 Cognitive function

Cognitive impairment can be measured using the mini-COG (mini-cog.com), assessing the patient’s ability to
make an informed decision and is deemed increasingly important in health status assessment) [312-314].
5.4.2.4 Physical function

Measures for overall physical functioning include: Karnofsky score and ECOG scores [315]. Measures for
dependence in daily activities include: Activities of Daily Living (ADL; basic activities) and Instrumental Activities
of Daily Living (IADL; activities requiring higher cognition and judgement) [316-318].
5.4.3 Conclusion
Individual health status and comorbidity, not only age, should be leading in clinical decisions on screening,
diagnostics, and treatment for PCa. A life expectancy of 10 years is most commonly used as a threshold for
benefit of local treatment. Older men may be undertreated. Resolution of impairments in frail men allows a
similar urological approach as in fit patients.

Table 5.4.1: G8 screening tool (adapted from [305])
Items Possible responses (score)

A Has food intake declined over the past 3 months 0 = severe decrease in food intake
due to loss of appetite, digestive problems, 1 = moderate decrease in food intake
chewing, or swallowing difficulties?
2 = no decrease in food intake
B Weight loss during the last 3 months? 0 = weight loss > 3 kg
1 = does not know
2 = weight loss between 1 and 3 kg
3 = no weight loss
C Mobility? 0 = bed or chair bound
1 = able to get out of bed/chair but does not go out
2 = goes out
E Neuropsychological problems? 0 = severe dementia or depression
1 = mild dementia
2 = no psychological problems
F BMI? (weight in kg)/(height in m2) 0 = BMI < 19
1 = BMI 19 to < 21
2 = BMI 21 to < 23
3 = BMI ≥ 23
H Takes more than three prescription drugs per 0 = yes
day? 1 = no
P In comparison with other people of the same 0.0 = not as good
age, how does the patient consider his/her 0.5 = does not know
health status?
1.0 = as good
2.0 = better
Age 0: > 85
1: 80-85
2: < 80
Total score 0-17

Figure 5.4.1: Decision tree for health status screening (men > 70 years)* [304]
Screening with G8 and mini-COGTM
Score > 14 Score ≤ 14

No simplified Simplified
geriatric geriatric
evalua on is evalua on is
needed mandatory
Reversible = Nonreversible =
- Abnormal ADL: 1 or 2 - Abnormal ADL: ≥ 2
- Weight loss 5–10% - Weight loss > 10%
- Comorbidi es CISR-G - Comorbidi es CISR-G
grades 1-2 grades 3-4
CGA then
geriatric
intervenon
Disabled/severe
Fit Frail
comorbidies
*Reproduced with permission of Elsevier, from Droz J-P, et al. Eur Urol 2017:72(4); 521 [304].
Mini-COGTM = cognitive test; ADL = activities of daily living; CIRS-G = cumulative illness rating score-geriatrics;
CGA = comprehensive geriatric assessment.
Table 5.4.2: Cumulative Illness Score Rating-Geriatrics (CISR-G)

1 Cardiac (heart only)
2 Hypertension (rating is based on severity; affected systems are rated separately)
3 Vascular (blood, blood vessels and cells, marrow, spleen. lymphatics)
4 Respiratory (lungs, bronchi, trachea below the larynx)
5 ENT (eye, ear, nose, throat, larynx)
6 Upper GI (esophagus, stomach, duodenum. Biliar and parcreatic trees; do not include diabetes)
7 Lower GI (intestines, hernias)
8 Hepatic (liver only)
9 Renal (kidneys only)
10 Other GU (ureters, bladder, urethra, prostate, genitals)
11 Musculo-Skeletal-Integumentary (muscles, bone, skin)
12 Neurological (brain, spinal cord, nerves; do not include dementia)
13 Endocrine-Metabolic (includes diabetes, diffuse infections, infections, toxicity)
14 Psychiatric/Behavioral (includes dementia, depression, anxiety, agitation, psychosis)
All body systems are scores on a 0 - 4 scale.
- 0: No problem affecting that system.
- 1: Current mild problem or past significant problem.
- 2: Moderate disability or morbidity and/or requires first line therapy.
- 3: Severe problem and/or constant and significant disability and/or hard to control chronic problems.
- 4: Extremely severe problem and/or immediate treatment required and/or organ failure and/or severe
functional impairment.
Total score 0-52

5.4.4 Guidelines for evaluating health status and life expectancy
Recommendations Strength rating

Systematically screen the health status of older men (> 70 years) diagnosed with PCa. Strong
Use the Geriatric-8 and mini-COG tools for health status screening. Weak
Perform a full specialist geriatric evaluation in patients with G8 score ≤ 14. Strong
Consider standard treatment in frail patients with reversible impairments (after resolution Weak
of geriatric problems) similar to fit patients, if life expectancy is > 10 years.
Offer adapted treatment in patients with irreversible impairment.
Offer palliation in patients with poor health status.
6. TREATMENT
This chapter reviews the available treatment modalities, followed by separate sections addressing treatment for
the various disease stages.
6.1 Treatment modalities

6.1.1 Deferred treatment (active surveillance/watchful waiting)
In localised disease a life expectancy of at least 10 years is considered mandatory for any benefit from local
treatment. Comorbidity is more important than age in predicting life expectancy in men with PCa. However, for
those men with a short life expectancy, watchful waiting (WW) with symptom-guided treatment is appropriate in
order to maintain QoL.
Many men with screening-detected localised PCa will not benefit from curative treatment [319] and
45% of them are suitable for AS. Mortality from untreated screen-detected PCa in patients with GS 5-7 might
be as low as 7% at fifteen years follow-up [319].
There are two distinct strategies for conservative management that aim to reduce over-treatment:
AS and WW (Table 6.1.1).
6.1.1.1 Definitions
Active surveillance aims to achieve correct timing for curative treatment in patients with clinically localised
PCa, rather than delay palliative treatment [320]. Patients remain under close surveillance, and treatment is
prompted by predefined thresholds indicative of potentially life-threatening disease, still potentially curable,
while considering individual life expectancy.
Watchful waiting refers to conservative management, until the development of local or systemic progression
with (imminent) disease-related complaints. Patients are then treated according to their symptoms, in order to
maintain QoL.
Table 6.1.1: Definitions of active surveillance and watchful waiting [319]
Active surveillance Watchful waiting

Treatment intent Curative Palliative
Follow-up Predefined schedule Patient-specific
Assessment/markers used DRE, PSA, re-biopsy, mpMRI Not predefined
Life expectancy > 10 years < 10 years
Aim Minimise treatment-related toxicity Minimise treatment-related toxicity
without compromising survival
Comments Low-risk patients Can apply to patients with all
stages
DRE = digital rectal examination; PSA = prostate-specific antigen; mpMRI = multiparametric magnetic
resonance imaging.

6.1.1.2 Active surveillance
No formal RCT is available comparing this modality to standard treatment. The ProtecT trial [321] is discussed later
as it is not a formal AS strategy, but rather Active Monitoring (AM), which would represent a ‘very light’ AS strategy.
One of the largest published cohorts with the longest follow up in a mainly low-risk population
includes 993 patients (mean age: 67.8 years) [322]. These men presented with stage T1c or T2a and PSA
≤ 10 ng/mL, age ≤ 70 years and a GS ≤ 6 or age > 70 years with a GS of ≤ 7. After a median follow-up of 6.4
years the ten- and fifteen-year OS were 80% and 62%, respectively, and DSS rates were 98.1% and 94.3%,
respectively. Twenty-seven percent of this cohort eventually underwent radical treatment, prompted by a PSA-
DT < 3 years (43.5%), a GS progression on repeat biopsies (35%) and patient preference (6%). Thirty men (3%)
developed metastases during follow up; 2% of those initially classified as Gleason 6 compared to 9.7% as
initially Gleason 7, and fifteen men died [323].
Several cohorts have investigated AS in organ-confined disease, the findings of which were summarised in a
SR including > 3,900 patients [324] (Table 6.1.2). There is considerable variation between studies regarding
patient selection, follow-up policies and when active treatment should be instigated. They have been
summarised and will be discussed in Section 6.2.1 [320].
Table 6.1.2: Active surveillance in screening-detected prostate cancer
Studies n Median FU (mo) pT3 in RP patients OS (%) CSS (%)

Van As, et al. 2008 [325] 326 22 8/18 (44%) 98 100
Carter, et al. 2007 [326] 407 41 10/49 (20%) 98 100
Adamy, et al. 2011 [327] 533-1,000 48 4/24 (17%) 90 99
Soloway, et al. 2010 [328] 99 45 0/2 100 100
Roemeling, et al. 2007 [329] 278 41 - 89 100
Khatami, et al. 2007 [330] 270 63 - n.r. 100
Klotz, et al. 2015 [322] 993 77 - 85 98.1
Total 2,130-3,000 43 90 99.7
* Patients receiving active therapy following initial active surveillance.
CSS = cancer-specific survival; FU = follow-up; mo = months; n = number of patients; n.r. = not reported;
OS = overall survival; RP = radical prostatectomy.
6.1.1.3 Watchful Waiting

6.1.1.3.1 Introduction
Studies on WW have included patients with up to 25 years of follow-up, with endpoints of OS and CSS.
Several series have shown a consistent CSS rate of 82-87% at ten years [331-336], and 80-95% for T1/T2 and
GS ≤ 7 [337]. In three studies with data beyond fifteen years, the DSS was 80%, 79% and 58% [333, 335, 336],
and two reported twenty-year CSS rates of 57% and 32%, respectively [333, 335]. Many patients classified
as GS 6 would now be classified as Gleason 7 based on the revised Gleason classification, suggesting that
the above-mentioned results should be considered as minimal. Patients with well-, moderately- and poorly-
differentiated tumours had ten-year CSS rates of 91%, 90% and 74%, respectively, correlating with data from
the pooled analysis [337]. Observation was most effective in men aged 65-75 years with low-risk PCa [338].
In an analysis at ten years follow up in 19,639 patients aged > 65 years who were not given curative treatment,
most men with a CCI score ≥ 2 died from competing causes at ten years whatever their initial age. Tumour
aggressiveness had little impact on OS suggesting that patients could have been spared biopsy and diagnosis
of cancer. Men with a CCI score ≤ 1 had a low risk of death at ten years, especially for well- or moderately-
differentiated lesions [306]. This highlights the importance of checking the CCI before considering a biopsy.
6.1.1.3.2 Outcome of watchful waiting compared with active treatment

The SPCG-4 study randomised patients to either WW or RP (Table 6.1.3) [295] before the PSA era and found
RP to provide superior CSS, OS and progression-free survival (PFS) compared to WW at a median follow-up
of 13.4 years (range 3 weeks - 23.2 years). The PIVOT trial made a similar comparison in 731 randomised men
(50% with non-palpable disease) [339] and found no benefit of treatment within a median follow-up period of
12.7 years (interquartile range, 7.3 to 15.5 years). Only patients with serum PSA > 10 ng/mL or high-risk PCa
had a significant OS benefit from RP, with a RR reduction in mortality of 33% and 31%, respectively. Patients
who underwent RP also had a significant reduction in bone metastases (4.7% vs. 10.6%). Overall, no major
perturbation of HRQoL and psychological well-being was apparent in the first years [340].

Table 6.1.3: Outcome of SPCG-4 at fifteen years follow-up [295]
RP Watchful waiting Relative risk p-value

(n = 348) (%) (n = 348) (%) (95% CI)
Disease-specific mortality 14.6 20.7 0.62 0.010
Overall mortality 46.1 57.2 0.75 (0.61-0.92) 0.007
Metastatic progression 21.7 33.4 0.59 (0.45-0.79) < 0.001
Local progression 21.5 49.3 0.34 (0.26-0.45) n.r.
CI = confidence interval; n.r. = not reported; RP = radical prostatectomy.
6.1.1.4 The ProtecT study

The ProtecT trial randomised 1,643 patients, three-ways, between active treatment (RP or EBRT) and AM [321].
In this AM schedule, patients with a PSA rise of more than 50% in twelve months underwent a repeat biopsy,
but none had systematic repeat biopsies (which presents an intermediary approach, between AS and WW).
Most patients had low-risk disease with 90% PSA < 10 ng/mL, 77% Gleason 6 (20% Gleason 7), 76% T1c.
After ten years of follow up, the CSS was the same between those actively treated and those on AM (99% and
98.8% respectively), as was the OS. Only metastatic progression differed (6% in the AM group as compared to
2.6% in the treated group).
The key finding is that AM is as effective as active treatment at ten years, at a cost of increased
progression and a double metastatic risk. Metastases remained quite rare (6%), but more frequent compared to
results from AS protocols based on patient selection. It is important to note that the AM arm in the study differs
from contemporary AS protocols in terms of a monitoring strategy based almost entirely on PSA measurements
alone; there was no use of mpMRI scan either at recruitment nor during the monitoring period, nor was there
any protocol-mandated repeat prostate biopsies at regular intervals.
Nevertheless, in spite of these caveats, the ProtecT study has reinforced the role of deferred active
treatment (i.e. either AS or some form of initial AM) as a feasible alternative to active curative interventions for
patients with low-grade and low-stage disease. Beyond ten years, no data is available yet and AS is possibly
safer, especially in younger men, based on initial patient selection. Individual life expectancy must be evaluated
before considering any active treatment in low-risk situations, and for those with up to ten years individual life
expectancy, AM or WW are probably very good options.
6.1.2 Radical prostatectomy

The goal of RP by any approach must be eradication of disease, while, whenever possible, preserving
continence and potency [341]. Increasing comorbidity greatly increases the risk of dying from non-PCa-related
causes [326]. An estimation of life expectancy is paramount in counselling a patient about surgery [331] (see
also Section 5.4 – Evaluating health status and life expectancy). The main results from multicentre RCTs
involving RP are summarised in Table 6.1.4.
Table 6.1.4: Oncological results of radical prostatectomy in organ-confined disease in RCTs
Study Acronym Population Year of Median Risk category CSS (%)

treatment FU (mo)
Bill-Axelson, et al. SPCG-4 Pre-PSA era 1989-1999 160 Low risk 89.8
2014 [295] Intermediate risk 84.9
(at 18 yr)
Wilt, et al. 2017 [339] PIVOT Early years of 1994-2002 152 Low risk 95.9
PSA testing Intermediate risk 91.5
(at 19.5 yr)
Hamdy, et al. 2016 ProtecT Screened 1999-2009 120 Mainly low- and 99
[321] population intermediate risk (at 10 yr)
CSS = cancer-specific survival; FU = follow-up; mo = months; PSA = prostate-specific antigen; yr = year.
6.1.2.1 Surgical techniques

Prostatectomy can be performed by open, laparoscopic or robot-assisted (RARP) approaches. In a randomised
phase III trial, RARP was shown to have reduced admission times and blood loss but not early (twelve weeks)
functional or oncological outcomes [342]. Increased surgical experience has lowered the complication rates
of RP and improved cancer cure [335-338]. Lower rates of positive surgical margins for high-volume surgeons
suggest that experience and careful attention to surgical details, can improve cancer control with RP [343-345].

There is a lack of studies comparing the different surgical modalities for these longer-term outcomes [295, 306,
333, 334, 339, 340, 346]. A first SR and meta-analysis of non-RCTs demonstrated that RARP had lower peri-
operative morbidity and a reduced risk of positive surgical margins compared with laparoscopic prostatectomy
(LRP), although there was considerable methodological uncertainty [333]. There was no evidence of differences
in urinary incontinence at twelve months and there was insufficient evidence to draw conclusions on
differences in cancer-related, patient-driven or erectile dysfunction (ED) outcomes. Another SR and meta-
analysis [347] included two small RCTs comparing RARP vs. LRP. The results suggested higher rates of return
of erectile function (RR 1.51; 95% CI: 1.19-1.92) and return to continence function (RR 1.14; 95% CI: 1.04-1.24)
in the RARP group. Consequently, there is emerging data to suggest some benefits of the robotic approach
over the laparoscopic and open approaches, in terms of peri-operative, recovery and short term functional
outcomes; however, uncertainty remains over oncological outcomes, longer term functional and QoL outcomes
[348]. Therefore, no surgical approach can be recommended over another.
6.1.2.1.1 Pelvic lymph node dissection

A recent SR demonstrated that performing pelvic lymph node dissection (PLND) during RP failed to improve
oncological outcomes, including survival [4]. However, it is generally accepted that extended pelvic LN
dissection (eLND) provides important information for staging and prognosis which cannot be matched by
any other currently available procedure [4]. The individual risk of finding positive LNs can be estimated using
preoperative tools. Only a few of these tools are based on eLND templates. A risk of nodal metastases over
5% (Briganti nomogram [349, 350] or Roach formula [351] which has been shown to be almost as good as the
nomogram) is an indication to perform nodal sampling by an extended nodal dissection [352-354].
Extended LND includes removal of the nodes overlying the external iliac artery and vein, the nodes
within the obturator fossa located cranially and caudally to the obturator nerve, and the nodes medial and
lateral to the internal iliac artery. With this template, 94% of patients are correctly staged [355].
6.1.2.1.2 Sentinel node biopsy analysis

The rationale for a sentinel node biopsy (SNB) is based on the concept that a sentinel node is the first to be
involved by migrating tumour cells. Therefore, when this node is negative, it is possible to avoid an ePLND. A
multi-disciplinary collaborative endeavour attempted to standardise definitions, thresholds and strategies in
relation to techniques of SNB [356]. Indeed SNB has been shown to have a sensitivity of 95.2% for detecting
men with metastases at eLND in a SR [357]. However, there is still insufficient quality evidence supporting
oncological effectiveness of SNB for nodal staging. Sentinel node biopsy is therefore still considered as an
experimental nodal staging procedure.
6.1.2.1.3 Nerve-sparing surgery

Nerve-sparing RP can be performed safely in most men with localised PCa [358, 359]. Clear contraindications
are patients in whom there is a high risk of extracapsular disease, such as any cT2c or cT3 PCa, any GS > 7
on biopsy. An externally validated nomogram predicting side-specific extracapsular extension can help guide
decision making [360, 361]. If any doubt remains regarding residual tumour, the surgeon should remove the
neurovascular bundle (NVB). Alternatively, the use of intra-operative frozen-section analysis can help guide
these decisions [362].
6.1.2.1.4 Neoadjuvant ADT

Several RCTs have analysed the impact of neoadjuvant ADT before RP, most of them using a 3 month period.
The main findings were summarised in a Cochrane review [363]. It is associated with a decreased rate of pT3
(downstaging); decreased positive margins, and a lower incidence of positive LNs. These benefits are greater
with increased treatment duration (up to 8 months). However, since neither the PSA relapse-free survival nor
the specific survival were shown to improve, neoadjuvant ADT should not be considered in clinical practice.
6.1.2.2 Comparing effectiveness of radical prostatectomy vs. other interventions for localised disease
6.1.2.2.1 Radical prostatectomy vs. deferred treatment
Currently, three large prospective RCTs have compared RP over deferred treatment (see Section 6.1.2). In
summary, there was conflicting evidence regarding the benefit of RP over deferred treatment. The only study to
find a benefit of RP over WW (SPCG-4) [295] was conducted in the pre-PSA era. When comparing RP against
WW [339], or against AM [321] no statistically significant benefit in OS at 10 years’ of follow-up was observed.
These findings highlight the importance of risk classification before discussing any form of surgery.

6.1.2.2.2 Radical prostatectomy vs. radiotherapy
ProtecT compared RP vs. AM vs. EBRT (combined with 6 months of ADT) [321]. At a median follow-up of ten
years, there were no differences between surgery vs. EBRT in all oncological outcomes.
6.1.2.3 Acute complications of surgery

Post-operative incontinence and ED are common problems following surgery for PCa. A key consideration
is whether these problems are reduced by using newer techniques such as robotic-assisted laparoscopic
prostatectomy (RALP). Recent SRs have documented complication rates after RALP [364-368], and can be
compared with contemporaneous reports after radical retropubic prostatectomy (RRP) [369]. From these
reports, the mean continence rates at twelve months were 89-100% for patients treated with RALP and
80-97% for patients treated with RRP. There is, as yet, no evidence from retrospective studies on differences
in urinary incontinence at twelve months and there was insufficient evidence to draw conclusions on
differences in cancer-related, patient-driven or ED outcomes. The major limitations of the included studies
were the retrospective study design and the use of different assessment tools preventing comparison
between techniques and series. Recently, a prospective, controlled, non-RCT of patients undergoing RP in
fourteen centres using RALP or RRP was published. At twelve months after RALP, 21.3% were incontinent,
as were 20.2% after RRP. The adjusted OR was 1.08 (95% CI: 0.87-1.34). Erectile dysfunction was observed
in 70.4% after RALP and 74.7% after RRP. The adjusted OR was 0.81 (95% CI: 0.66-0.98) [370]. A recent
RCT comparing RALP and RRP, has reported outcomes at twelve weeks in 326 patients [342]. Functional
outcomes were similar in the two groups, but longer follow up is needed to report on longer term effects. The
intra-and peri-operative complications of retropubic RP and RALP are listed in Table 6.1.5. The early use of
phosphodiesterase-5 (PDE5) inhibitors in penile rehabilitation remains controversial resulting in a lack of clear
recommendations (see Section 8.3.2).
Table 6.1.5: Intra-and peri-operative complications of retropubic RP and RALP (Adapted from [364])
Predicted probability of event RALP (%) Laparoscopic RP (%) RRP (%)

Bladder neck contracture 1.0 2.1 4.9
Anastomotic leak 1.0 4.4 3.3
Infection 0.8 1.1 4.8
Organ injury 0.4 2.9 0.8
Ileus 1.1 2.4 0.3
Deep-vein thrombosis 0.6 0.2 1.4
Predicted rates of event RALP (%) Laparoscopic RP (%) RRP (%)
Clavien I 2.1 4.1 4.2
Clavien II 3.9 7.2 17.5
Clavien IIIa 0.5 2.3 1.8
Clavien IIIb 0.9 3.6 2.5
Clavien IVa 0.6 0.8 2.1
Clavien V < 0.1 0.2 0.2
RALP = robot-assisted laparoscopic prostatectomy; RP = radical prostatectomy; RRP = radical retropubic
prostatectomy.
6.1.2.3.1 Early complications of extended lymph node dissection

Pelvic eLND increases morbidity in the treatment of PCa [4]. Overall complication rates of 19.8% vs. 8.2%
were noted for eLND vs. limited LND, respectively, with lymphoceles (10.3% vs. 4.6%) being the most common
adverse event. Other authors have reported more acceptable complication rates [371]. Similar rates of
lymphoceles have been observed in RALP series; however, in one subgroup analysis lymphoceles were more
common with the extraperitoneal approach (19%) vs. the transperitoneal approach (0%) [372, 373]. Briganti
et al. [374] also showed more complications after extended compared to limited LND. Twenty percent of men
suffer a complication of some sort after eLND. Thromboembolic events occur in less than 1% of cases.
6.1.3 Radiotherapy
Intensity-modulated radiotherapy (IMRT), with or without image-guided radiotherapy (IGRT), is the gold
standard for EBRT.

6.1.3.1 External Beam Radiation Therapy:
6.1.3.1.1 Technical aspects: intensity-modulated external-beam radiotherapy (IMRT) and volumetric arc
external-beam radiotherapy (VMAT)
Intensity-modulated external-beam radiotherapy and VMAT employ dynamic multileaf collimators, which
automatically and continuously adapt to the contours of the target volume seen by each beam. The advantage
of VMAT over IMRT is shorter treatment times, generally two to three minutes. Both techniques allow for a
more complex distribution of the dose to be delivered within the treatment field and provides concave isodose
curves, which are particularly useful as a means of sparing the rectum. Radiotherapy treatment planning
for IMRT and VMAT differs from that used in conventional EBRT, requiring a computer system capable of
‘inverse planning’, and the appropriate physics expertise. Treatment plans must conform to pre-specified dose
constraints to critical organs at risk of normal tissue damage, and a formal quality assurance process should be
routine.
With dose escalation using IMRT, organ movement becomes a critical issue, in terms of both tumour
control and treatment toxicity. Evolving techniques will therefore combine IMRT with some form of image-
guided radiotherapy (IGRT), in which organ movement can be visualised and corrected for in real time, although
the optimum means of achieving this is still unclear [375]. Tomotherapy is another technique for the delivery of
IMRT, using a linear accelerator mounted on a ring gantry that rotates as the patient is delivered through the
centre of the ring, analogous to spiral CT scanning.

6.1.3.1.2 Dose escalation
Several RCTs have shown that dose escalation (range 74-80 Gy) has a significant impact on 5-year biochemical
relapse [376-385]. These trials have generally included patients from several risk groups, and the use of
neoadjuvant/adjuvant hormone therapy (HT) has varied (see Table 6.1.6). The best evidence of an OS benefit
for patients with intermediate- or high-risk PCa, but not with low-risk PCa, comes from a non-randomised
but well conducted propensity matched retrospective analysis of the U.S. National Cancer Database covering
a total of 42,481 patients [386]. In everyday practice, a minimum dose of ≥ 74 Gy is recommended for EBRT
plus HT, with no different recommendations according to the patient’s risk group. If IMRT and IGRT are used
for dose escalation, rates of severe late side-effects (≥ grade III) for the rectum are 2-3% and for the GU tract
2-5% [378, 385, 387-400].
Table 6.1.6: Randomised trials of dose escalation in localised PCa
Trial n PCa condition Radiotherapy Follow-up Outcome Results

Dose (median)
MD Anderson 301 T1-T3, N0, M0, 70 vs.78 Gy 9 yr DSM vs. High risk/PSA > 10
study 2011 [376] PSA 10 ng/mL other cause 16% DSM at 70 Gy
vs. PSA > 10 ng/ of death 4% DSM at 78 Gy
mL (p = 0.05)
Higher risk
15% DSM at 70 Gy
2% DSM at 78 Gy
(p = 0.03)
PROG 95-09 393 T1b-T2b 70.2 vs.79.2 Gy 8.9 yr 10-year All patients:
[377] PSA 15 ng/mL including ASTRO BCF 32% BF at 70.2 Gy
75% GS < 6 proton boost 17% BF at 79.2 Gy
19.8 vs. 28.8 Gy (p < 0.0001)
Low-risk patients:
28% BF at 70.2 Gy
7% BF at 79.2 Gy
(p < 0.0001)
MRC RT01 843 T1b-T3a, N0, M0 64 vs. 74 Gy 10 yr BFS; OS 43% BFS at 64 Gy
[401] PSA < 50 ng/mL 55% BFS at 74 Gy
neoadjuvant HT (p = 0.0003) 71%
OS both groups
(p = 0.96)

Dutch 664 T1b-T4 143 pts. 68 vs. 78 Gy 110 mo. Freedom 43% FFF at 68 Gy
randomised with (neo) biochemical 49% FFF at 78 Gy
phase III trial adjuvant HT (Phoenix) (p = 0.045)
[385] and/or clinical
failure at 10 yr
GETUG 06 306 T1b-T3a, N0, M0 70 vs. 80 Gy 61 mo. BCF (ASTRO) 39% BF at 70 Gy
[380] PSA < 50 ng/mL 28% BF at 80 Gy
(B)CF = biochemical failure; BFS = biochemical progression-free survival; DSM = disease specific mortality;
FFF = freedom from biochemical or clinical failure; HT = hormone therapy; mo = months; n = number of
patients; OS = overall survival; PSA = prostate-specific antigen; yr = year.
6.1.3.1.3 Hypofractionation (HFX)

Fractionated RT utilises differences in the DNA repair capacity of normal and tumour tissue, and slowly
proliferating cells are very sensitive to an increased dose per fraction [383]. A meta-analysis of 25 studies
including > 14,000 patients concludes that because PCa has a slow proliferation rate, hypofractionated RT
could be more effective than conventional fractions of 1.8-2 Gy [384]. Hypofractionation (HFX) has the added
advantage of being more convenient for the patient and cheaper for the health care system.
Several studies report on HFX applied in various techniques and, in part, also including HT [97, 402-
410]. A SR concludes that studies on moderate HFX (2.5-4 Gy/fx) delivered with conventional 3D-CRT/IMRT
have sufficient follow-up to support the safety of this therapy, but long-term efficacy data are still lacking [411].
Moderate HFX should only be done by experienced teams using high quality EBRT using IGRT and IMRT in
carefully selected patients and adhere to published phase 3 protocols (see Table 6.1.7 below).
Table 6.1.7: Major phase 3 randomised trials of moderate hypofractionation for primary treatment
Study/ n Risk, GS, or ADT RT Regimen BED, Gy Median Outcome

Author NCCN FU, mo
Lee, et al. 550 low risk None 70 Gy/28 fx 80 70 5 yr DFS 86.3%
[412] 542 73.8 Gy/41 fx 69.6 (n.s.)
5 yr DFS 85.3%
Dearnaley, et 1077/19 fx 15% low 3-6 mo. 57 Gy/19 fx 73.3 62 5 yr BCDF
al. [402, 413] 1074/20 fx 73% before and 60 Gy/20 fx 77.1 85.9% (19 fx)
CHHiP 1065/37 fx intermediate during EBRT 74 Gy/37 fx 74 90.6% (20 fx)
12% high 88.3% (37 fx)
Aluwini, et 403 30% GS < 6 None 64.6 Gy/19 fx 90.4 60 5 yr RFS 80.5%
al. [405, 414, 392 45% GS > 7, 78 Gy/39 fx 78 (n.s.)
415] 25% GS 8-10 5 yr RFS 77.1%
Catton, et al. 608 intermediate None 60 Gy/20 fx 77.1 72 5 yr BCDF
[416] risk both arms 85%
53% T1c HR: 0.96 (n.s)
46% T2a-c
598 9% GS 6 78 Gy/39 fx 78
63% GS 7a
28% GS 7b
ADT = androgen deprivation therapy; BCDF = biochemical or clinical disease failure; BED = biologically
equivalent dose, calculated to be equivalent in 2 Gy fractions using an α/β of 1.5 Gy; DFS = disease-free
survival; EBRT = external beam radiotherapy; FU = follow-up; fx = fractions; GS = Gleason score; HR = hazard
ratio; n = number of patients; NCCN = National Comprehensive Cancer Network; n.s. = not significant; y = year.
Extreme HFX has been defined as radiotherapy with > 3.4 Gy per fraction [417]. It requires IGRT and
stereotactic body radiotherapy (SBRT). Table 6.1.8 gives an overview of selected studies. Short-term
biochemical control is comparable to conventional fractionation. However, there are concerns about high-grade
GU and rectal toxicity, and long-term side-effects may not all be known yet [411, 418, 419]. Therefore it seems
prudent to restrict extreme HFX to prospective clinical trials and to inform patients on the uncertainties of the
long-term outcome.

Table 6.1.8: Selected trial on extreme hypofractionation for intact localised PCa
Reference n med FU Risk-Group Regimen (TD/fx) Outcome

(mo)
Freeman, et al. 1743 - 41% low 35-40 Gy/4-5 fx FFBF 92% at 2 yr
[420] 42% intermediate (8% SBRT-boost 99% low risk
10% high 19.5-21.8 Gy/3 fx 97-85% intermediate
7% data missing after 45-50 Gy EBRT) 87% high risk
Katz, et al. [421] 515 72 63% low 35-36.25 FFBF at 7 yr
30% intermediate Gy/5 fx 96% low risk
7% high 89% intermediate
69% high risk
EBRT = external beam radiotherapy in standard fractionation; FFBF = freedom from biochemical failure;
FU = follow-up; fx = number fractions; mo = months; n = number of patients; TD = total dose;
SBRT = stereotactic body radiotherapy; y = year.
6.1.3.1.4 Neoadjuvant or adjuvant hormone therapy plus radiotherapy

The combination of RT with luteinising-hormone-releasing hormone (LHRH) ADT has definitively proven its
superiority compared with RT alone followed by deferred ADT on relapse, as shown by phase III RCTs [422-
426] (Table 6.1.9). The main message is that for intermediate risk a short duration of around 6 months is
optimal, while a longer one, around 3 years, is needed for high-risk patients.
Table 6.1.9: Selected studies of use and duration of ADT in combination with RT for PCa
Trial TNM stage n Trial ADT RT Effect on OS

RTOG 85-31 T3 or N1 M0 977 EBRT ± ADT Orchiectomy 65-70 Gy RT Significant benefit for
[423] or LHRH combined treatment
agonist (p = 0.002) seems to
15% RP be mostly caused by
patients with
GS 7-10
RTOG 94-13 T1c-4 N0-1 M0 1292 ADT timing 2 mo. Whole No significant difference
[427] comparison neoadjuvant pelvic RT vs. between neoadjuvant
plus prostate only; plus concomitant vs.
concomitant 70.2 Gy adjuvant androgen
vs. 4 mo. suppression therapy
adjuvant groups (interaction
suppression suspected)
RTOG 86-10 T2-4 N0-1 456 EBRT ± ADT Goserelin 65-70 Gy RT No significant difference
[424] plus flutamide at 10 yr
2 mo. before,
plus
concomitant
therapy
D’Amico AV, T2 N0 M0 206 EBRT ± ADT LHRH agonist 70 Gy Significant benefit
et al (2008) (localised plus flutamide 3D-CRT (HR: 0·55, 95%
[425] unfavourable for 6 mo. CI: 0.34-0.90, p = 0.01)
risk) that may pertain only to
men with no or minimal
comorbidity
RTOG T2c-4 N0-1 M0 1554 Short vs. LHRH agonist 65-70 Gy RT p = 0.73, p = 0.36
92-02 [428] prolonged given for overall; significant
ADT 2 yr as benefit (p = 0.044)
adjuvant after 4 (p = 0.0061) in subset
mo. as with GS 8-10
neoadjuvant

EORTC T1c-2ab N1 970 Short vs. LHRH agonist 70 Gy Better result with 3 yr
22961 [382] M0, T2c-4 prolonged for 6 mo. vs. 3D-CRT treatment than with 6
N0-1 M0 ADT 3 yr mo. (3.8% improvement
in survival at 5 yr)
EORTC T1-2 poorly 415 EBRT ± ADT LHRH agonist 70 Gy RT Significant benefit at
22863 [422] differentiated For 3 yr 10 yr for combined
and M0, or (adjuvant) treatment (HR: 0.60,
T3-4 N0-1 M0 95% CI: 0.45-0.80,
p = 0.0004).
TROG 96-01 T2b-4 N0 M0 802 Neoadjuvant Goserelin 66 Gy No significant difference
[426] ADT plus 3D-CRT in OS reported; benefit
duration flutamide 3 or in PCa-specific survival
6 mo. (HR: 0.56, 95% CI: 0.32-
before, plus 0.98, p = 0.04) (10 yr:
concomitant HR: 0.84, 0.65-1.08;
suppression p = 0.18)
RTOG 99-10 intermediate 1579 Short vs. LHRH agonist 70.2 Gy 67 vs. 68% p = 0.62,
[429] risk (94% prolonged 8 + 8 vs. 2D/3D confirms 8 + 8 wk LHRH
T1-T2, 6% ADT 8 + 28 wk as a standard
T3-4)
ADT = androgen deprivation therapy; CI = confidence interval; EBRT = external beam radiotherapy in standard
fractionation; GS = Gleason score; HR = hazard ratio; LHRH = luteinizing hormone-releasing hormone; mo =
months; n = number of patients; OS = overall survival; RP = radical prostatectomy; RT = radiotherapy; wk =
week; yr = year.
The question of the added value of EBRT combined with ADT has been clarified with 3 RCT. All showed a clear
benefit of adding EBRT to long-term ADT (see Table 6.1.10).
Table 6.1.10: Selected studies of ADT in combination with- or without RT for PCa
Trial Year TNM stage n Trial ADT RT Effect on OS

SPCG-7/ 2014 T1b-2 Grade 875 ADT ± EBRT LHRH agonist 70 Gy 18.9% (30.7%)
SFUO-3 [430] 2-3, T3 N0 M0 for 3 mo. plus 3D-CRT vs. 8.3% (12.4%)
continuous vs. CSM at 10 (15) yr
flutamide no RT favouring combined
treatment (HR:
0.35; p < 0.0001 for
15-yr results) NCIC
CTG PR.3/MRC
PRO7/SWOG 2015 T3-4 (88%), 1205 ADT ± EBRT Continuous 65-70 Gy 10-yr OS = 49%
[431, 432] PSA > 20 ng/mL LHRH agonist 3D-CRT vs. 55% favouring
(64%), GS 8-10 vs. no RT combined
(36%) N0 M0 treatment
HR: 0.7, p < 0.001)
Mottet 2012 T3-4 N0 M0 273 ADT ± EBRT LHRH 70 Gy Significant
2012 [433] 264 agonist for 3D-CRT reduction of clinical
3 yr vs. no RT progression;
5-yr OS 71.4% vs.
71.5%
ADT = androgen deprivation therapy; CSM = cancer-spefic mortality; EBRT = external beam radiotherapy;
GS = Gleason score; HR = hazard ratio; LHRH = luteinizing hormone-releasing hormone; mo = months;
n = number of patients; OS = overall survival; RT = radiotherapy.

6.1.3.1.5 Combined dose-escalated radiotherapy and androgen-deprivation therapy
Zelefsky et al. [434] reported a retrospective analysis comprising 571 patients with low-risk PCa, 1,074
with intermediate-risk PCa, and 906 with high-risk PCa. 3D-conformal RT or IMRT were administered. The
prostate dose ranged from 64.8 to 86.4 Gy; doses beyond 81 Gy were delivered during the last ten years of
the study using image-guided IMRT. Complete androgen blockade was administered at the discretion of the
treating physician to 623 high-risk PCa (69%), 456 intermediate-risk PCa (42%) and 170 low-risk PCa (30%)
patients. The duration of ADT was 3 months for low-risk patients and six months for intermediate-risk and
high-risk patients, starting at three months before RT. The ten-year biochemical disease-free rate (BDFR) was
significantly improved by dose escalation: above 75.6 Gy in low risk, and above 81 Gy for the intermediate- and
high-risk groups. It was also improved by adding six months of ADT in intermediate- and high-risk patients. In
the multivariate analysis, neither the dose > 81 Gy, nor adding ADT influenced OS. Published results from a
RCT are awaited, but adding ADT does not seem to compensate for the dose increase.
6.1.3.2 Proton beam therapy

In theory, proton beams are an attractive alternative to photon-beam RT for PCa, as they deposit almost all
their radiation dose at the end of the particle’s path in tissue (the Bragg peak), in contrast to photons, which
deposit radiation along their path. There is also a very sharp fall-off for proton beams beyond their deposition
depth, meaning that critical normal tissues beyond this depth could be effectively spared. In contrast, photon
beams continue to deposit energy until they leave the body, including an exit dose.
One RCT on dose escalation (70.2 vs. 79.2 Gy) has incorporated protons for the boost doses
of either 19.8 or 28.8 Gy. This trial shows improved outcome with the higher dose, but it cannot be used
as evidence for the superiority of proton therapy per se [377]. Thus, unequivocal information that shows
an advantage of protons over IMRT photon therapy is still not available. Studies from the SEER database,
and from Harvard [435, 436], describing toxicity and patient-reported outcomes do not point to an inherent
superiority for protons. In terms of longer-term gastrointestinal (GI) toxicity, proton therapy might even be
inferior to IMRT [436].
A RCT comparing equivalent doses of proton-beam therapy with IMRT is underway. Meanwhile,
proton therapy must be regarded as a promising, but experimental, alternative to photon-beam therapy.
6.1.3.3 Brachytherapy
6.1.3.3.1 Low-dose rate (LDR) brachytherapy
Low-dose rate brachytherapy uses radioactive seeds permanently implanted into the prostate. There is a
consensus on the following eligibility criteria for LDR monotherapy [437]: Stage cT1b-T2a N0, M0; GS 6
(ISUP grade 1) with ≤ 50% of biopsy cores involved with cancer or GS 7(3+4), ISUP grade 2) with ≤ 33% of
biopsy cores involved with cancer; An initial PSA level of ≤ 10 ng/mL; a prostate volume of < 50 cm3; and an
International Prostatic Symptom Score (IPSS) ≤ 12 and maximal flow rate > 15 mL/min on urinary flow tests
[438].
The only available RCT comparing RP and brachytherapy as monotherapy was closed due to poor accrual
[439]. Outcome data are available from a number of large population cohorts with mature follow-up [440-447].
The BDFS for Gleason 6 patients after five and ten years has been reported to range from 71% to 93% and
65% to 85%, respectively [440-447]. A significant correlation has been shown between the implanted dose
and biochemical control [448]. A D90 (dose covering 90% of the prostate volume) of > 140 Gy leads to a
significantly higher biochemical control rate (PSA < 1.0 ng/mL) after four years (92 vs. 68%). There is no benefit
in adding neoadjuvant or adjuvant ADT to LDR monotherapy [440].
Low-dose rate brachytherapy can be combined with EBRT in intermediate-/high-risk patients (see Section
6.2.3.2.3)
6.1.3.3.2 High-dose rate (HDR) brachytherapy

High-dose-rate brachytherapy uses a radioactive source temporarily introduced into the prostate to deliver
radiation. The technical differences are outlined in Table 6.1.11. The use of published guidelines is strongly
recommended [449]. High-dose rate brachytherapy can be delivered in single or multiple fractions and is often
combined with EBRT of at least 45 Gy [450]. A single RCT of EBRT (55 Gy in 20 fractions) vs. EBRT (35.75
Gy in 13 fractions), followed by HDR brachytherapy (17 Gy in two fractions over 24 hours) has been reported
[451]. In 218 patients with organ-confined PCa the combination of EBRT and HDR brachytherapy showed
a significant improvement in the BDFR (p = 0.04) at five and ten year (75% and 46% compared to 61% and
39%). There were no differences in the rates of late bowel, urinary or sexual patient QoL over a ten-year follow-
up period. However, a very high, uncommon, rate of early recurrences was observed in the EBRT arm alone,

even after two years, possibly due to a dose lower than the current standard used [451]. A SR of non-RCTs has
suggested outcomes with EBRT plus HDR brachytherapy are superior to brachytherapy alone, but this needs
confirmation in a prospective, randomised trial [452].
Fractionated HDR brachytherapy as monotherapy can be offered to patients with low- and
intermediate-risk PCa, informed that results are only available from limited series in very experienced centres
[408, 453]. Five year PSA control rates over 90% are reported, with late Grade 3+ GU toxicity rates < 5% and
no or very minimal Grade 3+ GI toxicity rates [408, 453].
Table 6.1.11: Difference between LDR and HDR brachytherapy
Differences in prostate brachytherapy techniques

Low dose rate (LDR) • Permanent seeds implanted
• Uses Iodine-125 (I-125) (most common), Palladium-103 (Pd-103) or
Cesium-131 isotopes
• Radiation dose delivered over weeks and months
• Acute side-effects resolve over months
• Radiation protection issues for patient and carers
High dose rate (HDR) • Temporary implantation
• Iridium-192 (IR-192) isotope introduced through implanted needles or
catheters
• Radiation dose delivered in minutes
• Acute side-effects resolve over weeks
• No radiation protection issues for patient or carers
6.1.3.4 Side-effects of external beam radiotherapy and brachytherapy

Gastrointestinal and urinary side-effects are common during and after EBRT. In the EORTC 22991 trial,
approximately 50% of patients reported acute GU toxicity of Grade I, 20% of Grade 2, and 2% Grade 3. In the
same trial, approximately 30% of patients reported acute Grade I GI toxicity, 10% Grade 2, and less than 1%
Grade 3. Common toxicities included dysuria, urinary frequency, urinary retention, haematuria, diarrhoea, rectal
bleeding and proctitis [391]. In addition, general side-effects such as fatigue are common. It should be noted
that the incidence of acute side-effects is greater than that of late effects (see Section 8.2.2.1), implying that
most acute effects resolve. In a randomised trial of conventional dose EBRT vs. EBRT plus LDR brachytherapy,
the incidence of acute proctitis was reduced in the brachytherapy arm, but other acute toxicities were
equivalent [454]. Acute toxicity of HDR brachytherapy has not been documented in a RCT, but retrospective
reports confirm lower rates of GI toxicity compared with EBRT alone and Grade 3 GU toxicity in 10% or fewer
patients, but a higher incidence of urinary retention [455]. Similar findings are reported using HFX. For example,
in a pooled analysis of 864 patients treated using extreme HFX and stereotactic radiotherapy, declines in
urinary and bowel domains were noted at three months, which returned to baseline or better by six months
[456].
6.1.4 Hormonal therapy

6.1.4.1 Introduction
6.1.4.1.1 Different types of hormonal therapy
Androgen deprivation can be achieved by either suppressing the secretion of testicular androgens or inhibiting
the action of circulating androgens at the level of their receptor. These two methods can be combined to
achieve what is known as complete (or maximal or total) androgen blockade (CAB) [457].
6.1.4.1.1.1 Testosterone-lowering therapy (castration)

6.1.4.1.1.1.1 Castration level
Surgical castration is still considered the primary treatment modality for ADT. It leads to a considerable decline
in testosterone levels: the ‘castration level’.
The castration level is < 50 ng/dL (1.7 nmol/L), which was defined more than 40 years ago, when
testosterone testing was limited. Current methods have shown that the mean value after surgical castration
is 15 ng/dL [458]. Therefore, a more appropriate level is defined as < 20 ng/dL (1 nmol/L). This new definition
is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL
[459-461]. However, the castrate level considered by the regulatory authorities and in clinical trials addressing
castration in PCa is still < 50 ng/dL (1.7 mmol/L).

6.1.4.1.1.1.2 Bilateral orchiectomy
Bilateral orchiectomy, or subcapsular pulpectomy, is a simple, cheap and virtually complication-free surgical
procedure. It is easily performed under local anaesthesia [462] and it is the quickest way to achieve a castration
level, which is usually reached within less than twelve hours. It is irreversible and therefore does not allow for
intermittent treatment.
6.1.4.1.1.2 Oestrogens
Treatment with oestrogens results in testosterone suppression and is not associated with bone loss [463].
Early studies tested oral diethylstilboestrol (DES) at several doses. Due to severe side-effects, especially
thromboembolic complications, even at lower doses [464-466] these drugs are not considered as standard
first-line treatment.
6.1.4.1.1.3 Luteinising-hormone-releasing hormone agonists

Long-acting LHRH agonists are currently the main forms of ADT. These synthetic analogues of LHRH, are
delivered as depot injections on a 1-, 2-, 3-, 6-monthly, or yearly basis. The first injection induces a transient
rise in luteinising hormone (LH) and follicle-stimulating hormone (FSH) leading to the ‘testosterone surge’
or ‘flare-up’ phenomenon, which starts two to three days after administration and lasts for about one week.
This may lead to detrimental clinical effects (the clinical flare) such as increased bone pain, acute bladder
outlet obstruction, obstructive renal failure, spinal cord compression, and cardiovascular death due to
hypercoagulation status [467]. Patients at risk are usually those with high-volume, symptomatic, bony disease.
Concomitant therapy with an anti-androgen decreases the incidence of clinical flare, but does not completely
remove the risk.
Anti-androgen therapy is usually continued for four weeks but neither the timing nor the duration of
anti-androgen therapy are based on strong evidence. In addition, the long-term impact of preventing ‘flare-up’
is unknown [468].
Chronic exposure to LHRH agonists results in the down-regulation of LHRH-receptors, suppressing
LH and FSH secretion and therefore testosterone production. A castration level is usually obtained within two
to four weeks [469]. Although there is no formal direct comparison between the various compounds, they are
considered to be equally effective [470] and at least comparable to orchiectomy [471].
The different products have practical differences that need to be considered in everyday practice,
including the storage temperature, whether a drug is ready for immediate use or requires reconstitution, and
whether a drug is given by subcutaneous or intramuscular injection.
6.1.4.1.1.4 Luteinising-hormone-releasing hormone antagonists

Luteinising-hormone releasing hormone antagonists immediately bind to LHRH receptors, leading to a rapid
decrease in LH, FSH and testosterone levels without any flare. The practical shortcoming of these compounds
is the lack of a long-acting depot formulation with, so far, only monthly formulations being available.
Degarelix is a LHRH antagonist. The standard dosage is 240 mg in the first month, followed by monthly
injections of 80 mg. Most patients achieve a castrate level at day three [472]. An extended follow-up has been
published, suggesting a better PSA PFS compared to monthly leuprorelin [471]. A SR did not show major
difference between agonists and Degarelix and highlighted the paucity of on-treatment data beyond twelve
months as well as the lack of survival data [473]. Its definitive superiority over the LHRH analogues remains to
be proven.
6.1.4.1.1.5 Anti-androgens
These oral compounds are classified according to their chemical structure as:
• steroidal, e.g. cyproterone acetate (CPA), megestrol acetate and medroxyprogesterone acetate;
• non-steroidal or pure, e.g. nilutamide, flutamide and bicalutamide.
Both classes compete with androgens at the receptor level. This leads to an unchanged or slightly elevated
testosterone level. Conversely, steroidal anti-androgens have progestational properties leading to central
inhibition by crossing the blood-brain barrier.
6.1.4.1.1.5.1 Steroidal anti-androgens

These compounds are synthetic derivatives of hydroxyprogesterone. Their main pharmacological side-effects
are secondary to castration (gynaecomastia is quite rare) whilst the non-pharmacological side-effects are
cardiovascular toxicity (4-40% for CPA) and hepatotoxicity.

6.1.4.1.1.5.1.1 Cyproterone acetate
Cyproterone acetate was the first licensed anti-androgen, but the least studied. Its most effective dose
as monotherapy is still unknown. Although CPA has a relatively long half-life (31-41 hours), it is usually
administered in two or three fractionated doses of 100 mg each. In one RCT, CPA showed a poorer OS when
compared with LHRH analogues [474]. An underpowered RCT comparing CPA monotherapy with flutamide
in M1b PCa did not show any difference in disease-specific and OS at a median follow-up of 8.6 years [475].
Other CPA monotherapy studies suffer from methodological limitations preventing firm conclusions.
6.1.4.1.1.5.2 Non-steroidal anti-androgens

Non-steroidal anti-androgen monotherapy does not suppress testosterone secretion and it is claimed that
libido, overall physical performance and bone mineral density (BMD) are frequently preserved [476]. Non-
androgen-related pharmacological side-effects differ between agents. Bicalutamide shows a more favourable
safety and tolerability profile than flutamide and nilutamide [477]. All three agents share the potential for liver
toxicity (occasionally fatal), requiring regular monitoring of patients’ liver enzymes.
6.1.4.1.1.5.2.1 Nilutamide
Nilutamide monotherapy has not been compared to castration and is not licensed for monotherapy. Direct
drug-related side-effects are visual disturbances (i.e. delayed adaptation to darkness), alcohol intolerance,
nausea, and of note, severe interstitial pneumonitis (potentially life-threatening). As a consequence it is rarely
used.
6.1.4.1.1.5.2.2 Flutamide
Flutamide has been studied as monotherapy. Flutamide is a pro-drug, and the half-life of the active metabolite
is five-six hours, requiring a three times daily dose. The recommended total daily dose is 750 mg. The non-
androgen-related pharmacological side-effect of flutamide is diarrhoea.
6.1.4.1.1.5.2.3 Bicalutamide
The dosage licensed for use in CAB is 50 mg/day, and 150 mg for monotherapy. The androgen
pharmacological side-effects are mainly gynaecomastia (70%) and breast pain (68%). However, bicalutamide
monotherapy offers clear bone protection compared with LHRH analogues and probably LHRH antagonists
[476, 478].
6.1.4.1.1.6 New compounds

Once on castration, the development of castration-resistance (CRPC) is imminent. It is considered to be
mediated through two main overlapping mechanisms: androgen-receptor (AR)-independent and AR-dependent
mechanisms (see Section 6.5 - Castrate-resistant PCa). In CRPC, the intracellular androgen level is increased
compared to androgen sensitive cells, and an over-expression of the AR has been observed, suggesting an
adaptive mechanism [479]. This has led to the development of several new compounds targeting the androgen
axis: the two licenced drugs are abiraterone acetate (AA) and enzalutamide, both approved for mCRPC.
Abiraterone acetate has also been approved for hormone-sensitive PCa, combined with ADT.
6.1.4.1.1.6.1 Abiraterone acetate

Abiraterone acetate is a CYP17 inhibitor (a combination of 17α-hydrolase and 17,20-lyase inhibition). By
blocking CYP17, AA significantly decreases the intracellular testosterone level by suppressing its synthesis at
the adrenal level and inside the cancer cells (intracrine mechanism). This compound must be used together
with prednisone/prednisolone to prevent drug-induced hyperaldosteronism.
6.1.4.1.1.6.2 Enzalutamide
Enzalutamide is a novel anti-androgen with a higher affinity for the AR receptor than bicalutamide. While non-
steroidal anti-androgens still allow transfer of ARs to the nucleus, enzalutamide also blocks AR transfer and
therefore suppresses any possible agonist-like activity.
6.1.5 Investigational therapies

6.1.5.1 Background
Besides RP, EBRT and brachytherapy, other modalities have emerged as therapeutic options in patients with
clinically localised PCa [480-483]. In this section, both whole gland and focal treatment will be considered,
looking particularly at high-intensity focused US (HIFU), cryotherapeutic ablation of the prostate (cryotherapy)
and focal photodynamic therapy, as sufficient data are available to form the basis of some initial judgements.
Other options - such as radiofrequency ablation and electroporation, among others - are considered to
be in the early phases of evaluation [484]. All these modalities have been developed as minimally invasive

procedures with the aim of providing equivalent oncological safety, reduced toxicity and improved functional
outcomes. In addition, a relatively newer development is focal ablative therapy [484, 485], whereby lesion-
targeted ablation is undertaken in a precise, organ-sparing manner.
6.1.5.2 Cryotherapy
Cryotherapy uses freezing techniques to induce cell death by dehydration resulting in protein denaturation,
direct rupture of cellular membranes by ice crystals and vascular stasis and microthrombi, resulting in
stagnation of the microcirculation with consecutive ischaemic apoptosis [480-483].
Freezing of the prostate is ensured by the placement of 17 gauge cryoneedles under TRUS
guidance, placement of thermosensors at the level of the external sphincter and rectal wall, and insertion of a
urethral warmer. Two freeze-thaw cycles are used under TRUS guidance, resulting in a temperature of -40°C
in the mid-gland and at the neurovascular bundle. Currently, third and fourth generation cryotherapy devices
are mainly used. Since its inception, cryotherapy has been used for whole-gland treatment in PCa either as a
primary or salvage treatment option.
The main adverse effects of cryosurgery are erectile dysfunction (ED) (18%), urinary incontinence
(2-20%), urethral sloughing (0-38%), rectal pain and bleeding (3%) and recto-urethral fistula formation
(0-6%) [486]. There is a lack of prospective comparative data regarding oncological outcomes of whole-
gland cryosurgery as a curative treatment option for men with localised PCa, with most studies being non-
comparative single-arm case series with short follow-up periods [486].
6.1.5.3 High-intensity focused ultrasound

High-intensity focused ultrasound consists of focused US waves, emitted from a transducer, that cause
tissue damage by mechanical and thermal effects as well as by cavitation [487]. The goal of HIFU is to heat
malignant tissues above 65°C so that it is destroyed by coagulative necrosis. High-intensity focused US is
performed under general or spinal anaesthesia, with the patient lying in the lateral or supine position. High-
intensity focused US has previously been widely used for whole-gland therapy. The major adverse effects of
HIFU include acute urinary retention (10%), ED (23%), urethral stricture (8%), rectal pain or bleeding (11%),
recto-urethral fistula (0-5%) and urinary incontinence 10%) [486]. Disadvantages of HIFU include difficulty in
achieving complete ablation of the prostate, especially in glands larger than 40 mL, and in targeting cancers
in the anterior zone of the prostate. Similar to cryosurgery, the lack of any long-term prospective comparative
data on oncological outcomes prevents whole-gland HIFU from being considered as a reasonable alternative to
the established curative treatment options [486].
6.1.5.4 Focal therapy

During the past two decades, there has been a trend towards earlier diagnosis of PCa as a result of greater
public and professional awareness, leading to the adoption of both formal and informal screening strategies.
The effect of this has been to identify men at an earlier stage with smaller tumours that occupy only 5-10%
of the prostate volume, with a greater propensity for unifocal or unilateral disease [488-490]. Most focal
therapies to date have been achieved with ablative technologies: cryotherapy, HIFU, photodynamic therapy,
electroporation, and focal RT by brachytherapy or CyberKnife Robotic Radiosurgery System technology
(Accuray Inc., Sunnyvale, CA, USA). The main purpose of focal therapy is to ablate tumours selectively whilst
limiting toxicity by sparing the neurovascular bundles, sphincter and urethra [491-493].
A previous SR and network meta-analysis [486] on ablative therapy in men with localised PCa
performed a sub-group analysis of focal therapy vs. RP and EBRT. Nine case series reporting on focal therapy
were identified (five studies reporting on focal cryosurgical ablation of the prostate (CSAP), three studies
on focal HIFU, and one study reported on both). For focal CSAP vs. RP or EBRT, no statistically significant
differences were found for BCR at three years. For focal HIFU vs. RP or EBRT, there were no comparable
data on oncological, continence nor potency outcomes at one year, or more. More recently, Valerio et al. [485]
performed a SR to summarise the evidence regarding the effectiveness of focal therapy in localised PCa.
Data from 3,230 patients across 37 studies were included, covering different energy sources including HIFU,
CSAP, photodynamic therapy, laser interstitial thermotherapy, focal brachytherapy, irreversible electroporation
and radiofrequency ablation. The overall quality of the evidence was low, due to the majority of studies being
single-centre, non-comparative and retrospective in design, heterogeneity of definitions, approaches, follow-
up strategies, outcomes, and duration of follow-up. Although the review suggests that focal therapy has a
favourable toxicity profile in the short to medium-term, its oncological effectiveness remains unproven due to
lack of reliable comparative data against standard interventions such as RP and EBRT.
Another RCT compared focal therapy using padeliporfin-based vascular-targeted photodynamic
therapy (PDT) vs. AS in men with low-risk PCa [494]. The study found at a median follow-up of 24 months,
less patients progressed in the PDT arm compared with the AS arm (adjusted HR: 0.34, 95% CI: 0.24–0.46).
In addition, more men in the PDT arm had a negative prostate biopsy at two years than men in the AS

arm (adjusted RR: 3.67, 95% CI: 2.53–5.33). Nevertheless, limitations of the study include inappropriately
comparing an intervention designed to destroy cancer tissue in men with low-risk PCa against an intervention
primarily aimed at avoiding unnecessary treatment in men with low-risk PCa, and an unusually high observed rate
of disease progression in the AS arm (58% in two years). Given the lack of robust comparative data on medium
to long-term oncological outcomes for focal therapy against curative interventions (i.e. RP or EBRT), focal therapy
should remain experimental for the time being; robust prospective trials reporting standardised outcomes [495] are
needed before recommendations in support of focal therapy for routine clinical practice can be made.
6.1.5.5 General guidelines for active treatment

Inform patients that no active treatment modality has shown superiority over any other Strong
active management options in terms of survival.
Inform patients that all active treatments have side-effects. Strong
Surgical treatment
Inform patients that no surgical approach (open, laparoscopic- or robotic radical Strong
prostatectomy) has clearly shown superiority in terms of functional or oncological results.
Perform an extended lymph node dissection (LND), when a LND is deemed necessary. Strong
Do not perform nerve sparing surgery when there is a risk of extracapsular extension Strong
(based on cT stage, Gleason score, nomogram, multiparametric magnetic resonance
imaging).
Do not offer neoadjuvant androgen deprivation therapy before surgery. Strong
Radiotherapeutic treatment
Offer intensity-modulated radiation therapy (IMRT) or volumetric arc external-beam Strong
radiotherapy (VMAT) for definitive treatment of PCa by external-beam radiation therapy.
Only offer moderate hypofractionation (HFX) with IMRT/VMAT, including image-guided Strong
radiation therapy to the prostate, to carefully selected patients with localised disease.
Ensure that moderate HFX adheres to radiotherapy protocols from trials with equivalent Strong
outcome and toxicity, i.e. 60 Gy/20 fractions in four weeks or 70 Gy/28 fractions in six
weeks.
Active therapeutic options outside surgery and radiotherapy
Only offer cryotherapy and high-intensity focused ultrasound within a clinical trial setting. Strong
Only offer focal therapy within a clinical trial setting. Strong
6.1.6 Discussing treatment options

Management decisions should be made after all treatments have been discussed in a multidisciplinary team
(including urologists, radiation oncologists, medical oncologists and radiologists), and after the balance of
benefits and side-effects of appropriate therapy modalities has been considered together with the patient.
In the following paragraphs we will only discuss active modalities where the aim is to try to be “curative” in
patients were that is appropriate.
6.2 Treatment by disease stages

6.2.1 Treatment of low-risk disease
6.2.1.1 Selection criteria for active surveillance
The main risk for men with low-risk disease is over-treatment. The ProtecT trial randomised 1,643 patients with
PSA detected PCa between active treatment (RP or EBRT) and AM (a less intense form of AS) [321]. Although
this included men with both low- and intermediate-risk disease, AM was as effective as active treatment at ten
years, at a cost of an increased progression and a doubling of metastatic risk. However, metastases remain
quite rare (6%), but more frequent when compared to results from AS protocols based on stricter patient
selection [323]. This confirms that especially for low-risk patients, some form of initial AM is safe.
6.2.1.1.1 Clinical and pathological variables

Selection criteria for AS are limited by a lack of prospective RCTs, or findings from a formal consensus meeting.
The criteria most often published include: Gleason 6, when specified < 2-3 positive cores with < 50% cancer
involvement in every positive core, a clinical T1c or T2a, a PSA < 10 ng/mL and a PSA density < 0.15 ng/mL/cc
[324, 496]. The latter threshold remains controversial [496, 497]. A pathology consensus group suggested

excluding men from AS when any of the following features were present: predominant ductal carcinoma
(including pure intraductal carcinoma), sarcomatoid carcinoma, small cell carcinoma, EPE or LVI in needle
biopsy [498] and perineal invasion [499].
A Canadian consensus group consider that AS is the treatment of choice for low-risk disease,
without stratifying for biopsy results, although they clearly recommend that men < 55 years should be
closely scrutinised for high-volume Gleason 6 cancer. In this setting, re-biopsy within six to twelve months
to exclude sampling error is mandatory [496, 500] even if this could be modified in the future [501]. A SR
and meta-analysis [502] found three clinico-pathological variables which were significantly associated with
reclassification, which were; PSA-density, ≥ 2 positive cores, and African-American race.
6.2.1.1.2 Biological markers

Biological markers, including urine PCA3, transmembrane protease, serine 2-TMPRSS2-ERG fusion, or PSA
isoforms appear promising, as does genomics on the tissue sample itself [503-505]. However, further data will
be needed before such markers can be used in standard clinical practice [132].
6.2.1.1.3 Imaging for treatment selection

Imaging with mpMRI is of particular interest due to its high NPV value for lesion upgrading in low-risk patients
[3] and for staging anterior prostate lesions [506, 507] and is summarised in a recent review of the literature
[508]. The added value of mpMRI and targeted biopsies could be promising in reducing misclassifications at
initial diagnosis and follow-up, reducing unnecessary (targeted or systematic) biopsies at follow-up, and aiding
in monitoring patients on AS. It may differ at different time points in an AS setting. At confirmatory biopsy in
men who did not have a mpMRI before, the reclassification rate due to targeted biopsies can be estimated
to be 2-22% (absolute numbers) [507, 509-512]. The added value of mpMRI for surveillance/repeat biopsies
(hence more than one year following the confirmatory biopsy) has not been evaluated yet. However, combined
data of confirmatory and surveillance repeat biopsies show a reclassification rate due to targeted biopsies of
2-14% (absolute numbers) [513-515]. These numbers are directly related to the eligibility criteria for AS, and the
reclassification criteria used within these populations.
The concordance of systematic and targeted biopsies at confirmatory biopsies is approximately
80%. However omitting systematic biopsies may induce a misclassification rate of 3-13% [507, 509-511, 513-
515], therefore systematic biopsy should be systematically performed, even facing a normal mpMRI.
Targeted biopsies of suspicious lesions on mpMRI are mainly performed for Likert/PIRADS (Prostate
Image Reporting and Data System) ≥ 3 lesions. Although increased rates of reclassification occur in PIRADS 4
and 5 lesions, a substantial proportion of PIRADS 3 lesions show reclassification following targeted biopsies
[509, 510], thereby confirming the significance to biopsy Likert/PIRADS ≥ 3 lesions within AS management.
6.2.1.1.4 Follow up
The follow up strategy is based on serial DRE (at least once yearly), PSA (at least once, every six months) and
repeated biopsy (at a minimum interval of three to five years). Based on two small single centre studies [516,
517], not all patients with progression/reclassification at biopsy had radiological progression and vice versa.
Therefore, mpMRI cannot be used as a stand-alone tool to trigger follow-up biopsies, but efforts are being
made to define and standardise radiological progression during AS [518].
Risk prediction in men on AS is under investigation to further reduce unnecessary biopsies and
misclassification [501]. In an AS cohort of 259 men with Gleason 6 and Gleason 7(3+4) cancers detected by
MRI-targeted and systematic biopsies, independent predictors of upgrading at 3 years were Gleason 7(3+4),
PSA density ≥ 0.15 ng/mL/cm3 and a score 5 lesion on MRI [519]. Thus, the role of mpMRI in risk prediction
should be further investigated.
6.2.1.1.5 Switching to active treatment

The decision to start active treatment should be based on a change in the biopsy results (GS, number of
positive cores, core length involvement), or T-stage progression. These criteria are recognised in all published
cohorts but are limited by the heterogeneity of inclusion criteria for AS. A PSA change (especially a PSA-DT
< three years) is a less powerful indicator to change management based on its weak link with grade
progression [520, 521]. Active treatment may also be instigated upon a patient’s request. This occurs in around
10% of patients on AS [522].
6.2.1.2 Active treatment

Patients not meeting criteria listed for AS or showing progression during surveillance or unwilling AS should be
discussed for active treatment.
6.2.1.2.1 Radical prostatectomy

At 10 years’ follow-up in the ProtecT study, where the majority of men had early localised disease (i.e. > 75%

had either clinical T1 or Gleason sum score 6 disease), a benefit for metastases-free and PFS, but neither
cancer-specific nor OS, for RP compared to AM and RT was seen [321]. In the SPCG-4 study [332], death
from any cause and distant metastases were significantly reduced in low-risk PCa at eighteen years for RP
compared with WW. However, death from PCa was not reduced. In the PIVOT trial, a pre-planned subgroup
analysis of men with low-risk PCa showed that RP did not significantly reduce all-cause mortality or death from
PCa at ten years compared with WW [339].
The decision to offer RP in cases of low-risk cancer should be based upon the probabilities of clinical
progression, side-effects and potential benefit to survival [523]. Individual patient preferences should always
be considered in shared decision-making. If RP is performed in low-risk PCa, pelvic LN dissection is not
necessary (pN+ risk ≤ 5%) [524].
6.2.1.2.2 Radiation therapy treatment policy

The ProtecT study also confirmed that RT combined with six months of ADT failed to improve cancer-specific
or OS in this PSA-screened population, but did improve PFS, as per RP [321]. As with RP, the decision to offer
treatment should be based upon the probabilities of clinical progression, side-effects and potential benefit to
survival [523]. Individual patient preferences should always be considered in shared decision-making. If RT is
performed in this group, intensity-modulated RT with escalated dose (74-80 Gy) and without ADT, or moderate
HFX (see Section 6.1.3.1.3) should be used. Low-dose rate brachytherapy is a valid alternative provided the
patient fulfils the criteria (see Section 6.1.3.3.1).
6.2.1.3 Other treatments

All other treatment modalities should be considered as investigational. Neither whole gland treatment nor focal
treatment can be considered as standard (see 6.1.4). Ideally, they should only be performed in a clinical trial
setting.
6.2.1.4 Guidelines for the treatment of low-risk disease

Watchful waiting (WW)
Offer a WW policy to asymptomatic patients with a life expectancy < ten years (based on Strong
comorbidities).
Active surveillance (AS)
Offer AS to patients suitable for curative treatment but with low-risk PCa. Strong
Perform multiparametric magnetic resonance imaging before a confirmatory biopsy. Strong
During confirmatory biopsy include systematic and targeted biopsies. Strong
Base follow up on digital rectal examination, prostate-specific antigen and repeated Strong
biopsies.
Counsel patients about the possibility of needing further treatment in the future. Strong
Active treatment
Offer surgery and radiotherapy as alternatives to AS to patients suitable for such Weak
treatments and who accept a trade-off between toxicity and prevention of disease
progression.
Pelvic lymph node dissection (PLND)
Do not perform a PLND (estimated risk for pN+ < 5%). Strong
Offer low-dose rate brachytherapy to patients with low-risk PCa, without a previous Strong
transurethral resection of the prostate and with a good International Prostatic Symptom
Score and a prostate volume < 50 mL.
Use intensity-modulated radiation therapy with a total dose of 74-80 Gy, without Strong
androgen deprivation therapy.
Offer moderate hypofractionation (60 Gy/20 fx in four weeks or 70 Gy/28 fx in six weeks) Strong
as an alternative treatment option.
Other therapeutic options
Only offer whole gland treatment (such as cryotherapy, high-intensity focused ultrasound, Strong
etc.) or focal treatment within a clinical trial setting.

6.2.2 Treatment of Intermediate-risk disease
When managed with non-curative intent, intermediate-risk PCa is associated with ten-year and fifteen-year
PCSM rates of 13 and 19.6%, respectively [525].
6.2.2.1 Active Surveillance

In the ProtecT trial, up to 22% of the randomised patients in the AM arm had a GS > 6 and 10% a PSA
> 10 ng/mL [321]. No data stratified by risk group have so far been reported. A Canadian consensus
group proposes that low volume Gleason 7(3+4) (< 10% pattern 4) may also be considered for AS. These
recommendations have also been endorsed by the American Society of Clinical Oncology ASCO [526]
However, recent findings suggest that any grade 4 pattern is associated with a three-fold increased risk of
metastases compared to Gleason 6, while a PSA up to 20 ng/mL might be an acceptable threshold [500, 527,
528]. Including mpMRI and a systematic rebiopsy (eventually targeted) might improve the accuracy of staging.
However clear evidence to support AS in the intermediate-risk group is not available and therefore care must
be taken if advocating this treatment strategy especially in patients with the longest life expectancy.
6.2.2.2 Surgery
Patients with intermediate-risk PCa should be informed about the results of two RCTs (SPCG-4 and PIVOT)
comparing RRP vs. WW in localised PCa. In the SPCG-4 study, death from any cause (RR: 0.71; 95% CI:
0.53-0.95), death from PCa (RR: 0.38; 95% CI: 0.23-0.62) and distant metastases (RR: 0.49; 95% CI: 0.32-
0.74) were significantly reduced in intermediate-risk PCa at eighteen years. In the PIVOT trial, according to a
pre-planned subgroup analysis among men with intermediate-risk tumours, RP significantly reduced all-cause
mortality (HR: 0.69 [95% CI: 0.49-0.98]), but not death from PCa (0.50; 95% CI: 0.21-1.21) at ten years.
The risk of having positive LNs in intermediate-risk PCa is between 3.7-20.1% [524]. An eLND
should be performed in intermediate-risk PCa if the estimated risk for pN+ exceeds 5% [524]. In all other
cases, eLND can be omitted, which means accepting a low risk of missing positive nodes.
6.2.2.3 Radiation therapy

6.2.2.3.1 Recommended external beam radiation therapy for intermediate-risk PCa
Patients suitable for ADT can be given combined IMRT with short-term ADT (4-6 months) [381, 529, 530]. For
patients unsuitable for ADT (e.g. due to comorbidities) or unwilling to accept ADT (e.g. to preserve their sexual
health), the recommended treatment is IMRT or VMAT at an escalated dose (76-80 Gy) or a combination of
IMRT or VMAT and brachytherapy (see Section 6.2.3.2.3).
6.2.2.3.2 Brachytherapy monotherapy

Low-dose rate brachytherapy can be offered to very selected patients (ISUP grade 2 with ≤ 33% of biopsy
cores involved with cancer), provided they fulfil all the other criteria. Fractionated HDR brachytherapy as
monotherapy can be offered to selected patients with intermediate-risk PCa although they should be informed
that results are only available from small series in very experienced centres. Five-year PSA control rates over
90% are reported, with late Grade 3+ GU toxicity rates < 5% and no, or very minimal, Grade 3+ GI toxicity
rates [408, 453]. There are no direct data to inform on the use of ADT in this setting.
6.2.2.4 Other options for the primary treatment of intermediate-risk PCa (experimental therapies)
All other treatment modalities should be considered as investigational. Neither whole gland treatment nor focal
treatment can be considered as standard (see Section 6.1.5). Ideally they should only be offered in clinical
trials [484].

6.2.2.5 Guidelines for the treatment of intermediate-risk disease

Active surveillance (AS)
Offer AS to highly selected patients (< 10% pattern 4) accepting the potential increased Weak
risk of further metastases.
Radical prostatectomy (RP)
Offer RP to patients with intermediate-risk disease and a life expectancy > ten years. Strong
Offer nerve-sparing surgery to patients with a low risk of extracapsular disease (refer to Strong
nomograms).
Pelvic lymph node dissection (ePLND)
Perform an ePLND in intermediate-risk disease if the estimated risk for positive lymph Strong
nodes exceeds 5%.
Offer low-dose rate brachytherapy to selected patients (see Section 6.2.3.2.3); patients Strong
without a previous transurethral resection of the prostate and with a good International
Prostatic Symptom Score and a prostate volume < 50 mL.
For external-beam radiation therapy (EBRT), use a total dose of 76-78 Gy, in combination Strong
with short-term neoadjuvant plus concomitant androgen deprivation therapy (ADT) (four
to six months).
In patients not willing to undergo ADT, use an escalated dose of EBRT (76-80 Gy) or a Weak
combination with brachytherapy.
Other therapeutic options
Only offer whole gland treatment (such as cryotherapy, high-intensity focused ultrasound, Strong
etc.) or focal treatment within a clinical trial setting.
6.2.3 Treatment of high-risk localised disease

Patients with high-risk PCa are at an increased risk of PSA failure, need for secondary therapy, metastatic
progression and death from PCa. Nevertheless, not all high-risk PCa patients have a uniformly poor prognosis
after RP [531]. When managed with non-curative intent, high-risk PCa is associated with ten-year and fifteen-
year PCSM rates of 28.8 and 35.5%, respectively [525]. There is no consensus regarding the optimal treatment
of men with high-risk PCa.
6.2.3.1 Radical prostatectomy

Provided that the tumour is not fixed to the pelvic wall, or that there is no invasion of the urethral sphincter, RP
is a reasonable option in selected patients with a low tumour volume. Extended PLND should be performed in
all high-risk PCa cases undergoing RP, as the estimated risk for positive LNs is 15-40% [524]. Patients should
be aware pre-operatively that surgery may be part of multi-modality treatment
6.2.3.1.1 Gleason score 8-10 (ISUP grade 4-5)

The incidence of organ-confined disease is 26-31% in men with a GS 8-10 on systematic biopsy. A high rate of
downgrading exists between the biopsy GS and the GS of the resected specimen [532]. Several retrospective
case series have demonstrated CSS rates over 60% at fifteen years after RP in the context of a multimodal
approach (adjuvant or salvage ADT and/or RT) for patients with a biopsy GS > 8 [295, 342, 533, 534].
6.2.3.1.2 Prostate-specific antigen > 20 ng/mL

Reports in patients with a PSA > 20 ng/mL who underwent surgery as initial therapy within a multimodal
approach demonstrated a CSS at fifteen years of over 70% [295, 342, 347, 535-537].
6.2.3.1.3 R
adical prostatectomy in cN0 patients who are found to have pathologically confirmed lymph node
invasion (pN1)
cN0 patients who undergo RP but who were found to have pN1 were reported to have an overall CSS and OS
of 45% and 42% respectively at fifteen years [538-544]. However, this is a very heterogeneous patient group
and further treatment must be individualised based on risk factors (see Section 6.2.4.5).

6.2.3.2 External beam radiation therapy
6.2.3.2.1 Recommended external beam radiation therapy treatment policy for localised high-risk PCa
For high-risk localised PCa, use a combined modality approach, consisting of dose-escalated IMRT or VMAT,
plus long-term ADT. The duration of ADT has to take into account PS, comorbidities, and the number of
poor prognostic factors. It is important to recognise that in several studies EBRT plus short-term ADT did
not improve OS in high-risk localised PCa [424, 425, 427], and long-term ADT (at least two to three years) is
currently recommended for these patients.
6.2.3.2.2 Lymph node irradiation in cN0

There is no level 1 evidence for prophylactic whole-pelvic irradiation, since RCTs have failed to show that
patients benefit from prophylactic irradiation (46-50 Gy) of the pelvic LNs in high-risk cases [545-547]. In the
RTOG 94-13 study [427], there were no differences in the PFS in patients treated with whole-pelvic or prostate-
only RT, but interactions between whole-pelvic RT and the duration of ADT were reported following the
subgroup analysis. Furthermore, in most trials dealing with high-risk PCa, a whole pelvis field was considered
standard of care. The benefits of pelvic nodal irradiation using IMRT or VMAT merit further investigation in RCTs
as conducted by the RTOG or the UK NCRI group. Performing an ePLND in order to decide whether or not
pelvic RT is required (in addition to combined prostate EBRT plus long-term ADT) remains purely experimental
in the absence of level 1 evidence.
6.2.3.2.3 Low-dose rate brachytherapy boost

In men with intermediate- or high-risk PCa, LDR brachytherapy boost with supplemental EBRT and hormonal
treatment [548] may be considered. Dose-escalated EBRT (total dose of 78 Gy) has been compared with
EBRT (total dose 46 Gy) followed by LDR brachytherapy boost (prescribed dose 115 Gy) in intermediate-risk
and high-risk patients in a randomised trial, with twelve months of ADT in both arms [549]. The LDR boost
resulted in five- and seven-year PSA PFS increase (89% and 86% respectively compared to 84% and 75%).
This improvement came with an increase in late Grade 3+ urinary toxicity (18% compared to 8%). Toxicity was
mainly due to urethral strictures and incontinence and great care should be taken during treatment planning.
6.2.3.3 Options other than surgery and radiotherapy for the primary treatment of localised prostate cancer.
Currently there is a lack of evidence supporting any other treatment option or focal therapy in localised high-
risk PCa.
6.2.3.4 Guidelines for radical treatment of high-risk localised disease
Recommendation Strength rating

Radical Prostatectomy (RP)
Offer RP to patients with high-risk localised PCa and a life expectancy of > ten years only Strong
as part of multi-modal therapy.
Extended pelvic lymph node dissection (ePLND)
Perform an ePLND in high-risk disease. Strong
Do not perform a frozen section of nodes during RP to decide whether to proceed with, or Strong
abandon, the procedure.
Radiotherapeutic treatments
In patients with high-risk localised disease, use external-beam radiation therapy (EBRT) Strong
with 76-78 Gy in combination with long-term androgen deprivation therapy (ADT) (two to
three years).
In patients with high-risk localised disease, use EBRT with brachytherapy boost (either Weak
high-dose rate or low-dose rate), in combination with long-term ADT (two to three years).
Other therapeutic options outside surgery and radiotherapy
Do not offer either whole gland or focal treatment to high-risk patients. Strong
Do not use ADT monotherapy in asymptomatic patients. Strong
6.2.4 Treatment of locally advanced prostate cancer

No standard treatment can be defined in the absence of level 1 evidence. But a local treatment combined with
a systemic one provides the best outcome, provided the patient is ready and fit enough to receive both. The
optimal local treatment is still a matter of debate. Randomised controlled trials are only available for EBRT.

6.2.4.1 Surgery
Surgery for locally advanced disease as part of a multimodal therapy has been reported [532, 550, 551].
Retrospective case series demonstrated over 60% CSS at fifteen years and over 75% OS at ten years [532,
550-556]. For cT3b-T4 disease, PCa cohort studies showed 10 year CSS of over 87% and OS of 65% [557-
559].
The indication for RP in all previously described stages assumes the absence of clinically detectable
nodal involvement. Although no RCT is available, data from prospective cohorts comparing the survival of
pN+ patients (as defined following pathological examination after RP) is another argument for omitting frozen
sections if a RP is planned as well as the continuation of the procedure in case of suspected nodes [560]. Only
limited evidence exists supporting RP for cN+ patients. Hsu et al. compared the outcomes of 50 patients with
cN+ with those of 252 patients with pN1, but cN0 at pre-operative staging. cN+ was not a significant predictor
of CSS [561]. An ePLND is considered standard if a RP is planned.
6.2.4.2 Radiotherapy for locally advanced PCa

In locally advanced disease, RCTs have clearly established that the additional use of long-term ADT combined
with RT produces better OS than ADT or RT alone (see Section 6.1.3.1.4 and Tables 6.1.9 and 6.1.10). In
clinical, or pathological node-positive disease, RT monotherapy is associated with poor outcomes [382], and
these patients should receive RT plus long-term ADT. A subgroup analysis from the RTOG 85-31 with a median
follow-up period of 6.5 years, showed that 95 of the 173 pN1 patients who received pelvic RT with immediate
HT had better five-year (54%) and nine-year (10%) PFS rates vs. 33% and 4%, respectively, for radiation alone
(p < 0.0001). Multivariate analysis showed that this combination had a statistically significant impact on the OS
[562]. These findings are also confirmed from the control arm of the STAMPEDE trial (HR: 0.48 [95% CI: 0.29-
0.79]) in a non-randomised comparison [563].
6.2.4.3 Options other than surgery and radiotherapy for primary treatment
Currently cryotherapy, HIFU or focal therapies have no place in the management of locally advanced PCa.
The deferred use of ADT as single treatment modality has been answered by the EORTC 30891trial [524].
Nine hundred and eighty-five patients with T0-4 N0-2 M0 PCa received ADT alone, either immediately or after
symptomatic progression or occurrence of serious complications. After a median follow-up of 12.8 years, the
OS HR was 1.21 (95% CI: 1.05-1.39), favouring immediate treatment. Surprisingly, no different disease-free or
symptom-free survival were observed, raising the question of survival benefit. In locally advanced T3-T4 M0
disease unsuitable for surgery or RT, immediate ADT may only benefit patients with a PSA > 50 ng/mL and a
PSA-DT < 12 months [524, 564], or those that are symptomatic. The median time to start deferred treatment
was seven years. In the deferred treatment arm, 25.6% died without needing treatment.
6.2.4.4 Guidelines for radical treatment of locally-advanced disease

Radical Prostatectomy (RP)
Offer RP to highly selected patients with (cT3b-T4 N0 or any T N1) only as part of multi- Strong
modal therapy.
Extended pelvic lymph node dissection (eLND)
Perform an eLND in high-risk PCa. Strong
Do not perform a frozen section of nodes during RP to decide whether to proceed with, or Strong
abandon, the procedure.
Radiotherapeutic treatments
In patients with locally advanced cN0 disease, offer radiotherapy in combination with Strong
long-term androgen deprivation therapy (ADT).
Offer long-term ADT for two to three years. Weak
Other therapeutic options outside surgery and radiotherapy
Do not offer whole gland treatment or focal treatment to high-risk patients. Strong
Only offer ADT monotherapy to those patients unwilling or unable to receive any form of Strong
local treatment and who are either symptomatic or asymptomatic, but with a prostate-
specific antigen (PSA)-doubling time < 12 months or a PSA > 50 ng/mL or a poorly-
differentiated tumour.

6.2.4.5 Adjuvant treatment after radical prostatectomy
Adjuvant treatment is by definition added to the primary or initial therapy; to decrease the risk of relapse.
With EBRT, short- or long-term ADT is selected based on the initial risk classification (see Section 6.1.3.1.4).
Regarding RP, the key factor is that the PSA must be below 0.1 ng/mL to be considered undetectable. All
information listed below, refers to patients with a post-operative undetectable PSA. A post-operative PSA
of above 0.1 ng/mL is an indication of persistent PCa cells. In such a case, further treatment will be salvage
treatment.
6.2.4.5.1 Risk factors for relapse

Gleason score ≥ 7 or patients classified as pT3 pN0 after RP due to positive margins (highest impact), capsule
rupture and/or invasion of the seminal vesicles are at high risk of relapse which can be as high as 50% after
five years [565]. Irrespective of the pT stage, the number of removed nodes [358, 566-572], tumour volume
within the LN and capsular perforation of the nodal metastases are predictors of early recurrence after RP for
pN1 disease [359]. A LN density (defined as the percentage of positive LNs in relation to the total number of
analysed/removed LNs) over 20% was found to be associated with poor prognosis [360]. Finally the number
of involved nodes [567, 568, 573] seems to be a major factor for predicting relapse, the threshold being
considered to be less than three positive nodes from an ePLND [4, 567, 573]. However, prospective data are
needed before defining a definitive threshold value.
6.2.4.5.2 Immediate (adjuvant) post-operative external irradiation after RP (cN0 or pN0)

Three prospective randomised trials have assessed the role of immediate post-operative RT (adjuvant RT
[ART]) (Table 6.2.1). It must be emphasised that PSA was undetectable at inclusion only in the ARO 96-02 trial,
representing a major limitation in interpretation, as patients with a detectable PSA would now be considered
for salvage therapy rather than adjuvant radiotherapy. Thus, for patients at increased risk of local relapse, who
present with a PSA level of < 0.1 ng/mL, two options can be offered in the framework of informed consent.
These are:
• Immediate ART to the surgical bed [574-576] after recovery of urinary function, during the first six months
post-surgery;
or
• Clinical and biological monitoring followed by salvage radiotherapy (SRT) before the PSA exceeds
0.5 ng/mL [577, 578] (see Section 6.3.5.1 on Salvage EBRT).
Table 6.2.1: Overview of all three randomised trials for adjuvant surgical bed radiation therapy after RP*
Reference n Inclusion Randomisation Definition Median Biochemical Overall survival

criteria of BCR PSA FU (mo) progression-
(ng/mL) free survival
SWOG 431 pT3 cN0 ± 60-64 Gy vs. > 0.4 152 10 yr: 53% 10 yr: 74% vs.
8794 [576] involved SM observation vs. 30% 66%
(p < 0.05) Median time:
15.2 vs. 13.3 yr
p = 0.023
EORTC 1,005 pT3 ± 60 Gy vs. > 0.2 127 10 yr: 60.6% 81% vs. 77%
22911 involved SM observation vs. 41% n.s.
[574] pN0 pT2 (p < 0.001)
involved SM
pN0
ARO 96-02 388 pT3 60 Gy vs. > 0.05 + 112 10 yr: 56% 10 yr: 82% vs.
[575] (± involved observation confirmation vs. 35% 86% n.s.
SM) (p = 0.0001)
pN0 PSA
post-RP
undetectable
*See Section 6.3.5.2.3 for delayed (salvage) post-radical prostatectomy external irradiation.
BCR = biochemical recurrence; FU = follow-up; mo = months; n = number of patients; n.s. = not significant;
PSA = prostate-specific antigen; RP = radical prostatectomy; SM = surgical margin.

6.2.4.5.3 Adjuvant androgen ablation
6.2.4.5.3.1 Adjuvant androgen ablation in men with N0 disease
Adjuvant androgen ablation with bicalutamide 150 mg daily did not improve PFS in localised disease while it
did for locally advanced disease after RT. However this never translated to an OS benefit [361] A SR showed a
possible benefit for PFS, but not OS for adjuvant androgen ablation [363].
6.2.4.5.3.2 Adjuvant androgen ablation in men with pN1 disease

The combination of RP and early adjuvant HT in pN+ PCa has been shown to achieve a ten-year CSS rate of
80% [579, 580]. In patients who prove to be pN+ after RP, early adjuvant HT has been shown to significantly
improve CSS and OS in a prospective RCT [580]. However, this trial included mostly patients with high-volume
nodal disease and multiple adverse tumour characteristics and the findings may not apply to men with less
extensive nodal metastases.
6.2.4.5.3.3 Adjuvant radiotherapy combined with ADT in men with pN1 disease
In a retrospective multicentre cohort study, maximal local control with RT to the prostatic fossa appeared to
be beneficial in PCa patients with pN1 after RP, treated adjuvantly with continuous ADT [581]. The beneficial
impact of adjuvant RT on survival in patients with pN1 PCa was highly influenced by tumour characteristics.
Men with low-volume nodal disease (< 3 LNs), GS 7-10 and pT3-4 or R1 as well as men with three to four
positive nodes were more likely to benefit from RT after surgery, while the other subgroups were not [282]. In
a SEER retrospective population-based analysis, adding RT to RP showed a non-significant trend to improved
OS but not PCa-specific survival, but data on the extent of additional RT is lacking in this study [280]. No
recommendations can be made on the extent of adjuvant RT in pN1 disease (prostatic fossa only or whole
pelvis) although whole pelvis RT was given in more than 70% of men in a large retrospective series that found a
benefit for adding RT to androgen ablation in pN1 patients [282]. No data is available regarding adjuvant EBRT
without ADT.
6.2.4.5.3.4 Adjuvant chemotherapy

The TAX3501 trial comparing the role of leuprolide (eighteen months) with and without docetaxel (six cycles)
ended prematurely due to poor accrual. Adjuvant chemotherapy after RP should only be considered in a
clinical trial [582].
6.2.4.5.4 Guidelines for adjuvant treatment options after radical prostatectomy

Only discuss adjuvant treatment in men with a post-operative prostate-specific antigen Strong
(PSA) < 0.1 ng/mL.
Do not prescribe adjuvant androgen deprivation therapy (ADT) in pN0 patients. Strong
Offer adjuvant external-beam radiation therapy to the surgical field to patients at Strong
increased risk of local relapse: pT3 pN0 with positive margins (highest impact), and/or
invasion of the seminal vesicles.
Discuss three management options with patients with pN+ disease after an extended Weak
lymph node dissection, based on nodal involvement characteristics:
1. Offer adjuvant ADT for node-positive (pN+).
2. Offer adjuvant ADT with additional radiotherapy.
3. O
ffer observation (expectant management) to a patient after eLND and ≤ 2 nodes
with microscopic involvement, and a PSA < 0.1 ng/mL and absence of extranodal
extension.

6.2.4.5.5 Guidelines for non-curative or palliative treatments in prostate cancer

Watchful waiting (WW) for localised prostate cancer
Offer WW to asymptomatic patients not eligible for local curative treatment and 1b Strong
those with a short life expectancy.
While on WW, base the decision to start non-curative treatment on symptoms and Strong
disease progression.
Watchful waiting for locally advanced prostate cancer
Offer a deferred treatment policy using androgen deprivation (ADT) monotherapy 1b Strong
to M0 asymptomatic patients with a prostate-specific antigen (PSA) doubling
time > twelve months, a PSA < 50 ng/mL and well differentiated tumour, who are
unwilling or unable to receive any form of local treatment.
6.3 Management of PSA-only recurrence after treatment with curative intent
The follow up policy is described in chapter 7 and will not be discussed here.
6.3.1 Background
Between 27% and 53% of all patients undergoing RP or RT develop PSA recurrence. Whilst a rising PSA level
universally precedes metastatic progression, physicians must inform the patient that the natural history of PSA-
only recurrence may be prolonged and that a measurable PSA may not necessarily lead to clinically apparent
metastatic disease. Physicians treating patients with PSA-only recurrence face a difficult set of decisions in
attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose
disease may never affect their OS or QoL. It should be emphasised that the treatment recommendations for
these patients should be given after discussion in a multidisciplinary team.
6.3.2 Definitions of clinically relevant PSA relapse

The PSA level that defines treatment failure depends on the primary treatment. Patients with PSA-recurrence
after RP or primary RT have different risks of subsequent symptomatic metastatic disease. Therefore,
physicians should carefully interpret BCR endpoints when comparing treatments.
After RP, the threshold that best predicts further metastases is a PSA > 0.4 ng/mL and rising [583-585]
However, with access to ultra-sensitive PSA testing, a rising PSA much below this level will be a cause for
concern for patients. After primary RT, with or without short-term hormonal manipulation, the RTOG-ASTRO
Phoenix Consensus Conference definition of PSA failure (with an accuracy of > 80% for clinical failure) is any
PSA increase ≥ 2 ng/mL higher than the PSA nadir value, regardless of the serum concentration of the nadir
[586].
After HIFU or cryotherapy, no endpoints have been validated against clinical progression or
survival; therefore, it is not possible to give a firm recommendation of an acceptable PSA threshold after these
alternative local treatments.
6.3.3 Natural history of biochemical recurrence

Once a PSA relapse has been diagnosed, it is important to determine, as far as possible, whether the
recurrence has developed at local or distant sites. The risk of subsequent metastases and PCSM may be
predicted by the initial clinical and pathologic factors (e.g. T-category, PSA, GS) and PSA kinetics (PSA-DT and
interval to PSA failure).
6.3.3.1 Post-radical prostatectomy biochemical recurrence

Not all patients with BCR after RP will develop clinical recurrences. In two studies of 1,997 and 2,400 men
treated by RP, only 23-34% of those with BCR developed a clinical recurrence and 6% subsequently died of
PCa [569, 587].
Several studies have attempted to identify risk factors for metastases and PCSM in patients experiencing
PSA-only recurrence following RP. A PSA-DT < three months, SVI (pT3b), specimen GS 8-10, or time to PSA
recurrence < 3 years indicate a high risk of metastases and PCSM. Conversely, a PSA-recurrence > three years
following surgery, specimen GS < 7, pathologic organ-confined disease or limited extracapsular extension
(pT3a), and PSA-DT > twelve months indicates a low risk of metastases and PCSM [588-591]. A rising PSA-DT,

≤ 0.2 ng/mL, has been associated with an increased risk of metastases and death [592]. Patients in the low-risk
subgroup typically respond very well to SRT with a high probability of PSA being undetectable [593]. However,
it must be stressed that most patients within the low-risk subgroup have an excellent outcome even without
any salvage treatment. Patients within the high-risk subgroup need early and aggressive salvage treatment
[594]. Trock et al. demonstrated that SRT was associated with a significant three-fold increase in PCa-specific
survival relative to those who received no salvage treatment. The increase in PCa-specific survival associated
with SRT was limited to men with a PSA-DT of < six months and remained after adjustment for pathological
stage and other established prognostic factors. Salvage RT initiated > two years after recurrence provided no
significant increase in PCa-specific survival [594].
6.3.3.2 Post-radiotherapy biochemical recurrence

In patients experiencing PSA-recurrence after RT, PSA-DT < three months, time to biochemical progression
< three years, biopsy GS 8-10 or clinical stage cT3b-T4 also indicate a high risk of metastases and PCSM.
Conversely, PSADT > fifteen months, biopsy GS < 7, clinical stage < cT3a and time to BCR > three years
indicate a low risk of metastases and PCSM [590, 595, 596].
Zumsteg et al. have designed a risk score to further subdivide patients who develop PSA recurrence
following RT. Those with > two high-risk factors (PSA-DT < three months, time to BCR < three years, biopsy GS
8-10 and clinical stage cT3b-T4) have an increased risk of developing metastases and PCSM as compared to
those with 0 or 1 risk factor [596].
6.3.4 The role of imaging in PSA-only recurrence

6.3.4.1 Assessment of metastases
6.3.4.1.1 Bone scan and abdominopelvic CT
Because BCR after RP or RT precedes clinical metastases by seven to eight years, on average [569, 597], the
diagnostic yield of common imaging techniques (bone scan and abdominopelvic CT) is low in asymptomatic
patients [598]. In men with PSA-only relapse after RP, the probability of a positive bone scan is < 5%, when the
PSA level is < 7 ng/mL [599, 600].
Only 11-14% of patients with BCR after RP have a positive CT [599]. In a series of 132 men with BCR after RP,
the mean PSA level and PSA velocity associated with a positive CT was 27.4 ng/mL and 1.8 ng/mL/month,
respectively [601].
6.3.4.1.2 Choline PET/CT

In two different meta-analyses, the combined sensitivities and specificities of choline PET/CT for all sites of
recurrence in patients with BCR were 86-89% and 89-93%, respectively [602, 603].
Choline PET/CT may detect multiple bone metastases in patients showing a single metastasis on
bone scan [604] and may be positive for bone metastases in up to 15% of patients with BCR after RP and
negative bone scan [605]. The specificity of choline PET/CT is also higher than bone scan with fewer false-
positive and indeterminate findings [279]. Detection of LN metastases using choline PET/CT remains limited by
the relatively poor sensitivity of the technique (see Section 5.3.2.2).
Choline PET/CT sensitivity is strongly dependent on the PSA level and kinetics [265, 606-608]. In
patients with BCR after RP, PET/CT detection rates are only 5-24% when the PSA level is < 1 ng/mL, but rises
to 67-100% when the PSA level is > 5 ng/mL. In a recent meta-analysis, choline PET/CT detection rates were
65% (95% CI: 58%-71%) when the PSA-DT was < six months, and were 71% (95% CI: 66%-76%) and 77%
(95% CI: 71%-82%) when the PSA velocity was > 1 and > 2 ng/mL/year, respectively [606].
Despite its limitations, choline PET/CT may change medical management in 18-48% of patients with BCR after
primary treatment [609-611]. In a retrospective bi-centric study of 150 patients, 14 of the 55 (25.5%) patients
scheduled for palliative treatment were switched to salvage therapy based on choline PET/CT results. Salvage
therapy induced a complete biochemical response in 35.7% of these patients at the end of a median follow-up
of 18.3 months (range, 10-48 months) [611].
Choline PET/CT cannot be recommended in all patients, but should be limited to patients who are fit enough
for curative loco-regional salvage treatment.
After RP, the optimal PSA cut-off level for choline PET/CT analysis seems to be between 1 and
2 ng/mL [607, 608]. It is unclear whether PSA velocity or PSA-DT thresholds can be used to further select
groups of patients in whom PET/CT could be recommended.
After RT, the PSA cut-off level is unclear due to the lack of sufficient data and because the PSA
level is more difficult to interpret due to the “physiological” amount of measurable PSA produced by the non-
tumoural prostate [607]. In a study of 46 patients with PSA relapse after RT or brachytherapy, the choline PET/

CT detection rate was 54.5%, 81%, 89% and 100% when the PSA level was 1-2 ng/mL, 2-4 ng/mL, 4-6 ng/mL
and > 6 ng/mL, respectively [612]. In another study of 140 patients the choline PET/CT detection rate was not
influenced by the PSA level, but only by PSA kinetics [613].
6.3.4.1.3 Fluoride PET and PET/CT

18F-Fluoride PET and PET/CT have a higher sensitivity than bone scan in detecting bone metastases [614].
However, 18F-Fluoride is limited by a relative lack of specificity and by the fact that it does not assess soft-
tissue metastases [615].
6.3.4.1.4 Prostate-specific membrane antigen-based PET/CT

Prostate-specific membrane antigen-based PET/CT has shown promising potential in patients with BCR,
although most studies are limited by their retrospective design. Detection rates of 15-58%, 25-73% and
69-100%, 71-100% have been reported for PSA ranges of 0.2-0.5 ng/mL, 0.5-1 ng/mL, 1-2 ng/mL and > 2 ng/
mL respectively [290, 616-620]. In these PSA ranges, the relative proportion of positive findings corresponding
to purely local recurrences or to distant metastases remains unclear. Nonetheless, PSMA PET/CT seems
substantially more sensitive than choline PET/CT, especially for PSA levels < 1 ng/mL. Two head-to-head
comparisons confirmed this finding [617, 621]. PSMA PET/CT identified the site of recurrence in 14 of 32
patients with negative choline PET/CT (44%; prostatic bed, n = 8; LNs, n = 6) [622]. Higher PSA velocity or
lower PSA doubling time seem associated with higher PSMA PET/CT positivity rates [275, 290, 616, 623], even
if some authors found no correlation between PSA kinetics and positivity rates [617].
In a prospective multicentre study of 323 patients with BCR, PSMA PET/CT changed the
management intent in 62% of patients as compared to conventional staging. This was due to a significant
reduction in the number of men in whom the site of disease recurrence was unknown (77% vs. 19%, p < 0.001)
and a significant increase in the number of men with metastatic disease (11% vs. 57%) [289].
A single-centre study assessed 164 men who underwent PSMA PET/CT for rising PSA after RP,
with PSA levels < 1 ng/mL. In men with a negative PSMA PET/CT who received salvage RT, 85% (n = 23/27)
demonstrated a treatment response, compared to further PSA increase in 65% (22/34) in those not treated. In
the 36/99 men with disease confined to the prostate fossa on PSMA, 83% (n = 29/36) responded to salvage RT
[624]. Thus, PSMA PET/CT might stratify men into a group with high response (negative findings or recurrence
confined to prostate) and poor response (positive nodes or distant disease) to salvage RT. However, these
results based on small numbers and short follow-up should be confirmed in other studies.
6.3.4.1.5 Whole-body and axial MRI

Little is known regarding the accuracy of whole-body or axial MRI in patients with BCR after RP or RT [625].
Therefore, the role of these techniques in detecting occult bone or LN metastases in the case of BCR remains
to be assessed.
6.3.4.2 Assessment of local recurrences

6.3.4.2.1 Local recurrence after radical prostatectomy
Because the sensitivity of anastomotic biopsies is low, especially for PSA levels < 1 ng/mL [598], salvage RT
is usually decided on the basis of the BCR, without histological proof of the local recurrence, preferably when
the PSA level is below 0.5 ng/mL. The dose delivered to the prostatic fossa tends to be uniform since it has not
been demonstrated that a focal dose escalation at the site of recurrence improves the outcome. Thus, most
patients undergo salvage RT without local imaging.
Multiparametric magnetic resonance imaging can detect local recurrences in the prostatic bed,
but its sensitivity in patients with PSA level < 0.5 ng/mL remains controversial [626, 627]. Choline PET/CT is
less sensitive than mpMRI when the PSA level is < 1 ng/mL [628]. Prostate-specific membrane antigen-based
PET/CT is positive in 15-58% of patients with BCR and PSA levels < 0.5 ng/mL [617, 618, 620], but published
series are difficult to interpret since they usually mix patients with history of RP and RT and do not specify the
proportion of local recurrences and distant metastases diagnosed at PSA levels < 0.5 ng/mL.
Precise detection and location of local recurrences after RP will be needed only if it is proven that
stereotaxic boost to the recurrence site during salvage RT improves the patient outcome.
6.3.4.2.2 Local recurrence after radiation therapy

In patients with BCR after RT, the biopsy status is a major predictor of outcome, provided the biopsies are
obtained 18-24 months after treatment. Given the morbidity of local salvage options it is necessary to obtain
histological proof of the local recurrence before treating the patient [598].
Transrectal US is not reliable in depicting local recurrences after RT. In contrast, mpMRI has yielded
excellent results [598, 629-631] and can be used for biopsy targeting and guiding local salvage treatment.
Detection of recurrent cancer is also feasible with choline PET/CT [613], but choline PET/CT has not been

compared to mpMRI yet. It is also too soon to know if PSMA PET/CT can play a role in the detection of local
recurrences after RT [275].
6.3.4.3 Summary of evidence on imaging in case of biochemical recurrence

Detection and localisation of the local recurrence site after RP is not necessary since it has not been proven
that stereotaxic boost to the recurrence site during salvage RT improves the outcome.
It is necessary to confirm the local recurrence after RT by biopsy and to localise it as precisely as
possible before salvage treatment. Multiparametric MRI is so far the best technique to localise the recurrence
and guide the biopsy.
Many recent studies suggest that PSMA PET/CT is substantially more sensitive than
abdominopelvic CT, bone scan and choline PET/CT in the detection of distant metastases in patients with
BCR. Although most studies are retrospective and/or monocentric, they all came to the same conclusion.
Early detection of metastases in a BCR setting is clinically highly relevant. This is particularly true in the post-
RT setting. Salvage therapies for local recurrences after RT induce a substantial morbidity and it is necessary
to detect metastatic patients with the highest possible sensitivity, to avoid the morbidity of useless salvage
therapies in these patients. After RP, unlike choline PET/CT, PSMA PET/CT showed high positivity rates,
even for PSA levels < 1 ng/mL. Because the localisation of the local recurrence is not useful, the indication
of a sensitive test like PSMA PET/CT in patients with PSA levels < 1 ng/mL will depend on their risk of having
metastatic disease. Prostate-specific antigen kinetics might be useful, but this needs to be proven.
6.3.4.4 Guidelines for imaging in patients with biochemical recurrence
Prostate-specific antigen (PSA) recurrence after radical prostatectomy LE Strength rating

Perform imaging only if the outcome will influence subsequent treatment Strong
decisions.
If the PSA level is ≥ 1 ng/mL, perform a prostate-specific membrane antigen 2b Weak
positron emission tomography computed tomography (PSMA PET/CT), if
available, or a choline PET/CT imaging otherwise.
PSA recurrence after radiotherapy
Perform prostate multiparametric magnetic resonance imaging to localise 3 Strong
abnormal areas and guide biopsies in patients who are considered candidates for
local salvage therapy.
Perform PSMA PET/CT (if available) or choline PET/CT imaging to rule out positive 2b Strong
lymph nodes or distant metastases in patients fit for curative salvage treatment.
6.3.5 Treatment of PSA-only recurrences

The timing and treatment modality for PSA-only recurrences after RP or RT remain a matter of controversy
based on the limited evidence.
6.3.5.1 Salvage radiotherapy [SRT] for PSA-only recurrence after radical prostatectomy
Early SRT provides the possibility of cure for patients with an increasing or persistent PSA after RP. More
than 60% of patients who are treated before the PSA level rises to > 0.5 ng/mL will achieve an undetectable
PSA level [632-635], corresponding to a ∼80% chance of being progression-free five years later [578].
A retrospective analysis of 635 patients who were followed after RP and experienced BCR and/or local
recurrence and either received no salvage treatment (n = 397) or salvage RT alone (n = 160) within two years
of BCR, showed that salvage RT was associated with a three-fold increase in PCa-specific survival relative
to those who received no salvage treatment (p < 0.001). Salvage RT has also been effective in patients with
a short PSA-DT [594]. Despite the indication for salvage RT, a “wait and see” strategy remains an option in
patients with a long PSA-DT of > twelve months [587]. For an overview, see Table 6.3.1.

Table 6.3.1: S
elected studies of post-prostatectomy salvage radiotherapy, stratified by pre-salvage
radiotherapy (SRT) PSA level*
Reference Year n Median FU pre-SRT RT dose bNED/PFS 5-yr results

(mo) PSA ADT (year)
(ng/mL)
median
Bartkowiak, et 2017 464 71 0.31 66.6 Gy 54% (5.9) 73% vs. 56%; PSA < 0.2
al. [636] vs. ≥ 0.2 ng/mL
p < 0.0001
Tendulkar, et al. 2016 2460 60 0.5 66 Gy 56% (5) SRT; PSA ≤ 0.2 ng/mL 71%
[637] 16% ADT 0.21-0.5 ng/mL 63%
0.51-1.0 ng/mL 54%
1.01-2.0 ng/mL 43%
> 2 ng/mL 37%
p < 0.001
Stish, et al. 2016 1106 107 0.6 68 Gy 50% (5) 44% vs. 58%; PSA ≤ 0.5
[632] 16% ADT 36% (10) vs. > 0.5 ng/mL
p < 0.001
Soto, et al. 2012 441 36 < 1 (58%) 68 Gy 63/55% (3) 44/40% ADT/no ADT
[638] 24% ADT ADT/no ADT p < 0.16
*Androgen deprivation therapy can influence the outcome ‘biochemically no evidence of disease (bNED)’
or ‘progression-free survival’. Therefore, data sets without ADT are highlighted. To facilitate comparisons,
5-year bNED/PFS read-outs from Kaplan-Meier plots are included.
ADT = androgen deprivation therapy; bNED = biochemically no evidence of disease; FU = follow up; mo =
months; n = number of patients; PFS = progression-free survival; PSA = prostate-specific antigen; SRT =
salvage radiotherapy; yr = year.
Although biochemical progression is now widely accepted as a surrogate marker of PCa recurrence, metastatic
disease, disease specific and OS are more clinically meaningful endpoints which are used to support clinical
decision making. However, low event rates and the necessity for long-term follow-up limit the volume of
available evidence, in terms both of statistics and of the effects of RT technical developments over time. Table
6.3.2 summarises results for recent studies on clinical endpoints after SRT.
Two studies report significantly better outcomes (DM, DSM and OS) in patients who re-achieve a
PSA nadir < 0.1 ng/mL after SRT without ADT [636, 639]. A recent, international, multi-institutional analysis of
pooled data from RCTs has suggested that metastasis-free survival is the surrogate endpoint of most validity, in
respect of its impact on OS [640].
Table 6.3.2: Recent studies reporting clinical endpoints after SRT
Reference Year n Median FU Regimen Outcome

(mo)
Tendulkar, et al. 2016 2,460 60 66 (64.8-68.4) Gy 10 yr DM
[637] incl. 16% ADT SRT; PSA 0.01-0.2 ng/mL 9%
SRT; PSA 0.21-0.50 ng/mL 15%
SRT; PSA 0.51-1.0 ng/mL 19%
SRT; PSA 1.01-2.0 ng/mL 20%
SRT; PSA > 2 ng/mL 37%, p < 0.001

Stish, et al. 2016 1106 107 68 (64.8-70.2) Gy 5 and 8.9 yr DM
[632] 39% 2D treatment SRT; PSA ≤ 0.5 ng/mL 7% and 12%
planning SRT; PSA > 0.5 ng/mL 14% and 23%
incl. 16% ADT p < 0.001
5 and 8.9 yr DSM
SRT; PSA ≤ 0.5 ng/mL < 1% and 6%
SRT; PSA > 0.5 ng/mL 5% and 10%
p = 0.02
5 and 8.9 yr OS
SRT; PSA ≤ 0.5 ng/mL 94% and 86%
SRT; PSA > 0.5 ng/mL 91% and 78%
p = 0.14
Jackson, et al. 2014 448 64 68.4 Gy 5 yr DM
[639] no ADT post-SRT PSA < 0.1 ng/mL 5%
post-SRT PSA ≥ 0.1 ng/mL 29%
p < 0.0001
5 yr DSM
post-SRT PSA < 0.1 ng/mL 2%
p < 0.0001
OS
post-SRT PSA < 0.1 ng/mL 97%
p < 0.0001
Bartkowiak, et 2017 464 71 66.6 (59.4- 72) Gy 5.9 yr OS
al. [636] no ADT post-SRT PSA < 0.1 ng/mL 98%
p = 0.005
ADT = androgen deprivation therapy; DM = distant metastasis; DSM = disease specific mortality;
FU = follow up; mo = months; n = number of patients; OS = overall survival; PSA = prostate specific antigen;
SRT = salvage radiotherapy.
Recent data from RTOG 9601 [641] suggested both CSS and OS benefits for adding two years of bicalutamide
to SRT. According to GETUG-AFU 16, also six months treatment with gonadotropin-releasing hormone (GnRH)
analogue can improve five-year PFS significantly, but a longer follow-up is required [642]. Both trials used
outdated radiation dosages and technique. Table 6.3.3 gives an overview of these two RCTs. A recent literature
review recommends risk stratification based on the pre-SRT PSA (> 0.7 ng/mL), margin status (positive), and
high GS, to personalise the use of hormone therapy with SRT [643].
Table 6.3.3: R
CTs comparing salvage radiotherapy alone and salvage radiotherapy combined with
androgen deprivation therapy
Reference Year n Risk groups Median FU Regimen Outcome

(mo)
GETUG-AFU 16 2016 369 RT + GS ≤ 7 89%, 63 66 Gy + GnRH analogue 5 yr PFS 80%
Carrie, et al. ADT GS ≥ 8 11% 6 mo p < 0.0001
[642] 374 RT cN0 66 Gy 5 yr PFS 62%
RTOG 9601 2017 384 pT2 R1, pT3 156 64.8 Gy + bicalutamide 12 yr DM 14%
Shipley, et al. RT + ADT cN0 24 mo p = 0.005
[641] 376 RT 64.8 Gy + placebo 12 yr DM 23%
12 yr OS 76%
p = 0.04
12 yr OS 71%
12 yr DSM 5.8%
p < 0.001
12 yr DSM 13.4%
ADT = androgen deprivation therapy; DM = distant metastasis; DSM = disease specific mortality; GS = Gleason
score; PFS = progression free survival; FU = follow-up; GnRH = gonadotropin-releasing hormone; OS = overall
survival; PFS = progression-free survival; mo = months; n = number of patients; RT = Radiotherapy; yr = years.

6.3.5.1.1 Target volume, dose, toxicity
There have been various attempts to define common outlines for “clinical target volumes” of PCa [644-647] and
for organs at risk of normal tissue complications [648]. However, given the variations of techniques and dose-
constraints, a satisfactory consensus has not yet been achieved
The optimal SRT dose has not been well defined. It should be at least 66 Gy to the prostatic fossa (plus/minus
the base of the seminal vesicles, depending on the pathological stage after RP) [633, 649]. A USA Guideline
Panel regarded 64-65 Gy as the minimum dose that should be delivered post RP [650]. However, more recent
data suggest that higher total doses can achieve higher rates of biochemical control at three to five years [651].
In a SR, the pre-SRT PSA level and SRT dose both correlated with BCR, showing that relapse-free survival
decreased by 2.4% per 0.1 ng/mL PSA and improved by 2.6% per Gy, suggesting that a treatment dose above
70 Gy should be administered at the lowest possible PSA level [652]. The combination of pT stage, margin
status and GS and the PSA at SRT seems to define the risk of biochemical progression, metastasis and overall
mortality [653-655]. The updated Stephenson nomograms incorporate the SRT-dose and ADT as predictive
factors for biochemical failure and distant metastasis [637]. In a study on 894 node-negative PCa patients,
sufficient doses ranging from 64 to ≥ 74 Gy were assigned to twelve risk groups, defined by the pre-SRT PSA
classes < 0.1, 0.1-0.2, 0.2-0.4, and > 0.4 ng/mL and the GS, ≤ 6 vs. 7 vs. ≥ 8 [656].
In one report on 464 SRT patients receiving median 66.6 (max. 72) Gy, acute Grade 2 toxicity was recorded in
4.7% for both the GI and GU tract. Two men had late Grade 3 reactions of the GI tract. Severe GU tract toxicity
was not observed. Late Grade 2 complications occurred in 4.7% (GI tract) and 4.1% (GU tract), respectively,
and 4.5% of the patients developed moderate urethral stricture [636]. In a retrospective cohort of 285 men
receiving 3D-CRT (38%) or IMRT (62%) with 66 Gy in 95% of cases, the high-dose subgroup did not show a
significant increase in toxicity [657].
In a RCT on dose escalation for SRT involving 350 patients, acute Grade 2 and 3 GU toxicity was observed in
13.0% and 0.6%, respectively, with 64 Gy and in 16.6% and 1.7%, respectively, with 70 Gy. Gastrointestinal
tract toxicity of Grades 2 and 3 occurred in 16.0% and 0.6%, respectively, with 64 Gy, and in 15.4% and 2.3%,
respectively, with 70 Gy. Late effects are yet to be reported [658].
With dose escalation over 72 Gy and/or up to a median of 76 Gy, the rate of severe side-effects, especially GU,
clearly increases, even with newer planning and treatment techniques [659, 660]. Of note, when compared with
3D-CRT, IMRT was associated with a reduction in Grade 2 GI toxicity from 10.2 to 1.9% (p = 0.02), but had no
differential effect on the relatively high level of GU toxicity (5-yr: 3D-CRT 15.8% vs. IMRT 16.8%) [659]. After a
median salvage IMRT dose of 76 Gy, the five-year risk of Grade 2-3 toxicity rose to 22% for GU and 8% for GI
symptoms, respectively [660].
6.3.5.1.2 Comparison of adjuvant radiotherapy (ART) and salvage radiotherapy (SRT)

The largest retrospective case-matching study to evaluate ART vs. early SRT included pT3N0 R0/R1 patients
only (ADT was excluded), in which 390 out of 500 observation-plus-early-SRT patients (median pre-SRT
PSA was 0.2 ng/mL) were propensity matched with 390 ART patients. Two and five years after surgery,
biochemically no evidence of disease (bNED) rates were 91% and 78% for ART vs. 93% and 82% after
salvage RT, respectively. Subgroup analyses did not yield significant differences for the two approaches. It was
concluded that early salvage RT does not impair PCa control, but clearly helps to reduce over-treatment, which
is a major issue in both ART and in SRT [661].
The results were confirmed for metastasis-free and OS [654]. However, these retrospective studies
are underpowered for high-risk cases such as pT3b/R1/GS 8-10.
Both approaches (ART and SRT) together with the efficacy of neoadjuvant ADT are currently being compared
in three prospective RCTs: the Medical Research Council (MRC) Radiotherapy and Androgen Deprivation
In Combination After Local Surgery (RADICALS) in the United Kingdom, the Trans-Tasman Oncology Group
(TROG) Radiotherapy Adjuvant Versus Early Salvage (RAVES), and Groupe d’Etude des Tumeurs Uro-Génitales
(GETUG 17).
Decision-making on whether to proceed with adjuvant RT, for high-risk PCa, pT3-4 pN0 M0 with undetectable
PSA after RP, or to postpone RT as an early salvage procedure in the event of biochemical relapse, remains
difficult. In everyday practice, the urologist should explain to the patient before RP that adjuvant RT may be of
benefit if the patient has negative prognostic risk factors. Ultimately, the decision on whether to treat requires
a multidisciplinary approach that takes into account the optimal timing of RT when it is used, and provides
justification when it is not, will best inform the discussion between the physician and the patient.

6.3.5.2 Management of PSA failures after radiation therapy
Therapeutic options in these patients are ADT or local procedures such as salvage RP (SRP), cryotherapy,
interstitial brachytherapy and HIFU [662-671]. Strong recommendations regarding the choice of any of these
techniques cannot be made as the available evidence for these treatment options is of low quality. The
following is an overview of the most important findings regarding each of these techniques with a proposal for
their indications.
6.3.5.2.1 Salvage radical prostatectomy

Salvage RP after RT has the longest history and best likelihood of local control relative to other salvage
treatments. However, this must be weighed against the possible adverse events, which are increased
compared to primary surgery because of the risk of fibrosis and poor wound healing due to radiation.
6.3.5.2.1.1 Oncological outcomes

In a recent SR of the literature, Chade, et al. showed that SRP gave five- and ten-year BCR-free survival
estimates ranging from 47-82% and from 28-53%, respectively. The ten-year CSS and OS rates ranged from
70-83% and from 54-89%, respectively. The pre-SRP PSA value and prostate biopsy GS were the strongest
predictors of the presence of organ-confined disease, progression, and CSS [672].
In most contemporary series, organ-confined disease, negative surgical margins, and the absence
of seminal vesicle and/or LN metastases were favourable prognostic indicators associated with a better DFS of
approximately 70-80%, in comparison with 40-60% in patients with locally advanced PCa [671].
Table 6.3.4: O
ncological results of selected salvage radical prostatectomy case series, including at least
30 patients
Reference n Median Pathologic PSM Lymph-node BCR-free CSS Time

FU (mo) organ- (%) involvement probability (%) probability
confined (%) (%) (%) (yr)
Sanderson, 51 - 25 36 28 47 - 5
et al. 2006
[673]
Leonardo, 32 35 53 34 0 75 - 3
et al. 2009
[674]
Heidenreich, 55 23 73 11 20 87 - 2
et al. 2010 (2-56)
[670]
Chade, et al. 404 55 55 25 16 37 83 10
2011 [675]
Mandel, et al. 55 36 50 27 22 49 89 5
2016 [676]
BCR = biochemical recurrence; CSS = cancer-specific survival; FU = follow-up; mo = months; n = number of
patients; PSM = positive surgical margin.
6.3.5.2.1.2 Morbidity
Compared to primary open RP, SRP is associated with a higher risk of later anastomotic stricture (47 vs.
5.8%), urinary retention (25.3% vs. 3.5%), urinary fistula (4.1% vs. 0.06%), abscess (3.2% vs. 0.7%) and rectal
injury (9.2 vs. 0.6%) [677]. In more recent series, these complications appear to be less common [669, 672].
Functional outcomes are also worse compared to primary surgery, with urinary incontinence ranging from 21%
to 90% and ED in nearly all patients [672].

Table 6.3.5: Peri-operative morbidity in selected salvage radical prostatectomy case series, including at
least 30 patients
Reference n Rectal injury Anastomotic Clavien 3-5 (%) Blood loss, mL,
(%) stricture (%) mean, range
Stephenson, et al. 2004 100 15 vs. 2* 30 33 vs. 13* -
[669]
Ward, et al. 2005 [678] 138 5 22 - -
Sanderson, et al. 2006 [673] 51 2 41 6 -
Gotto, et al. 2010 [677] 98 9 41 25 -
Heidenreich, et al. 2010 55 2 11 3.6 360 (150-1450)
[670]
* SRP performed before vs. after 1993.
n = number of patients.
6.3.5.2.1.3 Summary of salvage radical prostatectomy

In general, SRP should be considered only for patients with low comorbidity, a life expectancy of at least ten
years, a pre-SRP PSA < 10 ng/mL and biopsy GS ≤ 7, no LN involvement or evidence of distant metastatic
disease pre-SRP, and who’s initial clinical staging was T1 or T2 [672]. A meta-regression analysis suggested
that SRP may be associated with worse continence outcomes than non-surgical approaches [679].
6.3.5.2.2 Salvage cryoablation of the prostate

Salvage cryoablation of the prostate (SCAP) has been proposed as an alternative to SRP, as it has a potentially
lower risk of morbidity and equal efficacy. However, the very few studies available have shown disappointing
results. In a review of the use of SCAP for recurrent cancer after RT, the five-year BDFS estimates ranged from
50-70%. A durable response can be achieved in ∼50% of patients with a pre-SCAP PSA < 10 ng/mL [680].
In a multicentre study reporting the current outcome of SCAP in 279 patients, the five-year BCR-free survival
estimate according to the Phoenix criteria was 54.5 ± 4.9%. Positive biopsies were observed in 15/46 patients
(32.6%) who underwent prostate biopsy after SCAP [681].
A case-matched control study comparing SRP and SCAP was performed in men with recurrent PCa
after RT. The authors compared the oncological outcomes of the two salvage treatment options after mean
follow-up periods of 7.8 (SRP group) and 5.5 years (SCAP group). The five-year BCR-free survival was 61%
following SRP, significantly better than the 21% detected after SCAP. The five-year OS was also significantly
higher in the SRP group (95% vs. 85%) [682].
Table 6.3.6: O
ncological results of selected salvage cryoablation of the prostate case series, including at
least 50 patients
Reference n Median BCR-free Time probability Definition of failure

FU (mo) probability (%) (yr)
Pisters, et al. 1997 [682] 150 17 44 - Nadir + 0.2
Bahn, et al. 2003 [683] 59 82 59 7 PSA > 0.5
Ismail, et al. 2007 [680] 100 33 73 (low risk) 5 ASTRO
Pisters, et al. 2008 [681] 279 22 58 5 ASTRO and Phoenix
Williams, et al. 2011 [684] 187 7.46 yr 39 10 Nadir +2
Spiess, et al. 2010 [685] 450 40.8 34 - PSA > 0.5
ASTRO = American Society for Therapeutic Radiology and Oncology; BCR = biochemical recurrence; FU =
follow-up; mo = months; n = number of patients; PSA = prostate-specific antigen; yr = year.
According to Cespedes, et al. [686], the risks of urinary incontinence and ED at at least twelve months after
SCAP were as high as 28% and 90%, respectively. In addition, 8-40% of patients reported persistent rectal
pain, and an additional 4% of patients underwent surgical procedures for the management of treatment-
associated complications. In a recent study by Pisters, et al., the urinary incontinence rate was 4.4%. The
rectal fistulae rate was 1.2% and 3.2% of patients required a TURP for removal of sloughed tissue [681]. With
the use of third-generation technology, complications such as urinary incontinence and obstruction/retention
have significantly decreased during the last decade (see Table 6.3.5) [687].

Table 6.3.7: P
eri-operative morbidity, erectile function and urinary incontinence in selected salvage
cryoablation of the prostate case series, including at least 50 patients
Reference n Incontinence Obstruction/ Rectourethral ED (%)

(%) Retention (%) fistula (%)
Pisters, et al. 1997 [688] 150 73 67 1 72
Bahn, et al. 2003 [683] 59 8 - 3.4 -
Ismail, et al. 2007 [680] 100 13 4 1 -
Pisters, et al. 2008 [681] 279 4.4 3.2 1.2 -
Ahmad, et al. 2013 [689] 283 12 7 1.8 83
ED = erectile dysfunction; n = number of patients.
6.3.5.2.2.3 Summary of salvage cryoablation of the prostate

In general, SCAP should be considered only for patients with low comorbidity, a life expectancy of at least ten
years, an initial organ-confined PCa cT1c to cT2, initial GS ≤ 7, a pre-salvage PSA-DT ≥ sixteen months and a
pre-salvage PSA < 10 ng/mL.
6.3.5.2.3 Salvage brachytherapy for radiotherapy failure

Although there is no role for salvage EBRT following local recurrence after previous definitive RT, for carefully
selected patients with primary localised PCa and histologically proven local recurrence, HDR- or LDR
brachytherapy remain effective treatment options with an acceptable toxicity profile [690-692]. However, the
published series are relatively small and consequently this treatment should be offered in experienced centres
only. Fifty-two patients were treated at the Scripps Clinic with HDR brachytherapy over a period of nine years
[690]. With a median follow-up of 60 months the five-year biochemical control was 51% and only 2% Grade 3
GU toxicities were reported. Comparable with these data, 42 patients were treated in a phase-II-trial at MSKCC
in New York [693]. Of note, the median pre-treatment dose was 81 Gy given with IMRT and the prescription
HDR-dose of 32 Gy was delivered in four fractions over 30 hours. The biochemical relapse-free survival after
five years was 69% (median follow-up 36 months). Grade 2 late side-effects were seen in 15% and one patient
developed Grade 3 incontinence. However, older data with higher rates of side-effects have been reported
[694].
Using LDR brachytherapy with 103palladium, long-term outcome was reported in 37 patients with
a median follow-up of 86 months [691]. The biochemical control rate after ten years was 54%. However,
the crude rate of ≥ Grade 2 toxicity was 46% and ≥ Grade 3 toxicity was 11%. These side-effects were
comparable with a series of 31 patients treated with salvage I-125 brachytherapy in the Netherlands. Therefore,
in these small series, late side-effects seem to be lower with HDR brachytherapy [695]. In conclusion, freedom
from BCR after salvage HDR- and LDR brachytherapy is promising and the rate of severe side-effects in
experienced centres seem to be acceptable. Salvage brachytherapy remains a treatment option for selected
patients with histologically proven local recurrence after RT.
6.3.5.2.4 Salvage high-intensity focused ultrasound

Salvage HIFU has more recently emerged as an alternative thermal ablation option for radiation-recurrent PCa.
Most of the data were generated by one high-volume centre. Median follow-up was very short, and outcome
measures were non-standardised.
Table 6.3.8: O
ncological results of selected salvage high-intensity focused ultrasound case series,
including at least 20 patients
Reference n Median FU (mo) BCR-free probability (%) Negative biopsy

rate
Colombel, et al. 2006 [696] 224 15-18 - 80
Gelet, et al. 2000 [697] - - - -
Gelet, et al. 2004 [698] - - - -
Uchida, et al. 2011 [699] 22 24 59 (Phoenix) (24 mo.) 92 (only 12 biopsied)
Berge, et al. 2011 [700] 46 9 60.9 (9 mo) -
Crouzet, et al, 2017 [701] 418 42 49% (5 y); 82% CSS (7 yr) -
BCR = biochemical recurrence; CSS = cancer-specific survival; FU = follow-up; mo = months;
n = number of patients; yr = year.

Again, most of the data were generated by one high-volume HIFU centre. Important complication rates were
mentioned and are at least comparable to other salvage treatment options.
6.3.5.2.4.3 Summary of salvage high-intensity focused ultrasound

There is a lack of data which prohibits any recommendation regarding the indications for salvage HIFU.
6.3.6 Salvage lymph node dissection

Novel imaging modalities improve the early detection of nodal metastases [702]. The surgical management of
(recurrent) nodal metastases in the pelvis has been the topic of several retrospective analyses [410, 702, 703].
The majority of treated patients showed BCR but clinical recurrence-free and CSS ten-year survival over 70%
has been reported [410, 704]. Neither the template nor the real value of nodal salvage dissection is available.
It must, however, be remembered that the imaging modalities under-evaluate the real nodal involvement.
Biochemical recurrence rates were found to be dependent on PSA at surgery and location and number of
positive nodes [705]. Addition of RT to the lymphatic template after salvage LND may improve the BCR rate
[706]. The real efficacy of this salvage procedure remains unproven, as is its impact on survival [707].

The Guidelines Panel conducted a SR including studies published from 2000 onwards [708]. The key findings
are summarised below:
Conflicting results on the clinical effectiveness of HT after previous curative therapy of the primary
tumour were found. Some studies reported a favourable effect of HT, including the only RCT addressing the
research question of this review (86% vs. 79% advantage in OS in the early HT group) [709]. Other studies
did not find any differences between early vs. delayed, or no, HT. One study found an unfavourable effect of
HT [710]. This may be the result of selecting clinically unfavourable cases for (early) HT and more intensive
diagnostic work-up and follow-up in these patients.
The studied population is highly heterogeneous regarding their tumour biology and therefore clinical
course. The following factors were found predictive for poor outcomes; CRPC, distant metastases (DM),
CSS, OS, short PSA-DT, high GS, high PSA, increased age and comorbidities. In some studies, such as the
Boorjian, et al. study [587], high-risk patients, mainly defined by a high GS and a short PSA-DT (most often
less than six months), seem to benefit most from (early) HT, especially in men with a long life expectancy.
No data were found on the effectiveness of different types of HT, although it is unlikely that this will have a
significant impact on survival outcomes in this setting. Non-steroidal anti-androgens have been claimed to
be inferior compared to castration, but this difference was not seen in M0 patients [594]. One of the included
RCTs suggested that intermittent HT is not inferior to continuous HT in terms of OS and CSS [711]. A small
advantage was found in some QoL domains but not overall QoL outcomes. An important limitation of this RCT
is the lack of any stratifying criteria such as PSA-DT or initial risk factors.
Based on the lack of definitive efficacy and the undoubtedly associated significant side-effects, patients with
recurrence after primary curative therapy should not receive standard HT. Only a minority of them will progress
to metastases or PCa-caused death. The objective of HT should be to improve OS, postpone DM, and improve
QoL. Biochemical response to only HT holds no clinical benefit for a patient. For older patients and those
with comorbidities, the side-effects of HT may even decrease life expectancy; in particular, cardiovascular
risk factors need to be considered [712, 713]. Early HT should be reserved for those at highest risk of disease
progression, defined mainly by a short PSA-DT at relapse (less than six to twelve months) or a high initial GS (>
7), and a long life expectancy.
6.3.8 Observation
Observation until the development of clinically evident metastatic disease may represent a viable option for
patients with low-risk features (PSA-DT > 12 months, time to BCR > 3 years, GS ≤ 7 and stage ≤ T3a) or
unfit patients with a life expectancy less than ten years and/or are unwilling to undergo salvage treatment. In
unselected relapsing patients, the median actuarial time to the development of metastasis will be eight years
and the median time from metastasis to death will be a further five years [569].

6.3.9 Guidelines for second-line therapy after treatment with curative intent
Local salvage treatment Strength rating

Recommendations for biochemical recurrence after radical prostatectomy
Offer active surveillance and possibly delayed salvage radiotherapy (SRT) to patients with Strong
biochemical recurrence and favourable prognostic factors (≤ pT3a, time to biochemical
recurrence > three year, prostate-specific antigen doubling-time (PSA-DT) > twelve
months, Gleason score ≤ 7), who may not benefit from intervention.
Treat patients with a PSA rise from the undetectable range with SRT. Strong
The total dose of SRT should be at least 66 Gy and should be given early (PSA < 0.5 ng/mL).
Recommendations for biochemical recurrence after radiotherapy
Treat highly selected patients with localised PCa and a histologically proven local Weak
recurrence with salvage radical prostatectomy (SRP).
Salvage RP should only be performed in experienced centres. Strong
Do not offer high intensity focused ultrasound, cryosurgical ablation and salvage Strong
brachytherapy to patients with proven local recurrence since it is still experimental.
Recommendations for systemic salvage treatment
Do not offer androgen deprivation therapy to M0 patients with a PSA-DT > twelve months. Strong
6.4 Treatment: Metastatic prostate cancer

6.4.1 Introduction
A SR of ADT in PCa has been published [457].
6.4.2 Prognostic factors

Median survival of patients with newly diagnosed metastases is about 42 months [714]. However, the M1
population is heterogeneous. Several prognostic factors for survival have been suggested including the
number and location of bone metastases, visceral metastases, GS, PS status and initial PSA [715], alkaline
phosphatase [716], but none of these have been directly compared and only few have been validated [717]. In
most clinical trials, the number and location of bone metastases and the presence of visceral lesions were used
[718]. Visceral metastases, more than five bone metastases on bone scan, appendicular locations, and ISUP
groups > 3 are all independently associated with a decreased survival.
Based on a large SWOG 9346 cohort, the PSA level after seven months of ADT was used to create
three prognostic groups (see Table 6.4.1) [719]. This grouping, however, still requires independent confirmation.
Table 6.4.1: Prognostic factors based on the SWOG 9346 study
PSA after 7 months of castration Median survival

< 0.2 ng/mL 75 months
0.2 < 4 ng/mL 44 month
> 4 ng/mL 13 months
6.4.3 First-line hormonal treatment

Primary ADT has been the standard of care for over 50 years [457]. There is no level 1 evidence in favour
of a specific type of ADT, neither for orchiectomy nor for an LHRH analogue or antagonist. The exception
are patients with impending spinal cord compression for whom either a bilateral orchidectomy, or LHRH
antagonists are the preferred options.
6.4.4 Combination therapies

6.4.4.1 Complete androgen blockade
The largest RCT in 1,286 M1b patients found no difference between surgical castration with or without
flutamide [720]. However, results with other anti-androgens or castration modalities have differed and SRs have
shown that CAB using a non-steroidal anti-androgen (NSAA) appears to provide a small survival advantage
(< 5%) vs. monotherapy (surgical castration or LHRH agonists) [721, 722] beyond five years of survival [723]
but this minimal advantage in a small subset of patients must be balanced against the increased side-effects
associated with long-term use of NSAAs.

6.4.4.2 Non-steroidal anti-androgen monotherapy
Based on a Cochrane SR [724] comparing NSAA monotherapy to castration (either medical or surgical),
NSAA was considered to be less effective in terms of OS, clinical progression, treatment failure and treatment
discontinuation due to adverse events. The evidence quality of the studies included in this review was rated as
moderate.
6.4.4.3 Intermittent versus continuous androgen deprivation therapy

Three independent reviews [725-727] and two meta-analyses [728, 729], looked at the clinical efficacy of
intermittent androgen deprivation (IAD) therapy. All of these reviews included eight RCTs of which only three
were conducted in patients with exclusively M1 disease. The five remaining trials included different patient
groups, mainly locally advanced and metastatic patients relapsing.
So far, the SWOG 9346 [730] is the largest trial addressing IAD in M1b patients. Out of 3,040 screened patients,
only 1,535 patients finally met the inclusion criteria. This highlights that, at best, only 50% of M1b patients can
be expected to be candidates for IAD, i.e. the best PSA responders. This was a non-inferiority trial leading to
inconclusive results: the actual upper limit was above the pre-specified 90% upper limit of 1.2 (HR: 1.1; CI:
0.99-1.23), the pre-specified non-inferiority limit was not achieved, and the results did not show a significant
inferiority for any treatment arm. However, based on this study inferior survival with IAD cannot be completely
ruled out.
Other trials did not show any survival difference with an overall HR for OS of 1.02 (0.94-1.11) [725].
These reviews and the meta-analyses came to the conclusion that a difference in OS or CSS between IAD
and continuous ADT is unlikely. A recent review of the available phase III trials highlighted the limitations of
most trials and suggested a cautious interpretation of the non-inferiority results [731]. None of the trials that
addressed IAD vs. continuous ADT in M1 only patients showed a survival benefit in favour of the latter, but
there was a trend towards better OS and PFS with continuous ADT. Most of these trials, however, were non-
inferiority trials. There is a trend favouring IAD in terms of QoL, especially regarding treatment-related side-
effects, such as hot flushes. In some cohorts the negative impact on sexual function was less pronounced with
IAD. Two prospective trials came to the same conclusions [732, 733].
Other possible long-term benefits of IAD from non-RCT include a protective effect against bone loss, metabolic
syndrome and cardiovascular problems [734]. This possible protective effect was recently challenged by the
results from a detailed analysis of the SWOG 9346 trial [735]. These results showed an increased risk for
thrombotic and ischaemic events, while there was no benefit concerning endocrine, psychiatric, sexual and
neurological side-effects with IAD. Testosterone recovery was observed in most studies [736] leading to only
intermittent castration. These outcomes, as well as the lack of any survival benefit in M1 patients, suggest
that this treatment modality should only be considered as an option in a well-informed patient bothered by
significant side-effects.
The PSA threshold at which ADT must be stopped or resumed for IAD still needs to be defined in prospective
studies [726, 736]. Nevertheless, there is consensus amongst many authors on the following statements:
• IAD is based on intermittent castration; therefore, only drugs leading to castration are suitable.
• Luteinising-hormone releasing hormone antagonist might be a valid alternative to an agonist.
• The induction cycle should not be longer than nine months, otherwise testosterone recovery is unlikely.
• Androgen deprivation therapy should be stopped only if all of the following criteria have been met:
-- well-informed and compliant patient;
-- no clinical progression;
-- a clear PSA response, empirically defined as a PSA < 4 ng/mL in metastatic disease.
• Strict follow-up is mandatory which should include a clinical examination every three to six months. The
more advanced the disease, the closer the follow-up should be.
• PSA should always be measured by the same laboratory.
• Treatment is resumed when the patient progresses clinically, or has a PSA rising above a pre-determined
(empirically set) threshold: usually 10-20 ng/mL in metastatic patients.
• The same treatment is used for at least three to six months.
• Subsequent cycles of treatment are based on the same principles until the first sign of castration
resistance becomes apparent.
• The group of patients who will benefit most from IAD still has to be defined but the most important factor
seems to be the patient’s response to the first cycle of IAD, e.g. the PSA level response [726].
6.4.4.4 Immediate versus deferred androgen deprivation therapy

In symptomatic patients, immediate treatment is mandatory. However, controversy still exists for asymptomatic

metastatic patients due to the lack of quality studies. A Cochrane review extracted four good-quality RCTs:
the VACURG I and II trials, the MRC trial, and the ECOG 7887 study [724]. All of these studies were conducted
in the pre-PSA era and included patients with advanced PCa, who had received early vs. deferred ADT, either
as primary therapy or as adjuvant therapy after RP [737]. No improvement in OS was observed in the M1a/b
population, although early ADT significantly reduced disease progression and associated complications.
6.4.5 Androgen deprivation combined with other agents

6.4.5.1 Combination with abiraterone acetate
In two large RCTs (STAMPEDE, LATITUDE) the addition of abiraterone acetate (1000 mg daily) plus Prednisone
(5 mg daily) (AA plus P) to ADT in men with hormone-sensitive metastatic prostate cancer (mHSPC) was
studied [738, 739]. The primary objective of both trials was an improvement in OS. Both trials showed a
significant OS benefit of 38% at three years [HR: 0.62 (0.53-0.71) [740]. The inclusion criteria in the two trials
differed with respect to risk definition, but both trials were positive for OS. This suggests that the treatment with
ADT plus AA plus P should be a standard for all patients and not be restricted to a specific high-risk group e.g.
as defined in LATITUDE [738].
All secondary objectives such as progression-free survival, time to radiographic progression, time to
pain, or time to chemotherapy were positive and in favour of the combination. The key findings are summarised
in Table 6.4.2. No difference in treatment related deaths was observed with the combination of ADT plus AA
plus P compared to ADT monotherapy [HR: 1.37 (0.82-2.29]. However, twice as many patients discontinued
treatment due to for toxicity in the combination arms in STAMPEDE (20%) compared to LATITUDE (12%).
Based on these data, upfront docetaxel combined with ADT should be considered as a standard in men
presenting with metastases at first presentation, provided they are fit enough to receive the drug [741].
M0 and M1 relapsing patients were included in the STAMPEDE study, but not in LATITUDE [738,
739]. In the subgroup of M0 patients, there was no improvement in OS. This lack of benefit might be related
to the relatively short follow-up period and very few events. Therefore, combination treatment should not be
considered as standard in patients with M0 HSPC. As to patients relapsing after a local treatment [20] there is
also some uncertainty since only a small group of such patients was included in STAMPEDE [740]. Therefore,
combination treatment in such patients should be based on an individual discussion with the patient but
cannot be regarded as the standard of care.
Table 6.4.2: Results from the STAMPEDE arm G and LATITUDE studies
STAMPEDE LATITUDE [Fizazi]

[James] [739] [738]
ADT ADT + AA + P ADT + placebo ADT + AA + P
n 957 960 597 602
Newly diagnosed N+ 20% 19% 0 0
Newly diagnosed M+ 50% 48% 100% 100%
Key inclusion criteria Patients scheduled for long-term ADT Newly diagnosed M1 disease and 2 out
- newly diagnosed M1 or N+ situations of the 3 risk factors: GS ≥ 8, ≥ 3 bone
- locally advanced (at least two of cT3 cT4, lesions, measurable visceral metastasis
GS ≥ 8, PSA ≥ 40 ng/mL)
- relapsing locally treated disease with a
PSA > 4 ng/mL and a PSA-DT < 6 mo. OR
PSA > 20 ng/mL, OR nodal OR metastatic
relapse
Primary objective Overall survival Overall survival
Radiographic progression-free survival
Median follow up (mo) 40 30.4
3 years overall survival 83% (ADT + AA + P) 66% (ADT + AA + P)
76% (ADT) 49% (ADT + placebo)
HR (95% CI) 0.63 (0.52 - 0.76) 0.62 (0.51-0.76)

M1 only
n= 1002 1199
3 years overall survival NA 66% (ADT + AA + P)
49% (ADT + placebo)
HR (95% CI) 0.61 (0.49-0.75) 0.62 (0.51-0.76)
HR Failure-free survival (biological, Radiographic progression-free survival:
radiological, clinical or death): 0.29 (0.25- 0.49 (0.39-0.53)
0.34)
AA = abiraterone acetate; ADT = androgen deprivation therapy; CI = confidence interval; GS = Gleason score;
HR = hazard ratio; mo = month; n = number of patients; NA = not available; P = prednisone.
6.4.5.2 ADT combined with chemotherapy

Three large RCTs were conducted [718, 742, 743]. All trials compared ADT alone as the standard of care
with ADT combined with immediate docetaxel (75 mg/sqm, every three weeks) (within three months of ADT
initiation). The primary objective in all three studies was OS. The key findings are summarised in Table 6.4.3.
Table 6.4.3: Key findings - Hormonal treatment combined with chemotherapy
Study Population n Med FU Median OS (mo) HR p-value

(mo) ADT + D ADT
Gravis, et al. M1 385 50 58.9 54.2 1.01 (0.75-1.36) 0.955
[743]
ASCO GU HV : 47% 82.9 60.9 46.5 0.9 (0.7-1.2) 0.44
2015 [744]
Sweeney, et al. M1 HV: 65% 790 28.9 57.6 44 0.61 (0.47-0.8) < 0.001
[718]
STAMPEDE [742] M1 [61%]/N+ 1,184 /593 (D) 81 71 0.78 (0.66-0.93) 0.006
[15%]/relapse 593 (D + ZA)
76 n.r. 0.82 (0.69-0.97) 0.022
M1 only 725 + 362 (D) 60 45 0.76 (0.62-0.92) 0.005
D = docetaxel; FU = follow-up; HR = hazard ratio; HV = high volume: either visceral metastases or more than
four bone metastases, with at least one outside the spine and pelvis; n = number of patients; n.r. = not reported;
ZA = zoledronic acid.
In the GETUG 15 trial, all patients had newly diagnosed M1 PCa, either de novo or after a primary treatment
[743]. They were stratified based on previous treatment, and Glass risk factors [715]. In the Chemo-hormonal
Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED)
trial, the same inclusion criteria applied and patients were stratified according to disease volume; high volume
being defined as either presence of visceral metastases or four, or more, bone metastases, with at least one
outside the spine and pelvis [718].
STAMPEDE is a multi-arm multi-stage trial in which the reference arm (ADT monotherapy) included
1,184 patients. One of the experimental arms was docetaxel combined with ADT (n = 593), another was
docetaxel combined with zoledronic acid (n = 593). Patients were included with either M1, or N1, or having
two of the following three criteria: T3/4, PSA ≥ 40 ng/mL or Gleason 8-10. Also relapsed patients after local
treatment were included if they met one of the following criteria: PSA ≥ 4 ng/mL with a PSA-DT < 6 months or a
PSA ≥ 20 ng/mL, N1 or M1. No stratification was used regarding metastatic disease volume (high/low volume)
[742].
In all three trials toxicity was mainly haematological with around 12-15% Grade 3-4 neutropenia,
and 6-12% Grade 3-4 febrile neutropenia. The use of granulocyte colony-stimulating factor receptor (GCSF)
was shown to be beneficial in reducing febrile neutropenia. Primary or secondary prophylaxis with GCSF
should be based on available guidelines [741, 745].
Based on these data, upfront docetaxel combined with ADT should be considered as a standard in men
presenting with metastases at first presentation, provided they are fit enough to receive the drug [741].
Docetaxel is used at the standard dose of 75 mg/sqm combined with steroids as premedication. Prolonged
corticosteroid therapy is not mandatory.
6.4.5.3 Treatment selection and patient selection

The choice between six cycles of docetaxel and the long-term use of AA + P in newly diagnosed mHSPC

remains open. Both modalities have different and agent-specific side-effects. Mainly febrile neutropenia with
docetaxel and cardiovascular events potentially related to mineralocorticoid-associated side-effects as well
as hepatic disorders with AA plus P. Both treatments require a strict follow-up policy. Therefore, the choice will
most likely be driven by patient preference, the specific side-effects, availability and cost.
6.4.6 Deferred treatment for metastatic PCa (stage M1)

The only candidates with metastasised disease who may possibly be considered for deferred treatment are
asymptomatic patients with a strong wish to avoid treatment-related side-effects. However, since the median
survival is 42 months only, the time without treatment (before symptoms) is short in most cases. The risk of
developing symptoms, and even death from PCa, without receiving any benefit from hormone treatment has
been highlighted [525, 531]. Patients with deferred treatment for advanced PCa must be amenable to close
follow-up.
6.4.7 Treatment of the primary tumour in newly diagnosed metastatic disease

Several cohort studies suggest an OS and CSS benefit when RP or brachytherapy are added to ADT in newly
diagnosed M1 patients [746]. The lack of clear treatment selection criteria is a major limitation of these findings.
Prospective trials are ongoing addressing this important question and until they report, such interventions
should still be considered experimental.
6.4.8 Metastasis-directed therapy

In patients relapsing after a local treatment, a metastases-targeting therapy has been proposed, with the aim
to delay systemic treatment. A recent SR clearly highlighted that at this time this approach must, as yet, be
considered as experimental [705].
6.4.9 Guidelines for the first-line treatment of metastatic disease

In M1 symptomatic patients, offer immediate systemic treatment to palliate symptoms Strong
and reduce the risk for potentially serious sequelae of advanced disease (spinal cord
compression, pathological fractures, ureteral obstruction, extra-skeletal metastasis).
Offer luteinizing hormone-releasing hormone (LHRH) antagonists, especially to patients Weak
with an impending spinal cord compression or bladder outlet obstruction.
In M1 asymptomatic patients, offer immediate systemic treatment to improve survival, Strong
defer progression to a symptomatic stage and prevent serious disease progression-
related complications.
In M1 asymptomatic patients, discuss deferred castration with a well-informed patient Weak
since it lowers the treatment side-effects, provided the patient is closely monitored.
In M1 patients treated with a LHRH agonist, offer short-term administration of anti- Weak
androgens to reduce the risk of the ‘flare-up’ phenomenon.
Do not offer anti-androgen monotherapy for M1 disease. Strong
Offer castration combined with chemotherapy (docetaxel) to all patients whose first Strong
presentation is M1 disease and who are fit enough for docetaxel.
Offer castration combined with abiraterone acetate plus prednisone to all patients whose Strong
first presentation is M1 disease and who are fit enough for the regimen.
Offer castration alone, with or without an anti-androgen, to patients unfit for, or unwilling Strong
to consider, castration combined with docetaxel or abiraterone acetate plus prednisone.
Intermittent treatment
In asymptomatic M1 patients, only offer intermittent treatment to highly motivated men, Strong
with a major prostate-specific antigen (PSA) response after the induction period.
• In M1 patients, follow the schedules used in published clinical trials on timing of Weak
intermittent treatment.
• Stop treatment when the PSA level is < 4 ng/mL after six to seven months of
treatment.
• Resume treatment when the PSA level is > 10-20 ng/mL (or returned to the initial level
of < 20 ng/mL).
Do not use castration combined with any local treatment (radiotherapy/surgery) outside an Strong
investigational setting except for symptom control.

6.5 Treatment: Castration-resistant PCa (CRPC)
6.5.1 Definition of Castration-resistant PCa
Castrate serum testosterone < 50 ng/dL or 1.7 nmol/L plus either;
a. Biochemical progression: Three consecutive rises in PSA one week apart resulting in two 50% increases
over the nadir, and a PSA > 2 ng/mL or,
b. Radiological progression: The appearance of new lesions: either two or more new bone lesions on bone
scan or a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumours) [747].
Symptomatic progression alone must be questioned and subject to further investigation. It is not
sufficient to diagnose CRPC.
6.5.2 Non-metastatic castration-resistant PCa

Frequent PSA testing for men on treatment with ADT has resulted in earlier detection of biochemical
progression. Of these men approximately one-third will develop bone metastases detectable on bone scan
within two years [748], however, there are no available studies suggesting a benefit for immediate treatment.
In the STRIVE trial (a) Enzalutamide was compared to bicalutamide including a sub group of men with no
apparent evidence of metastatic disease and showed a decrease in rPFS but OS was not assessed and
currently there is insufficient evidence to allow a recommendation to be provided [749].
In men with CRPC and no detectable clinical metastases using bone scan and CT-scan, baseline
PSA level, PSA velocity and PSA-DT have been associated with time to first bone metastasis, bone metastasis-
free and OS [748, 750]. These factors may be used when deciding which patients should be evaluated for
metastatic disease. A consensus statement by the PCa Radiographic Assessments for Detection of Advanced
Recurrence (RADAR) group [751] suggested a bone scan and a CT scan when the PSA reached 2 ng/mL and if
this was negative it should be repeated when the PSA reached 5 ng/mL, and again after every doubling of the
PSA based on PSA testing every three months for asymptomatic men. Symptomatic patients should undergo
relevant investigation regardless of PSA level.
6.5.3 Metastatic castration-resistant PCa

The remainder of this Section focuses on the management of men with proven metastatic CRPC (mCRPC).
6.5.3.1 Conventional androgen deprivation in castration-resistant PCa

Eventually men with PCa will show evidence of disease progression despite castration. Two trials have
shown only a marginal survival benefit for patients remaining on LHRH analogues during second- and third-
line therapies [752, 753]. However, in the absence of prospective data, the modest potential benefits of a
continuing castration outweigh the minimal risk of treatment. In addition, all subsequent treatments have been
studied in men with ongoing androgen suppression and therefore it should be continued in these patients.
Table 6.5.1: R
andomised phase III controlled trials - first-line treatment of metastatic castration-resistant
PCa*
Author Intervention Comparison Selection Criteria Main outcomes

DOCETAXEL
SWOG 99-16 docetaxel/EMP, mitoxantrone, OS: 17.52 vs. 15.6 mo.
Petrylak, DP, et al. every 3 weeks, every 3 weeks, (p = 0.02, HR: 0.80;
2004 [754] 60 mg/m2, EMP 12 mg/m2 95% CI: 0.67-0.97)
3 x 280 mg/day prednisone 5 mg PFS: 6.3 vs. 3.2 mo.
BID (p < 0.001)
TAX 327 2008 [755, docetaxel, every mitoxantrone, OS: 19.2 for 3 weekly
756] 3 weeks, 75 mg/m2 every 3 weeks, vs. 17.8 mo. four
prednisone 5 mg 12 mg/m2, weekly and 16.3 in
BID Prednisone 5 the control group.
Or mg BID (p = 0.004, HR: 0.79
docetaxel, 95% CI: 0.67-0.93)
weekly, 30 mg/m2
prednisone 5 mg
BID

ABIRATERONE
COU-AA-302 abiraterone + placebo + - No previous OS: 34.7 vs. 30.3 mo.
Ryan CJ, et al. 2013 prednisone prednisone docetaxel. (HR: 0.81 p = 0.0033).
[757-759] - ECOG 0-1. FU: 49.2 mo.
- PSA or rPFS: 16.5 vs. 8.3 mo.
radiographic p < 0.0001)
progression.
- No or mild
symptoms.
- No visceral
metastases.
ENZALUTAMIDE
PREVAIL Beer TM, enzalutamide placebo - No previous OS: 32.4 vs. 30.2 mo.
et al.2014 [760] docetaxel. (p <.001). FU: 22 mo.
- ECOG 0-1. (p < 0.001 HR: 0.71,
- PSA or 95% CI: 0.60-0.84)
radiographic rPFS: 20.0 mo. vs.
progression. 5.4 mo.
- No or mild HR: 0.186 (95% CI:
symptoms. 0.15-0.23) p < 0.0001)
- 10% had visceral
mets.
SIPULEUCEL-T
Kantoff PW, et al. sipuleucel-T [762] placebo [762] - Some with OS: 25.8 vs. 21.7 mo.
2010 [761] previous (p = 0.03 HR: 0.78,
docetaxel. 95% CI: 0.61-0.98).
- ECOG 0-1. FU: 34.1 mo. PFS:
- Asymptomatic or 3.7 vs. 3.6 mo. (no
minimally difference)
symptomatic.
Small EJ, et al. 2006 sipuleucel-T [763] Placebo [763] - ECOG 0-1. OS: 25.9 vs. 21.4 mo.
[763] - No visceral (p. 01). FU: 36 mo.
metastases. PFS: 11.7 vs. 10.0 wk.
- No bone or cancer
pain.
- No corticosteroids.
BID = twice a day; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group;
EMP = estramustine; FU = follow-up; HR = hazard ratio; mo = month; PFS = progression-free survival;
rPFS = radiographic progression-free survival; OS = overall survival.
6.5.4 First-line treatment of metastatic castration-resistant PCa

6.5.4.1 Abiraterone
Abiraterone was evaluated in 1,088 chemo-naïve, asymptomatic or mildly symptomatic mCRPC patients in the
phase III trial COU-AA-302. Patients were randomised to abiraterone acetate or placebo, both combined with
prednisone [757]. Patients with visceral metastases were excluded. The main stratification factors were Eastern
Cooperative Oncology Group (ECOG) PS 0 or 1 and asymptomatic or mildly symptomatic disease. Overall
survival and radiographic PFS (rPFS) were the co-primary endpoints. After a median follow-up of 22.2 months,
there was significant improvement of rPFS (median 16.5 vs. 8.2 months, HR: 0.52, p < 0.001) and the trial was
unblinded. At the final analysis with a median follow-up of 49.2 months, the OS endpoint was significantly
positive (34.7 vs. 30.3 months, HR: 0.81, 95% CI: 0.70-0.93, p = 0.0033) [759]. Adverse events (AEs) related
to mineralocorticoid excess and liver function abnormalities were more frequent with abiraterone, but mostly
Grade 1-2. Sub-set analysis of this trial showed the drug to be equally effective in an elderly population (> 75
years) [764].
6.5.4.2 Enzalutamide
A randomised phase III trial (PREVAIL) [760] included a similar patient population and compared enzalutamide
and placebo. Men with visceral metastases were eligible but the numbers included were small. Corticosteroids
were allowed but not mandatory. PREVAIL was conducted in a chemo-naïve mCRPC population of 1,717
men and showed a significant improvement in both co-primary endpoints, rPFS (HR: 0.186; CI: 0.15-0.23,

p < 0.0001), and OS (HR: 0.706; CI: 0.6-0.84, p < 0.001). A ≥ 50% decrease in PSA was seen in 78%
of patients. The most common clinically relevant AEs were fatigue and hypertension. Enzalutamide was
equally effective and well tolerated in men > 75 years [765] as well as in those with or without visceral
metastases [766]. However, for men with liver metastases, there seems to be no discernible benefit [766,
767]. Enzalutamide has also been compared with bicalutamide in a phase II study [768] revealing a significant
improvement in PFS (15.7 months vs. 5.8 months, HR 0.44, p < 0.0001).
6.5.4.3 Docetaxel
A significant improvement in median survival of 2-2.9 months occurred with docetaxel-based chemotherapy
compared to mitoxantrone plus prednisone therapy [756, 769]. The standard first-line chemotherapy is
docetaxel 75 mg/m2 three-weekly doses combined with prednisone 5 mg BID, up to ten cycles. Prednisone
can be omitted if there are contraindications or no major symptoms. The following independent prognostic
factors: visceral metastases, pain, anaemia (Hb < 13 g/dL), bone scan progression, and prior estramustine
may help to stratify response to docetaxel. Patients can be categorised into three risk groups: low risk (0 or 1
factor), intermediate (2 factors) and high risk (3 or 4 factors), showing three significantly different median OS
estimates of 25.7, 18.7 and 12.8 months, respectively [770].
Age by itself is not a contraindication to docetaxel [771] but attention must be paid to careful
monitoring and comorbidities as discussed in Section 5.4 [772]. In men with mCRPC who are thought to be
unable to tolerate the standard dose and schedule, docetaxel 50 mg/m2 every two weeks seems to be well
tolerated with less Grade 3-4 AEs and a prolonged time to treatment failure [773].
6.5.4.4 Sipuleucel-T
In 2010, a phase III trial of sipuleucel-T showed a survival benefit in 512 asymptomatic or minimally
symptomatic mCRPC patients [750]. After a median follow-up of 34 months, the median survival was 25.8
months in the sipuleucel-T group compared to 21.7 months in the placebo group, with a HR of 0.78 (p = 0.03).
No PSA decline was observed and PFS was similar in both arms. The overall tolerance was very good, with
more cytokine-related AEs Grade 1-2 in the sipuleucel-T group, but the same Grade 3-4 AEs in both arms.
Sipuleucel-T is not available in Europe.
Table 6.5.2: Randomised controlled phase III - second-line trials in metastatic castration-resistant PCa*
Author Intervention Comparison Selection criteria Main outcomes

ABIRATERONE
Fizazi, et al. 2012 abiraterone + placebo + Previous docetaxel. OS: 15.8 vs. 11.2 mo (p < 0.0001).
[774] prednisone prednisone ECOG 0-2. FU: 20.2 mo.
HR PSA or radiographic
progression. Radiologic PFS: no change
de Bono, et al. 2011 OS: 14.8 vs. 10.9 mo.
[775] (p < 0.001 HR: 0.65; 95% CI:
0.54-0.77). FU: 12.8 mo.
Radiologic PFS: 5.6 vs. 3.6 mo.

Radium-223
Parker, et al. 2013 radium-223 Placebo Previous or no OS: 14.9 vs. 11.3 mo. (p = 0.002,
[776] previous docetaxel. HR: 0.61; 95% CI: 0.46-0.81).
ECOG 0-2.
Two or more All secondary endpoints show a
symptomatic bone benefit over best standard of care
metastases.
No visceral
metastases.

CABAZITAXEL
Bahl, et al. 2013 cabazitaxel + mitoxantrone Previous OS: 318/378 vs. 346/377 events
[777] prednisone + docetaxel. (odds ratio 2.11; 95% CI: 1.33-
prednisone ECOG 0-2. 3.33).
FU: 25.5 months
OS > 2y 27% vs. 16%
PFS: -
deBono, et al. 2010 OS: 15.1 vs. 12.7 mo.
[778] (p < 0.0001,
HR: 0.70; 95% CI: 0.59-0.83). FU:
12.8 mo.
PFS: 2.8 vs. 1.4 mo. (p < 0.0001,

HR: 0.74; 95% CI: 0.64-0.86)
ENZALUTAMIDE
Scher, et al. 2012 enzalutamide Placebo Previous OS: 18.4 vs. 13.6 mo. (p < 0.001
[779] docetaxel. HR: 0.63; 95% CI: 0.53-0.75).
ECOG 0-2. FU: 14.4 mo.
Radiologic PFS: 8.3 vs. 2.9 mo.

HR: 0.40; 95% CI: 0.35-0.47
p < 0.0001)
*Only studies reporting survival outcomes as primary endpoints have been included.
CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; FU = follow-up; HR = hazard ratio;
mo = months OS = overall survival; PFS = progression-free survival.
6.5.5 Second-line treatment for mCRPC

All patients who receive treatment for mCRPC will eventually progress. All treatment options in this setting are
presented in Table 6.5.2.
6.5.5.1 Cabazitaxel
Cabazitaxel is a novel taxane with activity in docetaxel-resistant cancers. It was studied in a large prospective,
randomised, phase III trial (TROPIC trial) comparing cabazitaxel plus prednisone vs. mitoxantrone plus
prednisone in 755 patients with mCRPC, who had progressed after or during docetaxel-based chemotherapy
[778]. Patients received a maximum of ten cycles of cabazitaxel (25 mg/m2) or mitoxantrone (12 mg/m2) plus
prednisone (10 mg/day), respectively. Overall survival was the primary end-point, which was significantly
longer with cabazitaxel (median: 15.1 vs. 12.7 months p < 0.0001). There was also a significant improvement
in PFS (median: 2.8 vs. 1.4 months, p < 0.0001), objective RECIST response (14.4% vs. 4.4%, p < 0.005), and
PSA response rate (39.2% vs. 17.8%, p < 0.0002). Treatment-associated WHO Grade 3-4 AEs developed
significantly more often in the cabazitaxel arm, particularly haematological (68.2% vs. 47.3%, p < 0.0002) but
also non-haematological (57.4 vs. 39.8%, p < 0.0002) toxicity [780]. In two post-marketing randomised phase
3 trials, firstly, cabazitaxel was shown not to be superior to docetaxel in the first-line setting and, secondly,
20 mg/m² cabazitaxel is not inferior to 25 mg/m² in the second-line setting in terms of OS, but it is less toxic.
Therefore, the lower dose should be preferred [781, 782]. In any case, cabazitaxel should preferably be
given with prophylactic granulocyte colony-stimulating factor and should be administered by physicians with
expertise in handling neutropenia and sepsis [783].
6.5.5.2 Abiraterone acetate after prior docetaxel

Positive results of the large phase III COU-AA-301 trial were reported after a median follow-up of 12.8 months
[775] and confirmed by the final analysis [774]. A total of 1,195 patients with mCRPC were randomised 2:1
to abiraterone acetate plus prednisone or placebo plus prednisone. All patients had progressive disease
based on the PCWG2 criteria after docetaxel therapy (with a maximum of two previous chemotherapeutic
regimens). The primary end-point was OS, with a planned HR of 0.8 in favour of abiraterone. After a median
follow-up of 20.2 months, the median survival in the abiraterone group was 15.8 months compared to 11.2
months in the placebo arm (HR: 0.74, p < 0.0001). The benefit was observed in all subgroups and all the
secondary objectives were in favour of abiraterone (PSA, radiologic tissue response, time to PSA or objective
progression). The incidence of the most common Grade 3-4 AEs did not differ significantly between arms, but
mineralocorticoid-related side-effects were more frequent in the abiraterone group, mainly Grade 1-2 (fluid
retention, oedema and hypokalaemia).

6.5.5.3 Enzalutamide after docetaxel
The planned interim analysis of the AFFIRM study was published in 2012 [779]. This trial randomised 1,199
patients with mCRPC in a 2:1 fashion to enzalutamide or placebo. The patients had progressed after docetaxel
treatment, according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria. Corticosteroids
were not mandatory, but could be prescribed, and were received by about 30% of the patients. The primary
end-point was OS, with an expected HR benefit of 0.76 in favour of enzalutamide. After a median follow-up of
14.4 months, the median survival in the enzalutamide group was 18.4 months compared to 13.6 months in the
placebo arm (HR: 0.63, p < 0.001). This led to the recommendation to halt and unblind the study. The benefit
was observed irrespective of age, baseline pain intensity, and type of progression. In the final analysis with
longer follow-up the OS results were confirmed despite crossover and extensive post progression therapies
[784].
All the secondary objectives were in favour of enzalutamide (PSA, soft tissue response, QoL, time
to PSA or objective progression). No difference in terms of side-effects was observed in the two groups, with
a lower incidence of Grade 3-4 AEs in the enzalutamide arm. There was a 0.6% incidence of seizures in the
enzalutamide group compared to none in the placebo arm.
6.5.5.4 Radium-223
The only bone-specific drug that is associated with a survival benefit is the α-emitter radium-223. In a large
phase III trial (ALSYMPCA), 921 patients with symptomatic mCRPC, who failed or were unfit for docetaxel,
were randomised to six injections of 50 kBq/kg radium-223 or placebo, plus standard of care. The primary
end-point was OS. Radium-223 significantly improved median OS by 3.6 months (HR: 0.70; p < 0.001) [776]. It
was also associated with prolonged time to first skeletal event, improvement in pain scores and improvement
in QoL. The associated toxicity was mild and, apart from slightly more haematologic toxicity and diarrhoea with
radium-223, it did not differ significantly from that in the placebo arm [776]. Radium-223 was effective and safe
no matter if the patients were docetaxel pre-treated, or not [785].
6.5.6 Treatment after docetaxel and one line of hormonal treatment for mCRPC
The choice of further treatment after docetaxel and one line of hormonal treatment for mCRPC is open [786].
Either Radium-223 or second-line chemotherapy (cabazitaxel) are reasonable options. In general, subsequent
treatments in unselected patients are expected to have less benefit than with earlier use [787, 788] and there
is evidence of cross-resistance between enzalutamide and abiraterone [789]. Poly(ADP-ribose) polymerase
(PARP) inhibitors have shown high rates of response in men with somatic homologous recombination
deficiency (HRD) in initial studies. Men previously treated with both docetaxel and at least one novel hormonal
agent and whose tumours demonstrated homozygous deletions or deleterious mutations in DNA-repair genes
showed an 88% response rate [790]. Patients without HRD did not show a clear benefit from olaparib. Although
not yet available, PARP inhibitors offer an exciting new opportunity to tailor therapy based on the mutation
profile contained within a tumour.
6.5.7 Monitoring of treatment

Baseline examinations should include history and clinical examination as well as baseline bloods (PSA,
FBC, renal function, LFTs, ALP), bone scan and CT of chest abdomen and pelvis [791]. Prostate-specific
antigen alone is not reliable enough [792] for monitoring disease activity in advanced CRPC, since visceral
metastases may develop in men without rising PSA [793]. Instead, PCWG2 recommends a combination of
bone scintigraphy and CT scans, PSA measurements and clinical benefit in assessing men with CRPC [769].
A majority of experts at a recent consensus meeting suggested regular review and repeat blood profile every
two to three months with bone scintigraphy and CT scans at least every six months, even in the absence
of a clinical indication [791]. This reflects that the agents with a proven OS survival benefit all have potential
toxicity and considerable cost, and patients with no objective benefit should have treatment modified. This
panel stressed that such treatments should not be stopped for PSA progression alone. Instead, at least two
of three criteria (PSA progression, radiographic progression and clinical deterioration) should be fulfilled to
stop treatment. For trial purposes, the updated PCWG3 put more weight on the importance of documenting
progression in existing lesions and introduced the concept of “no longer clinically benefiting” to underscore the
distinction between first evidence of progression and the clinical need to terminate or change treatment [794].
These recommendations also seem valid for clinical practice outside trials.
6.5.8 When to change treatment

The timing of mCRPC treatment change remains a matter of debate in mCRPC although it is clearly advisable
to start or change treatment immediately in men with symptomatic progressing metastatic disease. Although,
the number of effective treatments is increasing, head to head comparisons are still lacking, as are data
assessing the sequencing of available agents. Therefore it is not clear how to choose the appropriate “second-

line” treatment. In the absence of other data, the inclusion criteria from licensing trials have been used to
prioritise treatment sequencing.
The Eastern Cooperative Oncology group PS has been used to stratify patients. Generally men with
a PS of 0-1 are likely to tolerate treatments and those with PS of 2 or more are less likely to benefit. However,
it is important that treatment decisions are individualised. This applies particularly where symptoms related
to disease progression are determining PS. In such cases it may be appropriate to trial active life-prolonging
agents to establish if treatment would improve PS. Sequencing is discussed in a summery paper published
following the St. Gallen Advanced Prostate Cancer Consensus Conference 2017 [791, 795].
6.5.9 Symptomatic management in metastatic castration-resistant PCa

Castration-resistant PCa is usually a debilitating disease, often affecting the elderly male. A multidisciplinary
approach is required with input from urologists, medical oncologists, radiation oncologists, nurses,
psychologists and social workers [796]. Critical issues of palliation must be addressed when considering
additional systemic treatment, including management of pain, constipation, anorexia, nausea, fatigue and
depression.
6.5.9.1 Common complications due to bone metastases

Most patients with CRPC have painful bone metastases. External beam radiotherapy is highly effective [797],
even as a single fraction [798]. A single infusion of a third generation bisphosphonate could be considered
when RT is not available [799]. Common complications due to bone metastases include vertebral collapse
or deformity, pathological fractures and spinal cord compression. Cementation can be an effective treatment
for painful spinal fracture, whatever its origin, clearly improving both pain and QoL [800]. However, it is still
important to offer standard palliative surgery, which can be effective for managing osteoblastic metastases
[801, 802]. Impending spinal cord compression is an emergency. It must be recognised early and patients
should be educated to recognise the warning signs. Once suspected, high-dose corticosteroids must be given
and MRI performed as soon as possible. A systematic neurosurgery or orthopaedic surgeon consultation
should be planned to discuss a possible decompression, followed by EBRT [803]. Otherwise, EBRT, with or
without systemic therapy, is the treatment of choice.
6.5.10 Preventing skeletal-related events

6.5.10.1 Bisphosphonates
Zoledronic acid has been evaluated in mCRPC to reduce skeletal-related events (SRE). This study was
conducted when no active anticancer treatments but docetaxel were available. 643 patients who had CRPC
[804] with bone metastases were randomised to receive zoledronic acid, 4 or 8 mg every three weeks for fifteen
consecutive months, or placebo. The 8 mg dose was poorly tolerated and reduced to 4 mg but did not show
a significant benefit. However, at fifteen and 24 months of follow-up, patients treated with 4 mg zoledronic
acid had fewer skeletal-related events (SREs) compared to the placebo group (44 vs. 33%, p = 0.021) and
in particular fewer pathological fractures (13.1 vs. 22.1%, p = 0.015). Furthermore, the time to first SRE
was longer in the zoledronic acid group. No survival benefit has been seen in any prospective trial with
bisphosphonates.
6.5.10.2 RANK ligand inhibitors

Denosumab is a fully human monoclonal antibody directed against RANKL (receptor activator of nuclear factor
κB ligand), a key mediator of osteoclast formation, function, and survival. In M0 CRPC, denosumab has been
associated with increased bone-metastasis-free survival compared to placebo (median benefit: 4.2 months,
HR: 0.85, p = 0.028) [803]. This benefit did not translate into a survival difference (43.9 compared to 44.8
months, respectively) and neither the FDA nor the EMA have approved denosumab for this indication [805].
The efficacy and safety of denosumab (n = 950) compared with zoledronic acid (n = 951) in
patients with metastatic CRPC was assessed in a phase III trial. Denosumab was superior to zoledronic acid
in delaying or preventing SREs, as shown by time to first on-study SRE (pathological fracture, radiation or
surgery to bone, or spinal cord compression) of 20.7 vs. 17.1 months, respectively (HR: 0.82; p = 0.008). Both
urinary N-telopeptide (NTX) and bone-specific alkaline phosphatase (BAP) were significantly suppressed in
the denosumab arm compared with the zoledronic acid arm (p < 0.0001 for both). However, these findings
were not associated with any survival benefit and in a recent post-hoc re-evaluation of endpoints, denosumab
showed identical results when comparing skeletal-related events and symptomatic skeletal events [806].
The potential toxicity (e.g., osteonecrosis of the jaw) of these drugs must always be kept in mind [797, 803].
Patients should have a dental examination before starting therapy as the risk of jaw necrosis is increased by a
history of trauma, dental surgery or dental infection [807].

6.5.11 Summary of evidence and guidelines for life-prolonging treatments of castrate-resistant
disease
Summary of evidence LE
First-line treatment for metastatic castrate-resistant PCa (mCRPC) will be influenced by which 4
treatments were used when metastatic cancer was first discovered.
No clear-cut recommendation can be made for the most effective drug for first-line CRPC treatment 3
(i.e. hormone therapy, chemotherapy or radium-223) as no validated predictive factors exist.

Ensure that testosterone levels are confirmed to be < 50 ng/dL, before diagnosing Strong
castration-resistant PCa (CRPC).
Do not treat patients for non-metastatic CRPC outside of a clinical trial. Strong
Counsel, manage and treat patients with metastatic CRPC in a multidisciplinary team. Strong
Treat patients with mCRPC with life-prolonging agents. Strong
Base the choice of first-line treatment on the performance status, symptoms,
comorbidities, location and extent of disease, patient preference, and on the previous
treatment for hormone-sensitive metastatic PCa (HSPC) (alphabetical order: abiraterone,
docetaxel, enzalutamide, radium-223, sipuleucel-T).
6.5.12 Guidelines for cytotoxic treatment of castrate-resistant disease

Counsel, manage and treat patients with metastatic castration-resistant PCa (mCRPC) in Strong
a multidisciplinary team.
Offer patients with mCRPC who are candidates for cytotoxic therapy docetaxel with Strong
75 mg/m2 every three weeks.
In patients with mCRPC and progression following docetaxel chemotherapy offer further Strong
life-prolonging treatment options, which include abiraterone, cabazitaxel, enzalutamide
and radium-223.
Base second-line treatment decisions of mCRPC on pre-treatment performance status, Strong
symptoms, patient preference, comorbidities and extent of disease.
6.5.13 Guidelines for supportive care of castrate-resistant disease

These recommendations are in addition to appropriate systemic therapy.

Offer bone protective agents to patients with metastatic castration-resistant PCa (mCRPC) Strong
and skeletal metastases to prevent osseous complications.
Offer calcium and vitamin D supplementation when prescribing either denosumab or Strong
bisphosphonates.
Treat painful bone metastases early on with palliative measures such as external beam Strong
radiotherapy, and adequate use of analgesics.
In patients with spinal cord compression start immediate high-dose corticosteroids and Strong
assess for spinal surgery followed by irradiation. Offer radiation therapy alone if surgery is
not appropriate.

6.6 Summary of guidelines for the treatment of prostate cancer
Table 6.6.1: EAU risk groups for biochemical recurrence of localised and locally advanced prostate cancer
Definition
Low-risk Intermediate-risk High-risk
PSA < 10 ng/mL PSA 10-20 ng/mL PSA > 20 ng/mL any PSA
and GS < 7 (ISUP grade 1) or GS 7 (ISUP grade 2/3) or GS > 7 (ISUP grade 4/5) any GS (any ISUP grade)
and cT1-2a or cT2b or cT2c cT3-4 or cN+
Localised Locally advanced
GS = Gleason score; ISUP = International Society for Urological Pathology; PSA = prostate-specific antigen.
6.6.1 General guidelines recommendations for active treatment

Inform patients that no active treatment modality has shown superiority over any other Strong
active management options in terms of survival.
Inform patients that all active treatment have side-effects. Strong
Surgical treatment
Inform patients that no surgical approach (open, laparoscopic- or robotic radical Strong
prostatectomy) has clearly shown superiority in terms of functional or oncological results.
Perform an extended pelvic lymph node dissection (ePLND), when a LND is deemed Strong
necessary.
Do not perform nerve-sparing surgery when there is a risk of extracapsular extension Strong
(based on cT stage, Gleason score, nomogram, multiparametric magnetic resonance
imaging).
Do not offer neoadjuvant androgen deprivation therapy before surgery. Strong
Offer intensity-modulated radiation therapy (IMRT) or volumetric arc external-beam Strong
radiotherapy (VMAT) for definitive treatment of PCa by external-beam radiation therapy.
Only offer moderate hypofractionation (HFX) with IMRT/VMAT, including image-guided Strong
radiation therapy (IGRT) to the prostate, to carefully selected patients with localised
disease.
Ensure that moderate HFX adheres to radiotherapy protocols from trials with equivalent Strong
outcome and toxicity, i.e. 60 Gy/20 fractions in 4 weeks or 70 Gy/28 fractions in six
weeks.
Active therapeutic options outside surgery and radiotherapy
Only offer cryotherapy and high-intensity focused ultrasound within a clinical trial setting. Strong
Only offer focal therapy within a clinical trial setting. Strong
6.6.2 Guidelines recommendations for the various disease stages – first line treatment

Low-risk disease
Watchful waiting Offer a WW policy to asymptomatic patients with a life expectancy < Strong
(WW) 10 years (based on comorbidities).
Active Offer AS to patients suitable for curative treatment but with low-risk Strong
surveillance (AS) PCa.
Perform mpMRI before a confirmatory biopsy. Strong
During confirmatory biopsy include systematic and targeted biopsies. Strong
Base follow up on DRE, PSA and repeated biopsies. Strong
Counsel patients about the possibility of needing further treatment in Strong
the future.
Active treatment Offer surgery and radiotherapy as alternatives to AS to patients Weak
suitable for such treatments and who accept a trade-off between
toxicity and prevention of disease progression.

Pelvic lymph node Do not perform a PLND (estimated risk for pN+ < 5%). Strong
dissection (PLND)
Radiotherapy Offer LDR brachytherapy to patients with low-risk PCa, without a Strong
previous TURP and with a good IPSS and a prostate volume < 50 mL.
Use IMRT with a total dose of 74-80 Gy, without ADT. Strong
Offer moderate HFX (68 Gy/20 fx in four weeks or 70Gy/28 fx in six Strong
weeks) as an alternative treatment option.
Other options Only offer whole gland treatment (such as cryotherapy, HIFU, etc.) or Strong
focal treatment within a clinical trial setting.
Intermediate-risk disease
Active Offer AS to highly selected patients (< 10% pattern 4) accepting the Weak
surveillance (AS) potential increased risk of further metastases.
Radical Offer RP to patients with intermediate-risk disease and a life Strong
prostatectomy expectancy > 10 years.
(RP) Offer nerve-sparing surgery to patients with a low risk of Strong
extracapsular disease (refer to nomograms).
ePLND Perform an ePLND in intermediate-risk disease if the estimated risk Strong
for positive lymph nodes exceeds 5%.
Radiotherapy Offer LDR brachytherapy to selected patients; patients without a Strong
previous TURP and with a good IPSS and a prostate volume < 50 mL.
For EBRT, use a total dose of 76-78 Gy, in combination with short- Strong
term neoadjuvant plus concomitant ADT (four to six months).
In patients not willing to undergo ADT, use an escalated dose of EBRT Weak
(76-80 Gy) or a combination with brachytherapy.
Other options Only offer whole gland treatment (such as cryotherapy, HIFU, etc.) or Strong
focal treatment within a clinical trial setting.
High-risk localised disease
Radical Offer RP to patients with high-risk localised PCa and a life expectancy Strong
prostatectomy of > 10 years only as part of multi-modal therapy.
(RP)
ePLND Perform an ePLND in high-risk disease. Strong
Do not perform a frozen section of nodes during RP to decide Strong
whether to proceed with, or abandon, the procedure.
Radiotherapy In patients with high-risk localised disease, use EBRT with 76-78 Gy Strong
in combination with long-term ADT (two to three years).
In patients with high-risk localised disease, use EBRT with Weak
brachytherapy boost (either HDR or LDR), in combination with long-
term ADT (two to three years).
Other options Do not offer either whole gland or focal treatment to high-risk Strong
patients.
Do not use ADT monotherapy in asymptomatic patients. Strong
Locally-advanced disease
Radical Offer RP to highly selected patients with (cT3b-T4 N0 or any T N1) Strong
prostatectomy only as part of multi-modal therapy.
(RP)
ePLND Perform an ePLND in high-risk PCa. Strong
Do not perform a frozen section of nodes during RP to decide Strong
whether to proceed with, or abandon, the procedure.
Radiotherapy In patients with locally advanced cN0 disease, offer RT in Strong
combination with long-term ADT.
Offer long-term ADT for two to three years. Weak
Other options Do not offer whole gland treatment or focal treatment to high-risk Strong
patients.
Only offer ADT monotherapy to those patients unwilling or unable to Strong
receive any form of local treatment and who are either symptomatic
or asymptomatic, but with a PSA-DT < 12 months or a PSA
> 50 ng/mL or a poorly-differentiated tumour.

Adjuvant treatment after radical prostatectomy
Only discuss adjuvant treatment in men with a post-operative PSA Strong
< 0.1 ng/mL.
Do not prescribe adjuvant ADT in pN0 patients. Strong
Offer adjuvant EBRT to the surgical field to patients at increased risk Strong
of local relapse: pT3 pN0 with positive margins (highest impact), and/
or invasion of the seminal vesicles.
Discuss three management options with patients with pN+ disease Weak
after an ePLND, based on nodal involvement characteristics:
1. Offer adjuvant ADT for node-positive (pN+).
2. Offer adjuvant ADT with additional radiotherapy.
3. Offer observation (expectant management) to a patient after eLND
and ≤ 2 nodes with microscopic involvement, and a PSA
< 0.1 ng/mL and absence of extranodal extension.
Non-curative or palliative treatments
Localised disease
WW Offer WW to asymptomatic patients not eligible for local curative Strong
treatment and those with a short life expectancy.
While on WW, base the decision to start non-curative treatment on Strong
symptoms and disease progression.
Locally-advanced disease
WW Offer a deferred treatment policy using ADT monotherapy to M0 Strong
asymptomatic patients with a PSA doubling time > twelve months, a
PSA < 50 ng/mL and well differentiated tumour, who are unwilling or
unable to receive any form of local treatment.
Metastatic disease - first-line treatment
Symptomatic In M1 symptomatic patients, offer immediate systemic treatment to Strong
patients palliate symptoms and reduce the risk for potentially serious sequelae
of advanced disease (spinal cord compression, pathological fractures,
ureteral obstruction, extra-skeletal metastasis).
Asymptomatic In M1 asymptomatic patients, offer immediate systemic treatment Strong
patients to improve survival, defer progression to a symptomatic stage and
prevent serious disease progression-related complications.
In M1 asymptomatic patients, discuss deferred castration with a well- Weak
informed patient since it lowers the treatment side-effects, provided
the patient is closely monitored.
All M1 patients Offer LHRH antagonists, especially to patients with an impending Weak
spinal cord compression or bladder outlet obstruction.
In M1 patients treated with a LHRH agonist, offer short-term Weak
administration of anti-androgens to reduce the risk of the ‘flare-up’
phenomenon.
Do not offer anti-androgen monotherapy for M1 disease. Strong
Offer castration combined with chemotherapy (docetaxel) to all Strong
patients whose first presentation is M1 disease and who are fit
enough for docetaxel.
Offer castration combined with abiraterone acetate + prednisone to Strong
all patients whose first presentation is M1 disease and who are fit
enough for the regimen.
Offer castration alone, with or without an anti-androgen, to patients Strong
unfit for, or unwilling to consider, castration combined with docetaxel
or abiraterone acetate + prednisone.

M1 patients In asymptomatic M1 patients, only offer intermittent treatment to Strong
receiving highly motivated men, with a major PSA response after the induction
intermittent period.
treatment • In M1 patients, follow the schedules used in published clinical Weak
trials on timing of intermittent treatment.
• Stop treatment when the PSA level is < 4 ng/mL after six to
seven months of treatment.
• Resume treatment when the PSA level is > 10-20 ng/mL (or
returned to the initial level of < 20 ng/mL).
Do not use castration combined with any local treatment Strong
(radiotherapy/surgery) outside an investigational setting except for
symptom control.
6.6.3 Guidelines for second-line and palliative treatments
Biochemical recurrence after treatment with curative intent

Biochemical Offer AS and possibly delayed SRT to patients with a biochemical Strong
recurrence recurrence (BCR) and favourable prognostic factors (≤ pT3a, time to
after radical BCR > three years, PSA-DT > twelve months, GS ≤ 7), who may not
prostatectomy benefit from intervention.
(RP) Treat patients with a PSA rise from the undetectable range with SRT. Strong
The total dose of SRT should be at least 66 Gy and should be given
early (PSA < 0.5 ng/mL).
Biochemical Treat highly selected patients with localised PCa and a histologically Weak
recurrence after proven local recurrence with salvage radical prostatectomy (SRP).
radiotherapy (RT) Salvage RP should only be performed in experienced centres. Strong
Do not offer HIFU, cryosurgical ablation and salvage brachytherapy to Strong
patients with proven local recurrence since it is still experimental.
Systemic salvage Do not offer ADT to M0 patients with a PSA-DT > twelve months. Strong
treatment
Life-prolonging treatments of castrate-resistant disease
Ensure that testosterone levels are confirmed to be < 50 ng/mL, Strong
before diagnosing castration-resistant PCa (CRPC).
Do not treat patients for non-metastatic CRPC outside of a clinical Strong
trial.
Counsel, manage and treat patients with metastatic CRPC in a Strong
multidisciplinary team.
Treat patients with mCRPC with life-prolonging agents. Strong
Base the choice of first-line treatment on the PS, symptoms,
comorbidities, location and extent of disease, patient preference,
and on the previous treatment for hormone-sensitive PCa
(alphabetical order: abiraterone, docetaxel, enzalutamide, radium-223,
sipuleucel-T).
Cytotoxic treatment of castrate-resistant disease
Counsel, manage and treat patients with metastatic castration- Strong
resistant PCa (mCRPC) in a multidisciplinary team.
Offer patients with mCRPC who are candidates for cytotoxic therapy Strong
docetaxel with 75 mg/m2 every three weeks.
In patients with mCRPC and progression following docetaxel Strong
chemotherapy offer further life-prolonging treatment options, which
include abiraterone, cabazitaxel, enzalutamide and radium-223.
Base second-line treatment decisions of mCRPC on pre-treatment Strong
performance status, symptoms, patient preference, comorbidities and
extent of disease.

Supportive care of castrate-resistant disease
Offer bone protective agents to patients with metastatic castration- Strong
resistant PCa (mCRPC) and skeletal metastases to prevent osseous
complications.
Offer calcium and vitamin D supplementation when prescribing either Strong
denosumab or bisphosphonates.
Treat painful bone metastases early on with palliative measures such Strong
as external beam radiotherapy, and adequate use of analgesics.
In patients with spinal cord compression start immediate high-dose Strong
corticosteroids and assess for spinal surgery followed by irradiation.
Offer radiation therapy alone if surgery is not appropriate.
ADT = androgen deprivation therapy; AS = active surveillance; BCR = biochemical recurrence;
CPRC = castration-resistant prostate cancer; EBRT = external-beam radiation therapy; GS = Gleason score;
HDR = high-dose rate; HFX = hypofractionation; HIFU = high-intensity focused ultrasound; IGRT = image-
guided radiation therapy; IMRT = intensity-modulated radiation therapy; IPSS = International Prostatic Symptom
Score; LDR = low-dose rate; LHRH = luteinizing hormone-releasing hormone; mCRPC = metastatic castration-
resistant prostate cancer; mpMRI = multiparametric magnetic resonance imaging; PCa = prostate cancer; (e)
PLND = (extended) pelvic lymph node dissection; PS = performance score; PSA = prostate-specific antigen;
RP = radical prostatectomy; RT = radiotherapy; SRP = salvage radical prostatectomy; TURP = transurethral
resection of the prostate; VMAT = volumetric arc external-beam radiotherapy; WW = watchful waiting.
7. FOLLOW-UP
The rationale for following up patients is to assess immediate- and long-term oncological results, side-effects
or complications of therapy, functional outcomes and to provide psychological support to PCa survivors. Only
the oncological aspects are covered below; the functional outcomes and side-effects are covered in Chapter 8.
7.1 Follow-up: After local treatment

7.1.1 Definition
Local treatment is defined as RP or RT, either by EBRT or LDR- or HDR-brachytherapy, or any combination
of these. Unestablished alternative treatments, such as HIFU and cryosurgery do not have a well-defined,
validated PSA cut-off to define BCF, but follow the general principles as presented in this section.
7.1.2 Why follow-up?

Recurrence occurs after primary therapy in many patients who have previously received treatment with intent
to cure.
Patients who receive curative therapy are followed up to discuss the need and possibility of
second-line treatment either with curative or palliative intent. It will be based on initial treatment, patient age,
comorbidity and the patient’s own wishes
7.1.3 How to follow-up?

The procedures indicated at follow-up visits vary according to clinical situation. The examinations discussed
below are routinely used to detect PCa progression or residual disease. Prostate specific antigen level and DRE
are the only tests that should be performed routinely. A disease-specific history is mandatory at every follow-up
visit and includes psychological aspects, signs of disease progression, and treatment-related complications.
Evaluation of treatment-related complications must be individualised, which is beyond the scope of these
Guidelines. The examinations used for cancer-related follow-up after curative surgery or RT are discussed
below.
7.1.3.1 Prostate-specific antigen monitoring

Measurement of PSA is a cornerstone in follow-up after local treatment. Expectations differ after RP and RT,
but PSA recurrence often precedes clinical recurrence [585, 808]. A single, elevated, serum PSA level should
be confirmed before starting second-line therapy based solely on PSA elevation.
7.1.3.2 Definition of prostate-specific antigen progression

The PSA level for definition of treatment failure differs between RP and RT. No formal consensus exists
regarding the best definition of PSA relapse after RP. Recurrent cancer after RP is usually defined by two

consecutive PSA rises ≥ 0.2 ng/mL [809]. However, others have argued for a higher cut-off of 0.4 ng/mL to best
represent the risk of subsequent metastases (see Section 6.3.2) [585].
Ultrasensitive PSA assay remains controversial for routine follow-up after RP. Men with an ultrasensitive
PSA nadir < 0.01 ng/mL have a 4% likelihood of early biochemical relapse [810]. Detectable post-operative
ultrasensitive PSA does not predict BCR in all cases, although it adds prognostic value. In men with ultrasensitive
PSA > 0.05 ng/mL, 66.8% remained free of biochemical disease at five years [811]. If survival is improved by early
adjuvant treatment after RP (before PSA reaches > 0.2 ng/mL), lower PSA nadir levels may help identify suitable
candidates, as well as low PSADT calculated using the first detectable PSA up to 0.2 ng/mL [592].
At the 2006 RTOG-ASTRO Consensus Conference, a new definition of radiation failure was
proposed to establish better correlation between definition and clinical outcome, namely, an increase of
2 ng/mL above the post-treatment PSA nadir [586]. It applies to patients with or without HT.
After HIFU or cryotherapy, no endpoints have been validated to indicate clinical progression
or survival; therefore, it is not possible to give a firm recommendation of BCF after these alternative local
treatments.
7.1.3.3 Prostate-specific antigen monitoring after radical prostatectomy

Prostate-specific antigen is expected to be undetectable within six weeks after successful RP [812].
Persistently elevated PSA in patients treated with RP is thought to be due to residual cancer, either
micrometastases or residual pelvic disease.
A rapidly increasing PSA level suggests distant metastases, whereas a later, slowly increasing,
level most likely suggests local recurrence. Time to PSA recurrence and tumour differentiation are important
predictive factors distinguishing local and systemic recurrence [813]. Local treatment failure and distant
metastases can occur with undetectable PSA levels. This is rare and occurs mostly in patients with
undifferentiated tumours [814]. Thus, in patients with favourable pathology (< pT3, pN0, GS < 8), PSA
measurement and disease-specific history could be a single test in follow-up after RP.
7.1.3.4 Prostate-specific antigen monitoring after radiotherapy

Prostate-specific antigen level falls slowly after RT compared with RP. A nadir < 0.5 ng/mL is associated with
a favourable outcome after RT [815], although the optimal value is controversial. The interval before reaching
the nadir can be up to three years or more. After RT, PSA-DT is correlated with site of recurrence; patients with
local recurrence have a PSA-DT of thirteen months compared to three months for those with distant failure
[816].
7.1.3.5 Digital rectal examination

Local recurrence after curative treatment is possible without a concomitant rise in PSA level [814]. However,
this has only been proven in patients with unfavourable pathology, namely, undifferentiated tumours. Prostate-
specific antigen measurement and DRE comprise the most useful combination for first-line examination
in follow-up after RT or RP, but PSA measurement may be the only test needed in cases with favourable
pathology (< pT3, pN0, Gleason < 8) after RP [817].
7.1.3.6 Transrectal ultrasound, bone scintigraphy, computed tomography, magnetic resonance imaging, and
11C-choline positron emission tomography computed tomography
Imaging techniques have no place in routine follow-up of localised PCa. They are only justified in patients for
whom the findings affect treatment decisions, either with BCF or in patients with symptoms. (See Section
6.3.4.2.1 for a more detailed discussion).
7.1.3.6.1 Transrectal ultrasonography/magnetic resonance imaging guided biopsy.

Biopsy of the prostate bed and urethrovesical anastomosis or of the remaining prostate after radiotherapy, are
only indicated if local recurrence affects treatment decisions.
7.1.4 When to follow-up?

Most patients who fail treatment for PCa do so early, even if failure only becomes clinically obvious after years.
Patients should be followed up more closely during the initial post-treatment period when risk of failure is
highest. Prostate-specific antigen measurement, disease-specific history and DRE are recommended at three,
six and twelve months post-operatively, every six months thereafter until three years, and then annually.
The first post-treatment clinic visit mainly focusses on detecting treatment-related complications
and assist patients in coping with their new situation. Tumour or patient characteristics may allow alterations
to this schedule. Patients with poorly differentiated and locally advanced tumours or with positive margins may
be followed-up more closely than those with a well-differentiated, intracapsular or specimen-confined tumour.
Advanced age or associated comorbidity may make further follow-up in asymptomatic patients superfluous.

7.1.5 Summary of evidence and guidelines for follow-up after treatment with curative intent
Summary of evidence LE
After radical prostatectomy serum prostate-specific antigen (PSA) level > 0.2 ng/mL is associated 2a
with residual or recurrent disease.
After radiotherapy, an increase in PSA > 2 ng/mL above the nadir, rather than a specific threshold 2a
value, is the most reliable sign of recurrence.
Palpable nodules and increasing serum PSA are signs of local recurrence. 2a

Routinely follow-up asymptomatic patients, by obtaining a disease-specific history and Strong
serum prostate-specific antigen (PSA) measurement. These should be performed at three,
six and twelve months after treatment, then every six months until three years, and then
annually.
During follow up, perform a systematic DRE after surgery if unfavourable pathology (> pT3, Weak
pN1, Gleason ≥ 8).
During follow up, perform a systematic DRE after radiotherapy. Strong
At recurrence, only image to detect local recurrence if it affects treatment planning. Strong
Do not routinely offer bone scans and other imaging modalities to asymptomatic patients Strong
if there are no signs of biochemical relapse. In case patients have bone pain or other
symptoms of possible progression, restaging should be considered irrespective of serum
PSA level.
7.2 Follow-up: during first line hormonal treatment (androgen sensitive period)
7.2.1 Introduction
Follow up must be individualised as BCF might be associated with rapid symptomatic progression or evolve
without progression on imaging or symptoms over years. Follow-up for mCRPC is addressed in treatment
Section 6.10.4, as fist-line management of mCRPC and follow-up are closely linked.
7.2.2 Purpose of follow-up

The main objectives of follow-up in these patients are to ensure treatment compliance, to monitor treatment
response and side-effects, and to guide the treatment at the time of CRPC.
Complementary investigations must be restricted to those that are clinically helpful to avoid
unnecessary examinations and costs.
7.2.3 Methods of follow-up

7.2.3.1 Clinical follow-up
Clinical follow-up is mandatory on a regular basis, and cannot be replaced, neither by laboratory tests nor by
imaging modalities. Of utmost importance in metastatic situations is to advise patients about early signs of
spinal cord compression, check for occult cord compression, urinary tract complications (ureteral obstruction,
bladder outlet obstruction) or bone lesions that are at an increased fracture risk.
7.2.3.1.1 Prostate-specific antigen monitoring

Prostate-specific antigen is a key marker for following the course of androgen-sensitive PCa. Treatment
response may be assessed using the change in serum PSA level as a surrogate endpoint for survival in patients
with newly diagnosed metastatic PCa [719].
A rise in PSA level usually precedes the onset of clinical symptoms by several months. Importantly,
taking into account the PSA level alone is insufficient to define progression as clinical progression (usually bone
pain) with a stable PSA has been reported.
7.2.3.1.2 Creatinine, haemoglobin and liver function monitoring

Creatinine monitoring is good clinical practice as an increase may be linked to bilateral ureteral obstruction
or bladder retention. Liver function tests may suggest treatment toxicity (especially NSAA), but rarely disease
progression. A decline in Hb after three months of ADT is independently associated with shorter progression-
free and OS rates [818] and might explain significant fatigue. Alkaline phosphatase may increase secondary to
bone metastases and androgen-induced osteoporosis [819]. Therefore, it may be helpful to determine bone-
specific isoenzymes as none are directly influenced by HT.

7.2.3.1.3 Bone scan, ultrasound and chest X-ray
Asymptomatic patients with a stable PSA level should not undergo imaging at regular intervals [820]. New
symptomatic bone lesions require a bone scan, as well as a PSA progression suggesting CRPC status if a
treatment modification is considered. The PCWG has clarified the definition of bone scan progression as the
appearance of at least two new lesions [769], later confirmed.
Suspicion of disease progression indicates the need for additional imaging modalities, guided
by symptoms or possible subsequent treatments. In CRPC, imaging must be individualised with the aim of
maintaining the patient’s QoL.
7.2.3.1.4 Testosterone monitoring

This should be considered part of clinical practice for men on LHRH therapy. Many men receiving medical
castration will achieve a castrate testosterone level (< 20 ng/dL), and most a testosterone level < 50 ng/dL.
However, approximately 13-38% of patients fail to achieve this goal and up to 24% of men may experience
temporary testosterone surges (testosterone > 50 ng/dL) during long-term treatment [459], known as the ‘acute
on-chronic effect’ or ‘breakthrough response’.
The timing of measurements is not clearly defined. A three to six-month testosterone level
assessment has been suggested to ensure castration is achieved and maintained. If not, switching to another
agonist or antagonist, or to an orchiectomy, should be considered. In patients with a rising PSA and/or clinical
progression, serum testosterone must be evaluated in all cases to confirm a castrate-resistant state.
7.2.3.1.5 Monitoring of metabolic complications

Androgen deprivation therapy has a greater range of complications than might be expected. The most severe
are metabolic syndrome, cardiovascular morbidity and bone problems (see Section 8.2.4.5). The patient’s
general practitioner should probably be more involved at this stage.
All patients should be screened for diabetes by checking fasting glucose and HbA1c (at baseline
and regularly), as for blood lipid levels. Men with impaired glucose tolerance and/or diabetes should be
referred for an endocrine consultation. A cardiology consultation should be considered in men with a history of
cardiovascular disease and men older than 65 years prior to starting ADT. Monitoring serum levels of vitamin
D and calcium is important. It is suggested that routine bone monitoring should be performed every two years
during castration [821], or yearly if there are other risk factors [822, 823]. However, there is no evidence that this
favourably impacts on bone complications due to ADT. Prospective trials are needed.
Patients on ADT should be given advice on modifying their lifestyle (e.g. diet, exercise, smoking
cessation, etc.) and should be treated for existing conditions, such as diabetes, hyperlipidaemia, and/or
hypertension [818, 819]. Furthermore, the risk-to-benefit ratio of ADT must be considered in patients with a
higher risk of cardiovascular complications, especially if it is possible to delay starting ADT.
7.2.4 When to follow-up

After the initiation of ADT, it is recommended that patients are followed at three to six month intervals. This
must be individualised and each patient should be advised to contact his physician in the event of troublesome
symptoms.
7.2.4.1 Stage M0 - M1 patients

In case there is a favourable treatment response, i.e. PSA response (< 4 ng/mL), symptomatic improvement,
good psychological coping, good treatment compliance, follow-up visits may be scheduled every three to six
months.
7.2.5 Imaging as a marker of response in metastatic prostate cancer

Treatment response in soft-tissue metastases can be assessed by morphological imaging methods (CT or MRI)
using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria. However, these criteria cannot be
used in bone where response assessment is difficult [824, 825].
Quantitative estimation of tracer uptake at BS can be obtained through automated methods such as
the Bone Scan Index [826]. Nonetheless, BS is limited by the so-called flare phenomenon that is defined by the
development of new images induced by treatment on a first follow-up scan that actually represent a favourable
response on longer observation. Flare is observed within eight to twelve weeks of treatment initiation and can
lead to false-positive diagnosis of disease progression. As a result, the PCWG suggested that all patients with
at least two new lesions on the first follow-up BS require a confirmatory BS at least six weeks later while the
treatment is continued [769]. This means that management change for primary therapy resistance cannot occur
until after at least 14 weeks of treatment. Computed tomography cannot be used to monitor sclerotic bone
lesions because bone sclerosis can occur under effective treatment and reflects bone healing. The ability of
choline PET/CT to assess response has been assessed in a few studies that showed changes in disease extent

and specific uptake values. So far it has no place. It is of note that the flare phenomenon can also be observed
with choline PET/CT. Magnetic resonance imaging can directly assess the bone marrow and demonstrate
progression based on morphologic criteria or changes in apparent diffusion coefficient. A standardisation for
reporting is available and might help using these image modalities [827].
In practice, imaging to assess progression leading to treatment change must be limited to a clear progression:
RECIST criteria for non-bone lesions; for bone lesions, only BS progression (occurrence of two new hot spots
later confirmed) should be considered. The practical impact of mpMRI in assessing bone progression remains
unclear.
7.2.6 Guidelines for follow-up during hormonal treatment

Evaluate patients at three to six months after the initiation of treatment. Strong
The follow up strategy must be individualised based on stage of disease, prior symptoms, Strong
prognostic factors and the treatment given.
In patients with stage M0 disease, schedule follow-up every six months. As a minimum Strong
requirement, include a disease-specific history, DRE and serum PSA determination in the
diagnostic work-up.
In patients with stage M1 disease, schedule follow-up every three to six months. As a Strong
minimum requirement, include a disease-specific history, DRE, serum PSA, haemoglobin,
serum creatinine and alkaline phosphatase measurements in the diagnostic work-up. The
testosterone level should be checked, especially during the first year.
Counsel patients (especially with M1b status) about the clinical signs suggestive of spinal Strong
cord compression.
When disease progression is suspected, adapt/individualise follow up. Strong
In patients with suspected progression, assess the testosterone level. By definition, Strong
castration resistant PCa (CRPC) requires a testosterone level < 50 ng/dL (< 1 mL/L).
Do not offer routine imaging to otherwise stable asymptomatic patients. Strong
8. QUALITY OF LIFE OUTCOMES IN PROSTATE

CANCER
This chapter is presented in two parts. The first (8.2) will summarise long-term consequences (≥ 12 months)
of therapies for PCa. Based on two SRs, the second (8.3) will make evidence-based recommendations for
supporting patients when selecting primary treatment options for localised disease and also supportive
interventions aimed at improving disease-specific QoL across all stages of disease.
8.1 Introduction
Quality of life and personalised care go hand in hand. Treating PCa can affect an individual both physically and
mentally, as well as his close relations and his work or vocation. These multifaceted issues all have a bearing
on his perception of QoL [828]. Approaching care from a holistic point of view requires the intervention of
a multi-disciplinary team including urologists, medical oncologists, radiation oncologists, oncology nurses,
behavioural practitioners and many others. Attention to the psychosocial concerns of men with PCa is integral
to quality clinical care, and this can include the needs of carers and partners [783]. Prostate cancer care should
not be reduced to focusing on the organ in isolation: side-effects or late adverse effects of treatment can
manifest systemically and have a major influence on the patient’s QoL. Taking QoL into consideration relies on
understanding the patient’s values and preferences so that optimal treatment proposals can be formulated and
discussed.
8.2 Adverse effects of prostate cancer therapies

8.2.1 Surgery
The absence of standardisation in reporting surgical complications for RP and the introduction of different
techniques has resulted in a wide variation in the types of complications reported as well as variation in the
overall incidence of complications [829-832]. The most common post-operative issue is ED but other related

issues to consider include dry ejaculation which occurs with removal of the prostate, change in the quality of
orgasm and occasional pain on orgasm. Men also complain of loss of penile length (3.73%, 19/510 men) [833].
The second most commonly occurring complication is long-term incontinence [829-832] but voiding
difficulties may also occur associated with bladder neck contracture (e.g. 1.1% after RALP) [834].
For those men undergoing minimally invasive procedures port site hernia has been reported in
0.66% after inserting 12 mm bladeless trocar [835] and can occur more rarely with 8 mm and 5 mm trocars
[836]. A key consideration for men is whether long-term consequences of surgery are reduced by using newer
techniques such as RALP. Systematic reviews have documented complication rates after RALP [364-368], and
can be compared with contemporaneous reports after RRP [369]. From these reports, the mean continence
rates at twelve months were 89-100% for patients treated with RALP and 80-97% for patients treated with
RRP. There is, as yet, no evidence from retrospective studies of differences in urinary incontinence at twelve
months and there was insufficient evidence to draw conclusions on differences in cancer-related, patient-
driven or ED outcomes. The major limitations of the included studies were the retrospective study design and
the use of different assessment tools preventing comparison between techniques and series. More recently, a
prospective, controlled, non-randomised trial of patients undergoing RP in fourteen centres using RALP or RRP
was published. At twelve months after RALP, 21.3% were incontinent, as were 20.2% after RRP. The adjusted
OR was 1.08 (95% CI: 0.87-1.34). Erectile dysfunction was observed in 70.4% after RALP and 74.7% after
RRP. The adjusted OR was 0.81 (95% CI: 0.66-0.98) [370].
8.2.2 Radiotherapy
8.2.2.1 Side-effects of external beam radiotherapy
The introduction of IMRT to deliver radiotherapy has resulted in less long-term toxicity. The Memorial Sloan-
Kettering Cancer Center group have reported data on late toxicity from their experience in 1,571 patients with
T1-T3 disease treated with either 3D-CRT or IMRT at doses of between 66 Gy and 81 Gy, with a median follow-
up of ten years [837]. Both acute GI and GU toxicity appeared to be predictive for corresponding late toxicity.
The overall rate of NCIC/Common Toxicity Criteria (CTC) Grade 2 or more GI toxicity was 5% with IMRT vs.
13% with 3D-CRT. The incidence of Grade 2 or higher late GU toxicity was 20% in patients treated with 81 Gy
vs. 12% in patients treated with lower doses. The overall incidences of Grade 3 toxicity were 1% for GI toxicity
and 3% for GU toxicity. These data suggest that IMRT might offer better late GI toxicity outcomes. Owing
to the single centre and observational nature of these data, these results must be interpreted with caution,
however. Interestingly, with dose escalation, GU toxicity may become the predominant type of morbidity [837].
Radiotherapy affects erectile function to a lesser degree than surgery, according to retrospective surveys of
patients [838]. A meta-analysis has shown that the 1-year probability rates for maintaining erectile function
were 0.76 after brachytherapy, 0.60 after brachytherapy plus external irradiation, 0.55 after external irradiation,
0.34 after nerve-sparing RP, and 0.25 after standard RP. When studies with more than 2 years of follow-up were
selected (i.e. excluding brachytherapy), the rates became 0.60, 0.52, 0.25, and 0.25, respectively, with a greater
spread between the radiation techniques and surgical approaches [839].
The Memorial Sloan-Kettering Cancer Center group have reported data on late toxicity from their
experience in 1,571 patients with T1-T3 disease treated with either 3D-CRT or IMRT at doses of between 66 Gy
and 81 Gy, with a median follow-up of 10 years [837]. Both acute GI and GU toxicity appeared to be predictive
for corresponding late toxicity. The overall rate of NCIC/Common Toxicity Criteria (CTC) Grade 2 or more, GI
toxicity was 5% with IMRT vs. 13% with 3D-CRT. The incidence of Grade 2, or higher, late GU toxicity was
20% in patients treated with 81 Gy vs. 12% in patients treated with lower doses. The overall incidences of
Grade 3 toxicity were 1% for GI toxicity and 3% for GU toxicity. These data suggest that IMRT can successfully
protect against late GI toxicity. Interestingly, with dose escalation, GU toxicity may become the predominant
type of morbidity [837].
A SR and meta-analysis of observational studies comparing patients exposed or unexposed to
radiotherapy in the course of treatment for PCa demonstrate an increased risk of developing second cancers
for bladder (OR: 1.39), colorectal (OR: 1.68) and rectum (OR: 1.62) with similar risks over lag times of five
and ten years. Absolute risks over ten years are small (1-4%) but should be discussed with younger men in
particular [840].
8.2.2.2 Side-effects from brachytherapy

Some patients experience significant urinary complications following implantation, such as urinary retention
(1.5-22%), with post-implantation TURP reported as being required in up to 8.7% of cases, and incontinence
(0-19%) [841]. Chronic urinary morbidity can occur in up to 20% of patients, depending on the severity of the
symptoms before brachytherapy. Previous TURP for BPH increases the risk of post-implantation incontinence
and urinary morbidity. Prevention of morbidity depends on careful patient selection, and expert assessment of
IPSS score, backed up by urodynamic studies.

8.2.3 Local primary whole-gland treatments other than surgery or radiotherapy
8.2.3.1 Cryosurgery
In Ramsay et al.’s SR and meta-analysis [486], there was evidence that the rate of urinary incontinence at one
year was lower for CSAP than for RP, but the size of the difference decreased with longer follow-up. There was
no significant difference between CSAP vs. EBRT in terms of urinary incontinence at one year (< 1%); CSAP
had a similar ED rate (range 0-40%) to RP at one year. There was insufficient data to compare CSAP vs. EBRT
in terms of ED.
8.2.3.2 High-intensity focused ultrasound

In terms of toxicity, there are insufficient data on urinary incontinence, ED or bowel dysfunction to draw any
conclusions, although at one year HIFU had lower incontinence rates than RP (OR: 0.06, 95% CI: 0.01-0.48)
[486].

A summary of impacts on psychological factors due to the use of ADT such as sexual function, mood,
depression, cognitive function and impact on men’s partners can be found in two clinical reviews [842, 843].
A small RCT evaluated the QoL at one-year follow-up in patients with non-localised PCa, between various
ADT regimens, or no treatment. ADT patients reported a significant decline in spatial reasoning, spatial abilities
and working memory as well as increased depression, tension, anxiety, fatigue and irritability during treatment
[844]. A prospective observational study of non-metastatic PCa, found that immediate ADT was associated
with a lower overall QoL compared to deferred treatment [845]. Another retrospective, non-randomised study
suggested that men receiving LHRH agonists reported more worry and physical discomfort and poorer overall
health, and were less likely to believe themselves free of cancer than orchiectomised patients. The stage at
diagnosis had no effect on health outcomes [846].
Using a specific non-validated questionnaire, bicalutamide monotherapy showed a significant
advantage over castration in the domains of physical capacity and sexual interest (not sexual function)
at twelve months [847]. A post-hoc analysis, including only patients with sexual interest suggested that
bicalutamide was associated with better sexual preservation, including maintained sexual interest, feeling
sexually attractive [848], preserved libido and erectile function [849]. Intermittent androgen deprivation has
been discussed elsewhere (see Section 6.4.4.3).
8.2.4.1 Sexual function

Cessation of sexual activity is very common on men undergoing ADT, affecting up to 93% of men [850]. The
management of acquired ED is mostly non-specific [851].
8.2.4.2 Hot flushes

Hot flushes are a common side-effect of ADT (prevalence estimated between 44-80% of men on ADT) [850].
They appear three months after starting ADT, usually persist long-term and have a significant impact on QoL.
Oestrogen-receptor modulators or low-dose oestrogen therapies, e.g. DES, 0.5-1 mg/day, reduce
the frequency and severity of hot flushes. Both treatments carry a risk of cardiovascular complications [852].
Serotonin re-uptake inhibitors (e.g. venlafaxine or sertraline) appear to be effective in men, but less
than hormone therapies based on a prospective RCT comparing venlafaxine, 75 mg daily, with
medroxyprogesterone, 20 mg daily, or cyproterone acetate, 100 mg daily [853]. After six months of LHRH
(n = 919), 311 men had significant hot flushes and were randomised to one of the treatments. Based on median
daily hot-flush score, Venlafaxine was inferior -47.2% (IQR -74.3 to -2.5) compared to -94.5% (-100.0 to -74.5)
in the cyproterone group, and -83.7% (-98.9 to -64.3) in the medroxyprogesterone group.
With a placebo effect influencing up to 30% of patients [854], the efficacy of clonidine, veralipride,
gabapentine [855] and acupuncture [856] need to be compared in prospective RCTs.
8.2.4.3 Non-metastatic bone fractures

Due to increased bone turnover and decreased bone mineral density (BMD) in a time-dependent manner, ADT
use is linked to an increased risk of fracture (up to 45% RR with long-term ADT) [857]. Hip fractures in men
are associated with a significant risk of death [858]. A precise evaluation of BMD should be performed by
dual emission X-ray absorptiometry (DEXA) before starting long-term ADT. An initial low BMD (T-score < -2.5
or < -1, with other risk factors) indicates a high risk of subsequent non-metastatic fracture. The WHO FRAX tool
(http://www.shef.ac.uk/FRAX) should be used to evaluate individual risk. Obesity (increase in body fat mass by
up to 10%) and sarcopenia (decrease in lean tissue mass by up to 3%) are common and occur during the first
year of ADT [859]. Both changes increase the fracture risk.

8.2.4.3.1 Hormonal treatment modalities
Bicalutamide monotherapy could be a relative bone-protective treatment [860, 861], but is limited by its
suboptimal efficacy (see Section 6.1.4.1.1.5.2.3 - Metastatic PCa - Hormonal Therapy). The intermittent LHRH-
agonist modality might be associated with less bone impact [862].
8.2.4.3.2 Bisphosphonates
Bisphosphonates increase BMD in the hip and spine by up to 7% in 1 year. The optimal regimen for zoledronic
acid remains unclear: quarterly [863] or yearly [864] injections. The question is relevant as the risk of jaw
necrosis is both dose- and time-related [865]. A quarterly regimen could be considered for a BMD ≤ 2.5 as a
yearly injection is unlikely to provide sufficient protection [866].
8.2.4.3.3 Denosumab
In M0 patients, denosumab has been shown to increase the lumbar BMD by 5.6% compared to a 1% decrease
in the placebo arm after two years, using a 60 mg subcutaneous regimen every six months [867]. This was
associated with a significant decrease in vertebral fracture risk (1.5% vs. 3.9%, p = 0.006). The benefits were
similar whatever the age (< or > 70 years), the duration or type of ADT, the initial BMD, the patient’s weight or
the initial BMI. This benefit was not associated with any significant toxicity, e.g. jaw osteonecrosis or delayed
healing in vertebral fractures. In M0 patients, with the use of a higher dosage (120 mg every four weeks), a
delay in bone metastases of 4.2 months has been shown [806] without any impact on OS, but with an increase
in side-effects. Therefore, this later regimen cannot be recommended.
8.2.4.4 Metabolic effects

Lipid alterations are common and may occur as early as the first 3 months of treatment [859]. ADT also
decreases insulin sensitivity and increases fasting plasma insulin levels, which is a marker of insulin resistance.
In diabetic patients, metformin appears to be an attractive option for protection against metabolic effects
based on retrospective analysis [868], but there is insufficient data to recommend its use in non-diabetic
patients.
Metabolic syndrome is an association of independent cardiovascular disease risk factors, often associated with
insulin resistance. The definition requires at least three of the following criteria [869]:
• waist circumference > 102 cm;
• serum triglyceride > 1.7 mmol/L;
• blood pressure > 130/80 mmHg or use of medication for hypertension;
• high-density lipoprotein (HDL) cholesterol < 1 mmol/L;
• glycaemia > 5.6 mmol/L or the use of medication for hyperglycaemia.
The prevalence of a metabolic-like syndrome is higher during ADT compared with men not receiving ADT [870].
Skeletal muscle mass heavily influences basal metabolic rate and is in turn heavily influenced by endocrine
pathways [871]. Androgen deprivation therapy induced hypogonadism results in negative effects on skeletal
muscle health. A prospective longitudinal study involving 252 men on ADT for a median of 20.4 months
reported lean body mass decreases progressively over 3 years; 1.0% at one year, 2.1% at two years, and
2.4% at three years which appears more pronounced in men at ≥ 70 years of age [872].
8.2.4.5 Cardiovascular morbidity

Cardiovascular mortality is now the most common cause of death in PCa patients, even exceeding PCa
mortality [713, 873, 874]. Several studies showed that ADT, after only six months, was associated with an
increased risk of diabetes mellitus, cardiovascular disease, and myocardial infarction [875]. The RTOG 92-02
[876] and 94-08 [381] trials confirmed an increased cardiovascular risk, unrelated to the duration of ADT and
not accompanied by an overall increased cardiovascular mortality. No increase in cardiovascular mortality
has been reported in a systematic meta-analysis of trials RTOG 8531, 8610, 9202, EORTC 30891 or EORTC
22863 [877]. However, serious concerns about the conclusions of this meta-analysis have been raised due
to poor consideration of bias in the included studies [878, 879]. Meta-analysis of observational data reports
consistent links between ADT and the risk of CVD in men treated for PCa e.g. the associations between GnRH
agonists and nonfatal or fatal myocardial infarction or stroke RR: 1.57 (95% CI, 1.26-1.94) and RR: 1.51 (95%
CI, 1.24-1.84), respectively [880]. An increase in cardiovascular mortality has been reported in patients suffering
from previous congestive heart failure or myocardial infarction in a retrospective database analysis [881] or
presenting with a metabolic syndrome [882].

It has been suggested that LHRH antagonists might be associated with less cardiovascular morbidity
compared to agonists [883]. However, the methodology used in these studies does not provide convincing
evidence to show a clear superiority of these compounds.
These concerns resulted in an FDA warning and consensus paper from the American Heart, Cancer
Society and Urological Associations [712]. Preventive advice includes non-specific measures such as loss of
weight, increased exercise, improved nutrition and smoking cessation [884].
8.2.4.6 Fatigue
Fatigue often develops as a side-effect of ADT. Regular exercise appears to be the best protective measure.
Anaemia may be a cause of fatigue [850, 885]. Anaemia requires an etiological diagnosis (medullar invasion,
mainly inflammatory, renal insufficiency, iron deficiency, chronic bleeding) and individualised treatment. Iron
supplementation (using injectable formulations only) must be systematic if deficiency is observed. Regular
blood transfusions are required if severe anaemia is present. Erythropoiesis-stimulating agents might be
considered in dedicated cases, taking into account the possible increased risk of thrombovascular events
[886].
8.2.4.7 Neurological side-effects

Castration seems also to be associated with an increased risk of stroke [887], and is suspect to be associated
with an increased risk for depression and cognitive decline such as Alzheimer disease [888].
8.3 Overall quality of life in men with prostate cancer

Living longer with PCa, does not necessarily equate to living well [783, 828]. There is clear evidence of unmet
needs and ongoing support requirements for some men after diagnosis and treatment for PCa [889]. Radical
treatment for PCa can negatively impact long-term QoL (e.g. sexual, urinary and bowel dysfunction), as can
ADT used in short or long-term treatment e.g. sexual problems, fatigue, psychological morbidity, adverse
metabolic sequelae increased cardiovascular and bone fracture risk [842, 890]. Direct symptoms from
advanced or metastatic cancer e.g. pain, hypercalcaemia, spinal cord compression, pathological fractures, also
adversely affect health [891, 892]. Men’s QoL including domains such as sexual function, urinary function and
bowel function is worse after treatment for PCa compared to non-cancer controls [893, 894].
The concept of ‘quality of life’ is subjective and can mean different things to different men, but there are some
generally common features across virtually all patients. Drawing from these common features, specific tools or
‘patient-reported outcome measures’ (PROMs) have been developed and validated for men with PCa. These
questionnaires assess common issues that affect men after PCa diagnosis and treatment and generate scores
which reflect the impact on perceptions of HRQoL. During the process of undertaking two dedicated SRs
around cancer-specific QoL outcomes in men with PCa as the foundation for our guideline recommendations,
the following validated PROMs were found in our searches (see Table 8.3.1).
Table 8.3.1: PROMs assessing cancer specific quality of life
Questionnaire Domains / items

Functional Assessment of Cancer Therapy-General Physical well-being, Social/family well-being,
(FACT-G) [895] Emotional well-being, and Functional well-being
Functional Assessment of Cancer Therapy-Prostate 12 cancer site specific items to assess for prostate
(FACT-P) [896] related symptoms. Can be combined with FACT-G or
reported separately.
European Organisation for Research and Treatment of Five functional scales (physical, role, cognitive,
Cancer QLQ-C30 (EORTC QLQ-C30) [897] emotional, and social); Three symptom scales
(fatigue, pain, and nausea and vomiting); Global
health status/QoL scale; and a number of single items
assessing additional symptoms commonly reported
by cancer patients (dyspnoea, loss of appetite,
insomnia, constipation and diarrhoea) and perceived
financial impact of the disease.
European Organisation for Research and Treatment of Urinary, bowel and treatment-related symptoms, as
Cancer QLQ-PR 25 (EORTC QLQ-PR 25) [898] well as sexual activity and sexual function.
Expanded prostate cancer index composite (EPIC) Urinary, bowel, sexual, and hormonal symptoms.
[899]

Expanded prostate cancer index composite short Urinary, sexual, bowel, and hormonal domains.
form 26 (EPIC 26) [900]
UCLA Prostate Cancer Index (UCLA PCI) [901] Urinary, bowel, and sexual domains.
Prostate Cancer Quality of Life Instrument (PCQoL) Urinary, sexual, and bowel domains, supplemented by
[902] a scale assessing anxiety.
Prostate Cancer Outcome Study Instrument [903] Urinary, bowel, and sexual domains.
8.3.1 Long-term (≥ 12 months) quality of life outcomes in men with localised disease.
8.3.1.1 Men undergoing local treatments
The results of the Prostate Testing for Cancer and Treatment (ProtecT) trial (n = 1,643 men) [904] reported no
difference in EORTC QLQ-C30 assessed global QoL, up to five years of follow-up in men aged 50-69 years
with T1-T2 disease randomised for treatment with AM, RP or RT [904]. However, EPIC urinary summary scores
(at 6 years) were worse in men treated with RP compared to AM or RT (88.7 vs. 89.0 vs. 91.4, respectively) as
were urinary incontinence (80.9 vs. 85.8 vs. 89.4, respectively) and sexual summary, function and bother scores
(32.3 vs. 40.6 vs. 41.3 for sexual summary, 23.7 vs. 32.5 vs. 32.7 for sexual function and 51.4 vs. 57.9 vs. 60.1
for sexual bother, respectively) at six years of follow-up. Minimal clinically important differences for the 50 item
EPIC questionnaire are not available. For men receiving RT, EPIC bowel scores were poorer compared to AM
and RP in all domains: function (90.8 vs. 92.3 vs. 92.3, respectively), bother (91.7 vs. 94.2 vs. 93.7, respectively)
and summary (91.2 vs. 93.2 vs. 93.0, respectively) at six years of follow-up in the ProtecT trial.
The findings regarding RP and RT are supported by other observational studies, the most important being
The Prostate Cancer Outcomes Study (PCOS) [832] that studied a cohort of 1,655 men, of whom 1,164 had
undergone RP and 491 RT. The study reported that at five years of follow-up, men who underwent RP had a
higher prevalence of urinary incontinence and ED, while men treated with RT had a higher prevalence of bowel
dysfunction. However, despite these differences detected at five years, there were no significant differences in
the adjusted odds of urinary incontinence, bowel dysfunction or ED between RP and RT at fifteen years. More
recently, investigators reported that although EBRT was associated with a negative effect in bowel function, the
difference in bowel domain score was below the threshold for clinical significance 12 months after treatment
[905]. As 81% of patients in the EBRT arm of the study received IMRT, these data suggest that the risk of side-
effects in contemporary treatments may be slightly less.
With respect to brachytherapy cancer-specific QoL outcomes, the best available evidence come from one
small RCT (n = 200) evaluating bilateral nerve sparing RP and brachytherapy in men with localised disease (up
to T2a), which reported worsening of physical functioning as well as irritative urinary symptomatology in 20%
of brachytherapy patients at one year of follow-up. However, there were no significant differences in EORTC
QLQ-C30/PR-25 scores at five years of follow-up when comparing to pre-treatment values [906]. It should be
noted of this trial within group tests only were reported. These data and a synthesis of 18 randomised and non-
randomised studies in a SR involving 13,604 patients, are the foundation of the following recommendations
[907].
8.3.1.2 Guidelines for quality of life in men undergoing local treatments

Advise eligible patients for active surveillance, that global quality of life is equivalent for up Strong
to five years compared to radical prostatectomy or external beam radiotherapy.
Discuss the negative impact of surgery on urinary and sexual function, as well as the Strong
negative impact of radiotherapy on bowel function with patients.
Advise patients treated with brachytherapy of the negative impact on irritative urinary Weak
symptomatology at one year but not after five years.
8.3.2 Improving quality of life in men who have been diagnosed with prostate cancer
Men undergoing local treatments
In men with localised disease, nurse led multi-disciplinary rehabilitation (addressing sexual functioning, cancer
worry, dyadic adjustment, depression, managing bowel and urinary function problems) provided positive short-
term effects (four months) on sexual function (effect size 0.45) and long-term (twelve months) positive effects
on sexual limitation (effect size 0.5) and cancer worry (effect size 0.51) [908].
The use of PDE5 inhibitors in penile rehabilitation has been subject to some debate. A single centre,
double blind RCT of 100 men undergoing nerve-sparing surgery reported no benefit of nightly sildenafil (50
mg) compared to on-demand use [909]. However, a multi-centre double blind RCT (n = 423) in men aged

< 68 years, with normal pre-treatment erectile function undergoing either open, conventional or robot assisted
laparoscopic nerve-sparing RP, Tadalafil (5 mg) once per day improved participants EPIC sexual domain-scores
(least squares mean difference +9.6: 95% CI: 3.1-16.0) when compared to 20 mg ‘on demand’ or placebo at
nine months of follow-up [401]. Therefore, based on discordant results, no clear recommendation is possible,
even if a trend exists for early use of PDE5 inhibitors after RP for penile rehabilitation. A detailed discussion can
be found in the EAU Male Sexual Dysfunction Guidelines [910].
Men undergoing systemic treatments

Similar to men treated with a radical approach (see above) men with T1-T3 disease undergoing RT and ADT a
combined nurse led psychological support and physiotherapist led multi-disciplinary rehabilitation has reported
improvements in QoL. Specifically this intervention involved action planning around patients’ needs related to
lifestyle changes, weight control, toilet habits, sexuality, and psychological problems. This was complemented
with pelvic floor muscle therapy. Improvements in urinary (adjusted mean 4.5: 95% CI: 0.6-8.4), irritative
(adjusted mean 5.8: 95% CI: 1.4-10.3) and hormonal (adjusted mean 4.8: 95% CI: 0.8-8.8) EPIC domains were
found up to 22 weeks of follow-up [911].
Providing supervised aerobic and resistance exercise training of a moderate intensity improves
EORTC QLQ-C30 role (adjusted mean 15.8: 95% CI: 6.6-24.9) and cognitive domain outcomes (adjusted mean
11.4: 95% CI: 3.3-19.6) as well as symptom scales for fatigue (adjusted mean −11.0: 95% CI: −20.2,−1.7),
nausea (adjusted mean −4.0: 95% CI: −7.4,−0.25), and dyspnoea (adjusted mean −12.4: 95% CI: −22.5,−2.3)
up to three months in men treated with ADT [912]. Such interventions have also reported clinically relevant
improvements in FACT-P (mean difference 8.9: 95% CI: 3.7-14.2) in men on long-term ADT [913, 914]. These
findings are supported by a SR which reported improvements up to twelve weeks in cancer-specific QoL in a
meta-analysis of high quality trials (SMD 0.33: 95%, CI: 0.08-0.58) [885].
8.3.2.1 Guidelines for quality of life in men undergoing systemic treatments

Offer men on androgen deprivation therapy, twelve weeks of supervised (by trained Strong
exercise specialists) combined aerobic and resistance exercise.
Offer men with T1-T3 disease specialist nurse led, multi-disciplinary rehabilitation Strong
based on the patients’ personal goals addressing incontinence, sexuality,
depression and fear of recurrence, social support and positive lifestyle changes
after any radical treatment.
9. REFERENCES
1. Mottet, N., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis,
and Local Treatment with Curative Intent. Eur Urol, 2017. 71: 618.
https://www.ncbi.nlm.nih.gov/pubmed/27568654
2. Cornford, P., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of
Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol, 2017. 71: 630.
3. Moldovan, P.C., et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance
Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the
European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol, 2017. 72: 250.
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015021929
4. Fossati, N., et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During
Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol, 2017. 72: 84.
5. Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008.
336: 995.
6. Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of
recommendations. BMJ, 2008. 336: 924.

7. Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by
Jeremy Howick March 2009.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-
march-2009/
8. Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
9. Van den Broeck T., et al. How does biochemical recurrence following curative treatment for prostate
cancer impact on overall survival, cancer-specific survival and development of metastatic disease?.
PROSPERO International prospective register of systematic reviews, 2015. CRD42015026807
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026807
10. Van den Broeck T., et al. A systematic review of oncological effectiveness and harms of primary
local interventions for high-risk localized and locally advanced prostate cancer. PROSPERO
International prospective register of systematic reviews, 2017. CRD42017078862
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=78862
11. Willemse, P.M., et al. Systematic review of deferred treatment with curative intent for localised
prostate cancer to explore heterogeneity of definitions, thresholds and criteria and clinical
effectiveness. PROSPERO International prospective register of systematic reviews, 2018.
CRD42018071780.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=71780
12. Ferlay, J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer, 2015. 136: E359.
13. Haas, G.P., et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy
studies. Can J Urol, 2008. 15: 3866.
14. Bell, K.J., et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int
J Cancer, 2015. 137: 1749.
15. Jansson, K.F., et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur
Urol, 2012. 62: 656.
16. Hemminki, K. Familial risk and familial survival in prostate cancer. World J Urol, 2012. 30: 143.
17. Randazzo, M., et al. A positive family history as a risk factor for prostate cancer in a population-
based study with organised prostate-specific antigen screening: results of the Swiss European
Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int, 2016. 117: 576.
18. Tan, D.S., et al. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin
Oncol, 2016. 34: 91.
19. Eeles, R.A., et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS
custom genotyping array. Nat Genet, 2013. 45: 385.
20. Amin Al Olama, A., et al. Multiple novel prostate cancer susceptibility signals identified by fine-
mapping of known risk loci among Europeans. Hum Mol Genet, 2015. 24: 5589.
21. Pritchard, C.C., et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med, 2016. 375: 443.
22. Lynch, H.T., et al. Screening for familial and hereditary prostate cancer. Int J Cancer, 2016. 138:
2579.
23. Ewing, C.M., et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med, 2012.
366: 141.
24. Bancroft, E.K., et al. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers:
Results from the Initial Screening Round of the IMPACT Study. Eur Urol, 2014. 66: 489.

25. Leitzmann, M.F., et al. Risk factors for the onset of prostatic cancer: age, location, and behavioral
correlates. Clin Epidemiol, 2012. 4: 1.
26. Breslow, N., et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency
for Research on Cancer, Lyons, France. Int J Cancer, 1977. 20: 680.
27. Esposito, K., et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-
analysis. J Endocrinol Invest, 2013. 36: 132.
28. Blanc-Lapierre, A., et al. Metabolic syndrome and prostate cancer risk in a population-based case-
control study in Montreal, Canada. BMC Public Health, 2015. 15: 913.
29. Preston, M.A., et al. Metformin use and prostate cancer risk. Eur Urol, 2014. 66: 1012.
30. Freedland, S.J., et al. Statin use and risk of prostate cancer and high-grade prostate cancer: results
from the REDUCE study. Prostate Cancer Prostatic Dis, 2013. 16: 254.
31. YuPeng, L., et al. Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of
14 Prospective Studies. Cancer Epidemiol Biomarkers Prev, 2015. 24: 1086.
32. Vidal, A.C., et al. Obesity increases the risk for high-grade prostate cancer: results from the
REDUCE study. Cancer Epidemiol Biomarkers Prev, 2014. 23: 2936.
33. Davies, N.M., et al. The effects of height and BMI on prostate cancer incidence and mortality:
a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL
consortium. Cancer Causes Control, 2015. 26: 1603.
34. Dickerman, B.A., et al. Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a
30-year prospective cohort study of Finnish twins. Cancer Causes Control, 2016. 27: 1049.
35. Zhao, J., et al. Is alcohol consumption a risk factor for prostate cancer? A systematic review and
meta-analysis. BMC Cancer, 2016. 16: 845.
36. Key, T.J. Nutrition, hormones and prostate cancer risk: results from the European prospective
investigation into cancer and nutrition. Recent Results Cancer Res, 2014. 202: 39.
37. Alexander, D.D., et al. Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids
(LComega-3PUFA) and Prostate Cancer. Nutr Cancer, 2015. 67: 543.
38. Lippi, G., et al. Fried food and prostate cancer risk: systematic review and meta-analysis. Int J Food
Sci Nutr, 2015. 66: 587.
39. Chen, P., et al. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.
Medicine (Baltimore), 2015. 94: e1260.
40. Ilic, D., et al. Lycopene for the prevention and treatment of benign prostatic hyperplasia and
prostate cancer: a systematic review. Maturitas, 2012. 72: 269.
41. Bylsma, L.C., et al. A review and meta-analysis of prospective studies of red and processed meat,
meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J, 2015. 14: 125.
42. Zhang, M., et al. Is phytoestrogen intake associated with decreased risk of prostate cancer? A
systematic review of epidemiological studies based on 17,546 cases. Andrology, 2016. 4: 745.
43. Kristal, A.R., et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin
E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev, 2014. 23: 1494.
44. Nyame, Y.A., et al. Associations Between Serum Vitamin D and Adverse Pathology in Men
Undergoing Radical Prostatectomy. J Clin Oncol, 2016. 34: 1345.

45. Cui, Z., et al. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis.
Medicine (Baltimore), 2017. 96: e5944.
46. Allen, N.E., et al. Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen
Prospective Studies. J Natl Cancer Inst, 2016. 108.
47. Lippman, S.M., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers:
the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2009. 301: 39.
48. Kramer, B.S., et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention:
American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice
Guideline. J Clin Oncol, 2009. 27: 1502.
49. Andriole, G.L., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med, 2010. 362:
1192.
50. Thompson, I.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J
Med, 2003. 349: 215.
51. Haider, A., et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy:
observations from 5-year median followup of 3 registries. J Urol, 2015. 193: 80.
52. Zhou, C.K., et al. Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A
Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol, 2016. 183:
210.
53. Lian, W.Q., et al. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21
Epidemiologic Studies. Med Sci Monit, 2015. 21: 1902.
54. Rao, D., et al. Does night-shift work increase the risk of prostate cancer? a systematic review and
meta-analysis. Onco Targets Ther, 2015. 8: 2817.
55. Islami, F., et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality
and incidence in prospective cohort studies. Eur Urol, 2014. 66: 1054.
56. Ju-Kun, S., et al. Association Between Cd Exposure and Risk of Prostate Cancer: A PRISMA-
Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore), 2016. 95: e2708.
57. Zhang, X.L., et al. Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies. Int
J Clin Exp Med, 2015. 8: 17977.
58. Cremers, R.G., et al. Self-reported acne is not associated with prostate cancer. Urol Oncol, 2014.
32: 941.
59. Huang, T.B., et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic
studies. Int Urol Nephrol, 2014. 46: 1715.
60. Bhindi, B., et al. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on
the risk of prostate cancer detection on biopsy. Urology, 2014. 84: 1073.
61. Lin, S.W., et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the United
States. Int J Cancer, 2012. 131: E1015.
62. Pabalan, N., et al. Association of male circumcision with risk of prostate cancer: a meta-analysis.
Prostate Cancer Prostatic Dis, 2015. 18: 352.
63. Rider, J.R., et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an
Additional Decade of Follow-up. Eur Urol, 2016. 70: 974.

64. Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against
Cancer. 8th edn. 2017.
http://www.uicc.org/resources/tnm/publications-resources
65. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk
Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after
radical prostatectomy. J Urol, 2005. 173: 1938.
66. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 2005. 29: 1228.
67. Epstein, J.I., et al. The 2014 International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and
Proposal for a New Grading System. Am J Surg Pathol, 2016. 40: 244.
68. Epstein, J.I., et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the
Gleason Score. Eur Urol, 2016. 69: 428.
69. Gulati, R., et al. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of
Benefits and Harms. Cancer Epidemiol Biomarkers Prev, 2017. 26: 222.
70. IARC. IARC France All Cancers (excluding non-melanoma skin cancer) Estimated Incidence,
Mortality and Prevalence Worldwide in 2012. 2014.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
71. Etzioni, R., et al. Limitations of basing screening policies on screening trials: The US Preventive
Services Task Force and Prostate Cancer Screening. Med Care, 2013. 51: 295.
72. Loeb, S. Guideline of guidelines: prostate cancer screening. BJU Int, 2014. 114: 323.
73. Andriole, G.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J
Med, 2009. 360: 1310.
74. Schroder, F.H., et al. Screening and prostate-cancer mortality in a randomized European study. N
Engl J Med, 2009. 360: 1320.
75. Hugosson, J., et al. Mortality results from the Goteborg randomised population-based prostate-
cancer screening trial. Lancet Oncol, 2010. 11: 725.
76. Carter, H.B., et al. Early detection of prostate cancer: AUA Guideline. J Urol, 2013. 190: 419.
77. Chou, R., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive
Services Task Force. Ann Intern Med, 2011. 155: 762.
78. Tsodikov, A., et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC
and PLCO Trials. Ann Intern Med, 2017. 167: 449.
79. Bibbins-Domingo, K., et al. The US Preventive Services Task Force 2017 Draft Recommendation
Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. JAMA, 2017.
317: 1949.
80. Auffenberg, G.B., et al. Application of the 2013 American Urological Association early detection of
prostate cancer guideline: who will we miss? World J Urol, 2014. 32: 959.
81. Banerji, J.S., et al. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task
Force Recommendation against Prostate Specific Antigen Based Screening. J Urol, 2016. 195: 66.
82. U.S. Preventive Services, Task Force. Prostate Cancer Screening Draft Recommendations. 2017.
https://screeningforprostatecancer.org/

83. Arnsrud Godtman, R., et al. Opportunistic testing versus organized prostate-specific antigen
screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer
screening trial. Eur Urol, 2015. 68: 354.
84. Ilic, D., et al. Screening for prostate cancer. Cochrane Database Syst Rev, 2013. 1: CD004720.
85. Hayes, J.H., et al. Screening for prostate cancer with the prostate-specific antigen test: a review of
current evidence. JAMA, 2014. 311: 1143.
86. Booth, N., et al. Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur
Urol, 2014. 65: 39.
87. Vasarainen, H., et al. Effects of prostate cancer screening on health-related quality of life: results of
the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol, 2013. 52: 1615.
88. Heijnsdijk, E.A., et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med,
2012. 367: 595.
89. Schroder, F.H., et al. Screening and prostate cancer mortality: results of the European Randomised
Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 2014. 384: 2027.
90. The benefits and harms of breast cancer screening: an independent review. Lancet, 2012. 380:
1778.
91. Albright, F., et al. Prostate cancer risk prediction based on complete prostate cancer family history.
Prostate, 2015. 75: 390.
92. Kamangar, F., et al. Patterns of cancer incidence, mortality, and prevalence across five continents:
defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin
Oncol, 2006. 24: 2137.
93. Vickers, A.J., et al. Strategy for detection of prostate cancer based on relation between prostate
specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ, 2013. 346:
f2023.
94. Carlsson, S., et al. Influence of blood prostate specific antigen levels at age 60 on benefits and
harms of prostate cancer screening: population based cohort study. Bmj, 2014. 348: g2296.
95. Vedder, M.M., et al. The added value of percentage of free to total prostate-specific antigen, PCA3,
and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol,
2014. 66: 1109.
96. Leyten, G.H., et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as
diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol, 2014. 65: 534.
97. Boegemann, M., et al. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and
the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer
at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged </=65
years. BJU Int, 2016. 117: 72.
98. Bryant, R.J., et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein
markers measured in blood in the ProtecT study. J Natl Cancer Inst, 2015. 107.
99. Roobol, M.J., et al. Improving the Rotterdam European Randomized Study of Screening for Prostate
Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of
Urological Pathology Gleason Grading and Cribriform growth. Eur Urol, 2017. 72: 45.
100. Louie, K.S., et al. Do prostate cancer risk models improve the predictive accuracy of PSA
screening? A meta-analysis. Ann Oncol, 2015. 26: 848.

101. Loeb, S., et al. Pathological characteristics of prostate cancer detected through prostate specific
antigen based screening. J Urol, 2006. 175: 902.
102. Gelfond, J., et al. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate
Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. J
Urol, 2015. 194: 46.
103. Droz, J.P., et al. Management of prostate cancer in older patients: updated recommendations of a
working group of the International Society of Geriatric Oncology. Lancet Oncol, 2014. 15: e404.
104. Richie, J.P., et al. Effect of patient age on early detection of prostate cancer with serum prostate-
specific antigen and digital rectal examination. Urology, 1993. 42: 365.
105. Carvalhal, G.F., et al. Digital rectal examination for detecting prostate cancer at prostate specific
antigen levels of 4 ng./ml. or less. J Urol, 1999. 161: 835.
106. Okotie, O.T., et al. Characteristics of prostate cancer detected by digital rectal examination only.
Urology, 2007. 70: 1117.
107. Gosselaar, C., et al. The role of the digital rectal examination in subsequent screening visits in the
European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol, 2008.
54: 581.
108. Stamey, T.A., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
N Engl J Med, 1987. 317: 909.
109. Catalona, W.J., et al. Comparison of digital rectal examination and serum prostate specific antigen
in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol,
1994. 151: 1283.
110. Semjonow, A., et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-
specific antigen values. Prostate Suppl, 1996. 7: 3.
111. Thompson, I.M., et al. Prevalence of prostate cancer among men with a prostate-specific antigen
level < or =4.0 ng per milliliter. N Engl J Med, 2004. 350: 2239.
112. Dong, F., et al. Validation of pretreatment nomograms for predicting indolent prostate cancer:
efficacy in contemporary urological practice. J Urol, 2008. 180: 150.
113. Carter, H.B., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and
without prostate disease. JAMA, 1992. 267: 2215.
114. Schmid, H.P., et al. Observations on the doubling time of prostate cancer. The use of serial prostate-
specific antigen in patients with untreated disease as a measure of increasing cancer volume.
Cancer, 1993. 71: 2031.
115. Arlen, P.M., et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen
doubling time. J Urol, 2008. 179: 2181.
116. Heidenreich, A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA
doubling time, and PSA velocity. Eur Urol, 2008. 54: 976.
117. Ramirez, M.L., et al. Current applications for prostate-specific antigen doubling time. Eur Urol, 2008.
54: 291.
118. O’Brien, M.F., et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are
associated with outcome but neither improves prediction of outcome beyond pretreatment PSA
alone in patients treated with radical prostatectomy. J Clin Oncol, 2009. 27: 3591.

119. Vickers, A.J., et al. Systematic review of pretreatment prostate-specific antigen velocity and
doubling time as predictors for prostate cancer. J Clin Oncol, 2009. 27: 398.
120. Stephan, C., et al. The influence of prostate volume on the ratio of free to total prostate specific
antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer,
1997. 79: 104.
121. Catalona, W.J., et al. Use of the percentage of free prostate-specific antigen to enhance
differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical
trial. JAMA, 1998. 279: 1542.
122. Loeb, S., et al. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv
Urol, 2014. 6: 74.
123. de la Calle, C., et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive
Prostate Cancer in Biopsy Naive Men. J Urol, 2015. 194: 65.
124. Nordstrom, T., et al. Comparison Between the Four-kallikrein Panel and Prostate Health Index for
Predicting Prostate Cancer. Eur Urol, 2015. 68: 139.
125. Deras, I.L., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol,
2008. 179: 1587.
126. Hessels, D., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
Eur Urol, 2003. 44: 8.
127. Nakanishi, H., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume:
implication in selecting candidates for active surveillance. J Urol, 2008. 179: 1804.
128. Hessels, D., et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological
characteristics of prostate cancer. Prostate, 2010. 70: 10.
129. Auprich, M., et al. Contemporary role of prostate cancer antigen 3 in the management of prostate
cancer. Eur Urol, 2011. 60: 1045.
130. Nicholson, A., et al. The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate
cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a
systematic review and economic evaluation. Health Technol Assess, 2015. 19: 1.
131. Van Neste, L., et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-
Based Risk Score. Eur Urol, 2016. 70: 740.
132. Lamy, P.J., et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A
Systematic Review. Eur Urol Focus, 2017.
133. Roobol, M.J., et al. A risk-based strategy improves prostate-specific antigen-driven detection of
prostate cancer. Eur Urol, 2010. 57: 79.
134. Eastham, J.A., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year
fluctuations. JAMA, 2003. 289: 2695.
https://www.ncbi.nlm.nih.gov/pubmed/
135. Stephan, C., et al. Interchangeability of measurements of total and free prostate-specific antigen in
serum with 5 frequently used assay combinations: an update. Clin Chem, 2006. 52: 59.
136. Eggener, S.E., et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a
randomised, prospective, controlled multi-institutional trial. BJU Int, 2013. 112: 925.
137. Xue, J., et al. Comparison between transrectal and transperineal prostate biopsy for detection of
prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget, 2017. 8: 23322.

138. Roberts, M.J., et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors,
Prevention Strategies, and Management Approaches. Urology, 2017. 104: 11.
139. Ericson, K.J., et al. Prostate cancer detection following diagnosis of atypical small acinar
proliferation. Can J Urol, 2017. 24: 8714.
140. Epstein, J.I., et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical
foci suspicious for carcinoma: implications for patient care. J Urol, 2006. 175: 820.
141. Merrimen, J.L., et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk
factor for prostatic adenocarcinoma. J Urol, 2009. 182: 485.
142. Kronz, J.D., et al. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands
on prostate biopsy. Hum Pathol, 2001. 32: 389.
143. Guo, C.C., et al. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and
clinical significance. Mod Pathol, 2006. 19: 1528.
144. Partin, A.W., et al. Clinical validation of an epigenetic assay to predict negative histopathological
results in repeat prostate biopsies. J Urol, 2014. 192: 1081.
145. Moore, C.K., et al. Prognostic significance of high grade prostatic intraepithelial neoplasia and
atypical small acinar proliferation in the contemporary era. J Urol, 2005. 173: 70.
146. Walz, J., et al. High incidence of prostate cancer detected by saturation biopsy after previous
negative biopsy series. Eur Urol, 2006. 50: 498.
147. Moran, B.J., et al. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol,
2006. 176: 1376.
148. Donovan, J., et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health
Technol Assess, 2003. 7: 1.
149. Eichler, K., et al. Diagnostic value of systematic biopsy methods in the investigation of prostate
cancer: a systematic review. J Urol, 2006. 175: 1605.
150. Shariat, S.F., et al. Using biopsy to detect prostate cancer. Rev Urol, 2008. 10: 262.
151. Zigeuner, R., et al. Detection of prostate cancer by TURP or open surgery in patients with previously
negative transrectal prostate biopsies. Urology, 2003. 62: 883.
152. Linzer, D.G., et al. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer.
Urology, 1996. 48: 757.
153. Pelzer, A.E., et al. Are transition zone biopsies still necessary to improve prostate cancer detection?
Results from the tyrol screening project. Eur Urol, 2005. 48: 916.
154. Aron, M., et al. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized
controlled study. BJU Int, 2000. 85: 682.
155. Cuevas, O., et al. Significant ecological impact on the progression of fluoroquinolone resistance
in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/
clavulanic acid. J Antimicrob Chemother, 2011. 66: 664.
156. Loeb, S., et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol, 2011. 186:
1830.

157. von Knobloch, R., et al. Bilateral fine-needle administered local anaesthetic nerve block for pain
control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. Eur Urol,
2002. 41: 508.
158. Adamakis, I., et al. Pain during transrectal ultrasonography guided prostate biopsy: a randomized
prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of
lidocaine-prilocain cream. World J Urol, 2004. 22: 281.
159. NCCN Clinical practice Guidelines in OncologyTM: Prostate Cancer Early Detection, Version 2.
2015. 2015.
https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
160. Loeb, S., et al. Systematic review of complications of prostate biopsy. Eur Urol, 2013. 64: 876.
161. Giannarini, G., et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy:
results of a prospective randomized trial. Urology, 2007. 70: 501.
162. Garcia C, et al. Does transperineal prostate biopsy reduce complications compared with transrectal
biopsy? a systematic review and meta-analysis of randomised controlled trials. 2016. 195:4 SUPPL.
1 p. e328.
http://www.jurology.com/article/S0022-5347(16)03167-0/pdf
163. Smeenge, M., et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer:
report from a Consensus Panel. BJU Int, 2012. 110: 942.
164. Turkbey, B., et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer:
histopathological correlation using prostatectomy specimens processed in customized magnetic
resonance imaging based molds. J Urol, 2011. 186: 1818.
165. Selnaes, K.M., et al. Peripheral zone prostate cancer localization by multiparametric magnetic
resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol, 2012.
47: 624.
166. Bratan, F., et al. Influence of imaging and histological factors on prostate cancer detection and
localisation on multiparametric MRI: a prospective study. Eur Radiol, 2013. 23: 2019.
167. Le, J.D., et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance
imaging: correlation with whole-mount histopathology. Eur Urol, 2015. 67: 569.
168. Futterer, J.J., et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric
Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol, 2015. 68: 1045.
169. van Hove, A., et al. Comparison of image-guided targeted biopsies versus systematic randomized
biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies.
World J Urol, 2014. 32: 847.
170. Schoots, I.G., et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic
accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-
guided biopsy: a systematic review and meta-analysis. Eur Urol, 2015. 68: 438.
171. Valerio, M., et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance
Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. Eur Urol, 2015. 68: 8.
172. Wegelin, O., et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted
Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal
Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? Eur Urol, 2017. 71:
517.
173. Siddiqui, M.M., et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided
biopsy for the diagnosis of prostate cancer. JAMA, 2015. 313: 390.

174. Panebianco, V., et al. Multiparametric magnetic resonance imaging vs. standard care in men being
evaluated for prostate cancer: a randomized study. Urol Oncol, 2015. 33: 17 e1.
175. Baco, E., et al. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core
Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and
Traditional 12-core Systematic Biopsy. Eur Urol, 2016. 69: 149.
176. Tonttila, P.P., et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer
Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-
specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol,
2016. 69: 419.
177. Ahmed, H.U., et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate
cancer (PROMIS): a paired validating confirmatory study. Lancet, 2017. 389: 815.
178. Schoots, I.G., et al. From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Transl Androl
Urol, 2017. 6: 604.
179. Puech, P., et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive
and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.
Radiology, 2013. 268: 461.
180. Wysock, J.S., et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-
ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the
PROFUS trial. Eur Urol, 2014. 66: 343.
181. Arsov, C., et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided
in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in
patients with prior negative biopsies. Eur Urol, 2015. 68: 713.
182. Porpiglia, F., et al. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus
Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naive Patients with
Suspected Prostate Cancer. Eur Urol, 2017. 72: 282.
183. Hansen, N.L., et al. The influence of prostate-specific antigen density on positive and negative
predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10
prostate cancer in a repeat biopsy setting. BJU Int, 2016.
184. Weinreb, J.C., et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur
Urol, 2016. 69: 16.
185. Rosenkrantz, A.B., et al. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A
Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 2016. 280: 793.
186. Muller, B.G., et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised
Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 2015. 277:
741.
187. Zhao, C., et al. The efficiency of multiparametric magnetic resonance imaging (mpMRI) using
PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. Clin Imaging, 2016. 40:
885.
188. Kasel-Seibert, M., et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. Eur J
Radiol, 2016. 85: 726.
189. Niaf, E., et al. Prostate focal peripheral zone lesions: characterization at multiparametric MR
imaging--influence of a computer-aided diagnosis system. Radiology, 2014. 271: 761.

190. Litjens, G.J., et al. Clinical evaluation of a computer-aided diagnosis system for determining cancer
aggressiveness in prostate MRI. Eur Radiol, 2015. 25: 3187.
191. Hoang Dinh, A., et al. Quantitative Analysis of Prostate Multiparametric MR Images for Detection of
Aggressive Prostate Cancer in the Peripheral Zone: A Multiple Imager Study. Radiology, 2016. 280:
117.
192. Iczkowski, K.A., et al. Needle core length in sextant biopsy influences prostate cancer detection
rate. Urology, 2002. 59: 698.
193. Van der Kwast, T., et al. Guidelines on processing and reporting of prostate biopsies: the 2013
update of the pathology committee of the European Randomized Study of Screening for Prostate
Cancer (ERSPC). Virchows Arch, 2013. 463: 367.
194. Rogatsch, H., et al. Diagnostic effect of an improved preembedding method of prostate needle
biopsy specimens. Hum Pathol, 2000. 31: 1102.
195. Novis, D.A., et al. Diagnostic uncertainty expressed in prostate needle biopsies. A College of
American Pathologists Q-probes Study of 15,753 prostate needle biopsies in 332 institutions. Arch
Pathol Lab Med, 1999. 123: 687.
196. Iczkowski, K.A. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar
proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol
Lab Med, 2006. 130: 835.
197. Reyes, A.O., et al. Diagnostic effect of complete histologic sampling of prostate needle biopsy
specimens. Am J Clin Pathol, 1998. 109: 416.
198. Sauter, G., et al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and
Prostatectomy Specimens. Eur Urol, 2016. 69: 592.
199. Cole, A.I., et al. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting
Prostatectomy Pathology and Recurrence. J Urol, 2016. 196: 405.
200. Kweldam, C.F., et al. Disease-specific survival of patients with invasive cribriform and intraductal
prostate cancer at diagnostic biopsy. Mod Pathol, 2016. 29: 630.
201. Saeter, T., et al. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts
Prostate Cancer Mortality: A Population-Based Study. Prostate, 2017. 77: 859.
202. Sebo, T.J., et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by
assessing needle biopsy specimens for percent surface area and cores positive for carcinoma,
perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate
specific antigen: a report of 454 cases. Cancer, 2001. 91: 2196.
203. Grossklaus, D.J., et al. Percent of cancer in the biopsy set predicts pathological findings after
prostatectomy. J Urol, 2002. 167: 2032.
204. Freedland, S.J., et al. Preoperative model for predicting prostate specific antigen recurrence after
radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum
prostate specific antigen. J Urol, 2004. 171: 2215.
205. Brimo, F., et al. Prognostic value of various morphometric measurements of tumour extent in
prostate needle core tissue. Histopathology, 2008. 53: 177.
206. Bangma, C.H., et al. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol, 2013.
85: 295.

207. Shore, N., et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized
prostate cancer. Curr Med Res Opin, 2014. 30: 547.
208. Sommariva, S., et al. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate
Cancer: A Systematic Review and Meta-analysis. Eur Urol, 2016. 69: 107.
209. Sehdev, A.E., et al. Comparative analysis of sampling methods for grossing radical prostatectomy
specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol, 2001. 32:
494.
210. Ruijter, E.T., et al. Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-
II MPC Study Group. J Pathol, 1997. 183: 369.
211. Chan, N.G., et al. Pathological reporting of colorectal cancer specimens: a retrospective survey in
an academic Canadian pathology department. Can J Surg, 2008. 51: 284.
212. Partin, A.W., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for
the new millennium. Urology, 2001. 58: 843.
213. Harnden, P., et al. Should the Gleason grading system for prostate cancer be modified to account
for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol, 2007. 8:
411.
214. Magi-Galluzzi, C., et al. International Society of Urological Pathology (ISUP) Consensus Conference
on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic
extension, lymphovascular invasion and locally advanced disease. Mod Pathol, 2011. 24: 26.
215. Epstein, J.I., et al. Influence of capsular penetration on progression following radical prostatectomy:
a study of 196 cases with long-term followup. J Urol, 1993. 150: 135.
216. Marks, R.A., et al. The relationship between the extent of surgical margin positivity and prostate
specific antigen recurrence in radical prostatectomy specimens. Hum Pathol, 2007. 38: 1207.
217. Sung, M.T., et al. Radial distance of extraprostatic extension measured by ocular micrometer is an
independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of
pT3a prostate cancer. Am J Surg Pathol, 2007. 31: 311.
218. Aydin, H., et al. Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk
of biochemical progression. Urology, 2004. 64: 551.
219. Ploussard, G., et al. The prognostic significance of bladder neck invasion in prostate cancer: is
microscopic involvement truly a T4 disease? BJU Int, 2010. 105: 776.
220. Hoedemaeker, R.F., et al. Staging prostate cancer. Microsc Res Tech, 2000. 51: 423.
221. Stamey, T.A., et al. Prostate cancer is highly predictable: a prognostic equation based on all
morphological variables in radical prostatectomy specimens. J Urol, 2000. 163: 1155.
222. Epstein, J.I., et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy
and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl, 2005: 34.
223. Kikuchi, E., et al. Is tumor volume an independent prognostic factor in clinically localized prostate
cancer? J Urol, 2004. 172: 508.
224. van Oort, I.M., et al. Maximum tumor diameter is not an independent prognostic factor in high-risk
localized prostate cancer. World J Urol, 2008. 26: 237.

225. van der Kwast, T.H., et al. International Society of Urological Pathology (ISUP) Consensus
Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2
substaging and prostate cancer volume. Mod Pathol, 2011. 24: 16.
226. Evans, A.J., et al. Interobserver variability between expert urologic pathologists for extraprostatic
extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol, 2008.
32: 1503.
227. Chuang, A.Y., et al. Positive surgical margins in areas of capsular incision in otherwise organ-
confined disease at radical prostatectomy: histologic features and pitfalls. Am J Surg Pathol, 2008.
32: 1201.
228. Sammon, J.D., et al. Risk factors for biochemical recurrence following radical perineal
prostatectomy in a large contemporary series: a detailed assessment of margin extent and location.
Urol Oncol, 2013. 31: 1470.
229. Spigelman, S.S., et al. Rectal examination in volume determination of carcinoma of the prostate:
clinical and anatomical correlations. J Urol, 1986. 136: 1228.
230. Partin, A.W., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of
tumor differentiation, tumor volume and benign hyperplasia. J Urol, 1990. 143: 747.
231. Freedland, S.J., et al. Percent prostate needle biopsy tissue with cancer is more predictive of
biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen
or Gleason score. J Urol, 2002. 167: 516.
232. Quinn, D.I., et al. Prognostic significance of preoperative factors in localized prostate carcinoma
treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the
presence of biopsy perineural invasion. Cancer, 2003. 97: 1884.
233. Eifler, J.B., et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from
2006 to 2011. BJU Int, 2013. 111: 22.
234. Saliken, J.C., et al. Extraprostatic biopsy improves the staging of localized prostate cancer. Can
Assoc Radiol J, 2000. 51: 114.
235. Stone, N.N., et al. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node
dissection in men with localized carcinoma of the prostate. J Urol, 1995. 154: 1392.
236. Allepuz Losa, C.A., et al. Seminal vesicle biopsy in prostate cancer staging. J Urol, 1995. 154: 1407.
237. Guillonneau, B., et al. Indications for preoperative seminal vesicle biopsies in staging of clinically
localized prostatic cancer. Eur Urol, 1997. 32: 160.
238. Barqawi, A.B., et al. The role of 3-dimensional mapping biopsy in decision making for treatment of
apparent early stage prostate cancer. J Urol, 2011. 186: 80.
239. Smith, J.A., Jr., et al. Transrectal ultrasound versus digital rectal examination for the staging of
carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol, 1997. 157: 902.
240. Mitterberger, M., et al. The value of three-dimensional transrectal ultrasonography in staging
prostate cancer. BJU Int, 2007. 100: 47.
241. Sauvain, J.L., et al. Value of power doppler and 3D vascular sonography as a method for diagnosis
and staging of prostate cancer. Eur Urol, 2003. 44: 21.
242. de Rooij, M., et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer:
A Diagnostic Meta-analysis. Eur Urol, 2016. 70: 233.

243. Jager, G.J., et al. Local staging of prostate cancer with endorectal MR imaging: correlation with
histopathology. AJR Am J Roentgenol, 1996. 166: 845.
244. Cornud, F., et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of
pT3 tumor and of positive endorectal MR imaging examination results. Radiology, 2002. 224: 203.
245. Heijmink, S.W., et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3
T--comparison of image quality, localization, and staging performance. Radiology, 2007. 244: 184.
246. Futterer, J.J., et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR
imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology,
2005. 237: 541.
247. Wang, L., et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction
of extracapsular extension. Radiology, 2004. 232: 133.
248. Poulakis, V., et al. Preoperative neural network using combined magnetic resonance imaging
variables, prostate specific antigen and Gleason score to predict prostate cancer stage. J Urol,
2004. 172: 1306.
249. Schieda, N., et al. MRI assessment of pathological stage and surgical margins in anterior prostate
cancer (APC) using subjective and quantitative analysis. J Magn Reson Imaging, 2017. 45: 1296.
250. Lim, C., et al. Evaluation of apparent diffusion coefficient and MR volumetry as independent
associative factors for extra-prostatic extension (EPE) in prostatic carcinoma. J Magn Reson
Imaging, 2016. 43: 726.
251. Baco, E., et al. Predictive value of magnetic resonance imaging determined tumor contact length for
extracapsular extension of prostate cancer. J Urol, 2015. 193: 466.
252. Raskolnikov, D., et al. The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying
Men for Risk of Extracapsular Extension at Radical Prostatectomy. J Urol, 2015. 194: 105.
253. D’Amico, A.V., et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome
after radical prostatectomy in men with clinically localized prostate cancer. J Urol, 2000. 164: 759.
254. Engelbrecht, M.R., et al. Patient selection for magnetic resonance imaging of prostate cancer. Eur
Urol, 2001. 40: 300.
255. Albert, J.M., et al. Magnetic resonance imaging-based treatment planning for prostate
brachytherapy. Brachytherapy, 2013. 12: 30.
256. Abuzallouf, S., et al. Baseline staging of newly diagnosed prostate cancer: a summary of the
literature. J Urol, 2004. 171: 2122.
257. Kiss, B., et al. Current Status of Lymph Node Imaging in Bladder and Prostate Cancer. Urology,
2016. 96: 1.
258. Harisinghani, M.G., et al. Noninvasive detection of clinically occult lymph-node metastases in
prostate cancer. N Engl J Med, 2003. 348: 2491.
259. Hovels, A.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in
patients with prostate cancer: a meta-analysis. Clin Radiol, 2008. 63: 387.
260. Gabriele, D., et al. Is there still a role for computed tomography and bone scintigraphy in prostate
cancer staging? An analysis from the EUREKA-1 database. World J Urol, 2016. 34: 517.

261. Flanigan, R.C., et al. Limited efficacy of preoperative computed tomographic scanning for the
evaluation of lymph node metastasis in patients before radical prostatectomy. Urology, 1996. 48:
428.
262. Tiguert, R., et al. Lymph node size does not correlate with the presence of prostate cancer
metastasis. Urology, 1999. 53: 367.
263. Spevack, L., et al. Predicting the patient at low risk for lymph node metastasis with localized
prostate cancer: an analysis of four statistical models. Int J Radiat Oncol Biol Phys, 1996. 34: 543.
264. Thoeny, H.C., et al. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-
weighted MR imaging. Radiology, 2014. 273: 125.
265. Brogsitter, C., et al. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for
imaging prostate cancer patients. Eur J Nucl Med Mol Imaging, 2013. 40 Suppl 1: S18.
266. Poulsen, M.H., et al. [18F]fluoromethylcholine (FCH) positron emission tomography/computed
tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210
patients. BJU Int, 2012. 110: 1666.
267. von Eyben, F.E., et al. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of
patients with prostate cancer. Nucl Med Commun, 2014. 35: 221.
268. Van den Bergh, L., et al. Final analysis of a prospective trial on functional imaging for nodal staging
in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol, 2015. 33: 109
e23.
269. Pinaquy, J.B., et al. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with
diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate, 2015. 75:
323.
270. Heck, M.M., et al. Prospective comparison of computed tomography, diffusion-weighted magnetic
resonance imaging and [11C]choline positron emission tomography/computed tomography for
preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging, 2014.
41: 694.
271. Budiharto, T., et al. Prospective evaluation of 11C-choline positron emission tomography/computed
tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate
cancer with a high risk of lymph node metastases. Eur Urol, 2011. 60: 125.
272. Maurer, T., et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol, 2016. 13:
226.
273. Dias, A.H., et al. Prostate-Specific Membrane Antigen PET/CT: Uptake in Lymph Nodes With Active
Sarcoidosis. Clin Nucl Med, 2017. 42: e175.
274. Froehner, M., et al. PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed
Prostate Cancer: Imaging and Bone Biopsy Findings. Case Rep Urol, 2017. 2017: 1654231.
275. Perera, M., et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific
Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic
Review and Meta-analysis. Eur Urol, 2016. 70: 926.
276. Obek, C., et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk
prostate cancer. Eur J Nucl Med Mol Imaging, 2017.
277. van Leeuwen, P.J., et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen
positron emission tomography/computed tomography for preoperative lymph node staging in
prostate cancer. BJU Int, 2017. 119: 209.

278. Uprimny, C., et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason
score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol
Imaging, 2017. 44: 941.
279. Shen, G., et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis
of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol, 2014. 43:
1503.
280. Briganti, A., et al. When to perform bone scan in patients with newly diagnosed prostate cancer:
external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Eur Urol, 2010. 57: 551.
281. O’Sullivan, J.M., et al. Broadening the criteria for avoiding staging bone scans in prostate cancer: a
retrospective study of patients at the Royal Marsden Hospital. BJU Int, 2003. 92: 685.
282. Ayyathurai, R., et al. A study on staging bone scans in newly diagnosed prostate cancer. Urol Int,
2006. 76: 209.
283. Tateishi, U., et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of
metastatic bone tumor. Ann Nucl Med, 2010. 24: 523.
284. Evangelista, L., et al. Diagnostic imaging to detect and evaluate response to therapy in bone
metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol
Imaging, 2016. 43: 1546.
285. Picchio, M., et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA
progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J
Nucl Med Mol Imaging, 2012. 39: 13.
286. Gutzeit, A., et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for
the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol,
2010. 39: 333.
287. Lecouvet, F.E., et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging
replace Tc 99m bone scanning and computed tomography for single-step detection of metastases
in patients with high-risk prostate cancer? Eur Urol, 2012. 62: 68.
288. Pasoglou, V., et al. One-step TNM staging of high-risk prostate cancer using magnetic resonance
imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate, 2014. 74: 469.
289. Roach, P.J., et al. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer:
results of an Australian prospective multicenter study. J Nucl Med, 2017.
290. Eiber, M., et al. 68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography
for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?
Eur Urol, 2016. 70: 938.
291. Hicks, R.J., et al. Seduction by sensitivity; reality, illusion or delusion? The challenge of assessing
outcomes following PSMA-imaging selection of patients for treatment. J Nucl Med, 2017. 58: 1969.
292. Smith, B.D., et al. Future of cancer incidence in the United States: burdens upon an aging, changing
nation. J Clin Oncol, 2009. 27: 2758.
293. Arnold, M., et al. Recent trends in incidence of five common cancers in 26 European countries since
1988: Analysis of the European Cancer Observatory. Eur J Cancer, 2015. 51: 1164.
294. Liu, D., et al. Active surveillance versus surgery for low risk prostate cancer: a clinical decision
analysis. J Urol, 2012. 187: 1241.

295. Bill-Axelson, A., et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J
Med, 2014. 370: 932.
296. Kupelian, P.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the
prostate-specific antigen era: a large single-institution experience with radical prostatectomy and
external-beam radiotherapy. J Clin Oncol, 2002. 20: 3376.
297. Bubolz, T., et al. Treatments for prostate cancer in older men: 1984-1997. Urology, 2001. 58: 977.
298. Houterman, S., et al. Impact of comorbidity on treatment and prognosis of prostate cancer patients:
a population-based study. Crit Rev Oncol Hematol, 2006. 58: 60.
299. Ries LAG, M.D., Krapcho M et al. eds. SEER cancer Statistics Review, 1975-2005. 2008.
https://seer.cancer.gov/archive/csr/1975_2005/
300. Scosyrev, E., et al. Prostate cancer in the elderly: frequency of advanced disease at presentation
and disease-specific mortality. Cancer, 2012. 118: 3062.
301. Richstone, L., et al. Radical prostatectomy in men aged >or=70 years: effect of age on upgrading,
upstaging, and the accuracy of a preoperative nomogram. BJU Int, 2008. 101: 541.
302. Sun, L., et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the
early and late prostate specific antigen eras. J Urol, 2009. 182: 2242.
303. Hamilton, A.S., et al. Trends in the treatment of localized prostate cancer using supplemented
cancer registry data. BJU Int, 2011. 107: 576.
304. Droz, J.P., et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task
Force of the International Society of Geriatric Oncology. Eur Urol, 2017. 72: 521.
305. Bellera, C.A., et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening
tool. Ann Oncol, 2012. 23: 2166.
306. Albertsen, P.C., et al. Impact of comorbidity on survival among men with localized prostate cancer.
J Clin Oncol, 2011. 29: 1335.
307. Tewari, A., et al. Long-term survival probability in men with clinically localized prostate cancer: a
case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol,
2004. 171: 1513.
308. Parmelee, P.A., et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential
population. J Am Geriatr Soc, 1995. 43: 130.
309. Groome, P.A., et al. Assessing the impact of comorbid illnesses on death within 10 years in prostate
cancer treatment candidates. Cancer, 2011. 117: 3943.
310. Charlson, M.E., et al. A new method of classifying prognostic comorbidity in longitudinal studies:
development and validation. J Chronic Dis, 1987. 40: 373.
311. Blanc-Bisson, C., et al. Undernutrition in elderly patients with cancer: target for diagnosis and
intervention. Crit Rev Oncol Hematol, 2008. 67: 243.
312. Sachs, G.A., et al. Cognitive impairment: an independent predictor of excess mortality: a cohort
study. Ann Intern Med, 2011. 155: 300.
313. Robinson, T.N., et al. Preoperative cognitive dysfunction is related to adverse postoperative
outcomes in the elderly. J Am Coll Surg, 2012. 215: 12.
314. Borson, S., et al. The Mini-Cog as a screen for dementia: validation in a population-based sample.
J Am Geriatr Soc, 2003. 51: 1451.

315. Oken, M.M., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J
Clin Oncol, 1982. 5: 649.
316. Katz, S., et al. Studies of Illness in the Aged. The Index of ADL: A Standardized Measure of
Biological and Psychosocial Function. JAMA, 1963. 185: 914.
317. Lawton, M.P., et al. Assessment of older people: self-maintaining and instrumental activities of daily
living. Gerontologist, 1969. 9: 179.
318. Stineman, M.G., et al. All-cause 1-, 5-, and 10-year mortality in elderly people according to activities
of daily living stage. J Am Geriatr Soc, 2012. 60: 485.
319. Albertsen, P.C. Observational studies and the natural history of screen-detected prostate cancer.
Curr Opin Urol, 2015. 25: 232.
320. Bruinsma, S.M., et al. Expert consensus document: Semantics in active surveillance for men with
localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol, 2017.
14: 312.
321. Hamdy, F.C., et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized
Prostate Cancer. N Engl J Med, 2016. 375: 1415.
322. Klotz, L., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate
cancer. J Clin Oncol, 2015. 33: 272.
323. Yamamoto, T., et al. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
J Urol, 2016. 195: 1409.
324. Thomsen, F.B., et al. Active surveillance for clinically localized prostate cancer--a systematic review.
J Surg Oncol, 2014. 109: 830.
325. van As, N.J., et al. Predicting the probability of deferred radical treatment for localised prostate
cancer managed by active surveillance. Eur Urol, 2008. 54: 1297.
326. Carter, H.B., et al. Expectant management of prostate cancer with curative intent: an update of the
Johns Hopkins experience. J Urol, 2007. 178: 2359.
327. Adamy, A., et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting
progression during active surveillance for low risk prostate cancer. J Urol, 2011. 185: 477.
328. Soloway, M.S., et al. Careful selection and close monitoring of low-risk prostate cancer patients on
active surveillance minimizes the need for treatment. Eur Urol, 2010. 58: 831.
329. Roemeling, S., et al. Active surveillance for prostate cancers detected in three subsequent rounds of
a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol, 2007. 51: 1244.
330. Khatami, A., et al. PSA doubling time predicts the outcome after active surveillance in screening-
detected prostate cancer: results from the European randomized study of screening for prostate
cancer, Sweden section. Int J Cancer, 2007. 120: 170.
331. Chodak, G.W., et al. Results of conservative management of clinically localized prostate cancer. N
Engl J Med, 1994. 330: 242.
332. Sandblom, G., et al. Long-term survival in a Swedish population-based cohort of men with prostate
cancer. Urology, 2000. 56: 442.
333. Johansson, J.E., et al. Natural history of localised prostatic cancer. A population-based study in 223
untreated patients. Lancet, 1989. 1: 799.

334. Bill-Axelson, A., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl
J Med, 2005. 352: 1977.
335. Adolfsson, J., et al. The 20-Yr outcome in patients with well- or moderately differentiated clinically
localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and
comorbidity. Eur Urol, 2007. 52: 1028.
https://www.ncbi.nlm.nih.gov/pubmed/Eur Urol, 2007. 52: 1028.
336. Jonsson, E., et al. Adenocarcinoma of the prostate in Iceland: a population-based study of stage,
Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Scand J Urol Nephrol, 2006. 40: 265.
337. Lu-Yao, G.L., et al. Outcomes of localized prostate cancer following conservative management.
Jama, 2009. 302: 1202.
338. Hayes, J.H., et al. Observation versus initial treatment for men with localized, low-risk prostate
cancer: a cost-effectiveness analysis. Ann Intern Med, 2013. 158: 853.
339. Wilt, T.J., et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J
Med, 2017. 377: 132.
340. Steineck, G., et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med,
2002. 347: 790.
341. Adolfsson, J. Watchful waiting and active surveillance: the current position. BJU Int, 2008. 102: 10.
342. Yaxley, J.W., et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic
prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet, 2016. 388:
1057.
343. Albertsen, P.C., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed
conservatively for clinically localized prostate cancer. Jama, 1998. 280: 975.
344. Albertsen, P.C., et al. Statistical considerations when assessing outcomes following treatment for
prostate cancer. J Urol, 1999. 162: 439.
345. Iversen, P., et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant
to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup
from the Scandinavian Prostate Cancer Group Study Number 6. J Urol, 2004. 172: 1871.
346. Jacobs, B.L., et al. Use of advanced treatment technologies among men at low risk of dying from
prostate cancer. Jama, 2013. 309: 2587.
347. Allan, C., et al. Laparoscopic versus Robotic-Assisted Radical Prostatectomy for the Treatment of
Localised Prostate Cancer: A Systematic Review. Urol Int, 2016. 96: 373.
348. Chen, R.C., et al. Association Between Choice of Radical Prostatectomy, External Beam
Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among
Men With Localized Prostate Cancer. JAMA, 2017. 317: 1141.
349. Briganti, A., et al. Updated nomogram predicting lymph node invasion in patients with prostate
cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage
of positive cores. Eur Urol, 2012. 61: 480.
350. Gandaglia, G., et al. Development and Internal Validation of a Novel Model to Identify the
Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol, 2017. 72: 632.
351. Roach, M., 3rd, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate
specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat
Oncol Biol Phys, 1994. 28: 33.

352. Abdollah, F., et al. Indications for pelvic nodal treatment in prostate cancer should change.
Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol
Phys, 2012. 83: 624.
353. Dell’Oglio, P., et al. External validation of the European association of urology recommendations
for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. J
Endourol, 2014. 28: 416.
354. Hinev, A.I., et al. Validation of nomograms predicting lymph node involvement in patients with
prostate cancer undergoing extended pelvic lymph node dissection. Urol Int, 2014. 92: 300.
355. Mattei, A., et al. The template of the primary lymphatic landing sites of the prostate should be
revisited: results of a multimodality mapping study. Eur Urol, 2008. 53: 118.
356. van der Poel, H.G., et al. Sentinel node biopsy for prostate cancer: report from a consensus panel
meeting. BJU Int, 2017. 120: 204.
357. Wit, E.M.K., et al. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess
Diagnostic Accuracy. Eur Urol, 2017. 71: 596.
358. Bader, P., et al. Is a limited lymph node dissection an adequate staging procedure for prostate
cancer? J Urol, 2002. 168: 514.
359. Passoni, N.M., et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical
prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int, 2014.
114: 503.
360. Daneshmand, S., et al. Prognosis of patients with lymph node positive prostate cancer following
radical prostatectomy: long-term results. J Urol, 172: 2252.
http://www.jurology.com/article/S0022-5347(05)61388-2/abstract
361. Iversen, P., et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate
cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up
of 9.7 years. BJU Int, 2010. 105: 1074.
362. Beyer, B., et al. A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted
radical prostatectomy. Eur Urol, 2014. 66: 138.
363. Kumar, S., et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced
prostate cancer. Cochrane Database Syst Rev, 2006: CD006019.
364. Ramsay, C., et al. Systematic review and economic modelling of the relative clinical benefit and
cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men
with localised prostate cancer. Health Technol Assess, 2012. 16: 1.
365. Novara, G., et al. Systematic review and meta-analysis of studies reporting oncologic outcome after
robot-assisted radical prostatectomy. Eur Urol, 2012. 62: 382.
366. Novara, G., et al. Systematic review and meta-analysis of perioperative outcomes and
complications after robot-assisted radical prostatectomy. Eur Urol, 2012. 62: 431.
367. Ficarra, V., et al. Systematic review and meta-22749853analysis of studies reporting potency rates
after robot-assisted radical prostatectomy. Eur Urol, 2012. 62: 418.
368. Ficarra, V., et al. Systematic review and meta-analysis of studies reporting urinary continence
recovery after robot-assisted radical prostatectomy. Eur Urol, 2012. 62: 405.
369. Maffezzini, M., et al. Evaluation of complications and results in a contemporary series of 300
consecutive radical retropubic prostatectomies with the anatomic approach at a single institution.
Urology, 2003. 61: 982.

370. Haglind, E., et al. Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical
Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. Eur Urol, 2015. 68: 216.
371. Burkhard, F.C., et al. The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol, 2005. 2:
336.
372. Ploussard, G., et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy:
efficacy, limitations, and complications-a systematic review of the literature. Eur Urol, 2014. 65: 7.
373. Davis, J.W., et al. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of
radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient
selection needs. BJU Int, 2011. 108: 993.
374. Briganti, A., et al. Complications and other surgical outcomes associated with extended pelvic
lymphadenectomy in men with localized prostate cancer. Eur Urol, 2006. 50: 1006.
375. Ling, C.C., et al. From IMRT to IGRT: frontierland or neverland? Radiother Oncol, 2006. 78: 119.
376. Kuban, D.A., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for
prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys, 2011. 79: 1310.
377. Zietman, A.L., et al. Randomized trial comparing conventional-dose with high-dose conformal
radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton
radiation oncology group/american college of radiology 95-09. J Clin Oncol, 2010. 28: 1106.
378. Viani, G.A., et al. Higher-than-conventional radiation doses in localized prostate cancer treatment: a
meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys, 2009. 74: 1405.
379. Peeters, S.T., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch
multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol,
2006. 24: 1990.
380. Beckendorf, V., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06
randomized trial. Int J Radiat Oncol Biol Phys, 2011. 80: 1056.
381. Jones, C.U., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
N Engl J Med, 2011. 365: 107.
382. Bolla, M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med,
2009. 360: 2516.
383. Fowler, J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
Acta Oncol, 2005. 44: 265.
384. Dasu, A., et al. Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.
Acta Oncol, 2012. 51: 963.
385. Heemsbergen, W.D., et al. Long-term results of the Dutch randomized prostate cancer trial: impact
of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol, 2014. 110:
104.
386. Kalbasi, A., et al. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic
Prostate Cancer. JAMA Oncol, 2015. 1: 897.
387. Zietman, A.L., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in
clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA, 2005. 294:
1233.

388. Peeters, S.T., et al. Acute and late complications after radiotherapy for prostate cancer: results of
a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys, 2005. 61:
1019.
389. Dearnaley, D.P., et al. The early toxicity of escalated versus standard dose conformal radiotherapy
with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the
MRC RT01 trial (ISRCTN47772397). Radiother Oncol, 2007. 83: 31.
390. Kuban, D.A., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for
prostate cancer. Int J Radiat Oncol Biol Phys, 2008. 70: 67.
391. Matzinger, O., et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised
prostate cancer in the EORTC trial 22991. Eur J Cancer, 2009. 45: 2825.
392. Zapatero, A., et al. Risk-Adapted Androgen Deprivation and Escalated Three-Dimensional
Conformal Radiotherapy for Prostate Cancer: Does Radiation Dose Influence Outcome of Patients
Treated With Adjuvant Androgen Deprivation? A GICOR Study. J Clin Oncol, 2005. 23: 6561.
393. Zelefsky, M.J., et al. Long-term outcome of high dose intensity modulated radiation therapy for
patients with clinically localized prostate cancer. J Urol, 2006. 176: 1415.
394. Vora, S.A., et al. Analysis of biochemical control and prognostic factors in patients treated with
either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated
radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 2007. 68: 1053.
395. Kupelian, P.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per
fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys,
2007. 68: 1424.
396. Gomez-Iturriaga Pina, A., et al. Median 5 year follow-up of 125iodine brachytherapy as
monotherapy in men aged<or=55 years with favorable prostate cancer. Urology, 2010. 75: 1412.
397. Ishiyama, H., et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined
with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to
determine the correlation between dose-volume histogram parameters in HDR brachytherapy and
severity of toxicity. Int J Radiat Oncol Biol Phys, 2009. 75: 23.
398. Gelblum, D.Y., et al. Rectal complications associated with transperineal interstitial brachytherapy for
prostate cancer. Int J Radiat Oncol Biol Phys, 2000. 48: 119.
399. Lee, W.R., et al. Late toxicity and biochemical recurrence after external-beam radiotherapy
combined with permanent-source prostate brachytherapy. Cancer, 2007. 109: 1506.
400. Zelefsky, M.J., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned
permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol
Biol Phys, 2000. 47: 1261.
401. Dearnaley, D.P., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate
cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol, 2014. 15:
464.
402. Dearnaley, D., et al. Conventional versus hypofractionated high-dose intensity-modulated
radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled
trial. Lancet Oncol, 2012. 13: 43.
403. Kuban, D.A., et al. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer
using Hypofractionation. Int J Radiat Oncol Biol Phys, 2010. 78: S58.
http://www.redjournal.org/article/S0360-3016(10)01144-2/abstract

404. Pollack, A., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate
405. Aluwini, S., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with
prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Lancet Oncol, 2015. 16: 274.
406. Castellucci, P., et al. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging, 2013. 40
Suppl 1: S36.
407. Parker, W.P., et al. Identification of Site-specific Recurrence Following Primary Radiation Therapy
for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A
Nomogram for Predicting Extrapelvic Disease. Eur Urol, 2017. 71: 340.
408. Hauswald, H., et al. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
Int J Radiat Oncol Biol Phys, 2016. 94: 667.
409. Graziani, T., et al. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a
single-centre patient series. Eur J Nucl Med Mol Imaging, 2016. 43: 1971.
410. Suardi, N., et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent
prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol,
2015. 67: 299.
411. Koontz, B.F., et al. A systematic review of hypofractionation for primary management of prostate
cancer. Eur Urol, 2015. 68: 683.
412. Lee, W.R., et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy
Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol, 2016. 34: 2325.
413. Dearnaley, D., et al. Conventional versus hypofractionated high-dose intensity-modulated
radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3
CHHiP trial. Lancet Oncol, 2016. 17: 1047.
414. Aluwini, S., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients
with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Lancet Oncol, 2016. 17: 464.
415. Incrocci, L., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with
localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label,
phase 3 trial. Lancet Oncol, 2016. 17: 1061.
416. Catton, C.N., et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of
Localized Prostate Cancer. J Clin Oncol, 2017. 35: 1884.
417. Fossati, N., et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During
Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol, 2017.
418. Aluwini, S., et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as
monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol, 2013. 8:
84.
419. Katz, A., et al. Stereotactic Body Radiation Therapy for Low-, Intermediate-, and High-Risk Prostate
Cancer: Disease Control and Quality of Life at 6 Years. Int J Radiat Oncol Biol Phys, 2013. 87: S24.
420. Freeman, D., et al. Multi-institutional registry for prostate cancer radiosurgery: a prospective
observational clinical trial. Front Oncol, 2014. 4: 369.

421. Katz, A.J., et al. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a
7-Year Study. Front Oncol, 2014. 4: 301.
422. Bolla, M., et al. External irradiation with or without long-term androgen suppression for prostate
cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol,
2010. 11: 1066.
423. Pilepich, M.V., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate
carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys, 2005. 61: 1285.
424. Roach, M., 3rd, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam
radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol,
2008. 26: 585.
425. D’Amico, A.V., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a
randomized trial. JAMA, 2008. 299: 289.
426. Denham, J.W., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally
advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol,
2011. 12: 451.
427. Lawton, C.A., et al. An update of the phase III trial comparing whole pelvic to prostate only
radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG
94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys,
2007. 69: 646.
428. Horwitz, E.M., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase
III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin
Oncol, 2008. 26: 2497.
429. Pisansky, T.M., et al. Duration of androgen suppression before radiotherapy for localized prostate
cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol, 2015. 33: 332.
430. Fossa, S.D., et al. Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic
high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with
radiotherapy (SPCG VII). ASCO Meeting Abstracts, 2014. 32: 4.
http://meetinglibrary.asco.org/content/123789-142
431. Warde, P., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced
prostate cancer: a randomised, phase 3 trial. Lancet, 2011. 378: 2104.
432. Mason, M.D., et al. Final Report of the Intergroup Randomized Study of Combined Androgen-
Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally
Advanced Prostate Cancer. J Clin Oncol, 2015. 33: 2143.
433. Mottet, N., et al. Addition of radiotherapy to long-term androgen deprivation in locally advanced
prostate cancer: an open randomised phase 3 trial. Eur Urol, 2012. 62: 213.
434. Zelefsky, M.J., et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term
biochemical tumor control and distant metastases-free survival outcomes. Eur Urol, 2011. 60: 1133.
435. Gray, P.J., et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or
proton beam radiotherapy for localized prostate cancer. Cancer, 2013. 119: 1729.
436. Sheets, N.C., et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation
therapy and morbidity and disease control in localized prostate cancer. Jama, 2012. 307: 1611.
437. Ash, D., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized
prostate cancer. Radiother Oncol, 2000. 57: 315.

438. Martens, C., et al. Relationship of the International Prostate Symptom score with urinary flow
studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy, 2006. 5: 9.
439. Crook, J.M., et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical
Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol, 2011. 29: 362.
440. Machtens, S., et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the
treatment of patients with prostate cancer. World J Urol, 2006. 24: 289.
441. Grimm, P., et al. Comparative analysis of prostate-specific antigen free survival outcomes for
patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results
from the Prostate Cancer Results Study Group. BJU Int, 2012. 109 Suppl 1: 22.
442. Potters, L., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external
beam radiotherapy, or permanent seed implantation. Radiother Oncol, 2004. 71: 29.
443. Sylvester, J.E., et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and
overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle
experience. Int J Radiat Oncol Biol Phys, 2011. 81: 376.
444. Potters, L., et al. 12-year outcomes following permanent prostate brachytherapy in patients with
clinically localized prostate cancer. J Urol, 2005. 173: 1562.
445. Stone, N.N., et al. Intermediate term biochemical-free progression and local control following
125iodine brachytherapy for prostate cancer. J Urol, 2005. 173: 803.
446. Zelefsky, M.J., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate
cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys, 2007. 67: 327.
447. Lawton, C.A., et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive
implantation of the prostate for definitive management of localized adenocarcinoma of the prostate
(radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys, 2007. 67: 39.
448. Stock, R.G., et al. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur
Urol, 2002. 41: 434.
449. Hoskin, P.J., et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for
localised prostate cancer: an update. Radiother Oncol, 2013. 107: 325.
450. Galalae, R.M., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local
dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J
Radiat Oncol Biol Phys, 2002. 52: 81.
451. Hoskin, P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high-
dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol, 2012. 103: 217.
452. Pieters, B.R., et al. Comparison of three radiotherapy modalities on biochemical control and overall
survival for the treatment of prostate cancer: a systematic review. Radiother Oncol, 2009. 93: 168.
453. Zamboglou, N., et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically
localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys,
2013. 85: 672.
454. Hoskin, P.J., et al. High dose rate brachytherapy in combination with external beam radiotherapy in
the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother
Oncol, 2007. 84: 114.
455. Hoskin, P., et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for
locally advanced prostate cancer: acute toxicity. Radiother Oncol, 2014. 110: 268.

456. King, C.R., et al. Health-related quality of life after stereotactic body radiation therapy for localized
prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol
Biol Phys, 2013. 87: 939.
457. Pagliarulo, V., et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur
Urol, 2012. 61: 11.
458. Oefelein, M.G., et al. Reassessment of the definition of castrate levels of testosterone: implications
for clinical decision making. Urology, 2000. 56: 1021.
459. Morote, J., et al. Individual variations of serum testosterone in patients with prostate cancer
receiving androgen deprivation therapy. BJU Int, 2009. 103: 332.
460. Pickles, T., et al. Incomplete testosterone suppression with luteinizing hormone-releasing hormone
agonists: does it happen and does it matter? BJU Int, 2012. 110: E500.
461. Klotz, L., et al. MP74-01 Nadir testosterone on ADT predicts for time to castrate resistant
progression: a secondary analysis of the PR-7 intermittent vs continuous ADT trial. J Urol, 2014.
191: e855.
http://www.jurology.com/article/S0022-5347(14)02593-2/pdf
462. Desmond, A.D., et al. Subcapsular orchiectomy under local anaesthesia. Technique, results and
implications. Br J Urol, 1988. 61: 143.
463. Scherr, D.S., et al. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen
deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol, 2003.
170: 1703.
464. Klotz, L., et al. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate
carcinoma. J Urol, 1999. 161: 169.
465. Farrugia, D., et al. Stilboestrol plus adrenal suppression as salvage treatment for patients failing
treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int, 2000.
85: 1069.
466. Hedlund, P.O., et al. Parenteral estrogen versus combined androgen deprivation in the treatment
of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group
(SPCG) Study No. 5. Scand J Urol Nephrol, 2008. 42: 220.
467. Bubley, G.J. Is the flare phenomenon clinically significant? Urology, 2001. 58: 5.
468. Collette, L., et al. Why phase III trials of maximal androgen blockade versus castration in M1
prostate cancer rarely show statistically significant differences. Prostate, 2001. 48: 29.
469. Klotz, L., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-
label, parallel-group phase III study in patients with prostate cancer. BJU Int, 2008. 102: 1531.
470. Seidenfeld, J., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a
systematic review and meta-analysis. Ann Intern Med, 2000. 132: 566.
471. Ostergren, P.B., et al. Luteinizing Hormone-Releasing Hormone Agonists are Superior to
Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results
from a Randomized Clinical Trial. J Urol, 2017. 197: 1441.
472. Crawford, E.D., et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix:
comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J
Urol, 2011. 186: 889.

473. Sciarra, A., et al. A meta-analysis and systematic review of randomized controlled trials with
degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine
(Baltimore), 2016. 95: e3845.
474. Moffat, L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in
advanced prostate cancer. Eur Urol, 1990. 18 Suppl 3: 26.
475. Schroder, F.H., et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate.
Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC)
Protocol 30892. Eur Urol, 2004. 45: 457.
476. Smith, M.R., et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer:
effects on bone mineral density and body composition. J Clin Oncol, 2004. 22: 2546.
477. Iversen, P. Antiandrogen monotherapy: indications and results. Urology, 2002. 60: 64.
478. Wadhwa, V.K., et al. Long-term changes in bone mineral density and predicted fracture risk in
patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment
based on presenting values. BJU Int, 2009. 104: 800.
479. Montgomery, R.B., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a
mechanism for castration-resistant tumor growth. Cancer Res, 2008. 68: 4447.
480. Fahmy, W.E., et al. Cryosurgery for prostate cancer. Arch Androl, 2003. 49: 397.
481. Rees, J., et al. Cryosurgery for prostate cancer. BJU Int, 2004. 93: 710.
482. Han, K.R., et al. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int,
2004. 93: 14.
483. Beerlage, H.P., et al. Current status of minimally invasive treatment options for localized prostate
carcinoma. Eur Urol, 2000. 37: 2.
484. van der Poel , H.G., et al. Focal Therapy in Primary Localised Prostate Cancer: The European
Association of Urology Position in 2018. Eur Urol, 2018. S0302-2838: 30005-8. [Epub ahead of print]
485. Valerio, M., et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic
Review. Eur Urol, 2017. 71: 17.
486. Ramsay, C.R., et al. Ablative therapy for people with localised prostate cancer: a systematic review
and economic evaluation. Health Technol Assess, 2015. 19: 1.
487. Madersbacher, S., et al. High-energy shockwaves and extracorporeal high-intensity focused
ultrasound. J Endourol, 2003. 17: 667.
488. Mouraviev, V., et al. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol,
2009. 6: 205.
489. Cooperberg, M.R., et al. Contemporary trends in low risk prostate cancer: risk assessment and
treatment. J Urol, 2007. 178: S14.
490. Polascik, T.J., et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific
antigen era: implications for unilateral ablative therapy. Prostate, 2008. 68: 1380.
491. Ahmed, H.U., et al. Will focal therapy become a standard of care for men with localized prostate
cancer? Nat Clin Pract Oncol, 2007. 4: 632.
492. Eggener, S.E., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and
modalities. J Urol, 2007. 178: 2260.

493. Crawford, E.D., et al. Targeted focal therapy: a minimally invasive ablation technique for early
prostate cancer. Oncology (Williston Park), 2007. 21: 27.
494. Azzouzi, A.R., et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance
in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised
controlled trial. Lancet Oncol, 2016.
495. MacLennan, S., et al. A core outcome set for localised prostate cancer effectiveness trials. BJU Int,
2017. 120: E64.
496. Loeb, S., et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic
variables and biomarkers for risk stratification. Eur Urol, 2015. 67: 619.
497. Ha, Y.S., et al. Prostate-specific antigen density toward a better cutoff to identify better candidates
for active surveillance. Urology, 2014. 84: 365.
498. Montironi, R., et al. Consensus statement with recommendations on active surveillance inclusion
criteria and definition of progression in men with localized prostate cancer: the critical role of the
pathologist. Virchows Arch, 2014. 465: 623.
499. Moreira, D.M., et al. Baseline Perineural Invasion is Associated with Shorter Time to Progression in
Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. J Urol,
2015. 194: 1258.
500. Morash, C., et al. Active surveillance for the management of localized prostate cancer: Guideline
recommendations. Can Urol Assoc J, 2015. 9: 171.
501. Satasivam, P., et al. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer
Favorable Diagnostic Features on Active Surveillance? J Urol, 2016. 195: 74.
502. Petrelli, F., et al. Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for
Active Surveillance: A Systematic Review and Meta-analysis. Urology, 2016. 91: 136.
503. Klein, E.A., et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of
Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol, 2014. 66:
550.
504. Berg, K.D., et al. ERG protein expression in diagnostic specimens is associated with increased risk
of progression during active surveillance for prostate cancer. Eur Urol, 2014. 66: 851.
505. Cantiello, F., et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria
in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol, 2016.
34: 485.
506. Lawrentschuk, N., et al. ‘Prostatic evasive anterior tumours’: the role of magnetic resonance
imaging. BJU Int, 2010. 105: 1231.
507. Schoots, I.G., et al. Magnetic resonance imaging in active surveillance of prostate cancer: a
systematic review. Eur Urol, 2015. 67: 627.
508. Schoots, I.G., et al. Role of MRI in low-risk prostate cancer: finding the wolf in sheep’s clothing or
the sheep in wolf’s clothing? Curr Opin Urol, 2017. 27: 238.
509. Recabal, P., et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic
Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on
Active Surveillance. J Urol, 2016. 196: 374.
510. Pessoa, R.R., et al. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted
biopsy for improved risk stratification in patients considered for active surveillance. BJU Int, 2016.

511. Kamrava, M., et al. Multiparametric magnetic resonance imaging for prostate cancer improves
Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol, 2015. 5: 411.
512. Ouzzane, A., et al. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients
Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic
Biopsies. J Urol, 2015. 194: 350.
513. Da Rosa, M.R., et al. A prospective comparison of MRI-US fused targeted biopsy versus systematic
ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active
surveillance. J Magn Reson Imaging, 2015. 41: 220.
514. Ma, T.M., et al. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy
in Active Surveillance. Eur Urol, 2017. 71: 174.
515. Abdi, H., et al. Multiparametric magnetic resonance imaging enhances detection of significant tumor
in patients on active surveillance for prostate cancer. Urology, 2015. 85: 423.
516. Walton Diaz, A., et al. Use of serial multiparametric magnetic resonance imaging in the management
of patients with prostate cancer on active surveillance. Urol Oncol, 2015. 33: 202 e1.
517. Felker, E.R., et al. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer:
Incremental Value. J Urol, 2016. 195: 1421.
518. Moore, C.M., et al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for
Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology
Task Force. Eur Urol, 2016.
519. Nassiri, N., et al. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for
Men with Low versus Intermediate Risk Prostate Cancer. J Urol, 2016.
520. Ross, A.E., et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for
intervention in a prostate cancer surveillance program. J Clin Oncol, 2010. 28: 2810.
521. Thomsen, F.B., et al. Association between PSA kinetics and cancer-specific mortality in patients
with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. Ann Oncol, 2016.
27: 460.
522. Klotz, L., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with
localized prostate cancer. J Clin Oncol, 2010. 28: 126.
523. Loeb, S., et al. Population based study of use and determinants of active surveillance and watchful
waiting for low and intermediate risk prostate cancer. J Urol, 2013. 190: 1742.
524. Studer, U.E., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0
prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol, 2008. 53: 941.
525. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical
Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators
Group. Br J Urol, 1997. 79: 235.
526. Chen, R.C., et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer
Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline
Endorsement. J Clin Oncol, 2016. 34: 2182.
527. Musunuru, H.B., et al. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes
in the Sunnybrook Experience. J Urol, 2016. 196: 1651.
528. Raldow, A.C., et al. Risk Group and Death From Prostate Cancer: Implications for Active
Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol, 2015. 1: 334.

529. Krauss, D., et al. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated
radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol
Phys, 2011. 80: 1064.
530. Kupelian, P.A., et al. Effect of increasing radiation doses on local and distant failures in patients with
localized prostate cancer. Int J Radiat Oncol Biol Phys, 2008. 71: 16.
531. Walsh, P.C. Immediate versus deferred treatment for advanced prostatic cancer: initial results of
the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party
Investigators Group. J Urol, 1997. 158: 1623.
532. Donohue, J.F., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-
term outcome and incidence of pathological downgrading. J Urol, 2006. 176: 991.
533. Bianco, F.J., Jr., et al. Radical prostatectomy: long-term cancer control and recovery of sexual and
urinary function (“trifecta”). Urology, 2005. 66: 83.
534. Walz, J., et al. A nomogram predicting 10-year life expectancy in candidates for radical
prostatectomy or radiotherapy for prostate cancer. J Clin Oncol, 2007. 25: 3576.
535. Eastham, J.A., et al. Variations among individual surgeons in the rate of positive surgical margins in
radical prostatectomy specimens. J Urol, 2003. 170: 2292.
536. Vickers, A.J., et al. The surgical learning curve for laparoscopic radical prostatectomy: a
retrospective cohort study. Lancet Oncol, 2009. 10: 475.
537. Trinh, Q.D., et al. A systematic review of the volume-outcome relationship for radical prostatectomy.
Eur Urol, 2013. 64: 786.
538. Pisansky, T.M., et al. Correlation of pretherapy prostate cancer characteristics with histologic
findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys, 1996. 34: 33.
539. Joniau, S., et al. Pretreatment tables predicting pathologic stage of locally advanced prostate
cancer. Eur Urol, 2015. 67: 319.
540. Loeb, S., et al. Intermediate-term potency, continence, and survival outcomes of radical
prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology, 2007. 69: 1170.
541. Carver, B.S., et al. Long-term outcome following radical prostatectomy in men with clinical stage T3
542. Freedland, S.J., et al. Radical prostatectomy for clinical stage T3a disease. Cancer, 2007. 109: 1273.
543. Joniau, S., et al. Radical prostatectomy in very high-risk localized prostate cancer: long-term
outcomes and outcome predictors. Scand J Urol Nephrol, 2012. 46: 164.
544. Johnstone, P.A., et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer, 2006. 106:
2603.
545. Leibel, S.A., et al. The effects of local and regional treatment on the metastatic outcome in prostatic
carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys, 1994. 28: 7.
546. Asbell, S.O., et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of
RTOG 77-06. Int J Radiat Oncol Biol Phys, 1988. 15: 1307.
547. Pommier, P., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma?
Preliminary results of GETUG-01. J Clin Oncol, 2007. 25: 5366.

548. Lee, L.N., et al. Role of hormonal therapy in the management of intermediate- to high-risk prostate
cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys, 2002.
52: 444.
549. Morris, W.J., et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated
Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial
Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for
High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys, 2017. 98: 275.
550. Yossepowitch, O., et al. Radical prostatectomy for clinically localized, high risk prostate cancer:
critical analysis of risk assessment methods. J Urol, 2007. 178: 493.
551. Bastian, P.J., et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer
patients with a preoperative Gleason sum of 8 to 10. Cancer, 2006. 107: 1265.
552. Walz, J., et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients
after radical prostatectomy. BJU Int, 2011. 107: 765.
553. Chang, K., et al. Comparison of two adjuvant hormone therapy regimens in patients with high-risk
localized prostate cancer after radical prostatectomy: primary results of study CU1005. Asian J
Androl, 2016. 18: 452.
554. D’Amico, A.V., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical
prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin
Oncol, 1999. 17: 168.
555. Spahn, M., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific
antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol, 2010.
58: 1.
556. Zwergel, U., et al. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing
radical prostatectomy. Eur Urol, 2007. 52: 1058.
557. Magheli, A., et al. Importance of tumor location in patients with high preoperative prostate specific
antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J Urol, 2007. 178: 1311.
558. Gerber, G.S., et al. Results of radical prostatectomy in men with locally advanced prostate cancer:
multi-institutional pooled analysis. Eur Urol, 1997. 32: 385.
559. Ward, J.F., et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the
advent of prostate-specific antigen testing: 15-year outcome. BJU Int, 2005. 95: 751.
560. Engel, J., et al. Survival benefit of radical prostatectomy in lymph node-positive patients with
prostate cancer. Eur Urol, 2010. 57: 754.
561. Hsu, C.Y., et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution
experience. Eur Urol, 2007. 51: 121.
562. Lawton, C.A., et al. Androgen suppression plus radiation versus radiation alone for patients with
stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on
national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol, 2005.
23: 800.
563. James, N.D., et al. Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients
With Newly–Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control
Arm of the STAMPEDE Trial. Int J Radiat Oncol Biol Phys, 2014. 90: S13.

564. Studer, U.E., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not
suitable for local treatment with curative intent: European Organisation for Research and Treatment
of Cancer (EORTC) Trial 30891. J Clin Oncol, 2006. 24: 1868.
565. Hanks, G.E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care
studies in the United States. NCI Monogr, 1988: 75.
566. Briganti, A., et al. Two positive nodes represent a significant cut-off value for cancer specific
survival in patients with node positive prostate cancer. A new proposal based on a two-institution
experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic
lymph node dissection and adjuvant therapy. Eur Urol, 2009. 55: 261.
567. Schumacher, M.C., et al. Good outcome for patients with few lymph node metastases after radical
retropubic prostatectomy. Eur Urol, 2008. 54: 344.
568. Abdollah, F., et al. More extensive pelvic lymph node dissection improves survival in patients with
node-positive prostate cancer. Eur Urol, 2015. 67: 212.
569. Pound, C.R., et al. Natural history of progression after PSA elevation following radical
prostatectomy. JAMA, 1999. 281: 1591.
570. Aus, G., et al. Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective
study based on data from a Swedish population-based cohort. Eur Urol, 2003. 43: 627.
571. Cheng, L., et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer,
2001. 91: 66.
572. Seiler, R., et al. Removal of limited nodal disease in patients undergoing radical prostatectomy:
long-term results confirm a chance for cure. J Urol, 2014. 191: 1280.
573. Touijer, K.A., et al. Long-term outcomes of patients with lymph node metastasis treated with radical
prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol, 2014. 65: 20.
574. Bolla, M., et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer:
long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 2012. 380: 2018.
575. Wiegel, T., et al. Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year
Follow-up of the ARO 96-02/AUO AP 09/95 Trial. Eur Urol, 2014. 66: 243.
576. Thompson, I.M., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly
reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
J Urol, 2009. 181: 956.
577. Stephenson, A.J., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate
cancer after radical prostatectomy. J Clin Oncol, 2007. 25: 2035.
578. Wiegel, T., et al. Achieving an undetectable PSA after radiotherapy for biochemical progression
after radical prostatectomy is an independent predictor of biochemical outcome--results of a
retrospective study. Int J Radiat Oncol Biol Phys, 2009. 73: 1009.
579. Ghavamian, R., et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone
for pTxN+ prostate cancer: a matched comparison. J Urol, 1999. 161: 1223.
580. Messing, E.M., et al. Immediate versus deferred androgen deprivation treatment in patients with
node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet
Oncol, 2006. 7: 472.
581. Abdollah, F., et al. Impact of adjuvant radiotherapy on survival of patients with node-positive
prostate cancer. J Clin Oncol, 2014. 32: 3939.

582. Schweizer, M.T., et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk
prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer,
2013. 119: 3610.
583. Amling, C.L., et al. Defining prostate specific antigen progression after radical prostatectomy: what
is the most appropriate cut point? J Urol, 2001. 165: 1146.
584. Toussi, A., et al. Standardizing the Definition of Biochemical Recurrence after Radical
Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and
Subsequent Systemic Progression? J Urol, 2016. 195: 1754.
585. Stephenson, A.J., et al. Defining biochemical recurrence of prostate cancer after radical
prostatectomy: a proposal for a standardized definition. J Clin Oncol, 2006. 24: 3973.
586. Roach, M., 3rd, et al. Defining biochemical failure following radiotherapy with or without hormonal
therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO
Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 2006. 65: 965.
587. Boorjian, S.A., et al. Long-term risk of clinical progression after biochemical recurrence following
radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol, 2011. 59: 893.
588. Antonarakis, E.S., et al. The natural history of metastatic progression in men with prostate-specific
antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int, 2012. 109: 32.
589. Brockman, J.A., et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with
Biochemical Recurrence After Radical Prostatectomy. Eur Urol, 2015. 67: 1160.
590. D’Amico, A.V., et al. Prostate specific antigen doubling time as a surrogate end point for prostate
cancer specific mortality following radical prostatectomy or radiation therapy. J Urol, 2004. 172:
S42.
591. Freedland, S.J., et al. Risk of prostate cancer-specific mortality following biochemical recurrence
after radical prostatectomy. Jama, 2005. 294: 433.
592. Teeter, A.E., et al. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy,
Calculated Prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the
SEARCH Database Group. J Urol, 2017. S0022: 77427. [Epub ahead of print].
593. Briganti, A., et al. Prediction of outcome following early salvage radiotherapy among patients with
biochemical recurrence after radical prostatectomy. Eur Urol, 2014. 66: 479.
594. Trock, B.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in
men with biochemical recurrence after radical prostatectomy. Jama, 2008. 299: 2760.
595. Denham, J.W., et al. Time to biochemical failure and prostate-specific antigen doubling time as
surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised
controlled trial. Lancet Oncol, 2008. 9: 1058.
596. Zumsteg, Z.S., et al. The natural history and predictors of outcome following biochemical relapse
in the dose escalation era for prostate cancer patients undergoing definitive external beam
radiotherapy. Eur Urol, 2015. 67: 1009.
597. Zagars, G.K., et al. Kinetics of serum prostate-specific antigen after external beam radiation for
clinically localized prostate cancer. Radiother Oncol, 1997. 44: 213.
598. Rouviere, O., et al. Imaging of prostate cancer local recurrences: why and how? Eur Radiol, 2010.
20: 1254.

599. Beresford, M.J., et al. A systematic review of the role of imaging before salvage radiotherapy for
post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol), 2010. 22: 46.
600. Gomez, P., et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after
radical prostatectomy: when is it indicated? BJU Int, 2004. 94: 299.
601. Kane, C.J., et al. Limited value of bone scintigraphy and computed tomography in assessing
biochemical failure after radical prostatectomy. Urology, 2003. 61: 607.
602. Evangelista, L., et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a
systematic review and meta-analysis. Clin Nucl Med, 2013. 38: 305.
603. Fanti, S., et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with
biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol
Imaging, 2016. 43: 55.
604. Fuccio, C., et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a
single lesion on bone scintigraphy. Ann Nucl Med, 2010. 24: 485.
605. Fuccio, C., et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with
biochemical relapse and negative results at bone scintigraphy. Eur J Radiol, 2012. 81: e893.
606. Treglia, G., et al. Relationship between prostate-specific antigen kinetics and detection rate of
radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab
Med, 2014. 52: 725.
607. Calabria, F., et al. The optimal timing to perform 18F/11C-choline PET/CT in patients with suspicion
of relapse of prostate cancer: trigger PSA versus PSA velocity and PSA doubling time. Int J Biol
Markers, 2014. 29: e423.
608. Castellucci, P., et al. Early Biochemical Relapse After Radical Prostatectomy: Which Prostate
Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation
Therapy? J Nucl Med, 2014. 55: 1424.
609. Mitchell, C.R., et al. Operational characteristics of (11)c-choline positron emission tomography/
computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J
Urol, 2013. 189: 1308.
610. Soyka, J.D., et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.
Eur J Nucl Med Mol Imaging, 2012. 39: 936.
611. Ceci, F., et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate
cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging, 2014. 41: 2222.
612. Chondrogiannis, S., et al. Role of (1)(8)F-choline PET/CT in suspicion of relapse following definitive
radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging, 2013. 40: 1356.
613. Ceci, F., et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer
patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging, 2014. 41: 878.
614. Beer, A.J., et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol, 2011.
12: 181.
615. Beheshti, M., et al. Detection of bone metastases in patients with prostate cancer by 18F
fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging, 2008. 35:
1766.
616. Ceci, F., et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are
associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging, 2015. 42: 1284.

617. Morigi, J.J., et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/
CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being
Considered for Targeted Therapy. J Nucl Med, 2015. 56: 1185.
618. van Leeuwen, P.J., et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence
outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int,
2016. 117: 732.
619. Sanli, Y., et al. Relationships between serum PSA levels, Gleason scores and results of
68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med, 2017. 31: 709.
620. Mena, E., et al. Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with
biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging,
2017.
621. Afshar-Oromieh, A., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and
(18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol
Imaging, 2014. 41: 11.
622. Bluemel, C., et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence
and Negative 18F-Choline-PET/CT. Clin Nucl Med, 2016. 41: 515.
623. Verburg, F.A., et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-
HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med
Mol Imaging, 2016. 43: 397.
624. Emmett, L., et al. Treatment outcomes from 68GaPSMA PET CT informed salvage radiation
treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative
PSMA PET. J Nucl Med, 2017. 58: 1972.
625. Eiber, M., et al. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with
recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn
Reson Imaging, 2011. 33: 1160.
626. Liauw, S.L., et al. Evaluation of the prostate bed for local recurrence after radical prostatectomy
using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys, 2013. 85: 378.
627. Linder, B.J., et al. Early localization of recurrent prostate cancer after prostatectomy by endorectal
coil magnetic resonance imaging. Can J Urol, 2014. 21: 7283.
628. Kitajima, K., et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison
of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med,
2014. 55: 223.
629. Donati, O.F., et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted,
and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally
recurrent prostate cancer after radiation therapy? Radiology, 2013. 268: 440.
630. Abd-Alazeez, M., et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added
value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. Prostate
Cancer Prostatic Dis, 2015. 18: 128.
631. Alonzo, F., et al. Detection of locally radio-recurrent prostate cancer at multiparametric MRI: Can
dynamic contrast-enhanced imaging be omitted? Diagn Interv Imaging, 2016. 97: 433.
632. Stish, B.J., et al. Improved Metastasis-Free and Survival Outcomes With Early Salvage
Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate
Cancer. J Clin Oncol, 2016. 34: 3864.

633. Pfister, D., et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol, 2014. 65:
1034.
634. Siegmann, A., et al. Salvage radiotherapy after prostatectomy - what is the best time to treat?
Radiother Oncol, 2012. 103: 239.
635. Ohri, N., et al. Can early implementation of salvage radiotherapy for prostate cancer improve the
therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.
Eur J Cancer, 2012. 48: 837.
636. Bartkowiak, D., et al. Prostate-specific antigen after salvage radiotherapy for postprostatectomy
biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol, 2017. 57:
362.
637. Tendulkar, R.D., et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for
Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol, 2016. JCO679647. [Epub ahead of
print].
638. Soto, D.E., et al. Concurrent androgen deprivation therapy during salvage prostate radiotherapy
improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys, 2012. 82: 1227.
639. Jackson, W.C., et al. Combining prostate-specific antigen nadir and time to nadir allows for early
identification of patients at highest risk for development of metastasis and death following salvage
radiation therapy. Pract Radiat Oncol, 2014. 4: 99.
640. Sweeney, C., et al. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate
(ICECaP). J Natl Cancer Inst, 2015. 107: djv261.
641. Shipley, W., et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N
Eng J Med, 2017. 376: 417.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607529
642. Carrie, C., et al. Salvage radiotherapy with or without short-term hormone therapy for rising
prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised,
multicentre, open-label phase 3 trial. Lancet Oncol, 2016. 17: 747.
643. Spratt, D.E., et al. A Systematic Review and Framework for the Use of Hormone Therapy with
Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol, 2017. 73: 156.
644. Michalski, J.M., et al. Development of RTOG consensus guidelines for the definition of the clinical
target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol
Biol Phys, 2010. 76: 361.
645. Poortmans, P., et al. Guidelines for target volume definition in post-operative radiotherapy for
prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol, 2007. 84:
121.
646. Wiltshire, K.L., et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical
prostatectomy. Int J Radiat Oncol Biol Phys, 2007. 69: 1090.
647. Sassowsky, M., et al. Use of EORTC target definition guidelines for dose-intensified salvage
radiation therapy for recurrent prostate cancer: results of the quality assurance program of the
randomized trial SAKK 09/10. Int J Radiat Oncol Biol Phys, 2013. 87: 534.
648. Gay, H.A., et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation
Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys, 2012. 83: e353.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904368/
649. Pisansky, T.M., et al. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate
Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys,
2016. 96: 1046.

650. Valicenti, R.K., et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society
for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys,
2013. 86: 822.
651. Bernard, J.R., Jr., et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical
prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys, 2010. 76:
735.
652. King, C.R. The dose-response of salvage radiotherapy following radical prostatectomy: A
systematic review and meta-analysis. Radiother Oncol, 2016. 121: 199.
653. Fossati, N., et al. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with
Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol, 2016. 69: 728.
654. Fossati, N., et al. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0
Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional
Series. Eur Urol, 2017. 71: 886.
655. Abugharib, A., et al. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J
Urol, 2017. 197: 662.
656. Fiorino, C., et al. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy
Radiation Therapy in >/=PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model.
Int J Radiat Oncol Biol Phys, 2016. 96: 333.
657. Goenka, A., et al. Long-term outcomes after high-dose postprostatectomy salvage radiation
treatment. Int J Radiat Oncol Biol Phys, 2012. 84: 112.
658. Ghadjar, P., et al. Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy
for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized
Trial SAKK 09/10. J Clin Oncol, 2015. 33: 4158.
659. Goenka, A., et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation
therapy with intensity-modulated radiation therapy. Eur Urol, 2011. 60: 1142.
660. Ost, P., et al. High-dose salvage intensity-modulated radiotherapy with or without androgen
deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year
results. Eur Urol, 2011. 60: 842.
661. Briganti, A., et al. Early salvage radiation therapy does not compromise cancer control in patients
with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-
institutional analysis. Eur Urol, 2012. 62: 472.
662. Heidenreich, A., et al. [Radical salvage prostatectomy : Treatment of local recurrence of prostate
cancer after radiotherapy]. Urologe A, 2008. 47: 1441.
663. Ahlering, T.E., et al. Salvage surgery plus androgen deprivation for radioresistant prostatic
adenocarcinoma. J Urol, 1992. 147: 900.
664. Zincke, H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy
with curative intent: comparison of outcomes. J Urol, 1992. 147: 894.
665. Lerner, S.E., et al. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
J Urol, 1995. 154: 1103.
666. Rogers, E., et al. Salvage radical prostatectomy: outcome measured by serum prostate specific
antigen levels. J Urol, 1995. 153: 104.

667. Garzotto, M., et al. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer:
results at 5-year followup. J Urol, 1998. 159: 950.
668. Vaidya, A., et al. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity
revisited. J Urol, 2000. 164: 1998.
669. Stephenson, A.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for
locally recurrent prostate cancer after radiation therapy. J Urol, 2004. 172: 2239.
670. Heidenreich, A., et al. [Functional and oncological outcome of salvage prostatectomy of locally
recurrent prostate cancer following radiation therapy]. Urologe A, 2006. 45: 474.
671. Heidenreich, A., et al. Prognostic parameters, complications, and oncologic and functional
outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century
672. Chade, D.C., et al. Cancer control and functional outcomes of salvage radical prostatectomy for
radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol, 2012. 61: 961.
673. Sanderson, K.M., et al. Salvage radical prostatectomy: quality of life outcomes and long-term
oncological control of radiorecurrent prostate cancer. J Urol, 2006. 176: 2025.
674. Leonardo, C., et al. Salvage radical prostatectomy for recurrent prostate cancer after radiation
therapy. Int J Urol, 2009. 16: 584.
675. Chade, D.C., et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-
institutional collaboration. Eur Urol, 2011. 60: 205.
676. Mandel, P., et al. Salvage radical prostatectomy for recurrent prostate cancer: verification of
European Association of Urology guideline criteria. BJU Int, 2016. 117: 55.
677. Gotto, G.T., et al. Impact of prior prostate radiation on complications after radical prostatectomy. J
Urol, 2010. 184: 136.
678. Ward, J.F., et al. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J
Urol, 2005. 173: 1156.
679. Philippou, Y., et al. Comparative Oncologic and Toxicity Outcomes of Salvage Radical
Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta–
Regression Analysis. Eur Urol Focus, 2016. 2: 158.
http://www.europeanurology.com/article/S2405-4569(15)00141-8/abstract/
680. Ismail, M., et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a
prospective case series of the first 100 patients. BJU Int, 2007. 100: 760.
681. Pisters, L.L., et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J
Urol, 2008. 180: 559.
682. Pisters, L.L., et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of
salvage radical prostatectomy versus cryotherapy. J Urol, 2009. 182: 517.
683. Bahn, D.K., et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-
year follow-up. Clin Prostate Cancer, 2003. 2: 111.
684. Williams, A.K., et al. Disease-free survival following salvage cryotherapy for biopsy-proven radio-
recurrent prostate cancer. Eur Urol, 2011. 60: 405.
685. Spiess, P.E., et al. A pretreatment nomogram predicting biochemical failure after salvage
cryotherapy for locally recurrent prostate cancer. BJU Int, 2010. 106: 194.

686. Cespedes, R.D., et al. Long-term followup of incontinence and obstruction after salvage
cryosurgical ablation of the prostate: results in 143 patients. J Urol, 1997. 157: 237.
687. Mouraviev, V., et al. Salvage cryoablation for locally recurrent prostate cancer following primary
688. Pisters, L.L., et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol,
1997. 157: 921.
689. Ahmad, I., et al. Prostate gland lengths and iceball dimensions predict micturition functional
outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer.
PLoS One, 2013. 8: e69243.
690. Chen, C.P., et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive
radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys, 2013. 86: 324.
691. Burri, R.J., et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after
initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2010. 77: 1338.
692. Gomez-Veiga, F., et al. Brachytherapy for the treatment of recurrent prostate cancer after
radiotherapy or radical prostatectomy. BJU Int, 2012. 109 Suppl 1: 17.
693. Yamada, Y., et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of
locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy, 2014.
13: 111.
694. Lee, B., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer
recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat
Oncol Biol Phys, 2007. 67: 1106.
695. Moman, M.R., et al. Treatment outcome and toxicity after salvage 125-I implantation for prostate
cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy,
2010. 9: 119.
696. Colombel M, et al. Clinical results of the prostate HIFU project. Eur Urol Suppl, 2006: 491.
http://www.europeanurology.com/article/S1569-9056(06)00023-6/abstract/clinical-results-of-
theprostate-hifu-project
697. Gelet, A., et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized
prostate cancer. J Endourol, 2000. 14: 519.
698. Gelet, A., et al. Local recurrence of prostate cancer after external beam radiotherapy: early
experience of salvage therapy using high-intensity focused ultrasonography. Urology, 2004. 63: 625.
699. Uchida, T., et al. High-intensity focused ultrasound as salvage therapy for patients with recurrent
prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int, 2011. 107:
378.
700. Berge, V., et al. Health-related quality of life after salvage high-intensity focused ultrasound (HIFU)
treatment for locally radiorecurrent prostate cancer. Int J Urol, 2011. 18: 646.
701. Crouzet, S., et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate
cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int, 2017. 119:
896.
702. Karnes, R.J., et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by
11C-choline positron emission tomography/computerized tomography. J Urol, 2015. 193: 111.
703. Tilki, D., et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical
prostatectomy. J Urol, 2015. 193: 484.

704. Rigatti, P., et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with
radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline
positron emission tomography/computed tomography. Eur Urol, 2011. 60: 935.
705. Ost, P., et al. Metastasis-directed therapy of regional and distant recurrences after curative
treatment of prostate cancer: a systematic review of the literature. Eur Urol, 2015. 67: 852.
706. Rischke, H.C., et al. Adjuvant radiotherapy after salvage lymph node dissection because of nodal
relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol, 2015.
191: 310.
707. Ploussard, G., et al. Management of Node Only Recurrence after Primary Local Treatment for
Prostate Cancer: A Systematic Review of the Literature. J Urol, 2015. 194: 983.
708. van den Bergh, R.C., et al. Role of Hormonal Treatment in Prostate Cancer Patients with
Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol,
2016. 69: 802.
709. Duchesne, G.M., et al. Timing of androgen-deprivation therapy in patients with prostate cancer with
a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded,
phase 3 trial. Lancet Oncol, 2016. 17: 727.
710. Siddiqui, S.A., et al. Timing of androgen deprivation therapy and its impact on survival after radical
prostatectomy: a matched cohort study. J Urol, 2008. 179: 1830.
711. Crook, J.M., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J
Med, 2012. 367: 895.
712. Levine, G.N., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a
science advisory from the American Heart Association, American Cancer Society, and American
Urological Association: endorsed by the American Society for Radiation Oncology. Circulation,
2010. 121: 833.
713. O’Farrell, S., et al. Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy
in Men With Prostate Cancer. J Clin Oncol, 2015. 33: 1243.
http://ascopubs.org/doi/abs/10.1200/JCO.2014.59.1792
714. James, N.D., et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel
Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Eur Urol, 2015. 67: 1028.
715. Glass, T.R., et al. Metastatic carcinoma of the prostate: identifying prognostic groups using
recursive partitioning. J Urol, 2003. 169: 164.
716. Gravis, G., et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer:
Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur Urol,
2015. 68: 196.
717. Gravis, G., et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in
Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival
Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol, 2016. 70: 256.
718. Sweeney, C.J., et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med, 2015. 373: 737.
719. Hussain, M., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong
independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology
Group Trial 9346 (INT-0162). J Clin Oncol, 2006. 24: 3984.
https://www.ncbi.nlm.nih.gov/pubmed/flutamide

720. Eisenberger, M.A., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate
cancer. N Engl J Med, 1998. 339: 1036.
721. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.
Prostate Cancer Trialists’ Collaborative Group. Lancet, 2000. 355: 1491.
722. Schmitt, B., et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database
Syst Rev, 2000: Cd001526.
723. Akaza, H., et al. Combined androgen blockade with bicalutamide for advanced prostate cancer:
long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 2009. 115:
3437.
724. Kunath, F., et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-
releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Cochrane Database Syst Rev, 2014. 6: CD009266.
725. Niraula, S., et al. Treatment of prostate cancer with intermittent versus continuous androgen
deprivation: a systematic review of randomized trials. J Clin Oncol, 2013. 31: 2029.
726. Sciarra, A., et al. A novel therapeutic option for castration-resistant prostate cancer: after or before
chemotherapy? Eur Urol, 2014. 65: 905.
727. Botrel, T.E., et al. Intermittent versus continuous androgen deprivation for locally advanced,
recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol, 2014.
14: 9.
728. Brungs, D., et al. Intermittent androgen deprivation is a rational standard-of-care treatment for all
stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate
Cancer Prostatic Dis, 2014. 17: 105.
729. Magnan, S., et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A
Systematic Review and Meta-analysis. JAMA Oncol, 2015. 1: 1261.
730. Hussain, M., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J
Med, 2013. 368: 1314.
731. Hussain, M., et al. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The
Devil Is in the Details. J Clin Oncol, 2016. 34: 280.
732. Verhagen, P.C., et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate
cancer: results of a randomized trial. World J Urol, 2014. 32: 1287.
733. Calais da Silva, F., et al. Locally advanced and metastatic prostate cancer treated with intermittent
androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by
the South European Uroncological Group. Eur Urol, 2014. 66: 232.
734. Tsai, H.T., et al. Risks of Serious Toxicities from Intermittent versus Continuous Androgen
Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. J Urol, 2017. 197:
1251.
735. Hershman, D.L., et al. Adverse Health Events Following Intermittent and Continuous Androgen
Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol, 2015: 1.
736. Abrahamsson, P.A. Potential benefits of intermittent androgen suppression therapy in the treatment
of prostate cancer: a systematic review of the literature. Eur Urol, 2010. 57: 49.
737. Nair, B., et al. Early versus deferred androgen suppression in the treatment of advanced prostatic
cancer. Cochrane Database Syst Rev, 2002: Cd003506.

738. Fizazi, K., et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N
Engl J Med, 2017. 377: 352.
739. James, N.D., et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N
Engl J Med, 2017. 377: 338.
740. Rydzewska, L.H.M., et al. Adding abiraterone to androgen deprivation therapy in men with
metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J
Cancer, 2017. 84: 88.
741. Vale, C.L., et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised
or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of
aggregate data. Lancet Oncol, 2016. 17: 243.
742. James, N.D., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone
therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage,
platform randomised controlled trial. Lancet, 2016. 387: 1163.
743. Gravis, G., et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic
prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013. 14:
149.
744. Gravis G., et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for
hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase
III trial. J Clin Oncol 33, 2015 (suppl 7; abstr 140), 2015.
745. Smith, T.J., et al. Recommendations for the Use of WBC Growth Factors: American Society of
Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2015. 33: 3199.
746. Tosoian, J.J., et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment
considerations. Nat Rev Urol, 2017. 14: 15.
747. Eisenhauer, E.A., et al. New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer, 2009. 45: 228.
748. Smith, M.R., et al. Natural history of rising serum prostate-specific antigen in men with castrate
nonmetastatic prostate cancer. J Clin Oncol, 2005. 23: 2918.
749. Penson, D.F., et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The
STRIVE Trial. J Clin Oncol, 2016. 34: 2098.
750. Smith, M.R., et al. Disease and host characteristics as predictors of time to first bone metastasis
and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer,
2011. 117: 2077.
751. Crawford, E.D., et al. Challenges and recommendations for early identification of metastatic disease
in prostate cancer. Urology, 2014. 83: 664.
752. Hussain, M., et al. Effects of continued androgen-deprivation therapy and other prognostic factors
on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a
Southwest Oncology Group report. J Clin Oncol, 1994. 12: 1868.
753. Taylor, C.D., et al. Importance of continued testicular suppression in hormone-refractory prostate
754. Petrylak, D.P., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for
advanced refractory prostate cancer. N Engl J Med, 2004. 351: 1513.

755. Berthold, D.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008. 26: 242.
756. Tannock, I.F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer. N Engl J Med, 2004. 351: 1502.
757. Ryan, C.J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J
Med, 2013. 368: 138.
758. Rathkopf, D.E., et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate
in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-
AA-302). Eur Urol, 2014. 66: 815.
759. Ryan, C.J., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in
chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final
overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet
Oncol, 2015. 16: 152.
760. Beer, T.M., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med,
2014. 371: 424.
761. Kantoff, P.W., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-
based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol,
2010. 28: 1099.
762. Kantoff, P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J
Med, 2010. 363: 411.
763. Small, E.J., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T
(APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin
Oncol, 2006. 24: 3089.
764. Roviello, G., et al. Targeting the androgenic pathway in elderly patients with castration-resistant
prostate cancer: A meta-analysis of randomized trials. Medicine (Baltimore), 2016. 95: e4636.
765. Graff, J.N., et al. Efficacy and safety of enzalutamide in patients 75 years or older with
chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann
Oncol, 2016. 27: 286.
766. Evans, C.P., et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease
for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate
Cancer. Eur Urol, 2016. 70: 675.
767. Alumkal, J.J., et al. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic
Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin
Cancer, 2017. 15: 610.
https://www.ncbi.nlm.nih.gov/pubmed/Clin Genitourin Cancer, 2017. 15: 610.
768. Shore, N.D., et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with
metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol,
2016. 17: 153.
769. Scher, H.I., et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated
Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol, 2016.
34: 1402.
770. Armstrong, A.J., et al. Prediction of survival following first-line chemotherapy in men with castration-
resistant metastatic prostate cancer. Clin Cancer Res, 2010. 16: 203.

771. Italiano, A., et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with
castration-resistant prostate cancer. Eur Urol, 2009. 55: 1368.
772. Horgan, A.M., et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-
resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol, 2014. 5: 119.
773. Kellokumpu-Lehtinen, P.L., et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant
advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol, 2013. 14: 117.
774. Fizazi, K., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:
final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled
phase 3 study. Lancet Oncol, 2012. 13: 983.
775. de Bono, J.S., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med,
2011. 364: 1995.
776. Parker, C., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med,
2013. 369: 213.
777. Bahl, A., et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men
with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol, 2013.
24: 2402.
778. de Bono, J.S., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant
prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 2010.
376: 1147.
779. Scher, H.I., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl
J Med, 2012. 367: 1187.
780. Scher, H.I., et al. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst,
1996. 88: 1623.
781. Sartor, A., et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic
castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). J Clin Oncol
2016. 34: Abstract 5006.
782. de Bono, JS., et al. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/
m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously
treated with docetaxel (D). J Clin Oncol 2016. 34: abstr 5008.
783. Resnick, M.J., et al. Prostate cancer survivorship care guideline: American Society of Clinical
Oncology Clinical Practice Guideline endorsement. J Clin Oncol, 2015. 33: 1078.
784. Beer, T.M., et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant
Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol, 2017. 71: 151.
785. Hoskin, P., et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant
prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a
prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Lancet Oncol, 2014. 15: 1397.
786. de Bono, J.S., et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in
Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Eur Urol, 2017. 71: 656.
787. Badrising, S., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with
metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone
treatment. Cancer, 2014. 120: 968.

788. Zhang, T., et al. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic
castration-resistant prostate cancer. Expert Opin Pharmacother, 2015. 16: 473.
789. Antonarakis, E.S., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
N Engl J Med, 2014. 371: 1028.
790. Mateo, J., et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med,
2015. 373: 1697.
791. Gillessen, S., et al. Management of patients with advanced prostate cancer: recommendations of
the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol, 2015.
26: 1589.
792. Payne, H., et al. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment
evaluation in prostate cancer. Urol Oncol, 2011. 29: 593.
793. Pezaro, C.J., et al. Visceral disease in castration-resistant prostate cancer. Eur Urol, 2014. 65: 270.
794. Ohlmann C, et al. Second-line chemotherapy with docetaxel for prostate-specific antigen
relapse in men with hormone refractory prostate cancer previously treated with docetaxel based
chemotherapy. Eur Urol Suppl 2006. 5: abstract #289.
http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.4682
795. Gillessen, S., et al. Management of Patients with Advanced Prostate Cancer: The Report of the
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol, 2017.
796. Esper, P.S., et al. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol
Oncol, 1997. 15: 56.
797. Dy, S.M., et al. Evidence-based standards for cancer pain management. J Clin Oncol, 2008. 26:
3879.
798. Hartsell, W.F., et al. Randomized trial of short- versus long-course radiotherapy for palliation of
painful bone metastases. J Natl Cancer Inst, 2005. 97: 798.
799. Hoskin, P., et al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose
Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. J Natl Cancer Inst, 2015. 107.
800. Frankel, B.M., et al. Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk
in kyphoplasty as compared with vertebroplasty. Spine J, 2007. 7: 575.
801. Dutka, J., et al. Time of survival and quality of life of the patients operatively treated due to
pathological fractures due to bone metastases. Ortop Traumatol Rehabil, 2003. 5: 276.
802. Frankel, B.M., et al. Segmental polymethylmethacrylate-augmented pedicle screw fixation in
patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical
evaluation. Neurosurgery, 2007. 61: 531.
803. Marco, R.A., et al. Functional and oncological outcome of acetabular reconstruction for the
treatment of metastatic disease. J Bone Joint Surg Am, 2000. 82: 642.
804. Saad, F., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-
refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002. 94: 1458.
805. Fizazi, K., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with
castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011. 377: 813.
806. Smith, M.R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant
prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 2012. 379: 39.

807. Aapro, M., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an
international expert panel. Ann Oncol, 2008. 19: 420.
808. Horwitz, E.M., et al. Definitions of biochemical failure that best predict clinical failure in patients with
prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J
Urol, 2005. 173: 797.
809. Boccon-Gibod, L., et al. Management of prostate-specific antigen relapse in prostate cancer: a
European Consensus. Int J Clin Pract, 2004. 58: 382.
810. Shen, S., et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of
early relapse after radical prostatectomy. J Urol, 2005. 173: 777.
811. Eisenberg, M.L., et al. Prognostic implications of an undetectable ultrasensitive prostate-specific
antigen level after radical prostatectomy. Eur Urol, 2010. 57: 622.
812. Stamey, T.A., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of
the prostate. II. Radical prostatectomy treated patients. J Urol, 1989. 141: 1076.
813. Partin, A.W., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy
to distinguish local recurrence from distant metastases. Urology, 1994. 43: 649.
814. Oefelein, M.G., et al. The incidence of prostate cancer progression with undetectable serum
prostate specific antigen in a series of 394 radical prostatectomies. J Urol, 1995. 154: 2128.
815. Ray, M.E., et al. PSA nadir predicts biochemical and distant failures after external beam
radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys, 2006.
64: 1140.
816. Hancock, S.L., et al. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation
of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford
University. J Urol, 1995. 154: 1412.
817. Chaplin, B.J., et al. Digital rectal examination is no longer necessary in the routine follow-up of men
with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-
up. Eur Urol, 2005. 48: 906.
818. Beer, T.M., et al. The prognostic value of hemoglobin change after initiating androgen-deprivation
therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest
Oncology Group Study 8894. Cancer, 2006. 107: 489.
819. Daniell, H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Urology, 2001. 58: 101.
820. Miller, P.D., et al. Prostate specific antigen and bone scan correlation in the staging and monitoring
of patients with prostatic cancer. Br J Urol, 1992. 70: 295.
821. Conde, F.A., et al. Risk factors for male osteoporosis. Urol Oncol, 2003. 21: 380.
822. Hamdy, R.C., et al. Algorithm for the management of osteoporosis. South Med J, 2010. 103: 1009.
823. Higano, C.S. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol
Oncol, 2003. 21: 392.
824. Padhani, A.R., et al. Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur Urol
Focus, 2017. 3: 223.
http://www.europeanurology.com/article/S2405-4569(16)30097-9/abstract/rationale-for-
modernising-imaging-in-advanced-prostate-cancer

825. Lecouvet, F.E., et al. Monitoring the response of bone metastases to treatment with Magnetic
Resonance Imaging and nuclear medicine techniques: a review and position statement by the
European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer, 2014.
50: 2519.
826. Ulmert, D., et al. A novel automated platform for quantifying the extent of skeletal tumour
involvement in prostate cancer patients using the Bone Scan Index. Eur Urol, 2012. 62: 78.
827. Padhani, A.R., et al. METastasis Reporting and Data System for Prostate Cancer: Practical
Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance
Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol, 2017.
71: 81.
828. Bourke, L., et al. Survivorship and Improving Quality of Life in Men with Prostate Cancer. Eur Urol,
2015. 68: 374.
829. Carlsson, S., et al. Surgery-related complications in 1253 robot-assisted and 485 open retropubic
radical prostatectomies at the Karolinska University Hospital, Sweden. Urology, 2010. 75: 1092.
830. Ficarra, V., et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic
review and cumulative analysis of comparative studies. Eur Urol, 2009. 55: 1037.
831. Rabbani, F., et al. Comprehensive standardized report of complications of retropubic and
laparoscopic radical prostatectomy. Eur Urol, 2010. 57: 371.
832. Resnick, M.J., et al. Long-term functional outcomes after treatment for localized prostate cancer. N
Engl J Med, 2013. 368: 436.
833. Parekh, A., et al. Reduced penile size and treatment regret in men with recurrent prostate cancer
after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology, 2013. 81: 130.
834. Msezane, L.P., et al. Bladder neck contracture after robot-assisted laparoscopic radical
prostatectomy: evaluation of incidence and risk factors and impact on urinary function. J Endourol,
2008. 22: 377.
835. Chiong, E., et al. Port-site hernias occurring after the use of bladeless radially expanding trocars.
Urology, 2010. 75: 574.
836. Tonouchi, H., et al. Trocar site hernia. Arch Surg, 2004. 139: 1248.
837. Zelefsky, M.J., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal
radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol
Biol Phys, 2008. 70: 1124.
https://www.ncbi.nlm.nih.gov/pubmed/Int J Radiat Oncol Biol Phys, 2008. 70: 1124.
838. Fowler, F.J., Jr., et al. Outcomes of external-beam radiation therapy for prostate cancer: a study
of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol,
1996. 14: 2258.
839. Robinson, J.W., et al. Meta-analysis of rates of erectile function after treatment of localized prostate
carcinoma. Int J Radiat Oncol Biol Phys, 2002. 54: 1063.
840. Wallis, C.J., et al. Second malignancies after radiotherapy for prostate cancer: systematic review
and meta-analysis. BMJ, 2016. 352: i851.
841. Budaus, L., et al. Functional outcomes and complications following radiation therapy for prostate
cancer: a critical analysis of the literature. Eur Urol, 2012. 61: 112.

842. Nguyen, P.L., et al. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate
Them. Eur Urol, 2014: 67(5):825.
843. Donovan, K.A., et al. Psychological effects of androgen-deprivation therapy on men with prostate
cancer and their partners. Cancer, 2015. 121: 4286.
844. Cherrier, M.M., et al. Cognitive and mood changes in men undergoing intermittent combined
androgen blockade for non-metastatic prostate cancer. Psychooncology, 2009. 18: 237.
845. Herr, H.W., et al. Quality of life of asymptomatic men with nonmetastatic prostate cancer on
androgen deprivation therapy. J Urol, 2000. 163: 1743.
846. Potosky, A.L., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results
from the Prostate Cancer Outcomes Study. J Clin Oncol, 2001. 19: 3750.
847. Iversen, P., et al. Bicalutamide monotherapy compared with castration in patients with
nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 2000. 164: 1579.
848. Iversen, P., et al. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced
prostate cancer who wish to retain sexual interest and function. BJU Int, 2001. 87: 47.
849. Boccardo, F., et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer
patients: results of an Italian Prostate Cancer Project study. J Clin Oncol, 1999. 17: 2027.
850. Walker, L.M., et al. Luteinizing hormone--releasing hormone agonists: a quick reference for
prevalence rates of potential adverse effects. Clin Genitourin Cancer, 2013. 11: 375.
851. Elliott, S., et al. Androgen deprivation therapy for prostate cancer: recommendations to improve
patient and partner quality of life. J Sex Med, 2010. 7: 2996.
852. de Voogt, H.J., et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate,
medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced
prostatic cancer: results from European Organization for Research on Treatment of Cancer trials
30761 and 30762. J Urol, 1986. 135: 303.
853. Irani, J., et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for
the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues
for prostate cancer: a double-blind, randomised trial. Lancet Oncol, 2010. 11: 147.
854. Sloan, J.A., et al. Methodologic lessons learned from hot flash studies. J Clin Oncol, 2001. 19: 4280.
855. Moraska, A.R., et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a
longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol, 2010. 8: 128.
856. Frisk, J., et al. Two modes of acupuncture as a treatment for hot flushes in men with prostate
cancer--a prospective multicenter study with long-term follow-up. Eur Urol, 2009. 55: 156.
857. Smith, M.R., et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for
858. Cree, M., et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc, 2000. 48:
283.
859. Saylor, P.J., et al. Metabolic complications of androgen deprivation therapy for prostate cancer.
J Urol, 2009. 181: 1998.
860. Sieber, P.R., et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for
localized or locally advanced prostate cancer. J Urol, 2004. 171: 2272.

861. Wadhwa, V.K., et al. Bicalutamide monotherapy preserves bone mineral density, muscle strength
and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
BJU Int, 2011. 107: 1923.
862. Higano, C., et al. Bone mineral density in patients with prostate cancer without bone metastases
treated with intermittent androgen suppression. Urology, 2004. 64: 1182.
863. Smith, M.R., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men
receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 2003. 169: 2008.
864. Michaelson, M.D., et al. Randomized controlled trial of annual zoledronic acid to prevent
gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin
Oncol, 2007. 25: 1038.
865. Migliorati, C.A., et al. Bisphosphonate-associated osteonecrosis: a long-term complication of
bisphosphonate treatment. Lancet Oncol, 2006. 7: 508.
866. Wadhwa, V.K., et al. Frequency of zoledronic acid to prevent further bone loss in osteoporotic
patients undergoing androgen deprivation therapy for prostate cancer. BJU Int, 2010. 105: 1082.
867. Smith, M.R., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
N Engl J Med, 2009. 361: 745.
868. Nobes, J.P., et al. A prospective, randomized pilot study evaluating the effects of metformin and
lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU
Int, 2012. 109: 1495.
869. Grundy, S.M., et al. Diagnosis and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005. 112:
2735.
870. Braga-Basaria, M., et al. Metabolic syndrome in men with prostate cancer undergoing long-term
androgen-deprivation therapy. J Clin Oncol, 2006. 24: 3979.
871. Cheung, A.S., et al. Muscle and bone effects of androgen deprivation therapy: current and emerging
therapies. Endocr Relat Cancer, 2014. 21: R371.
872. Smith, M.R., et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin
Oncol, 2012. 30: 3271.
873. Saigal, C.S., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with
prostate cancer. Cancer, 2007. 110: 1493.
874. Lu-Yao, G., et al. Changing patterns in competing causes of death in men with prostate cancer: a
population based study. J Urol, 2004. 171: 2285.
875. Keating, N.L., et al. Diabetes and cardiovascular disease during androgen deprivation therapy:
observational study of veterans with prostate cancer. J Natl Cancer Inst, 2010. 102: 39.
876. Efstathiou, J.A., et al. Cardiovascular mortality and duration of androgen deprivation for locally
advanced prostate cancer: analysis of RTOG 92-02. Eur Urol, 2008. 54: 816.
877. Nguyen, P.L., et al. Association of androgen deprivation therapy with cardiovascular death in
patients with prostate cancer: a meta-analysis of randomized trials. Jama, 2011. 306: 2359.
878. Bourke, L., et al. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and
cost-effectiveness? Br J Cancer, 2013. 108: 9.
https://www.ncbi.nlm.nih.gov/pubmed/Br J Cancer, 2013. 108: 9.

879. Blankfield, R.P. Androgen deprivation therapy for prostate cancer and cardiovascular death. JAMA,
2012. 307: 1252; author reply 1252.
880. Bosco, C., et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular
disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol, 2015.
68: 386.
881. Nguyen, P.L., et al. Influence of androgen deprivation therapy on all-cause mortality in men with
high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J
Radiat Oncol Biol Phys, 2012. 82: 1411.
882. Tsai, H.K., et al. Androgen deprivation therapy for localized prostate cancer and the risk of
cardiovascular mortality. J Natl Cancer Inst, 2007. 99: 1516.
883. Albertsen, P.C., et al. Cardiovascular morbidity associated with gonadotropin releasing hormone
agonists and an antagonist. Eur Urol, 2014. 65: 565.
884. Gilbert, S.E., et al. Effects of a lifestyle intervention on endothelial function in men on long-term
androgen deprivation therapy for prostate cancer. Br J Cancer, 2016. 114: 401.
885. Bourke, L., et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol, 2015: 69(4):693.
886. Ahmadi, H., et al. Androgen deprivation therapy: evidence-based management of side effects. BJU
Int, 2013. 111: 543.
887. Meng, F., et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis
and systematic review. BMC Cancer, 2016. 16: 180.
888. Nead, K.T., et al. Androgen Deprivation Therapy and Future Alzheimer’s Disease Risk. J Clin Oncol,
2016. 34: 566.
889. King, A.J., et al. Prostate cancer and supportive care: a systematic review and qualitative synthesis
of men’s experiences and unmet needs. Eur J Cancer Care (Engl), 2015. 24: 618.
890. Bourke, L., et al. A qualitative study evaluating experiences of a lifestyle intervention in men with
prostate cancer undergoing androgen suppression therapy. Trials, 2012. 13: 208.
891. Berruti, A., et al. Incidence of skeletal complications in patients with bone metastatic prostate
cancer and hormone refractory disease: predictive role of bone resorption and formation markers
evaluated at baseline. J Urol, 2000. 164: 1248.
892. Carlin, B.I., et al. The natural history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer, 2000. 88: 2989.
893. Smith, D.P., et al. Quality of life three years after diagnosis of localised prostate cancer: population
based cohort study. BMJ, 2009. 339: b4817.
894. Taylor, K.L., et al. Long-term disease-specific functioning among prostate cancer survivors and
noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol,
2012. 30: 2768.
895. Cella, D.F., et al. The Functional Assessment of Cancer Therapy scale: development and validation
of the general measure. J Clin Oncol, 1993. 11: 570.
896. Esper, P., et al. Measuring quality of life in men with prostate cancer using the functional assessment
of cancer therapy-prostate instrument. Urology, 1997. 50: 920.

897. Groenvold, M., et al. Validation of the EORTC QLQ-C30 quality of life questionnaire through
combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol,
1997. 50: 441.
898. van Andel, G., et al. An international field study of the EORTC QLQ-PR25: a questionnaire for
assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer, 2008. 44:
2418.
899. Wei, J.T., et al. Development and validation of the expanded prostate cancer index composite (EPIC)
for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology,
2000. 56: 899.
900. Szymanski, K.M., et al. Development and validation of an abbreviated version of the expanded
prostate cancer index composite instrument for measuring health-related quality of life among
prostate cancer survivors. Urology, 2010. 76: 1245.
901. Litwin, M.S., et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a
health-related quality of life measure. Med Care, 1998. 36: 1002.
902. Giesler, R.B., et al. Assessing quality of life in men with clinically localized prostate cancer:
development of a new instrument for use in multiple settings. Qual Life Res, 2000. 9: 645.
903. Potosky, A.L., et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer
Outcomes Study. J Natl Cancer Inst, 1999. 91: 1719.
904. Donovan, J.L., et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for
Prostate Cancer. N Engl J Med, 2016. 375: 1425.
905. Barocas, D.A., et al. Association Between Radiation Therapy, Surgery, or Observation for Localized
Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA, 2017. 317: 1126.
906. Giberti, C., et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic
cancer: a prospective study. World J Urol, 2009. 27: 607.
907. Lardas, M., et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate
Cancer: A Systematic Review. Eur Urol, 2017. 72: 869.
908. Giesler, R.B., et al. Improving the quality of life of patients with prostate carcinoma: a randomized
trial testing the efficacy of a nurse-driven intervention. Cancer, 2005. 104: 752.
909. Pavlovich, C.P., et al. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive
nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU
Int, 2013. 112: 844.
910. Hatzimouratidis K, et al., EAU Guidelines on Male Sexual Dysfunction, in EAU Guidelines, E.G.
Office, Editor. 2018.
http://uroweb.org/guideline/male-sexu al-dysfunction/
911. Dieperink, K.B., et al. The effects of multidisciplinary rehabilitation: RePCa-a randomised study
among primary prostate cancer patients. Br J Cancer, 2013. 109: 3005.
912. Galvao, D.A., et al. Combined resistance and aerobic exercise program reverses muscle loss in
men undergoing androgen suppression therapy for prostate cancer without bone metastases: a
randomized controlled trial. J Clin Oncol, 2010. 28: 340.
913. Bourke, L., et al. Lifestyle changes for improving disease-specific quality of life in sedentary men
on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled
trial. Eur Urol, 2014. 65: 865.

914. Cella, D., et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer
Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory
prostate cancer. Value Health, 2009. 12: 124.
10. CONFLICT OF INTEREST

All members of the EAU - ESTRO – ESUR – SIOG Prostate Cancer Guidelines working panel have provided
disclosure statements on all relationships that they have that might be perceived to be a potential source of
a conflict of interest. This information is publically accessible through the European Association of Urology
website: http://www.uroweb.org/guidelines/.
This guidelines document was developed with the financial support of the European Association of Urology. No
external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding
is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements
have been provided.
11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the
citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location,
or an ISBN number may vary.
The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations-of-all-guidelines/
References to individual guidelines should be structured in the following way:

Contributors’ names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.

EAU ESUR ESTRO SIOG Guidelines On Prostate Cancer Large Text V2

Uploaded by

Copyright:

Available Formats

EAU ESUR ESTRO SIOG Guidelines On Prostate Cancer Large Text V2

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

EAU ESUR ESTRO SIOG Guidelines On Prostate Cancer Large Text V2

Uploaded by

Copyright:

Available Formats

EAU - ESTRO - ESUR -

© European Association of Urology 2018

3. EPIDEMIOLOGY AND AETIOLOGY 11

4. CLASSIFICATION AND STAGING SYSTEMS 13

2 PROSTATE CANCER - UPDATE MARCH 2018

PROSTATE CANCER - UPDATE MARCH 2018 3

4 PROSTATE CANCER - UPDATE MARCH 2018

PROSTATE CANCER - UPDATE MARCH 2018 5

6 PROSTATE CANCER - UPDATE MARCH 2018

8. QUALITY OF LIFE OUTCOMES IN PROSTATE CANCER 87

PROSTATE CANCER - UPDATE MARCH 2018 7

10. CONFLICT OF INTEREST 145

11. CITATION INFORMATION 145

8 PROSTATE CANCER - UPDATE MARCH 2018

1.2 Panel composition

1.3 Available publications

1.4 Publication history and summary of changes

1.4.2 Summary of changes

Key changes for the 2018 print:

Several new sections have been added:

PROSTATE CANCER - UPDATE MARCH 2018 9

10 PROSTATE CANCER - UPDATE MARCH 2018

3. EPIDEMIOLOGY AND AETIOLOGY

3.2.2 Risk factors

PROSTATE CANCER - UPDATE MARCH 2018 11

3.2.2.1 Metabolic syndrome (MetS)

3.2.2.2 Dietary factors

3.2.2.3 Hormonally active medication

12 PROSTATE CANCER - UPDATE MARCH 2018

3.2.2.4 Other potential risk factors

3.2.3 Summary of evidence and guidelines for epidemiology and aetiology

Recommendation Strength rating

4. CLASSIFICATION AND STAGING SYSTEMS

PROSTATE CANCER - UPDATE MARCH 2018 13

14 PROSTATE CANCER - UPDATE MARCH 2018

Gleason score ISUP grade

4.3 Prognostic relevance of stratification

PROSTATE CANCER - UPDATE MARCH 2018 15

Table 5.1: Follow-up data from the ERSPC study [89]

Years of follow-up Number needed to screen Number needed to treat

16 PROSTATE CANCER - UPDATE MARCH 2018

5.1.1 Guidelines for screening and early detection

Recommendations LE Strength rating

5.2 Clinical diagnosis

5.2.1 Digital rectal examination

5.2.2 Prostate-specific antigen

PROSTATE CANCER - UPDATE MARCH 2018 17

Table 5.2.1: Risk of PCa in relation to low PSA values

5.2.2.1 PSA density

5.2.2.2 PSA velocity and doubling time

5.2.2.3 Free/total PSA ratio

5.2.2.4 Additional serum testing

5.2.2.5 PCA3 marker/SelectMDX

18 PROSTATE CANCER - UPDATE MARCH 2018

5.2.2.6 Guidelines for risk-assessment of asymptomatic men

Recommendation LE Strength rating

5.2.3 Prostate biopsy

5.2.3.2 Repeat biopsy after previously negative biopsy

PROSTATE CANCER - UPDATE MARCH 2018 19